<SEC-DOCUMENT>0001390478-21-000030.txt : 20210812
<SEC-HEADER>0001390478-21-000030.hdr.sgml : 20210812
<ACCEPTANCE-DATETIME>20210812161717
ACCESSION NUMBER:		0001390478-21-000030
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210812
DATE AS OF CHANGE:		20210812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELLAS Life Sciences Group, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		211167810

	BUSINESS ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		6462005278

	MAIL ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galena Biopharma, Inc.
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sls-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:44c0be2c-a517-445c-901f-827aacd933ea,g:c47eecba-e87d-4369-b623-d76d853819d1,d:45635ddbe06c42738d10dbb9cae11665--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:sls="http://www.sellaslife.com/20210630" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sls-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80L2ZyYWc6NTk2YTc2YzY5MmNmNDFiNDkyYmM2N2Q0N2E2Njk4NjkvdGFibGU6ODk2ZjI4ZTQ4OTAxNGZlMjk5MDI3YmQwNzM4ZDI5NDIvdGFibGVyYW5nZTo4OTZmMjhlNDg5MDE0ZmUyOTkwMjdiZDA3MzhkMjk0Ml80LTEtMS0xLTA_91da2317-41c3-4ec9-b7a4-274c73b64da4">0001390478</ix:nonNumeric><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80L2ZyYWc6NTk2YTc2YzY5MmNmNDFiNDkyYmM2N2Q0N2E2Njk4NjkvdGFibGU6ODk2ZjI4ZTQ4OTAxNGZlMjk5MDI3YmQwNzM4ZDI5NDIvdGFibGVyYW5nZTo4OTZmMjhlNDg5MDE0ZmUyOTkwMjdiZDA3MzhkMjk0Ml81LTEtMS0xLTA_58670ac3-bf61-42b0-9a09-ed4fe0744195">December 31</ix:nonNumeric><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80L2ZyYWc6NTk2YTc2YzY5MmNmNDFiNDkyYmM2N2Q0N2E2Njk4NjkvdGFibGU6ODk2ZjI4ZTQ4OTAxNGZlMjk5MDI3YmQwNzM4ZDI5NDIvdGFibGVyYW5nZTo4OTZmMjhlNDg5MDE0ZmUyOTkwMjdiZDA3MzhkMjk0Ml85LTEtMS0xLTA_c150b96a-ccaa-4b53-85d7-df95cb3aaa9b">2021</ix:nonNumeric><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80L2ZyYWc6NTk2YTc2YzY5MmNmNDFiNDkyYmM2N2Q0N2E2Njk4NjkvdGFibGU6ODk2ZjI4ZTQ4OTAxNGZlMjk5MDI3YmQwNzM4ZDI5NDIvdGFibGVyYW5nZTo4OTZmMjhlNDg5MDE0ZmUyOTkwMjdiZDA3MzhkMjk0Ml8xMC0xLTEtMS0w_1217e832-7017-4963-8cb4-e1fb33128003">Q2</ix:nonNumeric><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80L2ZyYWc6NTk2YTc2YzY5MmNmNDFiNDkyYmM2N2Q0N2E2Njk4NjkvdGFibGU6ODk2ZjI4ZTQ4OTAxNGZlMjk5MDI3YmQwNzM4ZDI5NDIvdGFibGVyYW5nZTo4OTZmMjhlNDg5MDE0ZmUyOTkwMjdiZDA3MzhkMjk0Ml8xMS0xLTEtMS0w_558bc328-6d49-4772-b392-cdf516602924">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="id0a9aad2208d4af3861b03029b413458_D20210101-20210630" name="sls:BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjU0Nw_9e3118b3-4753-413f-9bca-561259d241ac">P5Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sls-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i9a892d5d25b8461b97fc446b4c189943_I20210812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i8d028055c2e64d5e9dab5f9331370054_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3da468c26204b08b77feb6a7b00001f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ibf4612fe88f64808b8d0d2c12012d345_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib69a37222fd941b78bea430bbe0462bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07c36ae937694c63b10658b767e16510_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d02464dad0041958b0fab78708a2174_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if863226dc0724e56bf43f3b1ff67fffc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d744a0c3d154b118fd1398efd967c38_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55be4a1b9d7945e1a7df3335dc287d83_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0549b9745c54a4a82c51e4b803e22ca_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i274e8814ad244aaa9f27ee58126839b1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d8817680df2485bab16391f20f795f3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bb7f8716a0d4caaa768d3669f37d68e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbab7f5989004cf9a988181f7b725951_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31ce168dc5e644718859ca9b623e68b2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61c430eb60c04fd480ba1b6c3c09ab45_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3800086248c45cebf643a6fcf7192a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefbe1927948046feaeb6e3e3ce6c19d5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b8fae89d58849ac8cd70c40f8a2da16_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bbe90aea6ce4ba897f9a44f95d343af_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70c599afdc614f3482861b5c48fd1e0a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcdc516de7334f91b176b211161b8e6e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfda986c11714d6bb1d5b24be92e2a2f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia79f32850e854189b3295d67b790dcdf_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i660f1425ddfa4dda85f51c113de04b3e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b35a3bd1e0a4431b15acba6941f5f47_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fcb89f394a14d90a5ea1862dbd7af35_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71259de5a94b42459fed552bab9b67b8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibedd4733b3614b92b8f20aa69691c575_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2be78beb508f4988ae137bb70fb5e7c4_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icce1dd99c16b4ec291627c253ff14547_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e81f95995f142afb3eaed854f43ad80_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea42d6c53bbb4f8783846d9ea9891e59_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id69a6adea6624cb7b4b433f41d4dc840_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ce9074c50144420a1bfafad23e559d3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i939616e9c3844b8b81fb48909a77e68e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e24296575c34c609ccf83d3d2c409eb_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e84c865aaab4f7d93617acbb36a98b3_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie077fe8f1fa546518ab2e7996f804236_D20210416-20210416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-16</xbrli:startDate><xbrli:endDate>2021-04-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib40089611a434490a15e807711e0febb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d5ca04db51e482796a8bcd426e5cf11_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6d6d49da9294db98abbd7d306232e0e_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8555ccfc9b945a59123f108d50b1d06_D20210702-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95e27891b14a478b8f8be763dda2f1fd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if65aed140a5941fa9eab141c9d95f9be_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabe6e36564484068baac5e49c21a346e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ab00b1183924bdb9188ae231bdbefd9_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i916c92e4c67d42dc92aa2fd9eccecc12_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i572c1e1b6c34427d95e51bbb5e40be56_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id299f8f9d64c460fbab097e59032b733_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20b6583c6c4a4427a2154f30c7a4d759_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2cfc63428564e92ac87c7615fb89ca7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63ad3d82d21047e2a9bb504f8640be57_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94e62635663940f0a1122ae9dd5b94de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14237fe221f44d34a5583869de1d051e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23b95e026b9d4e318900dfe9940adf09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa99ebdccce94e8caa2de707cacf92af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae6ab8b28e8405fb45e31fe8cff6e47_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42a0e682866c4ad485eb808d137a33a4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69f52ca633da4c9fa61aac1b2d469ba6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i707b6253a0f14414a1bc6beca9cc2c6f_I20111231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:AptheraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb2e72136f1d4a248d844448ac121df9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:AptheraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bdb237db5d747d296f136aa84ea8854_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:AptheraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09934cd16082484c8827742d0199f8e8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sls:MeasurementInputWeightedAverageCostOfCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:AptheraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25cd3b9620c54b4e9fce77a21dc1f63f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sls:MeasurementInputCostOfDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:AptheraInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0a9aad2208d4af3861b03029b413458_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:AptheraInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a03f8fd056b46cbb0fb3aa49612a705_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:AptheraInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia44788b499c14745a5543c4a56408ada_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sls:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06156e81794f42c1a865af738d386a08_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sls:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b25700382c9420ca66cff20eaedf21a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sls:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i375c691af6b54e09a2f25fecd7b8dc1a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sls:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c3f2fed3a4c4b6cb082afcd2c660434_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sls:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="complaint"><xbrli:measure>sls:complaint</xbrli:measure></xbrli:unit><xbrli:context id="i880559595c4c4de0b7dc3629958abd33_D20200713-20200716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-13</xbrli:startDate><xbrli:endDate>2020-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i111b00fe2e9a484ab732132f92c59d7e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09f2e17d90504212b4f4df2b5b769f5f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:A2019EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b1a536e4ed7497d9180567e5c395379_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53f109f3f922470f8caedb485b977400_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:A2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b57b69674ea45d89f949a22963281ef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2020PIPEOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i382d0ff9116248889bfe35c9548bb1ad_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2020PIPEOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1696facd34e04e7fabcf3bf12a67fc37_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2020PIPEOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i055485f92470418a8842a2c2ea3403fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:January2020OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae1ab75d176f43859c532c0d5a6b9757_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:January2020OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1abab26a331b4d2bbc52b859b5ddb6d1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:January2020OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27b4f5e1ef5b476eb4b27190b75d9193_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2019OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1602f66b4bcd4b2fa1f1a8b24f7dd4e1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2019OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i412c4e10b3ae49dd8a8769d97061c813_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2019OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b0b95c6b8aa4fb6baa41a60c4f64951_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:WarrantExerciseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i947de4d2c94b4605b378f1b0d070bc03_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:WarrantExerciseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icde798f1922a4c969d6f8e4f31c629b2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:WarrantExerciseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19c88fd5d77f4b98a7abbb7fbdd57812_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2018OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c3ab494f63a4840a5e8d7c78a0058e7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2018OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d5dabb9e85f4ddf985e3b83dbcc8a7f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2018OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i251355b170d24283aef38a929d6b4ddb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherWarrantIssuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b0f1fdbd95d469f9e4960e2aff67576_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherWarrantIssuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d574a5c54b4ecf988952bb6423ecf0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherWarrantIssuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if448fa0842d047f7b8837ba649615db8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherLiabilityClassifiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bb40a5e73b94b1b8f47f0ddc5d2a834_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherLiabilityClassifiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i144421cce0de42f196e8d03018a26b22_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherLiabilityClassifiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5503f2dea367480f98b7b0fa4b8c7314_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherLiabilityClassifiedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id11e0beb0d474e3e908dfebf56c545ca_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i407d77e6977a4e69b6cad45ca4a965ca_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i688ab895304a4f60b76983dc097aef85_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad04bd0225e946c686ea366ea6d4337c_I20171229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cdec16105b14f11a00088c335a3fc87_I20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id18a6212741d45d5b62f720726640f94_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3326b9a650f54279992091454bb1af76_D20190910-20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-10</xbrli:startDate><xbrli:endDate>2019-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c1fcbbb7fa2469ea57dccaece19d2c0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7eacc21cecb4153bd972290a5d92a75_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i524a7778f45b41d493eb970513cfe899_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i455f2bcd2a26422b8ef4b6956db962dd_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib57038e75a2e456f9153d4562f7875c9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib53ff491bb4d406dbfc18398cc46aed4_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6957c26fb4be459faf509b1dc44c22e1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34c6000daa9d4a529f676d7a949697c9_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if259b3f68de54eb69651fd71f0d90e8a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69480503f88f4c8b8e46355038c252d7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eabe9b7328c4b42883ac930dcae2966_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3b2daec188244b58b5c6404473e5b28_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd04b0465a9c4a3b89d3acede77717db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i018e48b1dacd47c68c32d3cc244c3f52_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9994aed68348440999b4cb1d1a4ac219_I20210422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5c340905f4d47a1a0096f2680c0f9f4_D20210422-20210422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-22</xbrli:startDate><xbrli:endDate>2021-04-22</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i45635ddbe06c42738d10dbb9cae11665_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDg0_03b88e82-ae69-4de1-b085-a4ee1d3fd600">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6ZGY1OWQ4ZTYxN2YzNDYzYTlmMTY2YWRlYjJhZmJlMTIvdGFibGVyYW5nZTpkZjU5ZDhlNjE3ZjM0NjNhOWYxNjZhZGViMmFmYmUxMl8wLTAtMS0xLTA_d7b66ed5-8c47-4723-a9f3-db91f6f76972">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18xOTE_d6f0b814-3440-4400-8cd0-6263cec49a05">June 30, 2021</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.595%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6OTk3MDgwMWY0ZTExNDllNGEzZWUxODJiMjYxMWMwODIvdGFibGVyYW5nZTo5OTcwODAxZjRlMTE0OWU0YTNlZTE4MmIyNjExYzA4Ml8wLTAtMS0xLTA_fbe1feb5-522a-4735-b7b8-4f03bf7e0c4d">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDg4_94f13906-ec19-4017-8d6f-a7fb762fa449"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDg4_f6c7a421-d3b6-48f5-8edc-aa1bc3d84b9d">001-33958</ix:nonNumeric></ix:nonNumeric> </span></div><div style="text-align:center"><img src="sls-20210630_g1.jpg" alt="sls-20210630_g1.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:173px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDg1_24908d17-6057-44ca-9dbd-f5b26f75a4b2"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDg1_e625ffae-dca7-44c0-88af-7df26ca26d61">SELLAS Life Sciences Group, Inc.</ix:nonNumeric></ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.861%"><tr><td style="width:1.0%"></td><td style="width:47.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.510%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6ZGY3NWJhOTZkYTgxNDlhYzhjZjhhZTVjMjhkOTdiNmQvdGFibGVyYW5nZTpkZjc1YmE5NmRhODE0OWFjOGNmOGFlNWMyOGQ5N2I2ZF8wLTAtMS0xLTA_82bab763-b37b-4e12-b3e7-210806c5b212">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6ZGY3NWJhOTZkYTgxNDlhYzhjZjhhZTVjMjhkOTdiNmQvdGFibGVyYW5nZTpkZjc1YmE5NmRhODE0OWFjOGNmOGFlNWMyOGQ5N2I2ZF8wLTItMS0xLTA_3f72ef83-4994-4b25-8bcb-6192c35050f1">20-8099512</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDg2_5a7894e7-4f08-4145-85de-46c5d0357a8a">7 Times Square, Suite 2503,</ix:nonNumeric> <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDc5_e4cc44b8-bc98-4ca7-81b7-ed10d5cae9fe">New York,</ix:nonNumeric> <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDgw_92e7d1fe-c0a9-473b-9883-85ab5f41a46b">NY</ix:nonNumeric> <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18zNjg_f6f9e3fe-f8df-40c6-bf53-748a7ef229c8">10036</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18zNzI_81b8e956-365e-44e7-9eb9-2dc3c7afd6a5">(646)</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDgx_d4d8b7aa-c9f8-45de-a36e-b1062746f7a1">200-5278</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">area code, of registrant's principal executive offices)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6NjQzYWU4MDI1YmNmNDIxZDk4ODgwNWVmMmFlZjQyMzkvdGFibGVyYW5nZTo2NDNhZTgwMjViY2Y0MjFkOTg4ODA1ZWYyYWVmNDIzOV8xLTAtMS0xLTA_4024339b-50e5-45bf-b617-9271a43c2f34">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6NjQzYWU4MDI1YmNmNDIxZDk4ODgwNWVmMmFlZjQyMzkvdGFibGVyYW5nZTo2NDNhZTgwMjViY2Y0MjFkOTg4ODA1ZWYyYWVmNDIzOV8xLTEtMS0xLTA_34b089bd-c4a5-4ecd-8e46-2c4f1061790b">SLS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6NjQzYWU4MDI1YmNmNDIxZDk4ODgwNWVmMmFlZjQyMzkvdGFibGVyYW5nZTo2NDNhZTgwMjViY2Y0MjFkOTg4ODA1ZWYyYWVmNDIzOV8xLTItMS0xLTA_6389dd70-098a-45c1-92eb-0c8dec27d12e">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDg5_84da9cf4-5e89-45e9-af1c-19e794c2f8e6">Yes</ix:nonNumeric>&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter time that the registrant was required to submit such files).&#160;&#160;&#160;<ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDgy_5c9a983b-1e2a-4765-85bd-8f9bec4ce296">Yes</ix:nonNumeric>&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act:</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6ZjQ2ZTE4N2ZjYTliNGZlZThhZTQ4Y2NkZTc4NGMzY2EvdGFibGVyYW5nZTpmNDZlMTg3ZmNhOWI0ZmVlOGFlNDhjY2RlNzg0YzNjYV8yLTAtMS0xLTA_a896f792-4ceb-4667-affd-b663e90cca58">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6ZjQ2ZTE4N2ZjYTliNGZlZThhZTQ4Y2NkZTc4NGMzY2EvdGFibGVyYW5nZTpmNDZlMTg3ZmNhOWI0ZmVlOGFlNDhjY2RlNzg0YzNjYV8yLTYtMS0xLTA_cce61055-926a-44b4-a8f1-e0800a6c60fd">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6ZjQ2ZTE4N2ZjYTliNGZlZThhZTQ4Y2NkZTc4NGMzY2EvdGFibGVyYW5nZTpmNDZlMTg3ZmNhOWI0ZmVlOGFlNDhjY2RlNzg0YzNjYV80LTItMS0xLTA_084b6d57-66ec-4a94-8cee-e32bd2533d0b">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDkw_41fdaeb9-6c9c-4684-ad06-9e3f0bd427ef">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Yes&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#160;No </span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of August&#160;12, 2021, SELLAS Life Sciences Group, Inc. had outstanding <ix:nonFraction unitRef="shares" contextRef="i9a892d5d25b8461b97fc446b4c189943_I20210812" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDUy_1345a8f2-e654-41a0-8229-66f15cc1552c">15,873,941</ix:nonFraction> shares of common stock.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i45635ddbe06c42738d10dbb9cae11665_7"></div><hr style="page-break-after:always"/><div style="min-height:99pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q - Quarterly Report</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarter Ended June&#160;30, 2021 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I - FINANCIAL INFORMATION</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_19">Unaudited Consolidated Balance Sheets As of June 30, 2021 and December 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_22">Unaudited Consolidated Statements of Operations </a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_22">F</a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_22">or the </a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_22">T</a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_22">hree and </a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_22">S</a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_22">ix </a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_22">M</a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_22">onths </a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_22">E</a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_22">nded June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_25">Unaudited Consolidated Statements of Stockholders' Equity For the Three and Six Months Ended June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_28">Unaudited Consolidated Statements of Cash Flows </a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_28">F</a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_28">or the </a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_28">S</a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_28">ix </a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_28">M</a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_28">onths </a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_28">E</a><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_28">nded June 30, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unaudited <a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_31">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_82">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_70">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_85">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_85">31</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_88">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_88">31</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II - OTHER INFORMATION</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_94">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_97">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_100">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_100">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_103">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_100">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_106">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_103">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_109">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_106">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_112">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_109">32</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i45635ddbe06c42738d10dbb9cae11665_115">Signatures</a></span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The names &#8220;SELLAS Life Sciences Group, Inc.,&#8221; &#8220;SELLAS,&#8221; the SELLAS logo, and other trademarks or service marks of SELLAS Life Sciences Group, Inc. appearing in this Quarterly Report on Form 10-Q are the property of SELLAS Life Sciences Group, Inc. Other trademarks, service marks or trade names appearing in this Quarterly Report on Form 10-Q are the property of their respective owners. We do not intend the use or display of other companies&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of or by either of, these other companies. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise indicates, references in these notes to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; refer to SELLAS Life Sciences Group, Inc. and its wholly owned subsidiaries. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i45635ddbe06c42738d10dbb9cae11665_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q includes forward-looking statements that reflect our current views with respect to our development programs, business strategy, business plan, financial performance and other future events. These statements include forward-looking statements both with respect to us, specifically, and our industry, in general. Such forward-looking statements include the words "expect," "intend,&#8221; "plan," "believe," "project," "estimate,&#8221; "may,&#8221; "should," "anticipate," "will" and similar statements of a future or forward-looking nature identify forward-looking statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. The COVID-19 pandemic has caused a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could impact our operating results. We expect the COVID-19 pandemic to continue to have both a direct and an indirect impact on our business operations and financial results, however, the extent of the impact on our clinical development and regulatory efforts, our corporate development objectives, our financial position and the value of and market for our common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, the emergence of new variants of COVID-19, the emergence of new geographic hotspots where the coronavirus is spreading more rapidly, travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, as well as the effectiveness of actions taken globally to contain and treat the disease, including the availability of safe and effective vaccines and the uptake thereof, and whether existing vaccines are effective with respect to new variants. There are or will be important factors that could cause actual results to differ materially from those indicated in these statements. These factors include, but are not limited to, those factors set forth in the sections captioned "Business &#8211; Overview,&#8221; &#8220;Risk Factors,&#8221; &#8220;Legal Proceedings,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; in this Quarterly Report on Form 10-Q, in our Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission ("SEC") on March 23, 2021 ("2020 Annual Report") and in our other public filings with the SEC, all of which you should review carefully. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i45635ddbe06c42738d10dbb9cae11665_13"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_16"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1. FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_19"></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNC0xLTEtMS0w_d5290e25-286e-4688-9892-ea11eeff9a9a">29,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNC0zLTEtMS0w_dc4be7fc-51b7-4234-9ee0-7572efde1a97">35,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNS0xLTEtMS0w_80516b8f-3a29-475d-b2ae-f17bd4bae76e">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNS0zLTEtMS0w_6ec93752-abc5-4170-866d-0965bf160d9d">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock subscription receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="sls:StockSubscriptionReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNi0xLTEtMS0w_4fc7ae6e-ccd6-4a62-b14f-65f20c4281b7">2,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:zerodash" name="sls:StockSubscriptionReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNi0zLTEtMS0w_dd59714c-0a0d-4a2b-a52c-c99a73c4feef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalizedContractCostNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfOS0xLTEtMS0w_30292dd4-0dcc-4e13-a0db-fd6fdbb2089c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfOS0zLTEtMS0w_891b9e71-6c57-4b61-8a2c-a7439ce0750f">1,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTAtMS0xLTEtMA_bc85a0bd-296b-4d29-9706-c26f2137ce1d">2,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTAtMy0xLTEtMA_2f5d943a-5143-40c8-9693-5d2c9bd6ff6d">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTItMS0xLTEtMA_d3523582-e8db-4a8c-a53e-bd38c4387711">34,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTItMy0xLTEtMA_cbf68d6b-2142-4281-b722-1866d8bda2f1">36,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTQtMS0xLTEtMA_f27b2d72-261d-4c73-834d-5b4050eb3189">812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTQtMy0xLTEtMA_656c9c92-2d0d-404f-b50e-00c900569be3">896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="sls:InProcessResearchDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTUtMS0xLTEtMA_2847e417-9ae6-4a1c-b9e3-d1751111c551">5,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sls:InProcessResearchDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTUtMy0xLTEtMA_62e5c3c6-a721-451f-b408-2d81c618301a">5,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTktMS0xLTEtMA_168e669b-43da-4f87-bddc-377fe5f52af1">1,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTktMy0xLTEtMA_38d0169a-97f8-46a6-b479-5ab28bda48d2">1,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deposits and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:DepositsAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjAtMS0xLTEtMA_67919464-c3fe-4f3d-a75f-4ad990916dd1">623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:DepositsAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjAtMy0xLTEtMA_f1871431-87f1-424a-a5f2-1fcdb2a2672a">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjEtMS0xLTEtMA_8e2ae47d-7657-4bca-ac6a-bf7ca6557d3b">43,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjEtMy0xLTEtMA_242e13e2-2fc9-4f00-98f0-590d65b4bd68">46,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjYtMS0xLTEtMA_4056e609-5884-4256-b0f0-da76214a1319">2,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjYtMy0xLTEtMA_196f7a1c-3367-4258-aef9-f4b669fb75da">4,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjctMS0xLTEtMA_a649b580-8de4-4388-8b61-9d31574aab48">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjctMy0xLTEtMA_b295c00e-e67f-42b5-b53b-d9d9d3552097">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjktMS0xLTEtMA_31d8d639-769a-4a65-8e82-62c5b2beef0b">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjktMy0xLTEtMA_d4fd9c61-9921-4a59-8d60-5a05992643d0">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzAtMS0xLTEtMA_57083ebc-005f-41f2-bd47-54c4ccbbcb6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzAtMy0xLTEtMA_3f2cfde7-58c9-4ca7-823e-a338a68b8d42">5,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzItMS0xLTEtMA_bab4da5e-ae4d-4aee-bea2-aa164a78b957">4,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzItMy0xLTEtMA_7ec8617f-a046-4651-8ba4-41f7ea04db63">12,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzQtMS0xLTEtMA_a246bbd9-3e5f-4c7a-b911-af3293b7da2b">721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzQtMy0xLTEtMA_6dd294cf-2c80-47f0-bbd5-0b27ec7d72dc">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzUtMS0xLTEtMA_94171886-e3bf-4569-b8a1-37fc4428bc4d">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzUtMy0xLTEtMA_ec67845d-a8c0-4e54-9a7d-3b39332833fe">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="sls:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzYtMS0xLTEtMA_46a31d4c-d062-4e65-bd63-d75fd205f1b0">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="sls:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzYtMy0xLTEtMA_28589249-b31b-4e63-a402-71cded683e47">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="sls:ContingentPurchasePriceConsiderationNetOfCurrentPortion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzctMS0xLTEtMA_3c87d984-4e72-4030-ad22-791ee0fd2130">4,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sls:ContingentPurchasePriceConsiderationNetOfCurrentPortion" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzctMy0xLTEtMA_205777a1-7da4-4465-a5f5-c868cb9e4bb0">4,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzktMS0xLTEtMA_00105100-ef77-4547-b024-16f105ba56dc">10,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzktMy0xLTEtMA_3180ef47-3a59-4c4f-98fc-95455193055e">18,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 6)</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDAtMS0xLTEtMA_3de36037-e4c1-42e2-95d5-87c179226c49"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDAtMy0xLTEtMA_f7bff818-e301-4dc3-a1b3-aba9f77c9732"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzIx_7713f8ea-0db8-4694-bf83-f85ab0692937"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzIx_a28ae16a-c385-4253-8f7e-ca389543c047">0.0001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction unitRef="shares" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzM1_0df6a240-c2fb-401c-bf3c-abca38a69c11"><ix:nonFraction unitRef="shares" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzM1_cf1fb8d9-81f0-4454-a336-ac2512e9619d">5,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized; Series A convertible preferred stock, <ix:nonFraction unitRef="shares" contextRef="ibf4612fe88f64808b8d0d2c12012d345_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzk1_537c4839-1094-4a81-bdcd-da5c5b7b1a6d"><ix:nonFraction unitRef="shares" contextRef="ib69a37222fd941b78bea430bbe0462bd_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzk1_eef7adae-cd47-4a18-b78e-75a41ef05b5a">17,500</ix:nonFraction></ix:nonFraction> shares designated; <ix:nonFraction unitRef="shares" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzExNw_0ec95f00-52e2-43d6-9965-89949729b967"><ix:nonFraction unitRef="shares" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzExNw_185a53fe-cd35-4f0b-8502-5ab776fc6efc"><ix:nonFraction unitRef="shares" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzExNw_48f517c9-1bb1-44a6-8afa-e867c173d925"><ix:nonFraction unitRef="shares" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzExNw_a71242eb-5337-459c-8f5b-6e563f4459a4">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at June 30, 2021 and December 31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMS0xLTEtMA_9f765783-9e7a-402c-b7b9-ac85d3ccc3de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMy0xLTEtMA_707e9eae-83a6-42aa-a8c6-d247c49a518c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzE4_1a6a5c34-c362-40b7-a3ba-ed2244b08956"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzE4_ec0264e3-df5c-4a5e-ac42-e01deb03280d">0.0001</ix:nonFraction></ix:nonFraction>&#160;par value; <ix:nonFraction unitRef="shares" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzMy_01496779-732c-41c5-937c-df77aa9063b7"><ix:nonFraction unitRef="shares" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzMy_2765e9ae-2ab5-4137-80c2-7299cfda9502">350,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized, <ix:nonFraction unitRef="shares" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzU0_7884d571-c2c7-43a2-9ab9-eaa186106a8b"><ix:nonFraction unitRef="shares" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzU0_b1aa6002-c6be-47ca-9051-4a77eabab04d">15,873,941</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzYx_12743c1e-6912-479b-980a-54daf712afeb"><ix:nonFraction unitRef="shares" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzYx_28f0976f-5efa-4563-b012-d17a2ffff284">14,254,554</ix:nonFraction></ix:nonFraction>&#160;shares issued and outstanding at June 30, 2021 and December&#160;31, 2020, respectively.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMS0xLTEtMA_77c28031-9bd2-4a8b-b234-93e1da194961">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMy0xLTEtMA_b98c6884-029a-4e8e-8b5f-513c68600a45">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDQtMS0xLTEtMA_3ef30dc8-5d8d-443d-ae2d-caa1ff8f9146">158,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDQtMy0xLTEtMA_d40f1a62-a4a9-4b6c-9728-b00954bd48ec">145,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDUtMS0xLTEtMA_4fe1e780-7ce4-44bd-8ae0-1c38fa74cfdb">124,920</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDUtMy0xLTEtMA_dd787028-e241-4fe9-b70c-b9e1b5eeb6c3">117,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDctMS0xLTEtMA_7dcd25ad-0b95-4da2-9a4e-2f87fd87c7ef">33,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDctMy0xLTEtMA_7302b952-29b4-4107-8e37-b55be755b71b">27,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDgtMS0xLTEtMA_32abc0b1-d424-4f8c-8923-7b048b81eeb8">43,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDgtMy0xLTEtMA_ba84b93a-46e8-4e0c-b473-37750df78c97">46,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i45635ddbe06c42738d10dbb9cae11665_22"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMi0xLTEtMS0w_8fd1a7b1-7c90-4a02-9115-b9239b12ac1e">1,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMi0zLTEtMS0w_7a678204-7fc3-49f7-b61c-0f40467eded5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMi01LTEtMS0w_46d2279c-8bea-4615-aedb-281fd159c58e">7,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMi03LTEtMS0w_8f0e6cd8-598a-43c8-9cb6-671c03131f65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of licensing revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNC0xLTEtMS0w_c739b611-e380-43cf-8ea3-1b9d2ecb6c27">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNC0zLTEtMS0w_79e184c5-16d2-43fb-b530-48632d5f11e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNC01LTEtMS0w_d5c69b27-9b5a-44a5-9e8b-10dc4217f2ce">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNC03LTEtMS0w_3d288565-ff54-44e1-b1cf-d71035ec3bad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNS0xLTEtMS0w_1d3cc98d-b6df-43f4-ad21-8c80c5a48095">3,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNS0zLTEtMS0w_e2fcc02b-6dda-49aa-a2b7-e5021256e157">2,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNS01LTEtMS0w_2c12e275-0db4-44d8-a4f8-b77b9d90e247">7,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNS03LTEtMS0w_2bf0844a-2e01-4e8f-94ed-45cd6f406160">4,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNi0xLTEtMS0w_5a1e6bd2-1bb3-44e1-bd18-1d07df028807">2,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNi0zLTEtMS0w_b85df19e-730d-4b07-b28c-830c79bdc5f8">1,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNi01LTEtMS0w_b479ddf7-61b5-4239-88c6-1759394104d8">6,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNi03LTEtMS0w_172bc47a-5fd2-4361-8505-1f79434d0145">4,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOC0xLTEtMS0w_cef8ee54-83a2-44c7-bdba-d995f903e159">6,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOC0zLTEtMS0w_fd85a601-84a4-447a-a5d8-065cad4d3903">4,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOC01LTEtMS0w_e1c822c7-97b6-4400-9803-01820b8d641e">14,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOC03LTEtMS0w_877ce647-38b9-466f-b721-60efd07892d3">8,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOS0xLTEtMS0w_6d45b1fd-d073-41cc-abb6-e09ca1fafb22">4,453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOS0zLTEtMS0w_944203eb-f4c3-44f6-8390-0ef67167514e">4,267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOS01LTEtMS0w_656fb4e3-2f62-4283-815a-38ecf023079e">6,698</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOS03LTEtMS0w_90d4a29d-5576-454f-8fbe-c9559bd4b19b">8,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income (expense), net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTItMS0xLTEtMA_de2e2de9-437a-4e85-b6d1-7b28ad5b7161">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTItMy0xLTEtMA_f6518495-a5fd-407f-bcd4-e1961d78537c">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTItNS0xLTEtMA_b7b6b720-6d36-42ba-a96b-f43e307eeaf6">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTItNy0xLTEtMA_02b4089f-557b-401a-a214-bde285388e0c">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" sign="-" name="sls:ChangeInFairValueOfContingentPurchasePriceConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTQtMS0xLTEtMA_7e410067-6c4a-451e-9ebd-72e76c8df042">134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" sign="-" name="sls:ChangeInFairValueOfContingentPurchasePriceConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTQtMy0xLTEtMA_9a480e99-46bb-4c5b-ab1c-e406da51b878">143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" name="sls:ChangeInFairValueOfContingentPurchasePriceConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTQtNS0xLTEtMA_f3b24d4c-e85e-41a2-995a-8369de34ce87">263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" sign="-" name="sls:ChangeInFairValueOfContingentPurchasePriceConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTQtNy0xLTEtMA_80dbf39d-bd78-40b7-9be9-9c5c7f7f1e5b">281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTctMS0xLTEtMA_31dcc68f-6cc8-44a9-b3a5-9b54963a88f9">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTctMy0xLTEtMA_f52c3ddb-18ef-4041-87f5-60af76d96dfe">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTctNS0xLTEtMA_31eb687d-b665-4697-967a-ea1831b451d9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" name="us-gaap:InterestIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTctNy0xLTEtMA_3bfe2918-4902-43c5-99ea-5912d60a0f46">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-operating expense, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTgtMS0xLTEtMA_aa3172d7-a6f2-4070-9b81-049c7f9cc109">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTgtMy0xLTEtMA_76b3cd41-eab6-4ae9-8d1b-62bd4dadbadc">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTgtNS0xLTEtMA_9f350e07-2ed4-4633-8fcc-164910a93813">318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTgtNy0xLTEtMA_0f9a9372-cb76-4bee-bc25-51410d16565a">237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjQtMS0xLTEtMA_d96add2b-6127-4158-a6e6-52d941b8ee6e">4,613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjQtMy0xLTEtMA_15f72bb2-0417-4487-be72-37c815f6bb86">4,425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjQtNS0xLTEtMA_10a1a9c0-6d62-49c1-a5d5-333304246015">7,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjQtNy0xLTEtMA_b6eb1825-5fc3-4150-8c71-cd170e2405ca">8,568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend arising from warrant modifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" format="ixt:zerodash" name="sls:DividendArisingFromWarrantModifications" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjctMS0xLTEtMA_f59d9ca9-ad53-490f-8ed0-4368049c445c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="sls:DividendArisingFromWarrantModifications" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjctMy0xLTEtMA_9aff95ae-26dd-4eb1-8168-e5d1d1645c4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:DividendArisingFromWarrantModifications" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjctNS0xLTEtMA_6badab47-fb1a-4e8c-bd5c-cf0f0a0578ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" name="sls:DividendArisingFromWarrantModifications" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjctNy0xLTEtMA_3f5d13fa-761f-4043-a04d-9971ee457b58">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtMS0xLTEtMA_61675c91-4635-41fd-8bf5-3a5602e8a2b3"><ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtMS0xLTEtMA_9a343ad0-2855-40c4-aa65-e2c5b6d0040e">4,613</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtMy0xLTEtMA_909a9721-ff79-4aff-9587-e10d45cec7fb"><ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtMy0xLTEtMA_d97beb5c-7f27-436a-8b09-23d96f0e68d7">4,425</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtNS0xLTEtMA_1165aee4-fd64-4cfb-8b3e-efaed380a2c2"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtNS0xLTEtMA_a11cf32c-e11e-426f-b247-008a8df063d4">7,016</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtNy0xLTEtMA_1b73711d-b494-4091-9731-fbca93cd7a6b"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtNy0xLTEtMA_6a0c1af1-98f3-4c53-a5cb-1d58387c77e9">8,646</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Per share information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share attributable to common stockholders, basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtMS0xLTEtMA_2dad3bf3-af0a-454c-9cc3-2229c72c8b2d"><ix:nonFraction unitRef="usdPerShare" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtMS0xLTEtMA_91fb524b-8ba0-46f3-8c4b-03b36424e24e">0.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtMy0xLTEtMA_c02aa38d-6ee9-43a5-9b71-c6c8f784ac62"><ix:nonFraction unitRef="usdPerShare" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtMy0xLTEtMA_e0c406d4-91b3-4279-8a94-e49c74d3575f">0.66</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtNS0xLTEtMA_0a79d185-d9a8-4780-88ca-ef5f534f83d6"><ix:nonFraction unitRef="usdPerShare" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtNS0xLTEtMA_605278f4-d0e9-4b0b-8db6-3d313166b044">0.47</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtNy0xLTEtMA_225ac51f-9751-48dd-bcc5-c8eb3475906b"><ix:nonFraction unitRef="usdPerShare" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtNy0xLTEtMA_71921689-1b16-436e-a6eb-698ad44846ce">1.32</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtMS0xLTEtMA_6b3a800e-9122-4e2a-8b32-068ab9d6c9ad"><ix:nonFraction unitRef="shares" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtMS0xLTEtMA_815c84c7-1696-4722-80aa-90ba93e59ce4">15,270,288</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtMy0xLTEtMA_15e5507b-dd8f-48ec-9bdd-e4fc369d7dc1"><ix:nonFraction unitRef="shares" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtMy0xLTEtMA_acd7f150-957e-4ae0-aff4-a2f3b4413097">6,717,900</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtNS0xLTEtMA_0ae09cb1-1b72-443f-baf1-739e2899240b"><ix:nonFraction unitRef="shares" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtNS0xLTEtMA_33d5d6a5-4815-44b3-b68c-6f5c70b10da7">15,074,887</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtNy0xLTEtMA_1384f45e-59bb-4bfb-8aae-d8419c6f9136"><ix:nonFraction unitRef="shares" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtNy0xLTEtMA_ad56cf1f-1081-4942-8a79-633f99c5b32f">6,546,440</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span><br/></span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i45635ddbe06c42738d10dbb9cae11665_25"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands, except share amounts)</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.786%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Stockholders' Equity (Deficit)</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d02464dad0041958b0fab78708a2174_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMy01LTEtMS0w_99186aff-0d18-456a-b2e7-5dc1075c1b38">15,084,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d02464dad0041958b0fab78708a2174_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMy03LTEtMS0w_8e50b56f-df81-420f-969d-639844d7c02c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if863226dc0724e56bf43f3b1ff67fffc_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMy05LTEtMS0w_80f0fcea-2c88-4fd6-a12d-487d7236992f">149,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d744a0c3d154b118fd1398efd967c38_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMy0xMS0xLTEtMA_ba0b18dd-8004-4242-85f7-2cc27ffd2e11">120,307</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55be4a1b9d7945e1a7df3335dc287d83_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMy0xNS0xLTEtMA_1bc16f05-5e9b-45d3-b8ef-63539ae80f10">28,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and common stock warrants, net of issuance costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0549b9745c54a4a82c51e4b803e22ca_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="sls:StockIssuedDuringPeriodSharesCommonStockandWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfNC01LTEtMS0w_c610a9bd-6244-4341-9156-bb2b44fde557">786,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274e8814ad244aaa9f27ee58126839b1_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="sls:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfNC05LTEtMS0w_1ffc23fe-3a54-45ba-9065-2cafca5bb43d">9,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="sls:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfNC0xNS0xLTEtMA_a3bf93dc-c84f-4e1a-a11a-8fc4ceaf3ea3">9,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants, net of offering costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0549b9745c54a4a82c51e4b803e22ca_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfNS01LTEtMS0w_09d372e4-378a-43b0-bbe8-3615d977e96b">2,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274e8814ad244aaa9f27ee58126839b1_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfNS05LTEtMS0w_1ab6c0e2-261b-4bd2-9c43-03978262f9b3">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfNS0xNS0xLTEtMA_3dbe94fb-c105-4f2b-bef0-b34e5bd5879c">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274e8814ad244aaa9f27ee58126839b1_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfOS05LTEtMS0w_81369b18-b0b9-43fb-bdd4-154e9315fcac">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfOS0xNS0xLTEtMA_ca64707e-04a5-44ab-952c-763e919d278d">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d8817680df2485bab16391f20f795f3_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTAtMTEtMS0xLTA_815ae175-a6ba-42f8-aecb-3e5fd8eadd61">4,613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTAtMTUtMS0xLTA_3d5c2f3f-f076-4a94-858e-a1629caee847">4,613</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bb7f8716a0d4caaa768d3669f37d68e_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTEtNS0xLTEtMA_adc3005f-b8b1-4407-9dbb-1234e21361b4">15,873,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb7f8716a0d4caaa768d3669f37d68e_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTEtNy0xLTEtMA_16c704f4-2180-4e84-bba5-ecd8b43ac731">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbab7f5989004cf9a988181f7b725951_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTEtOS0xLTEtMA_25cc0d4e-d6d8-4aca-8854-f8fdfe01cb2c">158,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31ce168dc5e644718859ca9b623e68b2_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTEtMTEtMS0xLTA_ce7acb5c-ba6b-4fe3-ad81-2b979ba2a74f">124,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTEtMTUtMS0xLTA_1989710e-9f44-44a6-98d8-eec99ef8fbda">33,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Stockholders' Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i61c430eb60c04fd480ba1b6c3c09ab45_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTYtNS0xLTEtMA_5e23585b-ff5d-45d5-853b-1e1bed9a2024">14,254,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c430eb60c04fd480ba1b6c3c09ab45_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTYtNy0xLTEtMA_b812d65f-eec9-4b0b-baa6-57ee731b610c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3800086248c45cebf643a6fcf7192a3_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTYtOS0xLTEtMA_b942449a-7c43-48c0-9b87-597c1292628a">145,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iefbe1927948046feaeb6e3e3ce6c19d5_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTYtMTEtMS0xLTA_35472348-f4b2-4138-90f5-c847aebcf7f2">117,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTYtMTUtMS0xLTA_0d41acc7-f00c-4222-92dc-2ae002469e5a">27,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and common stock warrants, net of issuance costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b8fae89d58849ac8cd70c40f8a2da16_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="sls:StockIssuedDuringPeriodSharesCommonStockandWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTctNS0xLTEtMA_ac1dfd6a-5c63-4bc8-8872-c0d7ba4fd91e">786,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bbe90aea6ce4ba897f9a44f95d343af_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="sls:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTctOS0xLTEtMA_15b9cc10-0c3e-4e4d-ba1b-dcbf8a6db3c5">9,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="sls:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTctMTUtMS0xLTA_487bed4f-4072-4ff7-bc92-7e40cff9d095">9,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b8fae89d58849ac8cd70c40f8a2da16_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzItNS0xLTEtMA_62b9c314-cb4b-4a06-b23a-20abfce963c7">832,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b8fae89d58849ac8cd70c40f8a2da16_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzItNy0xLTEtMA_27840fe6-73f7-4788-818d-8c779ba4a779">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bbe90aea6ce4ba897f9a44f95d343af_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzItOS0xLTEtMA_6c98647a-6f9d-428c-a356-f3e747fd5267">3,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzItMTUtMS0xLTA_92263eb8-b041-43da-a900-2f1cff379333">3,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bbe90aea6ce4ba897f9a44f95d343af_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzYtOS0xLTEtMA_34898026-8e8c-4a6f-a617-6138cb0e9dab">448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzYtMTUtMS0xLTA_fcff96e2-d4cc-44da-b87a-d3022c393124">448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70c599afdc614f3482861b5c48fd1e0a_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzgtMTEtMS0xLTA_c487c86c-0c92-408b-b4a8-dadc1746ea57">7,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzgtMTUtMS0xLTA_c4a56b8c-cf02-4ae8-a7ee-2cd5038b8ed7">7,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9bb7f8716a0d4caaa768d3669f37d68e_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzktNS0xLTEtMA_81930e1d-4af9-4010-b9d8-57ac4ad92333">15,873,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bb7f8716a0d4caaa768d3669f37d68e_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzktNy0xLTEtMA_b59c2ada-f104-4b15-9cb0-22edf892b877">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbab7f5989004cf9a988181f7b725951_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzktOS0xLTEtMA_90e00d49-3c3a-4c41-afd2-3c7702db30be">158,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31ce168dc5e644718859ca9b623e68b2_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzktMTEtMS0xLTA_b5356c83-5266-4efd-8853-0f0583772a5d">124,920</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzktMTUtMS0xLTA_4d28616f-ae8a-47fa-a508-609f3df8d5df">33,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.786%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended June 30, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Stockholders' Equity (Deficit)</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibcdc516de7334f91b176b211161b8e6e_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNC01LTEtMS0w_4948232a-8d97-4517-bb04-d062ee704271">6,717,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcdc516de7334f91b176b211161b8e6e_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNC03LTEtMS0w_a5a7f297-e6bc-449a-92ca-bda8f4602b5c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfda986c11714d6bb1d5b24be92e2a2f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNC05LTEtMS0w_c769903b-a5eb-47a4-a8a3-9a733d27b66d">113,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia79f32850e854189b3295d67b790dcdf_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNC0xMS0xLTEtMA_6dc4d405-18b6-409a-af20-bc1b49e867cd">105,290</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660f1425ddfa4dda85f51c113de04b3e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNC0xNS0xLTEtMA_691e09e8-c0aa-4f1a-a3af-dc0ef6bfedd3">8,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b35a3bd1e0a4431b15acba6941f5f47_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjAtOS0xLTEtMA_ad28d0fe-6eaf-45f5-af3f-76504ac528be">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjAtMTUtMS0xLTA_cf797d95-b9a0-47c6-8308-a99bab84198b">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fcb89f394a14d90a5ea1862dbd7af35_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjItMTEtMS0xLTA_11b1b410-18af-43be-b7cc-5be6e10cbca4">4,425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjItMTUtMS0xLTA_6a039072-77cb-4658-9e14-94d04e7f4575">4,425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71259de5a94b42459fed552bab9b67b8_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjMtNS0xLTEtMA_9d25d86a-fcbc-4457-8f64-1a5e0944a18b">6,717,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71259de5a94b42459fed552bab9b67b8_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjMtNy0xLTEtMA_b909929a-3c68-49c2-b37d-bd72bb41c1c9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedd4733b3614b92b8f20aa69691c575_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjMtOS0xLTEtMA_350ccf36-3176-49b1-8aa2-34380ac0c16d">113,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2be78beb508f4988ae137bb70fb5e7c4_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjMtMTEtMS0xLTA_fd8ae7e3-9f0e-4c52-9a0b-5cd362a9b628">109,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icce1dd99c16b4ec291627c253ff14547_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjMtMTUtMS0xLTA_41ff6e0d-02db-4339-acad-4078bfccaa3d">3,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Stockholders' Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e81f95995f142afb3eaed854f43ad80_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjgtNS0xLTEtMA_88d619c4-7348-4cf9-9a62-300f31947496">5,080,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e81f95995f142afb3eaed854f43ad80_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjgtNy0xLTEtMA_9c5c37cd-6e11-4693-93c2-ef5edc5c33c4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea42d6c53bbb4f8783846d9ea9891e59_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjgtOS0xLTEtMA_9fbd6681-6b60-4186-9e3c-d63da2d3b73e">107,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id69a6adea6624cb7b4b433f41d4dc840_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjgtMTEtMS0xLTA_dda65829-2f2b-41c9-8583-fc0ce1ac625a">101,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce9074c50144420a1bfafad23e559d3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjgtMTUtMS0xLTA_5d77f897-c70f-42ad-b8d3-197741bc70ff">6,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and common stock warrants, net of issuance costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i939616e9c3844b8b81fb48909a77e68e_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="sls:StockIssuedDuringPeriodSharesCommonStockandWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjktNS0xLTEtMA_62e3250b-6793-4d04-9201-d8e5f9b2700b">1,189,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e24296575c34c609ccf83d3d2c409eb_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="sls:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjktOS0xLTEtMA_1c50f4a5-48c9-4a37-a22a-f50ef4ae2e19">5,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="sls:StockIssuedDuringPeriodValueCommonStockandWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjktMTUtMS0xLTA_8a45d524-70a7-4445-9ddd-7f6daf529f99">5,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of pre-funded warrants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i939616e9c3844b8b81fb48909a77e68e_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="sls:StockIssuedDuringPeriodSharesPrefundedWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDMtNS0xLTEtMA_c4b209aa-20b8-4267-ba62-387d88a59beb">448,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e24296575c34c609ccf83d3d2c409eb_D20200101-20200630" decimals="-3" name="sls:StockIssuedDuringPeriodValuePreFundedWarrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDMtOS0xLTEtMA_12aa4fc3-b00c-4ec2-917d-37ffc1439f9d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" name="sls:StockIssuedDuringPeriodValuePreFundedWarrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDMtMTUtMS0xLTA_97ad59ad-baf5-451e-aef8-c7ee5339fc24">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e24296575c34c609ccf83d3d2c409eb_D20200101-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDUtOS0xLTEtMA_355832b3-0de0-4913-93e5-f77cda6bb20d">291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDUtMTUtMS0xLTA_01a3f1ef-1ef2-4561-9a70-c09d70a21b72">291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e84c865aaab4f7d93617acbb36a98b3_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDgtMTEtMS0xLTA_bb8c8058-9679-4c80-bebb-8b04f977ebf1">8,568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDgtMTUtMS0xLTA_cbc91a82-bd56-43e2-9257-babf4ec35cab">8,568</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i71259de5a94b42459fed552bab9b67b8_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDktNS0xLTEtMA_eb8e2933-9276-4714-b29f-f5dec8e2bdb5">6,717,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71259de5a94b42459fed552bab9b67b8_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDktNy0xLTEtMA_f5bbec70-48f0-404d-b88f-cfc5e1ba6ca9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedd4733b3614b92b8f20aa69691c575_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDktOS0xLTEtMA_396283f1-4931-4fdf-9c4c-42716a9b3beb">113,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2be78beb508f4988ae137bb70fb5e7c4_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDktMTEtMS0xLTA_82e9a3af-a70d-4ce6-9543-ca09c786f989">109,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icce1dd99c16b4ec291627c253ff14547_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDktMTUtMS0xLTA_0892e8c1-8723-4f59-9c1d-07440d9219f4">3,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i45635ddbe06c42738d10dbb9cae11665_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands)</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMy0xLTEtMS0w_6914ba79-96ae-48af-bff8-fd29fb941397">7,016</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMy0zLTEtMS0w_764c4107-bb20-4c48-aa47-9a755c5a029c">8,568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustment to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMTUtMS0xLTEtMA_f21731ed-6c92-4ee1-b730-fc0b3ca59fa7">448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMTUtMy0xLTEtMA_fbfe9920-c0f7-413a-b959-b02c2af0207a">291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMTctMS0xLTEtMA_1f00e25e-727f-442b-a12f-ebd451efb6ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" name="sls:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMTctMy0xLTEtMA_871dea1c-b3e5-4ebd-aa85-ddf8f4735453">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of common stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" name="sls:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjEtMS0xLTEtMA_63207f70-20b9-411b-8e61-5e362327c1df">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" name="sls:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjEtMy0xLTEtMA_d349f1ee-92fc-43ae-9230-662127c73470">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" name="sls:ChangeInFairValueOfContingentPurchaseConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjMtMS0xLTEtMA_27d7df3c-909b-447a-9033-931f66ad6fad">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" sign="-" name="sls:ChangeInFairValueOfContingentPurchaseConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjMtMy0xLTEtMA_b2353062-bf95-4b89-8e9d-221802a92497">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjgtMS0xLTEtMA_ba14c70c-7ea7-480d-a882-6ad8e1c47176">1,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjgtMy0xLTEtMA_400f500e-c3a4-4053-8403-425088edec30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjktMS0xLTEtMA_1f69178a-6076-4eab-a993-dc93c73210cc">1,932</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjktMy0xLTEtMA_00a2d9de-c309-4fda-9253-6779946c6dfc">1,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMzItMS0xLTEtMA_a3ed8811-2662-456c-9f13-9f0ceac74b0a">2,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMzItMy0xLTEtMA_ca4e80e6-3329-458e-ad62-9a5c6142948f">1,476</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMzMtMS0xLTEtMA_f465601a-b041-4cfc-8112-7d01e0c4a3f2">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMzMtMy0xLTEtMA_090d39b4-3f07-4b44-ba92-1a0f707eb47e">638</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sls:IncreaseDecreaseInContractWithCustomerLiabilityNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMzQtMS0xLTEtMA_6ecefe3e-5b7d-4f84-91c5-500cbfd8e298">5,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="sls:IncreaseDecreaseInContractWithCustomerLiabilityNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMzQtMy0xLTEtMA_b3d7345d-ad06-4bd4-af57-abed9320efd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNDEtMS0xLTEtMA_ab5ccae1-da74-4bce-805f-f1cc924156b6">15,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNDEtMy0xLTEtMA_6ee1ded3-a3e6-4f52-ba55-728679074cfe">10,212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNTYtMS0xLTEtMA_18838a3c-d9ea-46b6-ab95-c275bd0fbd08">6,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNTYtMy0xLTEtMA_50a15c9e-f3f8-48cb-830a-a50b63d47fca">5,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collection of stock subscription receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ProceedsFromStockSubscriptionReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNTgtMS0xLTEtMA_f2e351a0-fa84-4f2d-a391-dab951f70cff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" name="sls:ProceedsFromStockSubscriptionReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNTgtMy0xLTEtMA_7267a79d-27ba-4bb9-a5c0-1d6d25f1a50c">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNTktMS0xLTEtMA_df5084ff-be71-42c7-9a12-237d84e559c9">3,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNTktMy0xLTEtMA_fb98d43f-7adf-403c-99ce-6e30f6469af8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNjctMS0xLTEtMA_3d428414-5278-45f5-b1a5-2582fbba3435">9,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNjctMy0xLTEtMA_d720ecd9-3525-4d21-af02-8ff98e8b63c4">6,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNjgtMS0xLTEtMA_e0edf785-0cf5-4e1f-9aae-bce18851e198">5,385</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNjgtMy0xLTEtMA_3f515a72-6481-442c-8bab-ec23b9a398c0">3,937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNjktMS0xLTEtMA_2955dbb6-2283-42d1-bfb5-2b27c3eff0d3">35,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ce9074c50144420a1bfafad23e559d3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNjktMy0xLTEtMA_5e810e4a-654e-4159-b49a-26f0f8d9ec34">7,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNzAtMS0xLTEtMA_41b2a588-d3de-47d4-9354-350125ee5620">30,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icce1dd99c16b4ec291627c253ff14547_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNzAtMy0xLTEtMA_e7799d7b-d5b7-4678-96ec-cc59b20b2f81">3,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash received during the period for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNzMtMS0xLTEtMA_b292f862-a1c6-4a8e-8a95-782a1414b043">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" name="us-gaap:ProceedsFromInterestReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNzMtMy0xLTEtMA_3803ab7b-c1c3-4006-87f4-8445c6106fb6">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock subscription receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="sls:StockSubscriptionReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNzctMS0xLTEtMA_8ae5da80-9023-4fc4-83c2-f99a389a6b5a">2,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="sls:StockSubscriptionReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNzctMy0xLTEtMA_00a0c1ff-be53-4885-89d8-a82f2b3e7e66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating right of use asset and current and non-current lease liability</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfODMtMS0xLTEtMA_8050ec6e-915a-41ce-98ce-2229c0f762ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfODMtMy0xLTEtMA_676b1f97-9073-40e0-a20f-21946c9364d7">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Offering expenses in accounts payable and accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:NoncashOfferingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfODUtMS0xLTEtMA_0fe7e716-9d96-4fc1-96b6-9082678d987a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" name="sls:NoncashOfferingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfODUtMy0xLTEtMA_d342fbe7-1af1-4b57-9945-feb8559ed50f">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i45635ddbe06c42738d10dbb9cae11665_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span><br/></span></div></div><div><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_34"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.  <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNC9mcmFnOjZkMTU3MTM2NGE2MTQ5ODU5ZTY0YWM1YWRhZDI0MjI2L3RleHRyZWdpb246NmQxNTcxMzY0YTYxNDk4NTllNjRhYzVhZGFkMjQyMjZfMzIyNg_5332fef3-da6c-4b05-b412-0e284128714f" continuedAt="icadec247acb3412d844f18322b714a3d" escape="true">Description of Business</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="icadec247acb3412d844f18322b714a3d" continuedAt="ic674ca29313f4df3aa7157305efc1b9f"><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SELLAS Life Sciences Group, Inc. (the "Company" or "SELLAS") is a late-stage clinical biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS&#8217; lead product candidate, galinpepimut-S ("GPS"), is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center ("MSK") and targets the Wilms Tumor 1 ("WT1") protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. SELLAS&#8217; second product candidate, nelipepimut-S ("NPS"), is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 ("HER2") expressing cancers with potential for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer ("TNBC") patients, following standard of care.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Quarterly Report on Form 10-Q, the words the "Company," and "SELLAS" refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following the completion of the business combination with Galena Biopharma, Inc., a Delaware corporation ("Galena"), and SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company ("Private SELLAS"), in December 2017. This business combination is referred to as the Merger. Upon completion of the Merger, the Company's name changed from "Galena Biopharma, Inc." to "SELLAS Life Sciences Group, Inc." and the Company's financial statements became those of Private SELLAS.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="ic674ca29313f4df3aa7157305efc1b9f">On March 11, 2020, the World Health Organization declared the outbreak of a new coronavirus to be a &#8220;pandemic&#8221;. The COVID-19 pandemic continues to present substantial public health and economic challenges around the world which have impacted, and will continue to impact, millions of individuals and business worldwide. Efforts to contain the spread of the coronavirus since March 2020 have led to travel bans and restrictions, quarantines, shelter-in-place orders and shutdowns. The Company is continuously monitoring the impact of the pandemic on its clinical development programs. The full extent to which the COVID-19 pandemic directly or indirectly impacts the Company's business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and cannot be predicted with confidence, including the actions taken to contain or treat COVID-19, the ultimate overall duration of the pandemic, the emergence of new variants of COVID-19, the emergence of new geographic hotspots where the coronavirus is spreading more rapidly, and continued or new travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, as well as the effectiveness of actions taken globally to contain and treat the coronavirus, including the availability of safe and effective vaccines and the uptake thereof and whether existing vaccines are effective with respect to new variants. In particular, the continued spread of the coronavirus globally could adversely impact the Company's clinical trial operations and could have an adverse impact on our business and the financial results.</ix:continuation>  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i45635ddbe06c42738d10dbb9cae11665_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.  <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:LiquidationBasisOfAccountingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMzY5NA_78654806-6cc2-47aa-a8be-798058457110" continuedAt="i5ba4b33a0d43404493a366c766f43d16" escape="true">Liquidity</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i5ba4b33a0d43404493a366c766f43d16"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has incurred recurring losses and negative cash flows from operations and, as of June&#160;30, 2021, has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTY0_f0f3c510-a855-4af7-94cb-c15f63055660">124.9</ix:nonFraction> million. During the six months ended June&#160;30, 2021, the Company used $<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMjQ0_81942550-0e75-4a8e-8e82-4ec51e93c7e0">15.2</ix:nonFraction> million of cash in operations which included a net loss of $<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTA5OTUxMTYzNjg0NA_8efb7f02-d14b-40e4-a97e-71b071c99a4c">7.0</ix:nonFraction> million, a $<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfNDM4_b989745c-2f7f-4906-89ef-a2727e719755">1.9</ix:nonFraction>&#160;million increase in prepaid expenses and other assets primarily for insurance and prepaid clinical trial costs, a $<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMzI5ODUzNDg4ODQ0Mw_77f38fb0-dc6d-44a4-89a3-95fb69fb1383">5.6</ix:nonFraction>&#160;million decrease in deferred revenue due to the recognition of licensing revenues and a $<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfNTUw_9cc6e35a-12e1-4071-b74a-0bb94b1d1e4c">2.5</ix:nonFraction>&#160;million decrease in accounts payable and accrued expenses and other current liabilities, partially offset by a $<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTA5OTUxMTYzNjMxNg_04d82ec0-5c9a-4ac4-8971-0224e5f135a2">1.1</ix:nonFraction>&#160;million decrease of contract acquisition costs related to the out-licensing of intellectual property rights and transfer of technical know-how and various net non-cash charges of $<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="sls:NonCashCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTA5OTUxMTYzNjY5Mw_94dd864e-0f90-4ea3-97ef-2524e6b5bd7d">0.7</ix:nonFraction>&#160;million. The Company expects to continue to generate operating losses and negative cash flows for the next few years and will need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful development, approval, and commercialization of the Company's product candidates and the achievement of a level of revenues adequate to support its cost structure.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2021, the Company entered into a Controlled Equity Offering</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald &amp; Co. (the "Agent"). From time to time during the term of the Sales Agreement, the Company may offer and sell shares of common stock having an aggregate offering price up to a total of $<ix:nonFraction unitRef="usd" contextRef="ie077fe8f1fa546518ab2e7996f804236_D20210416-20210416" decimals="-5" format="ixt:numdotdecimal" name="sls:SaleOfStockAuthorizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTM5NQ_20b8f93f-a846-4a64-a34c-49541c43e67d">50.0</ix:nonFraction>&#160;million in gross proceeds. The Agent will collect a fee equal to <ix:nonFraction unitRef="number" contextRef="ie077fe8f1fa546518ab2e7996f804236_D20210416-20210416" decimals="2" name="sls:SaleOfStockAgentFeePercentageOfGrossProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTQ1NQ_f733042c-cd17-4b45-aa27-c6560878a937">3</ix:nonFraction>% of the gross sales price of all shares of common stock sold. Shares of common stock sold under the Sales Agreement will be offered and sold pursuant to the Company's registration statement on Form S-3, which was filed with the SEC on April 16, 2021 and was declared effective on April 29, 2021. During the three months ended June&#160;30, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="ib40089611a434490a15e807711e0febb_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMzI5ODUzNDg4NzQzNg_a5db9cc9-c5db-48ab-b7ca-c4ba001de89b">786,927</ix:nonFraction> shares of common stock pursuant to the Sales Agreement at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d5ca04db51e482796a8bcd426e5cf11_I20210630" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMzI5ODUzNDg4NzQ0NQ_d49323b0-2aa3-47f4-9668-131a16c44a07">12.04</ix:nonFraction> per share for aggregate net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ib40089611a434490a15e807711e0febb_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMzI5ODUzNDg4NzQ1Mw_4b7b3826-a1a6-4250-aa69-c93686b081df">9.0</ix:nonFraction>&#160;million, of which approximately $<ix:nonFraction unitRef="usd" contextRef="ia6d6d49da9294db98abbd7d306232e0e_D20210701-20210731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMzI5ODUzNDg5MTAwNg_a483966e-95d9-4cd5-808d-6658097f3f21">2.2</ix:nonFraction>&#160;million in net proceeds were received in July 2021 and classified as a stock subscription receivable as of June 30, 2021. Other than the Sales Agreement, the Company currently does not have any commitments to obtain additional funds.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received $<ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="sls:ProceedsFromResearchAndDevelopmentArrangementMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTA5OTUxMTYzNDE3OQ_26054262-ac45-4232-a391-03735dd997f8">1.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="sls:ProceedsFromResearchAndDevelopmentArrangementMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTA5OTUxMTYzNDE5Mw_19b8c857-f04c-4927-bf2e-feb28bac2cb4">2.0</ix:nonFraction>&#160;million during the three and six months ended June&#160;30, 2021, respectively, for the achievement of certain development milestones pursuant to the Company's Exclusive License Agreement (the "3DMed License Agreement) with 3D Medicines, Inc. ("3DMed"). An additional $<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="sls:ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTA5OTUxMTYzNDIxMQ_ba378ef0-2daf-456e-85f4-910b8e31877d">192.5</ix:nonFraction>&#160;million in potential future certain development, regulatory, and sales milestones remains under the 3DMed License Agreement, which milestones are variable in nature and not under the Company's control. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company had cash and cash equivalents of approximately $<ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfNDk0NzgwMjMyOTU0OQ_232a370b-0a63-477f-8fd9-6a9b43c9caf0">29.9</ix:nonFraction>&#160;million, restricted cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfNDk0NzgwMjMyOTU2NA_7a1b14f1-84b6-42a1-984c-ca156d47a20d">0.1</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-5" format="ixt:numdotdecimal" name="sls:StockSubscriptionReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfNjA0NzMxMzk2MDczMg_2b78f71e-26d7-4e48-a796-8fcdeb196b43">2.2</ix:nonFraction>&#160;million of stock subscription receivable which cash was received in July 2021. In accordance with Accounting Standards Codification ("ASC") 205-40, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements - Going Concern</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company expects its cash and cash equivalents, together with access to the Sales Agreement to sell common stock, will be sufficient to fund current planned operations for at least the next 12 months from the date of issuance of these financial statements, though it may pursue additional capital resources through public or private equity or debt financings or by entering into additional license agreements or collaborations with other companies. Management's expectations with respect to its ability to fund current planned operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management's estimates, the Company may need to seek additional strategic or financing opportunities sooner than would otherwise be expected. There is no guarantee that any of these strategic or financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders. If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research and development programs or be unable to expand its operations or otherwise prepare for the potential regulatory approval and commercialization of its product candidates, assuming positive data.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_40"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.  <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfNTc1OQ_c2a612ac-f5da-4601-b85c-53911f665fc1" continuedAt="iebe00548de7b457e81fa2437c7416cbe" escape="true">Basis of Presentation and Significant Accounting Policies</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><ix:continuation id="iebe00548de7b457e81fa2437c7416cbe" continuedAt="i1a67368469ce40fd864ebbe59feb7e5c"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's complete summary of significant accounting policies can be found in "Item 8. Financial Statements and Supplementary Data - Note 3. Basis of Presentation and Significant Accounting Policies" in the audited annual consolidated financial statements included in the 2020 Annual Report. The significant accounting policies summarized and included in the 2020 Annual Report have not materially changed, except as set forth below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfNTc2NQ_21e20f3a-a983-4716-8e8f-393d1d318fa2" continuedAt="i5890fbb7ea5448a4bc552a095bf9bde3" escape="true">Basis of Presentation </ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5890fbb7ea5448a4bc552a095bf9bde3">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates of the Financial Accounting Standards Board ("FASB").</ix:continuation>  </span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfNTc1MA_d02a942f-32ce-4fdd-9129-c684a139af57" escape="true"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and its wholly owned subsidiaries, Private SELLAS, SLSG Limited, LLC, Sellas Life Sciences Limited, and Apthera, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unaudited Interim Results </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements and accompanying notes should be read in conjunction with the Company's annual consolidated financial statements and the notes thereto included in the 2020 Annual Report. The accompanying consolidated financial statements as of&#160;June&#160;30, 2021&#160;and for the three and six months ended June 30, 2021 and 2020, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December&#160;31, 2020 have been derived from the audited financial statements as of that date.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfMjc0ODc3OTA4NzE3Mg_72195f79-319d-4601-b059-78b4d4aa580b" escape="true"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassification</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on the Company's loss from operations, net loss, and net loss per share.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Subscription Receivable</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with FASB ASC 505-10-45-2, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables for Issuance of Equity</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded a stock subscription receivable as of June&#160;30, 2021 related to the sale, prior to June&#160;30, 2021 and before the financial statements are issued or available to be issued, of <ix:nonFraction unitRef="shares" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfMzI5ODUzNDkwMDc2MQ_328a2d19-71c1-4894-87c3-06c83d46ca71">157,130</ix:nonFraction> shares of common stock pursuant to the Sales Agreement for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="id8555ccfc9b945a59123f108d50b1d06_D20210702-20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfMzI5ODUzNDkwMDc3MA_76a383b0-0168-4998-bfa6-ef96863ab1d6">2.2</ix:nonFraction>&#160;million which cash was collected on July 2, 2021. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfNTc2Mg_53d14a5b-e824-4949-afa2-6d3968cddeb7" escape="true"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Time-Vested Restricted Stock Units</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, the Board of Directors granted restricted stock units ("RSUs") to employees that vest based on continuous service. Time-vested RSUs awarded to employees vest one-fourth per year annually over <ix:nonNumeric contextRef="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfMjQ2MQ_715b7cde-45e2-488c-86f1-1f55b1804af6">four years</ix:nonNumeric>, provided the employee remains employed with the Company. The fair values of the RSUs are measured on the date of grant and are based on the Company's closing stock price on such date. Compensation expense for RSUs with only service conditions is recognized straight-line over the applicable service period. The Company accounts for forfeitures of RSUs when they occur. Previously recognized compensation expense for forfeited RSUs are reversed in the period the RSUs are forfeited.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i1a67368469ce40fd864ebbe59feb7e5c"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfNTc1MQ_adc91650-c9f5-46d9-ad72-ebe38d4e52e0" escape="true"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfNTc2Mw_d000c513-93fa-46ab-999a-aa15dbd4ac2f" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95e27891b14a478b8f8be763dda2f1fd_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfMi0xLTEtMS0w_97fc7374-94e8-4b03-9ced-4737955a741d">559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if65aed140a5941fa9eab141c9d95f9be_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfMi0zLTEtMS0w_18ad59c3-d420-4efa-bd7d-2a73ce6eeb5d">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabe6e36564484068baac5e49c21a346e_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfMy0xLTEtMS0w_b182eb14-b3cb-4857-8785-6721b18515a2">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ab00b1183924bdb9188ae231bdbefd9_D20200101-20200630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfMy0zLTEtMS0w_71945545-14d6-42c6-8335-1d39733b31de">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i916c92e4c67d42dc92aa2fd9eccecc12_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfNC0xLTEtMS0w_5000c735-73b8-4c7a-9d18-5dd7138621a8">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i572c1e1b6c34427d95e51bbb5e40be56_D20200101-20200630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfNC0zLTEtMS0w_93e25ea7-0d71-48e4-8e79-a13a317cdf64">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfNS0xLTEtMS0w_070d8718-ce48-4471-b7a4-9d75feef2dca">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfNS0zLTEtMS0w_b19b6db7-9333-4022-a067-ba9976f63093">1,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfMjc0ODc3OTA4NzE2OQ_727d430b-a49b-4e67-a1da-7ec712993f10" escape="true"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Standards Adopted and Recent Accounting Standards Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Standards Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which, among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard was adopted by the Company on January 1, 2021. This new standard did not have a material impact on the Company&#8217;s financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting standards not yet adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which, among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument.  As a result, after adopting the ASU&#8217;s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (ii) a convertible debt instrument was issued at a substantial premium. The standard becomes effective for the Company in the first quarter of 2022 and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_43"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.  <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjU2NQ_3fce455a-bbfe-427f-95ac-50c91e73e28d" continuedAt="ia12eb4356e8f4dca96ce97967eb216d4" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ia12eb4356e8f4dca96ce97967eb216d4" continuedAt="ia1a4544fc0e34d27ae09c0b1797dcbf3"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjU3NA_0356fd4a-69fd-4d78-8289-21e3dde13e7b" continuedAt="i2eac94c77270427bb4feecec6d2ec4a4" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ia1a4544fc0e34d27ae09c0b1797dcbf3" continuedAt="i9489bc801bc74a67b26fa8e99c0ac948"><ix:continuation id="i2eac94c77270427bb4feecec6d2ec4a4"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted&#160;Prices&#160;In<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant&#160;Other<br/>Observable&#160;<br/>Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable&#160;<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id299f8f9d64c460fbab097e59032b733_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMi0xLTEtMS0w_71a595c5-16bf-4518-8e6d-1cfeed5fcc34">29,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b6583c6c4a4427a2154f30c7a4d759_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMi0zLTEtMS0w_ebe4cc8b-934a-465c-9058-315f9ba1fc75">29,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cfc63428564e92ac87c7615fb89ca7_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMi01LTEtMS0w_a7899169-0ddb-494e-9ff7-c7683b8f89a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ad3d82d21047e2a9bb504f8640be57_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMi03LTEtMS0w_b39af5c0-cc6a-42b7-b324-4bd581af9555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id299f8f9d64c460fbab097e59032b733_I20210630" decimals="-3" name="sls:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMy0xLTEtMS0w_442ca541-d060-4b5a-8e74-f216ef8d6f2c">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b6583c6c4a4427a2154f30c7a4d759_I20210630" decimals="-3" name="sls:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMy0zLTEtMS0w_02e5f224-4124-41f5-ba6c-749e719b67f7">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cfc63428564e92ac87c7615fb89ca7_I20210630" decimals="-3" format="ixt:zerodash" name="sls:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMy01LTEtMS0w_8d92dc21-9b9e-4b07-bc07-434f7df2be1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ad3d82d21047e2a9bb504f8640be57_I20210630" decimals="-3" format="ixt:zerodash" name="sls:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMy03LTEtMS0w_ed894c25-fba4-487c-ab77-d8fdf1d7a2e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured and recorded at fair value</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id299f8f9d64c460fbab097e59032b733_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNC0xLTEtMS0w_c0aabafd-c69e-4ac5-afcf-829158bd69e6">29,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b6583c6c4a4427a2154f30c7a4d759_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNC0zLTEtMS0w_bd1c111f-7f42-4176-8573-af1a4780de8e">29,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cfc63428564e92ac87c7615fb89ca7_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNC01LTEtMS0w_a79358a1-d38d-4def-94af-d14a6cd7059e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ad3d82d21047e2a9bb504f8640be57_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNC03LTEtMS0w_4b843023-70eb-4010-8f89-448670de4489">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id299f8f9d64c460fbab097e59032b733_I20210630" decimals="-3" name="sls:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNi0xLTEtMS0w_d05e7a54-24bd-40da-86d7-f319776e30a6">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b6583c6c4a4427a2154f30c7a4d759_I20210630" decimals="-3" format="ixt:zerodash" name="sls:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNi0zLTEtMS0w_ae2dbb5f-df3f-4dba-a205-38a545b91981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cfc63428564e92ac87c7615fb89ca7_I20210630" decimals="-3" format="ixt:zerodash" name="sls:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNi01LTEtMS0w_6b40098e-573e-400d-a284-25b88b1c18a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ad3d82d21047e2a9bb504f8640be57_I20210630" decimals="-3" name="sls:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNi03LTEtMS0w_9bf51a2a-3105-45ab-9e2e-bad900a1bc6d">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id299f8f9d64c460fbab097e59032b733_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNy0xLTEtMS0w_587d4eeb-2c35-46be-ab8f-14c96496dcda">4,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b6583c6c4a4427a2154f30c7a4d759_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNy0zLTEtMS0w_a8407dc2-a643-4f2b-b7a5-97a9ce9628ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cfc63428564e92ac87c7615fb89ca7_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNy01LTEtMS0w_494b99eb-cc1b-4695-b6e3-395b36fcdcb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ad3d82d21047e2a9bb504f8640be57_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNy03LTEtMS0w_fe009ec5-4f48-43a3-9c56-a66c167e358f">4,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured and recorded at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id299f8f9d64c460fbab097e59032b733_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfOC0xLTEtMS0w_13e6f538-69df-43c3-a015-248d43ddc816">5,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20b6583c6c4a4427a2154f30c7a4d759_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfOC0zLTEtMS0w_91d9593a-0d51-4680-8f5d-fa7a1222a847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2cfc63428564e92ac87c7615fb89ca7_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfOC01LTEtMS0w_8708f7e2-89d2-4bed-af27-fe3bbfc83768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63ad3d82d21047e2a9bb504f8640be57_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfOC03LTEtMS0w_05e38a90-4774-4416-b3c6-8a7711598434">5,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted&#160;Prices&#160;In&#160;&#160;<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant&#160;Other<br/>Observable&#160;<br/>Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable&#160;<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e62635663940f0a1122ae9dd5b94de_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMi0xLTEtMS0w_0af49403-c08b-46d2-94a9-5048b30cbdc9">34,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14237fe221f44d34a5583869de1d051e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMi0zLTEtMS0w_9f0a8ddb-b904-4257-a020-482f26f90889">34,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b95e026b9d4e318900dfe9940adf09_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMi01LTEtMS0w_036350e1-1de2-4241-9ec4-e15e2f8f93f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa99ebdccce94e8caa2de707cacf92af_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMi03LTEtMS0w_efa661e7-d2bf-484f-831c-21a795346fca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e62635663940f0a1122ae9dd5b94de_I20201231" decimals="-3" name="sls:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMy0xLTEtMS0w_5a087169-c1b9-412a-bce6-47a7ab1bb62c">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14237fe221f44d34a5583869de1d051e_I20201231" decimals="-3" name="sls:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMy0zLTEtMS0w_cd3a13b1-191c-4206-b5eb-d9d47f47d548">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b95e026b9d4e318900dfe9940adf09_I20201231" decimals="-3" format="ixt:zerodash" name="sls:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMy01LTEtMS0w_8657931d-24f7-4155-8c16-03d59e83b1a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa99ebdccce94e8caa2de707cacf92af_I20201231" decimals="-3" format="ixt:zerodash" name="sls:RestrictedCashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMy03LTEtMS0w_c6f11b02-9887-4093-b9d8-037254d49869">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured and recorded at fair value</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e62635663940f0a1122ae9dd5b94de_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNC0xLTEtMS0w_49046f1b-c9d7-4477-a114-0c24250ac0e3">35,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14237fe221f44d34a5583869de1d051e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNC0zLTEtMS0w_50335553-136e-4a5d-ab44-ee737adad062">35,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b95e026b9d4e318900dfe9940adf09_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNC01LTEtMS0w_0fd5d69b-0a3c-4442-b1fb-e5af8222207f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa99ebdccce94e8caa2de707cacf92af_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNC03LTEtMS0w_a6a3a285-4857-4f4b-9784-76f531f9e325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e62635663940f0a1122ae9dd5b94de_I20201231" decimals="-3" name="sls:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNi0xLTEtMS0w_a73dfa62-13bb-4390-80f7-f9665f1aa476">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14237fe221f44d34a5583869de1d051e_I20201231" decimals="-3" format="ixt:zerodash" name="sls:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNi0zLTEtMS0w_4b412776-39ad-45dc-b098-e81415a2f8b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b95e026b9d4e318900dfe9940adf09_I20201231" decimals="-3" format="ixt:zerodash" name="sls:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNi01LTEtMS0w_582d234a-97c8-4c5b-a08e-2ca9179a1ceb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa99ebdccce94e8caa2de707cacf92af_I20201231" decimals="-3" name="sls:FairValueOfWarrantsPotentiallySettleableInCash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNi03LTEtMS0w_5c069086-c304-461b-853d-6ab9129522ba">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e62635663940f0a1122ae9dd5b94de_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNy0xLTEtMS0w_05c484e2-85ff-4189-81df-05c956024678">4,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14237fe221f44d34a5583869de1d051e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNy0zLTEtMS0w_676f287a-614d-4d6a-a499-edb1afaa02b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b95e026b9d4e318900dfe9940adf09_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNy01LTEtMS0w_5ad11e73-f227-469c-ac6e-cb41900684ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa99ebdccce94e8caa2de707cacf92af_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNy03LTEtMS0w_2aaa8652-99d1-4786-9621-58fbb956fbfb">4,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured and recorded at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94e62635663940f0a1122ae9dd5b94de_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfOC0xLTEtMS0w_69dc8531-2277-42b4-807d-bb1c9f770122">4,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14237fe221f44d34a5583869de1d051e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfOC0zLTEtMS0w_73db9f60-dcc5-447c-b02a-4320efb912f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b95e026b9d4e318900dfe9940adf09_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfOC01LTEtMS0w_d93b1c35-0c2f-4f93-a550-931701180cb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa99ebdccce94e8caa2de707cacf92af_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfOC03LTEtMS0w_710dd59b-fcea-4485-a2b9-a043a08fde85">4,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not transfer any financial instruments into or out of Level 3 classification during the six months ended June&#160;30, 2021 or during the year ended December 31, 2020.  See Note 8, Warrants to Acquire Shares of Common Stock, for a reconciliation of the changes in the fair value of the warrant liability for the six months ended June&#160;30, 2021. </span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjU4OA_8fb54975-c26e-4a11-a12f-b9dd6664f4a3" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in the fair value of the contingent consideration liability for the six months ended June&#160;30, 2021 is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value<br/>Measurements<br/>Using&#160;Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae6ab8b28e8405fb45e31fe8cff6e47_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOmJkMGYwNjk0NjNlMjQ5NjQ5YjJiN2M3NDRiNTc2MWM2L3RhYmxlcmFuZ2U6YmQwZjA2OTQ2M2UyNDk2NDliMmI3Yzc0NGI1NzYxYzZfMS0xLTEtMS0w_e24ec615-2751-460d-a088-41406c48bd8a">4,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the estimated fair value of the contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a0e682866c4ad485eb808d137a33a4_D20210101-20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOmJkMGYwNjk0NjNlMjQ5NjQ5YjJiN2M3NDRiNTc2MWM2L3RhYmxlcmFuZ2U6YmQwZjA2OTQ2M2UyNDk2NDliMmI3Yzc0NGI1NzYxYzZfMi0xLTEtMS0w_92715dc6-8f41-430a-b012-2a54f950f971">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69f52ca633da4c9fa61aac1b2d469ba6_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOmJkMGYwNjk0NjNlMjQ5NjQ5YjJiN2M3NDRiNTc2MWM2L3RhYmxlcmFuZ2U6YmQwZjA2OTQ2M2UyNDk2NDliMmI3Yzc0NGI1NzYxYzZfMy0xLTEtMS0w_42711eee-cce1-44d9-af21-bb4945f9ad9a">4,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena's acquisition of Apthera, Inc. in 2011 and the future contingent payments of up to $<ix:nonFraction unitRef="usd" contextRef="i707b6253a0f14414a1bc6beca9cc2c6f_I20111231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfOTcy_49693db4-c947-40b9-86cc-ee5f33e21d0c">32.0</ix:nonFraction> million based on the achievement of certain development and commercial milestones relating to the Company&#8217;s NPS product candidate, of which $<ix:nonFraction unitRef="usd" contextRef="ibb2e72136f1d4a248d844448ac121df9_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMTEwNw_6fc5c1a2-3e89-43a7-82c3-598f87ccc7cd">2.0</ix:nonFraction> million has been paid to date. The remaining contingent consideration of up to $<ix:nonFraction unitRef="usd" contextRef="i2bdb237db5d747d296f136aa84ea8854_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMTE4MQ_2618d687-8b80-448e-bb87-98247a84cb2e">30.0</ix:nonFraction> million is payable at the election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration, unless it has first obtained approval from its stockholders in accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9489bc801bc74a67b26fa8e99c0ac948">The significant unobservable assumptions include the probability of achieving each milestone, the date the Company expects to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. Changes in fair value reflect new information about the probability and anticipated timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time. As of June&#160;30, 2021, estimated future contingent milestone payments related to the Company's business range from <ix:nonFraction unitRef="usd" contextRef="i2bdb237db5d747d296f136aa84ea8854_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjEzOQ_8f0b76f5-c9aa-4a89-bda9-62a2d29c8e79">zero</ix:nonFraction>, if no milestone events are achieved, to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i2bdb237db5d747d296f136aa84ea8854_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjE5Ng_2e4a4412-9ee4-4529-a9f1-b8aa4cf550fd">30.0</ix:nonFraction> million if all development and commercial milestones are reached. As of June&#160;30, 2021, resulting probability-weighted cash flows were discounted using a weighted average cost of capital of <ix:nonFraction unitRef="number" contextRef="i09934cd16082484c8827742d0199f8e8_I20210630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjM2OQ_92b6b7d3-434f-403a-98a5-282e9b0158e8">11.8</ix:nonFraction>% for development milestones and cost of debt of <ix:nonFraction unitRef="number" contextRef="i25cd3b9620c54b4e9fce77a21dc1f63f_I20210630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjQxOQ_4826bd97-a30f-44c9-b3ad-817148375f08">5.4</ix:nonFraction>% for the commercial milestones. The Company estimates the timing of achievement of these development milestones to range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjU0Nw_9e3118b3-4753-413f-9bca-561259d241ac">five</span> to <ix:nonNumeric contextRef="i1a03f8fd056b46cbb0fb3aa49612a705_D20210101-20210630" format="ixt-sec:durwordsen" name="sls:BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjU1Mw_75a8de2e-52de-45db-ab41-a8cb258a6b5d">eight years</ix:nonNumeric> as of June&#160;30, 2021.</ix:continuation></span></div><div><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_46"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.  <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RleHRyZWdpb246NTAyY2NjYjJiMmZhNDc3MWE1YTNhODA2YmIyY2Q4ZTJfMjEx_3bb356c0-3c18-40ca-85b0-eaa86ccf7931" continuedAt="i926c7d45bc0f475fbafdeac19697baf2" escape="true">Balance Sheet Accounts</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i926c7d45bc0f475fbafdeac19697baf2"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RleHRyZWdpb246NTAyY2NjYjJiMmZhNDc3MWE1YTNhODA2YmIyY2Q4ZTJfMjIx_71cb7e51-31fa-432a-b9af-560ea3c1465b" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfMS0xLTEtMS0w_62d99996-99e4-42b9-8a81-fff984e7adf8">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfMS0zLTEtMS0w_fa931aaa-078f-42b0-8cdb-ac84cca0ca21">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="sls:PrepaidResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfMi0xLTEtMS0w_188e8dbf-fdbb-42e5-b724-4d2dd0114bfe">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="sls:PrepaidResearchAndDevelopment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfMi0zLTEtMS0w_6bca4430-dc09-408c-9031-bbb2974496ea">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="sls:PrepaidProfessionalServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfMy0xLTEtMS0w_c96023b6-9a89-48f0-8f41-8742937f6b00">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="sls:PrepaidProfessionalServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfMy0zLTEtMS0w_f4a7b2a7-b6af-4c70-b8e9-cc530fefdb09">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfNC0xLTEtMS0w_f4946eaa-1ca1-47f5-94b6-0daa59464572">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfNC0zLTEtMS0w_5315b071-73a0-4cbd-84cb-091c27a72a62">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfNS0xLTEtMS0w_38b920f9-6252-4ee4-8665-c3ba6cc53133">2,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfNS0zLTEtMS0w_850899b5-c8bd-42f9-be98-e309053d0a51">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RleHRyZWdpb246NTAyY2NjYjJiMmZhNDc3MWE1YTNhODA2YmIyY2Q4ZTJfMjA5_26546c15-fb6b-49c0-ba86-ab97ab5b72cd" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="sls:ContractResearchPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMS0xLTEtMS0w_fd9ad198-2210-47c2-95d9-6b56734599a2">806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="sls:ContractResearchPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMS0zLTEtMS0w_39278edd-fea7-43f8-80c3-431a564ac9d1">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMi0xLTEtMS0w_8d1346f7-2aa7-47b8-8f72-ec975b48207c">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMi0zLTEtMS0w_b4cc87b3-ed15-49b2-ac19-19ba688e6780">812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMy0xLTEtMS0w_e2785f3b-ce9b-48ef-a8b2-217d5d4e7cc4">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMy0zLTEtMS0w_82369057-8638-4bb5-b6c1-29b7c8c46ca4">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMTMtMS0xLTEtMA_904d76f6-630b-4e21-92b8-d4b9d04660da">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMTMtMy0xLTEtMA_6d5a67bb-e537-4002-9710-a07228dea771">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMTUtMS0xLTEtMA_11eec0b7-5e11-467a-b3c8-dda7eb543a82">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMTUtMy0xLTEtMA_6c9cb4f1-5a70-4436-ac62-3719ca43b578">1,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_49"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfNTk5Ng_e8e9f5aa-965d-4e80-a371-9c8ca508d8c6" continuedAt="ibdbb9d480f00433c81fd15c788335aab" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><ix:continuation id="ibdbb9d480f00433c81fd15c788335aab" continuedAt="ie925e99b32174ca8be87d2fec5efda21"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a non-cancelable operating lease for certain executive, administrative, and general business office space for its headquarters in New York, New York, which began on June 5, 2020 and has a term through December 31, 2024. The discount rate of the Company's operating lease under ASC 842: </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the Company's estimated incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="ia44788b499c14745a5543c4a56408ada_I20210630" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfNzIz_12bb03e8-6e97-4eee-a9f2-b004b4c5dd54">13</ix:nonFraction>%. As of June&#160;30, 2021, the lease has a remaining term of <ix:nonNumeric contextRef="i06156e81794f42c1a865af738d386a08_D20210101-20210630" format="ixt-sec:duryear" name="sls:OperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfNzcx_779b224f-3b43-401e-b4f8-40a2cff6a569">3.5</ix:nonNumeric> years.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense related to the Company's operating lease was approximately $<ix:nonFraction unitRef="usd" contextRef="i9b25700382c9420ca66cff20eaedf21a_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfODQ4_eccf3f29-7b89-4d00-ab4f-a284c94b767b"><ix:nonFraction unitRef="usd" contextRef="i375c691af6b54e09a2f25fecd7b8dc1a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfODQ4_fcf85631-0550-4c1d-9dee-38835dbca1fa">0.1</ix:nonFraction></ix:nonFraction> million for each of the three months ended June&#160;30, 2021 and 2020 and $<ix:nonFraction unitRef="usd" contextRef="i06156e81794f42c1a865af738d386a08_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfMzI5ODUzNDg4OTkwNg_84537e26-01aa-465c-8ba5-728fe7158301">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0c3f2fed3a4c4b6cb082afcd2c660434_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfMTA5OTUxMTYzNDUyMQ_89a35c1f-3661-412a-ae38-5443444d7147">0.2</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> f</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the six months ended June&#160;30, 2021 and 2020, respectively. The Company made cash payments related to its operating lease of approximately $<ix:nonFraction unitRef="usd" contextRef="i375c691af6b54e09a2f25fecd7b8dc1a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfOTc2_96f2a6bf-2162-414f-ad6e-42f90369f8a0"><ix:nonFraction unitRef="usd" contextRef="i9b25700382c9420ca66cff20eaedf21a_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfOTc2_c20b6d4c-5dd3-4f3f-8464-dd61a595e6d9">0.1</ix:nonFraction></ix:nonFraction>&#160;million for each of the three months ended June&#160;30, 2021 and 2020 and $<ix:nonFraction unitRef="usd" contextRef="i06156e81794f42c1a865af738d386a08_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfMzI5ODUzNDg4OTk3Mw_4e75e646-bc5c-4389-a8fd-ce4440f07906"><ix:nonFraction unitRef="usd" contextRef="i0c3f2fed3a4c4b6cb082afcd2c660434_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfMzI5ODUzNDg4OTk3Mw_b3b0d62e-8fd8-427f-a803-60b3ddae9ada">0.2</ix:nonFraction></ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for each of</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the six months ended June&#160;30, 2021 and 2020. <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfNjAwMQ_823b3ba8-3102-407b-838c-d3aec9f72367" continuedAt="i2cb4ccaecbbe402799fa6373f0973793" escape="true">Future minimum lease payments under the Company's non-cancelable operating lease are as follows as of June&#160;30, 2021 (in thousands):</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i2cb4ccaecbbe402799fa6373f0973793"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum lease payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RhYmxlOmNmZDUzY2EyYmFkMzQzMGM4YmZmNjU4YWIyMmE5YmI5L3RhYmxlcmFuZ2U6Y2ZkNTNjYTJiYWQzNDMwYzhiZmY2NThhYjIyYTliYjlfMS0yLTEtMS0w_8f08b19e-e8ce-4886-b042-40b0379fcfc1">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RhYmxlOmNmZDUzY2EyYmFkMzQzMGM4YmZmNjU4YWIyMmE5YmI5L3RhYmxlcmFuZ2U6Y2ZkNTNjYTJiYWQzNDMwYzhiZmY2NThhYjIyYTliYjlfMi0yLTEtMS0w_59f99fce-eb1f-40a3-af17-975e533b2968">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RhYmxlOmNmZDUzY2EyYmFkMzQzMGM4YmZmNjU4YWIyMmE5YmI5L3RhYmxlcmFuZ2U6Y2ZkNTNjYTJiYWQzNDMwYzhiZmY2NThhYjIyYTliYjlfMy0yLTEtMS0w_a1266a3a-185f-4fca-a80d-c6fab90d0a6a">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RhYmxlOmNmZDUzY2EyYmFkMzQzMGM4YmZmNjU4YWIyMmE5YmI5L3RhYmxlcmFuZ2U6Y2ZkNTNjYTJiYWQzNDMwYzhiZmY2NThhYjIyYTliYjlfNC0yLTEtMS0w_abe8c841-7451-4232-a025-6dbf9e94feb8">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RhYmxlOmNmZDUzY2EyYmFkMzQzMGM4YmZmNjU4YWIyMmE5YmI5L3RhYmxlcmFuZ2U6Y2ZkNTNjYTJiYWQzNDMwYzhiZmY2NThhYjIyYTliYjlfNS0yLTEtMS0w_55c05738-6c5c-4b7c-9a00-4fc3c4b4bef7">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RhYmxlOmNmZDUzY2EyYmFkMzQzMGM4YmZmNjU4YWIyMmE5YmI5L3RhYmxlcmFuZ2U6Y2ZkNTNjYTJiYWQzNDMwYzhiZmY2NThhYjIyYTliYjlfNi0yLTEtMS0w_2b25647b-ce8a-4edb-a993-c14fd4227b61">211</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current and non-current operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RhYmxlOmNmZDUzY2EyYmFkMzQzMGM4YmZmNjU4YWIyMmE5YmI5L3RhYmxlcmFuZ2U6Y2ZkNTNjYTJiYWQzNDMwYzhiZmY2NThhYjIyYTliYjlfNy0yLTEtMS0w_681d2651-15c3-472c-b867-40a6ba315b4f">903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company&#8217;s consolidated results of operations, financial position or cash flows. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s predecessor company, Galena, was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal. The remaining legal proceedings to which the Company is now subject are as follows: </span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ie925e99b32174ca8be87d2fec5efda21"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2017, certain putative shareholder securities class action complaints were filed in federal court alleging, among other things, that Galena and certain of Galena's former officers and directors failed to disclose that Galena&#8217;s promotional practices for Abstral&#174; (fentanyl sublingual tablets) were allegedly improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena&#8217;s statements about its business misleading. The actions were consolidated, lead plaintiffs were named by the U.S. District Court for the District of New Jersey and a consolidated complaint was filed. The Company filed a motion to dismiss the consolidated complaint. On August 21, 2018, the Company's motion to dismiss the consolidated complaint was granted without prejudice to file an amended complaint. On September 20, 2018, the plaintiffs filed an amended complaint. On October 22, 2018, the Company filed a motion to dismiss the amended complaint. On November 13, 2019, the U.S. District Court for the District of New Jersey granted the Company's motion to dismiss without prejudice to file an amended complaint. On December 20, 2019, the lead plaintiffs filed a second Amended Consolidated Class Action Complaint. On January 29, 2020, the Company filed a motion to dismiss the amended complaint. On January 5, 2021, the U.S. District Court for the District of New Jersey granted the Company's motion to dismiss without prejudice to file an amended complaint. On February 18, 2021, the lead plaintiffs filed a third Amended Consolidated Class Action Complaint. The Company has reached a settlement in principle with the plaintiffs in this action which is subject to final documentation and court approval and which will be fully covered by the Company's directors and officers insurance policy applicable to this case.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors and Galena, as a nominal defendant. In July 2017, a derivative complaint was filed in California state court against the Company&#8217;s former directors and Galena, as a nominal defendant. In January 2018, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors, officers and employees, and the Company as a nominal defendant. These complaints purport to assert derivative claims for breach of fiduciary duty on the Company&#8217;s behalf against the Company&#8217;s former directors and, in certain of the complaints, the Company&#8217;s current directors, and the Company&#8217;s former officers and former employees, based on substantially similar facts as alleged in the putative shareholder securities class action complaints mentioned above. The derivative lawsuit filed in California state court is currently stayed pending resolution of a motion to dismiss in the referenced securities class action. On July 13, 2020 and July 16, 2020, respectively, the Company filed motions to dismiss the <ix:nonFraction unitRef="complaint" contextRef="i880559595c4c4de0b7dc3629958abd33_D20200713-20200716" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LossContingencyClaimsDismissedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfNTc2MA_7f7a6fed-a7a2-4615-a5b9-577ace19024f">two</ix:nonFraction> complaints filed in the U.S. District Court for the District of New Jersey. The Company has reached a settlement in principle with the plaintiffs in these three cases which is subject to final documentation and court approval and which will be fully covered by the Company's directors and officers insurance policy applicable to these cases.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_52"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.  <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RleHRyZWdpb246Y2EyYTlhY2Y2YWIwNDYwZWEyMTVkMGI1MGUwZThjMzVfMzg1_243c5237-31f5-4c16-837d-5e9f7c761c63" continuedAt="ib1068226af23443b95d1d5121e1f1c89" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><div style="text-indent:49.5pt"><span><br/></span></div><ix:continuation id="ib1068226af23443b95d1d5121e1f1c89"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized up to <ix:nonFraction unitRef="shares" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RleHRyZWdpb246Y2EyYTlhY2Y2YWIwNDYwZWEyMTVkMGI1MGUwZThjMzVfODE_0f387138-d0dd-4b19-8d8a-dedcad62c8cc">5,000,000</ix:nonFraction>&#160;shares of preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RleHRyZWdpb246Y2EyYTlhY2Y2YWIwNDYwZWEyMTVkMGI1MGUwZThjMzVfMTEx_70efc906-4941-489b-9a29-77c8da908962">0.0001</ix:nonFraction>&#160;par value per share, for issuance. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized up to <ix:nonFraction unitRef="shares" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RleHRyZWdpb246Y2EyYTlhY2Y2YWIwNDYwZWEyMTVkMGI1MGUwZThjMzVfMzI5ODUzNDg4Mzc5Ng_37d58a8c-ab83-4b6c-8e6b-360c78b44294">350,000,000</ix:nonFraction>&#160;shares of common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RleHRyZWdpb246Y2EyYTlhY2Y2YWIwNDYwZWEyMTVkMGI1MGUwZThjMzVfMjI2_8c67aaff-5d65-4797-95da-c18e4b49afbc">0.0001</ix:nonFraction>&#160;par value per share, for issuance. </span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="sls:CommonStockAreReservedForFutureIssuanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RleHRyZWdpb246Y2EyYTlhY2Y2YWIwNDYwZWEyMTVkMGI1MGUwZThjMzVfMzc2_be9bb6b8-5fbc-4d57-9c14-ed40a4927db2" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company has shares of common stock reserved for future issuance as follows (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RhYmxlOmQ5ZGEwNTk4NmZkYzQyNDA4NzA4ZGQwZWQ2NTg2Mzk1L3RhYmxlcmFuZ2U6ZDlkYTA1OTg2ZmRjNDI0MDg3MDhkZDBlZDY1ODYzOTVfMC0xLTEtMS0w_0638aa43-a62a-43c1-aebc-dd339c4a18bf">559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RhYmxlOmQ5ZGEwNTk4NmZkYzQyNDA4NzA4ZGQwZWQ2NTg2Mzk1L3RhYmxlcmFuZ2U6ZDlkYTA1OTg2ZmRjNDI0MDg3MDhkZDBlZDY1ODYzOTVfMi0xLTEtMS0w_6deb8795-c87b-48d7-b335-41e04123f24b">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i111b00fe2e9a484ab732132f92c59d7e_I20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RhYmxlOmQ5ZGEwNTk4NmZkYzQyNDA4NzA4ZGQwZWQ2NTg2Mzk1L3RhYmxlcmFuZ2U6ZDlkYTA1OTg2ZmRjNDI0MDg3MDhkZDBlZDY1ODYzOTVfMy0xLTEtMS0w_b7789d16-2764-4e42-9e54-3644a0d51697">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Company&#8217;s 2019 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09f2e17d90504212b4f4df2b5b769f5f_I20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RhYmxlOmQ5ZGEwNTk4NmZkYzQyNDA4NzA4ZGQwZWQ2NTg2Mzk1L3RhYmxlcmFuZ2U6ZDlkYTA1OTg2ZmRjNDI0MDg3MDhkZDBlZDY1ODYzOTVfNC0xLTEtMS0w_45242d98-966b-47c4-a4a2-f41a10fc1a9c">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the 2021 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b1a536e4ed7497d9180567e5c395379_I20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RhYmxlOmQ5ZGEwNTk4NmZkYzQyNDA4NzA4ZGQwZWQ2NTg2Mzk1L3RhYmxlcmFuZ2U6ZDlkYTA1OTg2ZmRjNDI0MDg3MDhkZDBlZDY1ODYzOTVfNS0xLTEtMS0xMDI4_e344a617-605c-4ae9-9e81-eee23bbbebfa">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the 2017 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53f109f3f922470f8caedb485b977400_I20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RhYmxlOmQ5ZGEwNTk4NmZkYzQyNDA4NzA4ZGQwZWQ2NTg2Mzk1L3RhYmxlcmFuZ2U6ZDlkYTA1OTg2ZmRjNDI0MDg3MDhkZDBlZDY1ODYzOTVfNS0xLTEtMS0w_fa7564b8-0255-4965-baee-0a31a4d8ff9e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RhYmxlOmQ5ZGEwNTk4NmZkYzQyNDA4NzA4ZGQwZWQ2NTg2Mzk1L3RhYmxlcmFuZ2U6ZDlkYTA1OTg2ZmRjNDI0MDg3MDhkZDBlZDY1ODYzOTVfNy0xLTEtMS0w_32869fac-7afd-4602-804b-9ead6ae96884">2,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_58"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.  <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RleHRyZWdpb246NjQ3N2ZjYWQwM2NlNGNiN2ExYmJhZmQ5NjY3ZTZiYWVfMjY5Mw_b8535618-c0f4-4833-8283-992d233c7618" continuedAt="i6d85b184720145be9e3d151f2c5c1343" escape="true">Warrants to Acquire Shares of Common Stock</ix:nonNumeric></span></div><div style="text-indent:49.5pt"><span><br/></span></div><ix:continuation id="i6d85b184720145be9e3d151f2c5c1343" continuedAt="i70ba2778a85d47769488d8f2f9a3d153"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants Outstanding</span></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="sls:ScheduleOfWarrantActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RleHRyZWdpb246NjQ3N2ZjYWQwM2NlNGNiN2ExYmJhZmQ5NjY3ZTZiYWVfMjcwMw_4071b8b0-46cb-4e32-952a-42eaff901470" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity of the Company's warrants to acquire shares of common stock for the six months ended June&#160;30, 2021 (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled/Expired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2020 PIPE Offering</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b57b69674ea45d89f949a22963281ef_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMS0xLTEtMS0w_4c057fc2-fbe0-4aa1-843f-a5c7a7bac98b">445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i382d0ff9116248889bfe35c9548bb1ad_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMS0zLTEtMS0w_09ec37ac-0b7c-4d58-b921-2ca83090c62d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i382d0ff9116248889bfe35c9548bb1ad_D20210101-20210630" decimals="-3" name="sls:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMS01LTEtMS0w_e16bb4d6-9ab0-4c07-8756-1c5f44e7ef52">420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i382d0ff9116248889bfe35c9548bb1ad_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMS03LTEtMS0w_16adfdaf-981a-41c2-a501-924a39eb4b78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1696facd34e04e7fabcf3bf12a67fc37_I20210630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMS05LTEtMS0w_f9665c58-b401-4d22-8152-f6005f42f084">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2020 Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i055485f92470418a8842a2c2ea3403fc_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMi0xLTEtMS0w_269f580c-3a34-4b78-be74-b7717ea4932d">719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae1ab75d176f43859c532c0d5a6b9757_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMi0zLTEtMS0w_231ff82d-0b59-42c5-82ac-6f642331c828">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iae1ab75d176f43859c532c0d5a6b9757_D20210101-20210630" decimals="-3" name="sls:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMi01LTEtMS0w_70ab27d2-2170-4961-8d03-fb8ff3a0cf53">410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae1ab75d176f43859c532c0d5a6b9757_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMi03LTEtMS0w_34fa09bf-5abe-4bb7-afc9-8c3c8f5528dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1abab26a331b4d2bbc52b859b5ddb6d1_I20210630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMi05LTEtMS0w_0db177f4-04db-4da6-82b1-91ab119b91b8">309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2025</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2019 Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27b4f5e1ef5b476eb4b27190b75d9193_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNC0xLTEtMS0w_5174844c-710b-4eac-884b-43f472062042">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1602f66b4bcd4b2fa1f1a8b24f7dd4e1_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNC0zLTEtMS0w_c494605c-b7f3-4a4d-b553-59c3df797f8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1602f66b4bcd4b2fa1f1a8b24f7dd4e1_D20210101-20210630" decimals="-3" name="sls:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNC01LTEtMS0w_9aa7ce38-3316-4c91-a87d-b16f40207ae9">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1602f66b4bcd4b2fa1f1a8b24f7dd4e1_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNC03LTEtMS0w_2391e353-905b-4914-ac18-24947f71b6fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i412c4e10b3ae49dd8a8769d97061c813_I20210630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNC05LTEtMS0w_5280e458-029d-4877-9c55-4340532e20b3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2019 Exercise Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b0b95c6b8aa4fb6baa41a60c4f64951_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNi0xLTEtMS0w_7a5af1aa-57be-44a5-9940-32b501501e2f">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i947de4d2c94b4605b378f1b0d070bc03_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNi0zLTEtMS0w_a7241be0-9615-43cc-aa6a-2c1889a17273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i947de4d2c94b4605b378f1b0d070bc03_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNi01LTEtMS0w_1c2041b6-f913-4eb6-8138-a165aeed2733">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i947de4d2c94b4605b378f1b0d070bc03_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNi03LTEtMS0w_2246faa6-2583-497c-b9d3-6dc15786301f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icde798f1922a4c969d6f8e4f31c629b2_I20210630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNi05LTEtMS0w_2eaf2583-3c33-4637-af2c-414f2446fb2e">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2018 Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19c88fd5d77f4b98a7abbb7fbdd57812_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNy0xLTEtMS0w_64242737-5308-4140-8ca3-f92fa21116fa">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c3ab494f63a4840a5e8d7c78a0058e7_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNy0zLTEtMS0w_6176aaf3-ebd4-4865-8457-9a4918ee93ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1c3ab494f63a4840a5e8d7c78a0058e7_D20210101-20210630" decimals="-3" name="sls:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNy01LTEtMS0w_b26912ca-441c-4371-bb6d-74e3ba4da8eb">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c3ab494f63a4840a5e8d7c78a0058e7_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNy03LTEtMS0w_e2156866-3406-4c11-bb39-41ffb52299e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d5dabb9e85f4ddf985e3b83dbcc8a7f_I20210630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNy05LTEtMS0w_80dfcadb-6f9a-4a20-ad34-348b8fb364b3">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i251355b170d24283aef38a929d6b4ddb_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTItMS0xLTEtMA_232c5ad0-1207-454f-9f09-77f2a17f6807">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b0f1fdbd95d469f9e4960e2aff67576_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTItMy0xLTEtMA_6fd810f6-52a5-4ee1-b125-a29f267a2640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b0f1fdbd95d469f9e4960e2aff67576_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTItNS0xLTEtMA_4dc4e65c-d726-4afa-824c-46a9c2a67591">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9b0f1fdbd95d469f9e4960e2aff67576_D20210101-20210630" decimals="-3" name="sls:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTItNy0xLTEtMA_f6b60f39-a24b-4a9d-85f9-47a5dadf4189">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7d574a5c54b4ecf988952bb6423ecf0_I20210630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTItOS0xLTEtMA_3c5998b4-fad3-4d3c-8b9d-32ed7df38df6">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 2021 - November 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTktMS0xLTEtMA_f5bd43e6-f9e9-4b53-9459-2c3567f6271b">1,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sls:ClassOfWarrantOrRightNumberOfWarrantsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTktMy0xLTEtMA_5e5ba82f-0c6f-42f7-9b46-ab72aa47dfd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" name="sls:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTktNS0xLTEtMA_c8a735b4-2985-4217-b702-b4f5324a141e">832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" name="sls:ClassofWarrantorRightCanceledOrExpired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTktNy0xLTEtMA_84857660-41a7-43f8-b986-c0c207d0f858">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTktOS0xLTEtMA_d1b6fb37-a42b-405c-b7a5-bed97f2e985d">559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to acquire shares of common stock consist of warrants that may be settled in cash, which are liability-classified warrants, and equity-classified warrants.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i70ba2778a85d47769488d8f2f9a3d153"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants Classified as Liabilities </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability-classified warrants consist of warrants to acquire common stock issued in connection with certain previous equity financings. These warrants may be settled in cash and were determined not to be indexed to the Company&#8217;s common stock. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of operations as change in fair value of warrant liability. <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="sls:ScheduleOfWarrantValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RleHRyZWdpb246NjQ3N2ZjYWQwM2NlNGNiN2ExYmJhZmQ5NjY3ZTZiYWVfMjcwNA_b08e4f62-5c11-4ed7-a7ae-e0314c4aacde" continuedAt="i9a5f3d0536974f50a32b990f620a0ca6" escape="true">The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: </ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><div><ix:continuation id="i9a5f3d0536974f50a32b990f620a0ca6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:27.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of June 30, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Strike price (per share)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Volatility %</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free rate %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other warrants (liability-classified)</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if448fa0842d047f7b8837ba649615db8_I20210630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMy0xLTEtMS0w_fcb037b0-5410-41ed-8ab6-2983c64853e5">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if448fa0842d047f7b8837ba649615db8_I20210630" decimals="INF" name="sls:WarrantStrikePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMy0zLTEtMS0w_7a760801-401d-46af-a9b2-f06b978112fb">7.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2bb40a5e73b94b1b8f47f0ddc5d2a834_D20210101-20210630" format="ixt-sec:duryear" name="sls:FairValueOfWarrantLiabilityAssumptionsExpectedTerm" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMy01LTEtMS0w_936c9c4a-c889-41e3-bbb6-7b2d19ee7ee5">2.26</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if448fa0842d047f7b8837ba649615db8_I20210630" decimals="4" name="sls:WarrantsFairValueAssumptionsExpectedVolatility" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMy03LTEtMS0w_545fd78d-c763-4531-824e-bcbceb0f30bb">151.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if448fa0842d047f7b8837ba649615db8_I20210630" decimals="4" name="sls:WarrantsFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMy05LTEtMS0w_42ef9667-3433-47da-940e-7842ba9dcfd3">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding (in thousands)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Strike price (per share)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Volatility %</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free rate %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other warrants (liability-classified)</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i144421cce0de42f196e8d03018a26b22_I20201231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMTItMS0xLTEtMA_7927849b-235e-43fa-b745-63dc4da31c1a">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i144421cce0de42f196e8d03018a26b22_I20201231" decimals="INF" name="sls:WarrantStrikePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMTItMy0xLTEtMA_728309cb-0d3b-4bf6-85ca-1c2987b1ef9e">7.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5503f2dea367480f98b7b0fa4b8c7314_D20200101-20201231" format="ixt-sec:duryear" name="sls:FairValueOfWarrantLiabilityAssumptionsExpectedTerm" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMTItNS0xLTEtMA_1d1b6c05-07ec-4a2b-88f3-671c494f0da5">2.75</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i144421cce0de42f196e8d03018a26b22_I20201231" decimals="4" name="sls:WarrantsFairValueAssumptionsExpectedVolatility" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMTItNy0xLTEtMA_0df17c58-54e8-491e-8089-22a7ff9cfb93">150.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i144421cce0de42f196e8d03018a26b22_I20201231" decimals="4" name="sls:WarrantsFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMTItOS0xLTEtMA_4a2060c4-a1d1-43fd-bc97-9bed0f0730a9">0.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the <ix:nonFraction unitRef="number" contextRef="id11e0beb0d474e3e908dfebf56c545ca_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RleHRyZWdpb246NjQ3N2ZjYWQwM2NlNGNiN2ExYmJhZmQ5NjY3ZTZiYWVfMjQxOQ_46d4ff7c-bfd3-4bed-9659-4b5b07092ee5">zero</ix:nonFraction> coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is <ix:nonFraction unitRef="number" contextRef="i407d77e6977a4e69b6cad45ca4a965ca_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RleHRyZWdpb246NjQ3N2ZjYWQwM2NlNGNiN2ExYmJhZmQ5NjY3ZTZiYWVfMjUxOQ_aa7ba07a-46ba-4168-9571-d659d0ead8c6">zero</ix:nonFraction>, because the Company has no present intention to pay cash dividends.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="sls:ChangesInFairValueOfWarrantLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RleHRyZWdpb246NjQ3N2ZjYWQwM2NlNGNiN2ExYmJhZmQ5NjY3ZTZiYWVfMjY5OA_85771d3f-2313-4e59-b9a1-dfde77e1177b" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in fair value of the warrant liability for the six months ended June 30, 2021 were as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability, June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other warrants (liability-classified)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144421cce0de42f196e8d03018a26b22_I20201231" decimals="-3" name="sls:FairValueOfWarrantsLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOjNlNmNmZjc5NWY1MDRkODA4OTczYzQzODdlYWRkMTllL3RhYmxlcmFuZ2U6M2U2Y2ZmNzk1ZjUwNGQ4MDg5NzNjNDM4N2VhZGQxOWVfMS0xLTEtMS0w_7b23d66f-3168-4ad7-bff4-8bf17c7afef1">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bb40a5e73b94b1b8f47f0ddc5d2a834_D20210101-20210630" decimals="-3" name="sls:ChangeInFairValueOfWarrantLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOjNlNmNmZjc5NWY1MDRkODA4OTczYzQzODdlYWRkMTllL3RhYmxlcmFuZ2U6M2U2Y2ZmNzk1ZjUwNGQ4MDg5NzNjNDM4N2VhZGQxOWVfMS05LTEtMS0w_6a696ddc-5b31-424a-9da4-d1c73b28b623">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if448fa0842d047f7b8837ba649615db8_I20210630" decimals="-3" name="sls:FairValueOfWarrantsLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOjNlNmNmZjc5NWY1MDRkODA4OTczYzQzODdlYWRkMTllL3RhYmxlcmFuZ2U6M2U2Y2ZmNzk1ZjUwNGQ4MDg5NzNjNDM4N2VhZGQxOWVfMS0xMS0xLTEtMA_080189b1-3b45-4f0b-b581-e31f6fe6ae6d">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="sls:FairValueOfWarrantsLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOjNlNmNmZjc5NWY1MDRkODA4OTczYzQzODdlYWRkMTllL3RhYmxlcmFuZ2U6M2U2Y2ZmNzk1ZjUwNGQ4MDg5NzNjNDM4N2VhZGQxOWVfOC0xLTEtMS0w_89450ce2-fc69-4e67-ab0e-13b370116669">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" name="sls:ChangeInFairValueOfWarrantLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOjNlNmNmZjc5NWY1MDRkODA4OTczYzQzODdlYWRkMTllL3RhYmxlcmFuZ2U6M2U2Y2ZmNzk1ZjUwNGQ4MDg5NzNjNDM4N2VhZGQxOWVfOC05LTEtMS0w_433c1634-11d7-432f-b5a7-cb615b567177">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="sls:FairValueOfWarrantsLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOjNlNmNmZjc5NWY1MDRkODA4OTczYzQzODdlYWRkMTllL3RhYmxlcmFuZ2U6M2U2Y2ZmNzk1ZjUwNGQ4MDg5NzNjNDM4N2VhZGQxOWVfOC0xMS0xLTEtMA_003fe86a-c4d0-465f-953c-0f1d70521a77">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_61"></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.  <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfOTI0Nw_2cc413d8-5028-43f8-95eb-b08184ace4d4" continuedAt="i732010ec54654d26937beabc00d01295" escape="true">License Revenue with 3D Medicines, Inc.</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i732010ec54654d26937beabc00d01295" continuedAt="i3b80896013df4458b2792b96cb54bb6b"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exclusive License Agreement with 3D Medicines, Inc.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company, together with its wholly-owned subsidiary, SLSG Limited, LLC, entered into an Exclusive License Agreement (the &#8220;3DMed License Agreement&#8221;) with 3D Medicines Inc. ("3DMed"), pursuant to which the Company granted 3DMed a sublicensable, royalty-bearing license, under certain intellectual property owned or controlled by the Company, to develop, manufacture and have manufactured, and commercialize GPS and heptavalent GPS (referred to as GPS Plus) product candidates ("GPS Licensed Products") for all therapeutic and other diagnostic uses in mainland China, Hong Kong, Macau and Taiwan ("3DMed Territory"). The license is exclusive, except with respect to certain know-how that has been non-exclusively licensed to the Company and is sublicensed to 3DMed on a non-exclusive basis. The Company has retained development, manufacturing and commercialization rights with respect to the GPS Licensed Products in the rest of the world.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In partial consideration for the rights granted by the Company, 3DMed agreed to pay the Company (i) a one-time upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="sls:ResearchAndDevelopmentArrangementCashPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfMTE4NQ_008b7a86-4945-48f9-96cc-d4103e0ed56e">7.5</ix:nonFraction>&#160;million, and (ii) milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="sls:ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfMTIzMg_1f884f5a-1f1b-412f-ba8d-bd3a0e2d8521">194.5</ix:nonFraction>&#160;million in the aggregate upon the achievement of certain technology transfer, development and regulatory milestones, as well as sales milestones based on certain net sales thresholds of GPS Licensed Products in the 3DMed Territory in a given calendar year. The Company is responsible for providing the licensed technology and data (the "3DMed License") as well as transferring certain technological and manufacturing know-how (the "transfer of know-how").</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3DMed also agreed to pay tiered royalties based upon a percentage of annual net sales of GPS Licensed Products in the 3DMed Territory ranging from the high single digits to the low double digits. The royalties are payable on a GPS Licensed Product-by-GPS Licensed Product and region-by-region basis commencing on the first commercial sale of a GPS Licensed Product in a region and continuing until the latest of (i) the date that is <ix:nonNumeric contextRef="i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231" format="ixt-sec:duryear" name="sls:ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfMjExNw_474390f2-17d8-4e4e-b229-ecb266ffba3b">15</ix:nonNumeric> years from the receipt of marketing authorization for such GPS Licensed Product in such region and (ii) the date that is <ix:nonNumeric contextRef="i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231" format="ixt-sec:duryear" name="sls:ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfMjIzNQ_f71e8e5e-75ad-4502-943b-8d378ef76d19">10</ix:nonNumeric> years from the expiration of the last valid claim of a licensed patent covering or claiming such GPS Licensed Product in such region. The royalty rate is subject to reduction under certain circumstances, including when generic competition for a GPS Licensed Product exists in a particular region.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3DMed is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the GPS Licensed Products in the 3DMed Territory. 3DMed is required to use commercially reasonable best efforts to develop and obtain regulatory approval for, and upon receipt of regulatory approval, commercialize the GPS Licensed Products in the 3DMed Territory. A joint steering committee has been established between 3DMed and the Company to coordinate and review the development, manufacturing and commercialization plans with respect to the GPS Licensed Products in the 3DMed Territory. The Company and 3DMed also agreed to negotiate in good faith the terms and conditions of a clinical supply agreement, a commercial supply agreement, and related quality agreements pursuant to which the Company will manufacture or have manufactured and supply 3DMed with all quantities of the GPS Licensed Products necessary for 3DMed to develop and commercialize the GPS Licensed Products in the 3DMed Territory until 3DMed has received all approvals required for 3DMed or its designated contract manufacturing organization to manufacture the GPS Licensed Products in the 3DMed Territory.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 3DMed License Agreement will expire on a GPS Licensed Product-by-GPS Licensed Product and region-by-region basis on the date of the expiration of all of 3DMed&#8217;s payment obligations to the Company. Upon expiration of the 3DMed License Agreement, the license granted to 3DMed will become fully paid-up, perpetual and irrevocable. Either party may terminate the 3DMed License Agreement for the other party&#8217;s material breach following a cure period or upon certain insolvency events. The Company may terminate the 3DMed License Agreement if 3DMed or its affiliates or sublicensees challenge the validity or enforceability of the licensed patents. At any time following the two-year anniversary of the effective date, 3DMed has the right to terminate the 3DMed License Agreement for convenience, subject to certain requirements. 3DMed may terminate the 3DMed License Agreement upon prior notice to the Company if the grant of the license to 3DMed is prohibited or delayed for a period of time due to a change of U.S. export laws and regulations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 3DMed License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i3b80896013df4458b2792b96cb54bb6b" continuedAt="ia80b53cb9d62441ba5172fc1a94fda54"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 3DMed License Agreement and concluded that 3DMed was a customer and the 3DMed License Agreement should be evaluated under ASC 606. In determining the appropriate amount of revenue to be recognized under ASC 606 as the Company fulfills its obligations under the 3DMed License Agreement, the Company performs the following steps: (i) identifies the promised goods or services in the contract; (ii) determines whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measures the transaction price, including any constraints on variable consideration; (iv) allocates the transaction price to the performance obligations; and (v) recognizes revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the 3DMed License and the transfer of know-how to be the material promises under the 3DMed License Agreement. The Company determined that the 3DMed License and the transfer of know-how are not distinct from each other. As such, for the purposes of ASC 606, the Company determined that these two material promises, described above, should be combined into a single performance obligation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price of the single performance obligation to be $<ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNjI3NQ_87fe7754-5701-455c-9eac-eda42b243553">9.5</ix:nonFraction>&#160;million, which includes the $<ix:nonFraction unitRef="usd" contextRef="i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="sls:ResearchAndDevelopmentArrangementCashPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNjI5OA_276db935-c99c-4f14-b50d-aa9eedac2199">7.5</ix:nonFraction>&#160;million upfront fee as well as $<ix:nonFraction unitRef="usd" contextRef="i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="sls:ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNjMyNA_a437dc70-c5d5-40d4-b4d2-3ac9f5a9a536">2.0</ix:nonFraction>&#160;million in development milestones that are assessed to be probable of being achieved at the inception of the 3DMed License Agreement and therefore were not constrained. The Company achieved $<ix:nonFraction unitRef="usd" contextRef="i688ab895304a4f60b76983dc097aef85_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="sls:ProceedsFromResearchAndDevelopmentArrangementMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNjUwOQ_894c9c74-c465-4ff4-845b-4c304e5a33d8">1.0</ix:nonFraction>&#160;million of these milestones in the first quarter of 2021 and achieved the remaining $<ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="sls:ProceedsFromResearchAndDevelopmentArrangementMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNjU5OA_c21c00dc-ab47-4d93-91cd-3c6ed6aa189a">1.0</ix:nonFraction>&#160;million milestone in the second quarter of 2021. The Company determined that $<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="sls:ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNjY2MA_7d0e54d1-d3fa-4281-9d41-d98d2816fef9">192.5</ix:nonFraction>&#160;million in future certain development, regulatory, and sales milestones to be variable consideration subject to constraint at inception. At the end of each subsequent reporting period, the Company will reevaluate the probability of achievement of the future development, regulatory, and sales milestones subject to constraint and, if necessary, will adjust its estimate of the overall transaction price. Any such adjustments will be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the sales-based royalties, the Company will recognize revenue when the related sales occur. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 3DMed benefited from the combined single performance obligation relating to the 3DMed License and the transfer of know-how as the technology transfer occurred, the Company recognized the transaction price over the technology transfer period, which was finalized in the second quarter of 2021. The revenue recognized was based on an output method to measure progress, using a straight-line convention, which the Company believes reasonably approximates its efforts in satisfying the combined performance obligation. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="sls:ContractWithCustomerLiabilityNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfMTY0OTI2NzQ1MTA5MQ_3bc1276a-48e5-44ac-bba9-b93c6b4f4fdb">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="sls:ContractWithCustomerLiabilityNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNzk3MA_004aaf22-1dee-43ae-b29c-5d59d4f1decb">7.6</ix:nonFraction>&#160;million of license revenue during the three and six months ended June&#160;30, 2021, respectively. As of June 30, 2021, the initial transaction price of the single performance obligation of $<ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNjA0NzMxMzk2MjcwNQ_6f387353-e9ef-41ca-acfe-ddd3eef8c86d">9.5</ix:nonFraction>&#160;million has been fully recognized as licensing revenue. There was <ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="sls:ContractWithCustomerLiabilityNewContractRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfODAzNg_670c011b-7a71-4cf3-bab1-2729e42a0d89"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="sls:ContractWithCustomerLiabilityNewContractRevenueRecognized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfODAzNg_98be0ddc-5615-4bee-b1c1-739f2c85e2b2">no</ix:nonFraction></ix:nonFraction> license revenue recognized during the three and six months ended June 30, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfOTI0OA_390f04f5-3c37-4884-921a-c449889061ef" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the activity in the Company's deferred revenue, related to the total cash payments received of $<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="sls:ResearchAndDevelopmentArrangementCashPaymentReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfODI1MA_95253805-d71b-41ae-bf5a-b3f30be62212">9.5</ix:nonFraction>&#160;million to date under the 3DMed License, during the six months ended June&#160;30, 2021 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Recognized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RhYmxlOmMwOGFkYzM4ZWRlNTRjZDBiMDg3N2U5MGY0ZGMwNWRjL3RhYmxlcmFuZ2U6YzA4YWRjMzhlZGU1NGNkMGIwODc3ZTkwZjRkYzA1ZGNfMS0xLTEtMS0w_93e51278-ae45-4ae3-be3b-01fec892c065">5,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RhYmxlOmMwOGFkYzM4ZWRlNTRjZDBiMDg3N2U5MGY0ZGMwNWRjL3RhYmxlcmFuZ2U6YzA4YWRjMzhlZGU1NGNkMGIwODc3ZTkwZjRkYzA1ZGNfMS0zLTEtMS0w_f0cfb491-4a5a-4587-87bd-4e9d7d0ab35a">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="sls:ContractWithCustomerLiabilityNewContractRevenueRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RhYmxlOmMwOGFkYzM4ZWRlNTRjZDBiMDg3N2U5MGY0ZGMwNWRjL3RhYmxlcmFuZ2U6YzA4YWRjMzhlZGU1NGNkMGIwODc3ZTkwZjRkYzA1ZGNfMS01LTEtMS0w_77583ab8-b375-466f-9de3-743f155b15ff">7,600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RhYmxlOmMwOGFkYzM4ZWRlNTRjZDBiMDg3N2U5MGY0ZGMwNWRjL3RhYmxlcmFuZ2U6YzA4YWRjMzhlZGU1NGNkMGIwODc3ZTkwZjRkYzA1ZGNfMS03LTEtMS0w_edace3be-b722-4168-aa2c-19cab41d01d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="ia80b53cb9d62441ba5172fc1a94fda54"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Contract Acquisition</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred contract acquisition costs (commissions) recorded as a contract asset amounting to approximately $<ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfODQ4Nw_67d70434-0979-4daa-9241-32ce4af70fc1">1.4</ix:nonFraction>&#160;million at inception of the 3DMed License Agreement which were capitalized under ASC 340-40 as incremental costs of obtaining the 3DMed License Agreement. These costs are amortized through general and administrative expense over the technology transfer period, commensurate with when the license revenue is recognized. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfMTA5OTUxMTYzNzEzMg_f69a5508-aacb-4b6f-a936-35ac32c0cf74">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfODgyNA_879e9d62-cb98-4bcc-b24f-52e0ca38fcb5">1.1</ix:nonFraction>&#160;million in expense associated with these costs during the three and six months ended June&#160;30, 2021, respectively. There was <ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfODkxMA_d0980b61-f14b-445a-83bc-41c01a4ce697"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfODkxMA_e7806925-dfcd-477f-bccf-0b7da059a89a">no</ix:nonFraction></ix:nonFraction> contract acquisitions expense during the three and six months ended June 30, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of License Revenue</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfMTY0OTI2NzQ1MTIwNA_78459b02-706b-49e0-9579-7c1adc219fb7">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfOTAzNg_0fb8335d-2615-4784-a922-93b8b572c7df">0.2</ix:nonFraction>&#160;million of sublicensing fees payable under its license from MSK in connection with the 3DMed License during the three and six months ended June&#160;30, 2021, respectively. There was <ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfOTE3Ng_4b7df5a4-1f8b-4486-b630-b1667235e24d"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfOTE3Ng_63c90eb5-b4bf-4cfe-9538-1c2ae4983378">no</ix:nonFraction></ix:nonFraction> cost of license revenue during the three and six months ended June 30, 2020.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_64"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.  <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDE1MA_cb17b692-c0ac-4688-8d8f-b30464760f7f" continuedAt="i54fa65f368c14c249ace4aad628fd3ff" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i54fa65f368c14c249ace4aad628fd3ff" continuedAt="i266be3018bc44f6eb0f582e91f607afe"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Equity Incentive Plan </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the 2017 Equity Incentive Plan was approved by the stockholders of the Company, which provided for the issuance of up to a maximum of <ix:nonFraction unitRef="shares" contextRef="iad04bd0225e946c686ea366ea6d4337c_I20171229" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMjIx_f55c2fa6-4d3d-4960-8136-94e6f3372ad3">24,204</ix:nonFraction> shares of common stock underlying stock options granted prior to September 10, 2019. The 2017 Equity Incentive Plan was terminated upon the approval of the 2019 Incentive Plan subject to outstanding stock options granted under the 2017 Equity Incentive Plan that remain exercisable through maturity for the Company's employees and directors. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Equity Incentive Plan </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2019, the 2019 Equity Incentive Plan was approved by the stockholders of the Company, which currently allows for issuance of up to approximately (i) <ix:nonFraction unitRef="shares" contextRef="i2cdec16105b14f11a00088c335a3fc87_I20190910" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNzYz_e1df2341-7dcb-462f-8fde-84eef3f54c30">1,191,000</ix:nonFraction> shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate plus (ii) <ix:nonFraction unitRef="shares" contextRef="id18a6212741d45d5b62f720726640f94_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfOTky_b1e29ecd-e783-48de-a2f0-a7a365daf8ad">2,684</ix:nonFraction> shares of common stock under the 2017 Equity Incentive Plan that were forfeited back to the Company subsequent to September 10, 2019 and are available for future issuance. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares reserved for issuance under the 2019 Equity Incentive Plan will automatically increase on January 1&#160;of each year, for a period of not more than <ix:nonNumeric contextRef="i3326b9a650f54279992091454bb1af76_D20190910-20190910" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMTMzNA_927df775-fc1d-4812-9a07-5cab84b2cbd0">four years</ix:nonNumeric>, commencing on January 1, 2020 and ending on (and including) January&#160;1, 2023, by an amount equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="i3326b9a650f54279992091454bb1af76_D20190910-20190910" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMTQ1NQ_767ae8e7-c646-4472-9c8a-1d93cb455e2c">5</ix:nonFraction>% of the total number of shares of common stock outstanding at the end of the prior fiscal year; and (ii) an amount determined by the board of directors or authorized committee. As of June&#160;30, 2021, approximately <ix:nonFraction unitRef="shares" contextRef="i7c1fcbbb7fa2469ea57dccaece19d2c0_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMTY1OA_c8b7b6a3-4304-478a-a6bb-be546b1b09a6">463,000</ix:nonFraction> shares of common stock were reserved for future grants under the 2019 Equity Incentive Plan. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options to Purchase Shares of Common Stock </span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDE0Nw_3d93d932-fc35-46bc-bb7d-f0befc983383" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity of the Company for the six months ended June 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Number of<br/>Shares <br/>(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (In Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfMS0xLTEtMS0w_41e3b61b-c267-4fcc-b05f-dabf573b79af">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfMS0zLTEtMS0w_da627da1-573a-49df-a502-e464e538dade">13.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic7eacc21cecb4153bd972290a5d92a75_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfMS01LTEtMS0w_d6db4d4a-c5cf-4608-bd4f-b42e20ddf439">9.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfMS03LTEtMS0w_f6d98d9b-1609-4068-8522-613a4ac1dfcf">733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfMi0xLTEtMS0w_c8587579-a1c5-47a0-b5e8-a5805f20d9fa">312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfMi0zLTEtMS0w_c2a4354b-9e32-41c6-adeb-71bbba1f73cd">7.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNS0xLTEtMS0w_00782922-25de-438f-917f-333cc33f7ce8">520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNS0zLTEtMS0w_fd31b450-36cb-4abe-98c5-41965fdc7d0c">10.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNS01LTEtMS0w_70e18881-28c7-4fec-b0d5-7fd203b68a92">9.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNS03LTEtMS0w_aeeee0e4-3b96-41d8-9cf3-c271b6232955">2,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNi0xLTEtMS0w_83724371-d792-493b-b59d-599f9b2b39b5">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNi0zLTEtMS0w_7996eea8-e33e-43b3-83c9-c39653a2a286">23.36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNi01LTEtMS0w_57fc09a9-2f05-4975-a413-21a7379d47c1">8.48</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNi03LTEtMS0w_2d9cead3-fb76-4c96-b1f1-050c09114b26">695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:49.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><ix:continuation id="i266be3018bc44f6eb0f582e91f607afe" continuedAt="ic1d158e8b62447a894dbea94b2d18801"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values of outstanding and exercisable stock options at June&#160;30, 2021 were calculated based on the closing price of the Company&#8217;s common stock as reported on the Nasdaq Capital Market on June&#160;30, 2021 of $<ix:nonFraction unitRef="usdPerShare" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="INF" name="sls:ClosingPriceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMjA4OQ_b00f3a9e-11eb-4f8e-aeac-9bb311e22a23">11.10</ix:nonFraction> per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company&#8217;s common stock and the exercise price of the underlying stock options.</span></div><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDE0OQ_ecddf231-d4c2-426c-aed8-2fe43134123d" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three and six months ended June&#160;30, 2021 and 2020, respectively (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524a7778f45b41d493eb970513cfe899_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMi0xLTEtMS0w_82519406-05bf-4488-96e4-098e3b7c93ee">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i455f2bcd2a26422b8ef4b6956db962dd_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMi0zLTEtMS0w_a5c7dd7e-0b4a-472b-9eef-8d75b7e4de35">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib57038e75a2e456f9153d4562f7875c9_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMi01LTEtMS0w_e433c318-9df6-4b31-b80d-46a87b304a19">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53ff491bb4d406dbfc18398cc46aed4_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMi03LTEtMS0w_ddeca4f2-b661-430f-baaf-a14d6be5a49b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6957c26fb4be459faf509b1dc44c22e1_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMy0xLTEtMS0w_79d2cbfa-db5f-4775-8f6e-a74527a261bc">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c6000daa9d4a529f676d7a949697c9_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMy0zLTEtMS0w_35be9862-2720-4192-a08b-b0d50eb4f77d">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if259b3f68de54eb69651fd71f0d90e8a_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMy01LTEtMS0w_ce5bf1bd-e7af-41d0-87cf-4c752d51e1e6">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69480503f88f4c8b8e46355038c252d7_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMy03LTEtMS0w_01d0a9c8-fc57-4cf2-b012-336d65b0c4f2">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfNC0xLTEtMS0w_42cca71d-a0d2-4b99-86db-b9c1433b30b9">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfNC0zLTEtMS0w_9c748253-92f3-4746-b73a-7ceb504c887e">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfNC01LTEtMS0w_488a9116-32b4-4d5b-b177-7c432647d47b">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfNC03LTEtMS0w_48352a68-543f-46f2-803b-e67b9b3eb3cc">291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDE1NA_e1c3d781-1cd3-428c-868e-6783d4401192" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to determine the fair value of all its stock options granted. The assumptions used during the three and six months ended June&#160;30, 2021 and 2020, respectively, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMi0xLTEtMS0w_2e676166-ad16-47a1-9edd-c2f9ca01b49b">1.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMi0zLTEtMS0w_9bfbd6f8-0b7f-4672-b061-aff5fb196088">0.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMi01LTEtMS0w_05034f18-fd02-4021-9e09-c6968463b855">1.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMi03LTEtMS0w_8ab817cc-6df8-47cb-ba58-c8413b4ad834">0.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMy0xLTEtMS0w_434cbf27-1961-4111-85bd-953a97e16d64">121.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMy0zLTEtMS0w_8004b511-b1c8-4f04-b3ab-ca50bf9fb837">108.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMy01LTEtMS0w_b7e26c56-94a7-454c-b01e-bae25e3b75c3">121.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMy03LTEtMS0w_b271e054-8917-4126-af11-5cdbc513dae0">106.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected lives (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNC0xLTEtMS0w_28f3ab72-311e-4614-b677-01cf4ea49716">6.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNC0zLTEtMS0w_0bf44671-e2ff-4994-83f7-bb49041ff3df">6.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNC01LTEtMS0w_453d41bf-22ed-4b53-a05b-57a8c84dc10c">6.18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNC03LTEtMS0w_ae27991c-5813-4ff6-88c7-c14f00f3f2cd">6.15</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNS0xLTEtMS0w_802d69a8-9ddb-4ee8-9d70-859a2465ba1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNS0zLTEtMS0w_5f5a54d6-623d-4945-802b-47e6abd885bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNS01LTEtMS0w_73a263b2-ae06-42ce-9546-12c96e352383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNS03LTEtMS0w_81715e5b-7d56-41e9-9cdb-d3999bf5d9a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the three months ended June&#160;30, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzI5ODUzNDg5MDcxMQ_0d29b7d5-e21f-4eba-b93b-5b99fc39b10a">6.89</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzI5ODUzNDg5MDcwNg_ee806dce-fddd-4059-9cf8-6940900076bc">1.35</ix:nonFraction>, respectively. The weighted-average grant date fair value of options granted during the six months ended June 30, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzI5ODUzNDg5MDcxOQ_43f382be-4d3c-4ffc-87f3-33179fb72f46">6.97</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzI5ODUzNDg5MDcyNw_a79efa40-dd86-4d40-a642-769e56de269b">1.53</ix:nonFraction>, respectively. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company&#8217;s options of <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzE4Mw_75814b5b-1f0c-4077-ba86-7c0ba4fe9057">ten years</ix:nonNumeric> with the average vesting term of <ix:nonNumeric contextRef="i1eabe9b7328c4b42883ac930dcae2966_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzIxOQ_1b235e73-16e0-490b-836d-bb1d992e42a1">four years</ix:nonNumeric> for an average of approximately <ix:nonNumeric contextRef="ic3b2daec188244b58b5c6404473e5b28_D20210101-20210630" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzI1NA_33c39ff9-e5c7-43cb-bd2e-0aef5c5d4586">six years</ix:nonNumeric>. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is <ix:nonFraction unitRef="number" contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzM5MQ_eecaf4ac-dec1-4961-9eee-e0ad0e873af0">zero</ix:nonFraction> because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzY2NA_a260fe5e-06de-4b4d-8f09-1adf98386efb">2.4</ix:nonFraction> million of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company&#8217;s operating expenses over a weighted-average period of <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" format="ixt-sec:duryear" name="sls:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDk0NzgwMjMzMjE0MA_2b12ec91-f67b-4162-8c24-bb345b4e3544">2.98</ix:nonNumeric> years.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Time-vested RSUs and RSUs with Performance Conditions </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDEzNw_44bbd153-3b99-4fed-9a2e-9eccc32c80e4" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity of the Company for the six months ended June 30, 2021:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares<br/>(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd04b0465a9c4a3b89d3acede77717db_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfMS0xLTEtMS0w_e3c603af-ca7f-408c-b1ae-572d6e143d47">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idd04b0465a9c4a3b89d3acede77717db_I20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfMS0zLTEtMS0w_08085594-f515-441c-8c4d-de26d2ff8df2">1.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfMi0xLTEtMS0w_4053df9a-e320-4232-a7e7-694310f88329">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfMi0zLTEtMS0w_b14a628f-62e6-4310-8f09-118f95b00c9f">8.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfMy0xLTEtMS0w_ea7e022b-42b2-43bb-a1c4-68df9958e315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630" decimals="2" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfMy0zLTEtMS0w_d07618be-76ca-4c13-94f4-907c7a05bb1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i111b00fe2e9a484ab732132f92c59d7e_I20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfNC0xLTEtMS0w_3328c4a2-d7d0-4fe0-b71d-824fd03922a6">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i111b00fe2e9a484ab732132f92c59d7e_I20210630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfNC0zLTEtMS0w_dc93bd5f-2b12-4a8a-80c6-717afb592fdd">3.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i45635ddbe06c42738d10dbb9cae11665_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SELLAS LIFE SCIENCES GROUP, INC.</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span><br/></span></div><ix:continuation id="ic1d158e8b62447a894dbea94b2d18801"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i111b00fe2e9a484ab732132f92c59d7e_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzI5ODUzNDg5MDczMg_ea01e095-5bc5-4625-a467-2f21722a08bb">0.6</ix:nonFraction> million of unrecognized compensation cost related to outstanding RSUs that is expected to be recognized as a component of the Company's operating expenses over a weighted-average period of <ix:nonNumeric contextRef="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630" format="ixt-sec:duryear" name="sls:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNjA0NzMxMzk2MTUxNQ_51c11c95-4e2b-4848-9c29-6b9d2d14c8d5">2.94</ix:nonNumeric> years. <ix:nonFraction unitRef="shares" contextRef="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMjc0ODc3OTA3Njg4Mw_2bdad1c3-a5ae-4f42-926a-d1c9a81beacf"><ix:nonFraction unitRef="shares" contextRef="i018e48b1dacd47c68c32d3cc244c3f52_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMjc0ODc3OTA3Njg4Mw_7f42dddc-9faf-4be6-ab10-233e12a9ee83">No</ix:nonFraction></ix:nonFraction> RSUs vested during the three and six months ended June&#160;30, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2021, the Board of Directors adopted the 2021 Employee Stock Purchase Plan ("2021 ESPP") which was approved by the Company's stockholders on June 8, 2021. The 2021 ESPP allows employees to contribute up to <ix:nonFraction unitRef="number" contextRef="i9994aed68348440999b4cb1d1a4ac219_I20210422" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDk0NzgwMjMzMjE0Mg_69763ba4-ed58-4c04-a53a-cb6e464277e4">20</ix:nonFraction>% of their cash earnings, subject to a maximum of $25,000 per year under Internal Revenue Service rules, to be used to purchase shares of the Company&#8217;s common stock on semi-annual purchase dates. The 2021 ESPP allows eligible employees to purchase shares of common stock at a price per share equal to <ix:nonFraction unitRef="number" contextRef="ie5c340905f4d47a1a0096f2680c0f9f4_D20210422-20210422" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDk0NzgwMjMzMjE0Nw_cf3eed79-8a14-4f3f-84d5-1d91b40a4670">85</ix:nonFraction>% of the lower of the fair market value of the common stock at the beginning or end of each six-month offering period during the term of the 2021 ESPP. The first offering period will begin in September 2021. There are currently <ix:nonFraction unitRef="shares" contextRef="i9994aed68348440999b4cb1d1a4ac219_I20210422" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDk0NzgwMjMzMjE1Mg_00e41ded-1f0e-497b-be2a-d11267ed3255">300,000</ix:nonFraction> shares of common stock reserved for issuance under the 2021 ESPP.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_67"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.  <ix:nonNumeric contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82Ny9mcmFnOjQyZGE5ZWJmNDA5MDQ5OTY5MjdiZWIxNDAwZjIyNmRiL3RleHRyZWdpb246NDJkYTllYmY0MDkwNDk5NjkyN2JlYjE0MDBmMjI2ZGJfMzE0_ddefd509-3947-4c8e-ada8-7400d2ee7d8d" continuedAt="iab0bf7f88f9740df83b69408647c6937" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iab0bf7f88f9740df83b69408647c6937">The Company evaluated all events or transactions that occurred after June&#160;30, 2021 up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the consolidated financial statements, the Company did not have any material subsequent events.</ix:continuation></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i45635ddbe06c42738d10dbb9cae11665_70"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This management&#8217;s discussion and analysis of financial condition as of June&#160;30, 2021 and results of operations for the three and six months ended June 30, 2021 and 2020, respectively, should be read in conjunction with Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission, or SEC, on March 23, 2021, or our 2020 Annual Report, and our other public reports filed with the SEC.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_73"></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S and nelipepimut-S.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Galinpepimut-S, or GPS</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, galinpepimut-S, or GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, we commenced a Phase 3 trial, or the REGAL study, for GPS monotherapy in patients with acute myeloid leukemia, or AML, in the maintenance setting after achievement of second complete remission, or CR2, following successful completion of second-line antileukemic therapy. We expect this study will be used as the basis for submission of a Biologics License Application, or BLA, subject to a statistically significant and clinically meaningful data outcome and agreement with the U.S. Food &amp; Drug Administration, or the FDA. We expect to enroll approximately 116 patients at up to approximately 135 clinical sites primarily in the United States and Europe with a planned interim safety and futility analysis after 80 events (deaths) which we anticipate will take place in the first half of 2022, provided that the ongoing COVID-19 pandemic does not significantly adversely impact our projected timeline for enrollment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we initiated a Phase 1/2 multi-arm "basket" type clinical study of GPS in combination with Merck &amp; Co., Inc.&#8217;s anti-PD-1 therapy, pembrolizumab (Keytruda&#174;). The tumor type currently being studied is ovarian cancer (second or third line).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, a Phase I open-label investigator-sponsored clinical trial of GPS, in combination with Bristol-Myers Squibb&#8217;s anti-PD-1 therapy, nivolumab (Opdivo&#174;), in patients with malignant pleural mesothelioma, or MPM, who harbor relapsed or refractory disease after having received frontline standard of care multimodality therapy (the "MPM IST") was commenced at MSK.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GPS was granted Orphan Drug Product Designations from the FDA, as well as Orphan Medicinal Product Designations from the European Medicines Agency, or EMA, for GPS in AML, MPM and multiple myeloma, or MM, as well as Fast Track Designation for AML, MPM, and MM from the FDA.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nelipepimut-S or NPS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nelipepimut-S, or NPS, is a cancer immunotherapy targeting the human epidermal growth factor receptor 2, or HER2, expressing cancers. Data presented in 2018 from a Phase 2b clinical trial of the combination of trastuzumab (Herceptin&#174;) plus NPS in HER2 low expressing (1+ or 2+ per immunohistochemistry, or IHC) breast cancer patients in the adjuvant setting to prevent recurrences showed a clinically and statistically significant improvement in the disease-free survival, or DFS, rate for the triple negative breast cancer, or TNBC, cohort at 24 months for patients treated with NPS plus trastuzumab of 92.6% compared to 70.2% for those treated with trastuzumab alone. Following ongoing discussions with the FDA and based upon written feedback from the FDA and on the totality of clinical, safety and translational NPS data to date, we have finalized the design and plan for a Phase 3 registration-enabling study of NPS in combination with trastuzumab for the treatment of patients with TNBC in the adjuvant setting after standard treatment. If successful, we believe this study may be considered as the basis for a BLA submission to the FDA. We are seeking out-licensing opportunities to fund and conduct the future clinical development of NPS in order to maximize the potential of the program and we do not plan to conduct and fund a Phase 3 program for NPS on our own.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GPS Program Update</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2021, we reported encouraging updated clinical data from the MPM IST. For the four evaluable patients, all of whom had the epithelioid and/or sarcomatoid variant and have received and progressed with, or are refractory to, frontline pemetrexed-based chemotherapy, the average overall survival, or OS, was 35.3 weeks with a median OS of 35.4 weeks at a median follow-up of 35.4 weeks. OS for relapsed/refractory patients receiving standard of care (pemetrexed, a chemotherapy) is approximately 28 weeks.</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Average progression-free survival, of PFS, was 8.8 weeks with a median PFS of seven weeks at a median follow-up of 35.4 weeks. The safety profile of the GPS-nivolumab combination was similar to that seen with nivolumab alone, with the addition of only low-grade, temporary local reactions at the GPS injection site which was consistent with previous clinical studies of GPS.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2021, we also reported updated clinical data and immune response profiles from the basket study of GPS in combination with pembrolizumab for treating WT1+ advanced ovarian cancer. Of the 11 evaluable patients, 66.7% were refractory to or had failed their second-line therapies and 33.3% had failed third-line or later therapy and all patients were resistant to the standard of care platinum-based therapy. The expected overall survival for patients receiving standard of care platinum-based therapy is nine to 12 months. The median OS among the patients in this trial is not yet known as all patients remained alive at the time of analysis which time period exceeds nine months. In an ad hoc analysis of the clinical outcomes for the cohort of 11 patients, the disease control rate, or DCR, which is the sum of overall response rate and rate of stable disease, was 63.6% with a median follow-up of 15.4 weeks. At the time of follow-up analysis, median PFS was 11.8 weeks. The safety profile of the GPS-pembrolizumab combination was similar to that seen with pembrolizumab alone, with the addition of only low-grade, temporary local reactions at the GPS injection site, consistent with previously performed clinical studies with GPS. We also reported immunobiological data from this study. CD8+ and CD4+ T-lymphocytes were isolated from peripheral blood mononuclear cells from three patients from whom samples had been collected both at baseline and at the time of the sixth GPS dose (i.e., 18 weeks after starting investigational therapy). The T-cells were assayed ex-vivo for immune responses against the pool of the four peptides that comprise GPS using the validated assay intracellular cytokine staining with fluorescence-activated single cell sorting (ICS-FACS) (Scorpion Biological Services, San Antonio, Texas), with appropriate positive and negative controls. A total of five cytokine &#8220;channels&#8221; were used for the analysis (i.e., interferon-g, TNF-a, interleukin-2, CD107a and MIP-1b). The peptide re-challenge incubation period was seven days. At the 18-week time point versus pre-vaccination baseline, the assay demonstrated a relative increase in WT1-specific T-lymphocyte frequencies in peripheral blood averaging +242% (range: +104 to +385% across five cytokines) for CD8+ and +80.5% (range: +1 to +174%) for CD4+. There was also evidence of polyfunctional T-cell activation (increases in secretion of &gt;2 cytokines) in two out of three patients (66%).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:110%">        </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:110%">In June 2021, a peer-reviewed article was published in the journal</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%"> Bone Marrow Transplantation</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> which included a comprehensive retrospective analysis of survival outcomes in 4,280 AML patients treated in more than 450 blood and marrow transplant centers worldwide between 2007 and 2015. The analysis demonstrates the high unmet medical need to extend survival in AML patients. The published analysis showed that even among patients eligible to receive a bone marrow transplant, considered to be the only potential curative therapy in AML, less than half of the patients are alive five years after initial diagnosis. The analysis highlights the importance of the presence of minimal residual disease, or MRD, with patients who harbored MRD at the time of transplant having only 34%-37% probability of surviving five years. In our completed Phase 2 study of AML patients who achieved first remission, or CR1, OS for patients treated with GPS was 48.5 months from time of enrollment in the study. The retrospective analysis of the pooled outcomes for AML patients who underwent a transplant in the article published in </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Bone Marrow Transplantation </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:110%">indicates that the median OS from the time of transplant is approximately 26 months. In our Phase 2 AML CR1 study the median OS from the time of initial AML diagnosis was 67.6 months. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 11, 2020, the World Health Organization declared the outbreak of a new coronavirus to be a &#8220;pandemic&#8221;. The COVID-19 pandemic continues to present substantial public health and economic challenges around the world which have impacted, and will continue to impact, millions of individuals and businesses worldwide. Efforts to contain the spread of the coronavirus since March 2020 have led to travel bans and restrictions, quarantines, shelter-in-place orders and shutdowns. As we have historically functioned operationally as a semi-virtual company, the transition to &#8220;work-from-home&#8221; for our employees has not materially altered our business operations. We have implemented a return-to-work policy in compliance with federal, state and local requirements and guidance, which provides for a hybrid of remote and in-office work, and we have operated on such a semi-virtual basis during the first half of 2021. We are continuously monitoring the impact of the pandemic on our clinical development programs. Our Phase 3 REGAL study is progressing, with the necessary work to activate additional sites in the United States and Europe continuing. Throughout 2020 and first half of 2021, we initiated additional sites as planned. However, we have observed that clinical site initiations and patient enrollment may be delayed due to prioritization of hospital resources towards the COVID-19 pandemic. Clinicians and patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt operations at sites. Accordingly, we are uncertain at this time the extent to which these newly initiated sites will be fully operational, which we believe could have an impact on the projected timing of the REGAL study. Additionally, several European Union countries in which we plan to initiate clinical sites, including Germany, France, and Italy, continue to impose restrictions in response to the continued surge in coronavirus cases throughout the European Union. We believe that the COVID-19 pandemic has not materially impacted our efforts to out-license NPS. The full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and cannot be predicted with confidence, including the actions taken to contain or treat COVID-19, the ultimate overall duration of the pandemic, the emergence of new variants of COVID-19, the emergence of new geographic hotspots where the coronavirus is spreading more rapidly, and continued or new travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, as well as the effectiveness of actions taken globally to contain and treat the coronavirus, including the availability of safe and effective vaccines and the uptake thereof and whether existing vaccines are effective with respect to new variants. In particular, the continued spread of the coronavirus globally could adversely impact our clinical trial operations and could have an adverse impact on our business and the financial results.</span></div><div><span><br/></span></div><div style="padding-right:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenue</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue consists of revenue recognized pursuant to our Exclusive License Agreement with 3D Medicines Inc., or 3DMed, dated December 7, 2020, or the 3DMed License Agreement. In the future, we may generate revenue from a combination of reimbursements, up-front payments, milestone payments and royalties in connection with the 3DMed License Agreement.</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of License Revenue</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of license revenue consists of sublicensing fees payable under our license from MSK in connection with the 3DMed License Agreement.</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of expenses incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred. These expenses include: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing expenses; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality control and quality assurance services;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">outsourced professional scientific development services; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, which include salaries, benefits and stock-based compensation; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payments made under our license agreements, under which we acquired certain intellectual property; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses relating to certain regulatory activities, including filing fees paid to regulatory agencies; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory materials and supplies used to support our research activities; and </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allocated expenses, utilities and other facility-related costs. </span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development of our current and future product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of, or when, if ever, material net cash inflows may commence from any current or future product candidates. This uncertainty is due to the numerous risks and uncertainties associated with the duration and cost of our clinical trials, which vary significantly over the life of a project as a result of many factors, including, but not limited to: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of clinical sites included in the trials; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the length of time required to enroll suitable patients; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of patients that ultimately participate in the trials; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the number of doses patients receive; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the duration of patient follow-up; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the results of clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the expenses associated with manufacturing; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the receipt of marketing approvals; </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the commercialization of current and future product candidates; and</span></div><div style="padding-left:72pt;text-indent:-9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the impact of the COVID-19 pandemic.</span></div><div style="padding-left:72pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Cancer immunotherapy product candidates in the later stages of clinical development generally have higher development costs than those in the earlier stages of clinical development, primarily due to the increased size and duration of the later-stage clinical trials. We expect our research and development expenses to increase for the foreseeable future as we conduct and complete our ongoing early and late stage clinical trials and initiate additional clinical trials. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals. We may never succeed in achieving regulatory approval for any of our current or future product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or target indications or focus on others. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials due to the COVID-19 pandemic or otherwise, we could be required to expend significant additional financial resources and time on the completion of clinical development. Cancer immunotherapy product commercialization may take several years and millions of dollars in development costs. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist principally of salaries and related costs for personnel in executive, administrative, finance and legal functions, including stock-based compensation, travel expenses and recruiting expenses, fees for outside legal counsel, amortization of contract acquisition costs (commissions), and director and officer insurance premiums. Other general and administrative expenses include facility related costs, patent filing and prosecution costs, professional fees for business development, accounting, consulting, legal and tax-related services associated with maintaining compliance with our Nasdaq listing and SEC reporting requirements, investor relations costs, and other expenses associated with being a public company.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and when we believe that regulatory approval of a product candidate appears likely, we anticipate that an increase in general and administrative expenses will occur as a result of our preparation for commercial operations, particularly as it relates to the sales and marketing of such product candidate. Cancer immunotherapy product commercialization may take several years and millions of dollars in development costs.</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Operating (Expense) Income, Net</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating (expense) income, net consists of changes in fair value of our warrant liability, changes in fair value of our contingent consideration, and interest income.  Interest income primarily reflects interest earned from our cash and cash equivalents.</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the 2020 Annual Report, we disclosed our critical accounting policies and estimates upon which our financial statements are derived. There have been no material changes to these policies since December&#160;31, 2020 that are not included in Note 3 of the accompanying consolidated financial statements for the six months ended June&#160;30, 2021. Readers are encouraged to read the 2020 Annual Report in conjunction with this Quarterly Report on Form 10-Q.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i45635ddbe06c42738d10dbb9cae11665_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Three and Six Months Ended June&#160;30, 2021 and 2020 </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:51.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,900&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of license revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,353&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,267&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,086&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,453)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,267)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,613)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,425)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:51.685%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.151%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,600&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,600&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of license revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,298&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,331&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,967&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,698)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,331)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,016)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,568)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,552&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further analysis of the changes and trends in our operating results are discussed below.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Revenue</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing revenue for the three and six months ended June 30, 2021 was $1.9 million and $7.6 million, respectively, and related to the out-licensing of intellectual property rights and transfer of technical know-how associated with the 3DMed License Agreement for the development and commercialization of GPS in China, Hong Kong, Macau, and Taiwan. There was no licensing revenue for the six months ended June 30, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of License Revenue</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred $0.1 million and $0.2&#160;million of sublicensing fees payable under our license from MSK in connection with the 3DMed License Agreement during the three and six months ended June 30, 2021, respectively. There was no cost of license revenue during for the six months ended June 30, 2020.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $3.5 million for the three months ended June 30, 2021 compared to $2.3 million for the three months ended June 30, 2020. The $1.2 million increase was primarily attributable to a $0.8 million increase in clinical trial expenses primarily related to our Phase 3 REGAL clinical trial of GPS in AML, a $0.4 million increase in manufacturing and drug supply costs due to the ramp up of the manufacture of clinical trial materials and registration batches of GPS, and a $0.1 million increase in personnel related expenses due to increased headcount. These increases were partially offset by a $0.1&#160;million decrease in licensing fees. We anticipate that our research and development expenses will increase in the future as we continue to advance the development of GPS, including our Phase 3 trial of GPS in AML and the ongoing basket trial of GPS in combination with pembrolizumab. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $7.7 million for the six months ended June 30, 2021 compared to $4.1 million for the six months ended June 30, 2020. The $3.6 million increase was primarily attributable to a $1.7&#160;million increase in manufacturing and drug supply costs due to the ramp up of the manufacture of clinical trial materials and registration batches of GPS, a technology transfer to a new contract manufacturer, and clinical drug supply purchase costs in the European Union as we prepared to open sites and enroll patients in European Union countries for our Phase 3 REGAL clinical trial for GPS in AML, a $1.5&#160;million increase in clinical trial expenses related to our ongoing Phase 3 REGAL clinical trial for GPS in AML, a $0.3&#160;million increase in personnel related expenses due to increased headcount, and a $0.1 million increase in clinical and regulatory consulting costs. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $2.8 million for the three months ended June 30, 2021 compared to $2.0 million for the three months ended June 30, 2020. The $0.8 million increase was primarily due to a $0.3 million amortization expense of our contract asset associated with the 3DMed License Agreement, a $0.4 million increase in legal fees as compared to the second quarter of 2020 in which we received a credit in legal fees that offset the majority of legal expenses incurred for the quarter, and a $0.2&#160;million increase in personnel related expenses due to a $0.1 million increase in stock based-based compensation and increased headcounts. These increases were partially offset by a $0.1 million decrease in other general and administrative related expenses. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $6.4 million for the six months ended June 30, 2021 compared to $4.2 million for the six months ended June 30, 2020. The $2.2 million increase was primarily due to a $1.1 million amortization expense of our contract asset associated with the 3DMed License Agreement, as well as a $0.8&#160;million increase in legal fees as compared to the first half of 2020 in which we received a credit in legal fees that offset the majority of legal expenses incurred for the period, and a $0.3&#160;million increase in personnel related expenses due a $0.1 million increase in stock-based compensation and increased headcount. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Operating Income (Expense), Net</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income (expense), net for the three and six months ended June 30, 2021 and 2020, respectively, was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-operating expense, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:40.5pt"><span><br/></span></div><div style="text-indent:40.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net non-operating income (expense) was nominal for the three months ended June 30, 2021 and 2020.</span></div><div style="text-indent:40.5pt"><span><br/></span></div><div style="text-indent:40.5pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net non-operating expense of $0.3 million during the six months ended June 30, 2021 was primarily due to the increase in the change in the fair value of the contingent consideration liability and a slight increase in the change in the fair value of the warrant liability partially offset by nominal interest income. The change in the fair value of the contingent consideration liability reflects the interest component of contingent consideration related to the passage of time. The increase in the estimated fair value of our warrant liability was primarily due to an increase in our common stock price. Interest income consisted of interest earned from our cash and cash equivalents.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of warrant liability and change in fair value of contingent consideration are non-cash in nature.</span></div><div style="text-indent:40.5pt"><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no income tax expense for the three and six months ended June 30, 2021 and 2020. We continue to maintain a full valuation allowance against our net deferred tax assets.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_79"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not generate any revenue from product sales during the three and six months ended June&#160;30, 2021 and 2020. Through June&#160;30, 2021, the Company has only generated licensing revenue from the 3DMed License Agreement. Since inception, we have incurred net losses, used net cash in our operations, and have funded substantially all of our operations through proceeds of the sale of equity securities and convertible notes. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2021, we entered into a Controlled Equity Offering</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement , or Sales Agreement, with Cantor Fitzgerald &amp; Co., or the "Agent. From time to time during the term of the Sales Agreement, we may offer and sell shares of common stock having an aggregate offering price up to a total of $50.0&#160;million in gross proceeds. The Agent will collect a fee equal to 3% of the gross sales price of all shares of common stock sold. Shares of common stock sold under the Sales Agreement will be offered and sold pursuant to our registration statement on Form S-3, which was filed with the SEC on April 16, 2021 and was declared effective on April 29, 2021.  During the three months ended June&#160;30, 2021 we sold 786,927 shares of our common stock pursuant to the Sales Agreement at an average price of $12.04 per share for aggregate net proceeds of approximately $9.0&#160;million. Other than the Sales Agreement, we do not have any commitments to obtain additional funds.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received $1.0&#160;million and $2.0&#160;million during the three and six months ended June&#160;30, 2021, respectively, for the achievement of certain development milestones pursuant to our 3DMed License Agreement. An additional $192.5&#160;million in potential future certain development, regulatory, and sales milestones remains under the 3DMed License Agreement which milestones are variable in nature and not under our control.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had an accumulated deficit of $124.9 million, cash and cash equivalents of $29.9 million, restricted cash and cash equivalents of $0.1 million, and a stock subscription receivable of $2.2 million, which cash was received in July 2021. In addition, we had accounts payable and accrued expenses and other current liabilities of $4.1 million as of June&#160;30, 2021. We expect our cash and cash equivalents, together with access to the Sales Agreement, will be sufficient to fund current planned operations for at least the next twelve months from the date of issuance of these financial statements, although we may pursue additional capital resources through public or private equity or debt financings or by establishing additional collaborations with other companies. Our expectations with respect to our ability to fund current planned operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management's estimates, we may need to seek additional strategic or financing opportunities sooner than would otherwise be expected. There is no guarantee that any of these strategic or financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders. If we are unable to obtain additional funding on a timely basis, we may be forced to significantly curtail, delay, or discontinue one or more of our planned research and development programs or be unable to expand our operations or otherwise prepare for the potential regulatory approval and commercialization of our product candidates, assuming positive data.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future operations are highly dependent on a combination of factors, including (i)&#160;the timely and successful completion of any additional financings, (ii)&#160;our ability to complete revenue-generating partnerships with pharmaceutical and biotechnology companies, (iii)&#160;the success of our research and development activities, (iv)&#160;the development of competitive therapies by other biotechnology and pharmaceutical companies, and, ultimately, (v)&#160;regulatory approval and market acceptance of our proposed future products. on is imminent.</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows from operating and financing activities for the six months ended June 30, 2021 and 2020 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,385)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,937)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no investing activities during the during the six months ended June&#160;30, 2021 and 2020.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities of $15.2 million during the six months ended June&#160;30, 2021 was primarily attributable to a $8.9&#160;million change in our operating assets and liabilities and our net loss of $7.0 million, which was offset by various net non-cash charges of $0.7&#160;million. The net change in our operating assets and liabilities of $8.9 million is primarily attributable to a decrease in deferred revenue of $5.6&#160;million, a $1.9&#160;million increase in prepaid expenses and other assets primarily for prepaid insurance premiums and clinical trial costs and a $2.5&#160;million decrease in accounts payable and accrued expenses and other current liabilities, partially offset by a $1.1 million decrease in contract acquisition costs related to the out-licensing of intellectual property rights and transfer of technical know-how associated with the 3DMed License Agreement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities of $10.2 million during the six months ended June 30, 2020 was primarily attributable to our net loss of $8.6 million and the prepayment of certain expenses and payment of certain payables. The net change in our operating assets and liabilities of $2.2 million is primarily attributable to an increase in prepaid expenses of $1.4 million and a $0.8 million decrease in accounts payable and accrued expenses and other current liabilities. The increase in prepaid expenses was primarily from payments of $1.0 million for insurance premiums and $0.4 million for clinical trial expenses related to our Phase 3 REGAL study.</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by Financing Activities</span></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generated $9.8 million of net cash from financing activities for the six months ended June&#160;30, 2021. We received $6.8&#160;million in net proceeds from the issuance of common stock under the Sales Agreement, with an additional $2.2 million in net proceeds received in July 2021, as well as $3.0&#160;million from the exercise of warrants to acquire shares of common stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generated $6.3 million of net cash from financing activities for the six months ended June 30, 2020. We received $6.0 million in net proceeds from the sale of securities in a registered direct offering in January 2020 and $0.3 million from the collection of our stock subscription receivable.</span></div><div><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_82"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into any off-balance sheet financing arrangements as of June&#160;30, 2021.</span></div><div><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_85"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_88"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this Quarterly Report on Form 10-Q, our principal executive officer and our principal financial officer (the &#8220;Certifying Officer&#8221;), evaluated the effectiveness of our disclosure controls and procedures. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure. Based on these evaluations, the Certifying Officers have concluded, that, as of the end of the period covered by this Quarterly Report on Form 10-Q:</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms; and</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">our disclosure controls and procedures were effective to provide reasonable assurance that material information required to be disclosed by us in the reports we file or submit under the Exchange Act was accumulated and communicated to our management, including the Certifying Officers, as appropriate to allow timely decisions regarding required disclosure.</span></div><div><span><br/></span></div><div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended June 30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i45635ddbe06c42738d10dbb9cae11665_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_94"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note 6 (Commitments and Contingencies) to our consolidated financial statements contained in Part I, Item 1 (Financial Statements) of this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.</span></div><div><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_97"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to our note on forward-looking statements on page 2 of this Quarterly Report on Form 10-Q, which is incorporated into this item by reference.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in our 2020 Annual Report. The risks described in such 2020 Annual Report are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition, operating results and stock price.</span></div><div><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_100"></div><div style="margin-bottom:12pt"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_103"></div><div style="margin-bottom:12pt"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_106"></div><div style="margin-bottom:12pt"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:12pt"><span><br/></span></div><div id="i45635ddbe06c42738d10dbb9cae11665_109"></div><div><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5. OTHER INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i45635ddbe06c42738d10dbb9cae11665_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6. EXHIBITS</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.203%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>#</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518117053/d556278dex31.htm">Composite Amended and Restated Certificate of Incorporation of the Registrant (formerly, Galena Biopharma, Inc.) amended as of December 27, 2017</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 13, 2018</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1390478/000119312518004463/d515897dex33.htm">Amended and Restated By-Laws of the Registrant</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 5, 2018</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sls-20160630ex101.htm">2021 Employee Stock Purchase Plan * **</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sls-20210630ex311.htm">Certification of Principal Executive Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.**</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sls-20210630ex312.htm">Certification of Principal Financial Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.**</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sls-20210630ex321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ***</a></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document.*</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema.*</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase.*</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase.*</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase.*</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase.*</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plans or arrangements.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">***</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The certification attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i45635ddbe06c42738d10dbb9cae11665_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SELLAS Life Sciences Group, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Angelos M. Stergiou</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angelos M. Stergiou, MD, ScD h.c.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 12, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>sls-20160630ex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i45e8487087af481aae6e58271f914222_33"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Exhibit 10.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">EMPLOYEE STOCK PURCHASE PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The following constitute the provisions of the 2021 Employee Stock Purchase Plan (the &#8220;Plan&#8221;) of Sellas Life Sciences Group, Inc. (the &#8220;Company&#8221;).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:27pt;text-decoration:underline">Purpose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock of the Company.  It is the intention of the Company to have the Plan qualify as an &#8220;Employee Stock Purchase Plan&#8221; under Section 423 of the Code.  The provisions of the Plan shall, accordingly, be construed so as to extend and limit participation in a manner consistent with the requirements of that section of the Code.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:27pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean the Board of Directors of the Company, or a committee of the Board of Directors named by the Board to administer the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean the Internal Revenue Code of 1986, as amended, including any successor statute, regulation and guidance thereto.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean the common stock, $0.0001 par value per share, of the Company.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(d.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean Sellas Life Sciences Group, Inc., a Delaware corporation.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(e.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean the regular rate of salary or wages received by the Employee from the Company or a Designated Subsidiary that is taxable income for federal income tax purposes or applicable tax law, including payments for overtime and shift premium, but excluding incentive compensation, incentive payments, bonuses, commissions, relocation, expense reimbursements, tuition or other reimbursements or compensation received from the Company or a Designated Subsidiary.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(f.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Continuous Status as an Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean the absence of any interruption or termination of service as an Employee.  Continuous Status as an Employee shall not be considered interrupted in the case of a leave of absence agreed to in writing by the Company, provided that such leave is for a period of not more than ninety (90) days or reemployment upon the expiration of such leave is guaranteed by contract or statute.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(g.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Contributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean all amounts credited to the account of a participant pursuant to the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(h.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Designated Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean the Subsidiaries which have been designated by the Board from time to time in its sole discretion as eligible to participate in the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean any person who is employed by the Company or one of its Designated Subsidiaries for tax purposes and who is customarily employed for at least </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">twenty (20) hours per week and more than five (5) months in a calendar year by the Company or one of its Designated Subsidiaries.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(j.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exercise Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean the last business day of each Offering Period of the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(k.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean with respect to an Offering Period, an amount equal to 85% of the fair market value (as defined in Section 7(b)) of a share of Common Stock on the Offering Date or on the Exercise Date, whichever is lower.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(l.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Offering Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean the first business day of each Offering Period of the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(m.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:15.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Offering Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean a period of six months as set forth in Section 4 of the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(n.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean this Sellas Life Sciences Group, Inc. Employee Stock Purchase Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(o.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; shall mean a corporation, domestic or foreign, of which not less than 50% of the voting shares are held by the Company or a Subsidiary, whether or not such corporation now exists or is hereafter organized or acquired by the Company or a Subsidiary.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:27pt;text-decoration:underline">Eligibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.7pt">Any person who has been continuously employed as an Employee for one (1) month as of the Offering Date of a given Offering Period shall be eligible to participate in such Offering Period under the Plan and further, subject to the requirements of Section 5(a) and the limitations imposed by Section 423(b) of the Code.  All Employees granted options under the Plan with respect to any Offering Period will have the same rights and privileges except for any differences that may be permitted pursuant to Section 423.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.02pt">Any provisions of the Plan to the contrary notwithstanding, no Employee shall be granted an option under the Plan (i) if, immediately after the grant, such Employee (or any other person whose stock would be attributed to such Employee pursuant to Section 424(d) of the Code) would own stock and&#47;or hold outstanding options to purchase stock possessing five percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or of any Subsidiary of the Company or (ii) which permits his or her rights to purchase stock under all employee stock purchase plans (described in Section 423 of the Code) of the Company and its Subsidiaries to accrue at a rate which exceeds $25,000 of fair market value of such stock as defined in Section 7(b) (determined at the time such option is granted) for each calendar year in which such option is outstanding at any time. In addition, the maximum number of shares of Common Stock that may be purchased by any participant during an Offering Period shall equal the lesser of (i) 5,000 shares of Common Stock or (ii) $25,000 divided by the fair market value of the Common Stock on the first trading day of such Offering Period, which price shall be adjusted if the price per share is adjusted pursuant to Section 18. </font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Any option granted under the Plan shall be deemed to be modified to the extent necessary to satisfy this Section 3(b).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:27pt;text-decoration:underline">Offering Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Plan shall be implemented by a series of Offering Periods, with a new Offering Period commencing on March 15 and September 15 of each year or the first business day thereafter (or at such other time or times as may be determined by the Board).  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:27pt;text-decoration:underline">Participation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.7pt">An</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">eligible Employee may become a participant in the Plan by completing an Enrollment Form provided by the Company and filing it with the Company or its designee at least ten (10) days prior to the applicable Offering Date, unless a later time for filing the Enrollment Form is set by the Board for all eligible Employees with respect to a given Offering Period.  The Enrollment Form and its submission may be electronic as directed by the Company.  The Enrollment Form shall set forth the percentage of the participant&#8217;s Compensation (which shall be not less than one percent (1%) and not more than twenty percent (20%) to be paid as Contributions pursuant to the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.02pt">Payroll deductions shall commence with the first payroll following the Offering Date, unless a later time is set by the Board with respect to a given Offering Period, and shall end on the last payroll paid on or prior to the Exercise Date of the Offering Period to which the Enrollment Form is applicable, unless sooner terminated as provided in Section 10.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:27pt;text-decoration:underline">Method of Payment of Contributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.7pt">Each participant shall elect to have payroll deductions made on each payroll during the Offering Period in an amount not less than one percent (1%) and not more than twenty percent (20%) of such participant&#8217;s Compensation on each such payroll (or such other percentage as the Board may establish from time to time before an Offering Date).  All payroll deductions made by a participant shall be credited to his or her account under the Plan.  A participant may not make any additional payments into such account.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">A participant may discontinue his or her participation in the Plan as provided in Section 10, or, on one occasion only during the Offering Period, may decrease, but may not increase, the rate of his or her Contributions during the Offering Period by completing and filing with the Company a new Enrollment Form authorizing a change in the deduction rate.  The change in rate shall be effective as of the beginning of the next payroll period following the date of filing of the new Enrollment Form, if the Enrollment Form is submitted at least ten (10) days prior to such date, and, if not, as of the beginning of the next succeeding payroll period.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.02pt">Notwithstanding the foregoing, to the extent necessary to comply with Section 423(b)(8) of the Code and Section 3(b), a participant&#8217;s payroll deductions may be decreased to 0% at such time during any Offering Period which is scheduled to end during the current calendar year that the aggregate of all payroll deductions accumulated with respect to such Offering Period and any other Offering Period ending within the same calendar year equals $21,250.  Payroll deductions shall recommence at the rate provided in such participant&#8217;s Enrollment Form at the beginning of the first Offering Period which is scheduled to end in the following calendar year, unless terminated by the participant as provided in Section 10.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:27pt;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.7pt">On the Offering Date of each Offering Period, each eligible Employee participating in such Offering Period shall be granted an option to purchase on the Exercise Date of such Offering Period a number of shares of the Common Stock determined by dividing such Employee&#8217;s Contributions accumulated prior to such Exercise Date and retained in the participant&#8217;s account as of the Exercise Date by the applicable Exercise Price&#59; provided however, that such purchase shall be subject to the limitations set forth in Sections 3(b) and 12.  The fair market value of a share of the Common Stock shall be determined as provided in Section 7(b).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.02pt">The fair market value of the Common Stock on a given date shall be (i) if the Common Stock is listed on a national securities exchange or traded in the over-the-counter market and sales prices are regularly reported for the Common Stock, the closing or last sale price of the Common Stock for such date (or, in the event that the Common Stock is not traded on such date, on the immediately preceding trading date), on the composite tape or other comparable reporting system&#59; or (ii) if the Common Stock is not listed on a national securities exchange and such price is not regularly reported, the mean between the bid and asked prices per share of the Common Stock at the close of trading in the over-the-counter market.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:27pt;text-decoration:underline">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Unless a participant withdraws from the Plan as provided in Section 10, his or her option for the purchase of shares will be exercised automatically on the Exercise Date of the Offering Period, and the maximum number of full shares subject to the option will be purchased for him or her at the applicable Exercise Price with the accumulated Contributions in his or her account.  If a fractional number of shares results, then such number shall be rounded down to the next whole number and any unapplied cash shall be carried forward to the next Exercise Date, unless the participant requests a cash payment.  The shares purchased upon exercise of an option hereunder shall be deemed to be transferred to the participant on the Exercise Date.  During a participant&#8217;s lifetime, a participant&#8217;s option to purchase shares hereunder is exercisable only by him or her.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:27pt;text-decoration:underline">Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Upon the written request of a participant, certificates representing the shares purchased upon exercise of an option will be issued as promptly as practicable after the Exercise Date of each Offering Period to participants who wish to hold their shares in certificate form, except that the Board may determine that such shares shall be held for each participant&#8217;s benefit by a broker designated by the Board.  Any payroll deductions accumulated in a participant&#8217;s account which are not sufficient to purchase a full Share shall be retained in the participant&#8217;s account for the subsequent Offering Period, subject to earlier withdrawal by the participant as provided in Section 10 below.  Any other amounts left over in a participant&#8217;s account after an Exercise Date shall be returned to the participant.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Withdrawal&#59; Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  A participant may withdraw all but not less than all the Contributions credited to his or her account under the Plan at any time prior to the Exercise Date of the Offering Period by giving written notice to the Company or its designee.  All of the participant&#8217;s Contributions credited to his or her account will be paid to him or her promptly after receipt of his or her notice of withdrawal and his or her option for the current period will be automatically terminated, and no further Contributions for the purchase of shares will be made during the Offering Period.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.7pt">Upon termination of the participant&#8217;s Continuous Status as an Employee prior to the Exercise Date of the Offering Period for any reason, including retirement or death, the Contributions credited to his or her account will be returned to him or her or, in the case of his or her death, to the person or persons entitled thereto under Section 14, and his or her option will be automatically terminated.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.02pt">In the event an Employee fails to remain in Continuous Status as an Employee for at least 20 hours per week during the Offering Period in which the Employee is a participant, he or she will be deemed to have elected to withdraw from the Plan and the Contributions credited to his or her account will be returned to him or her and his or her option terminated.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">A participant&#8217;s withdrawal from an Offering Period will not have any effect upon his or her eligibility to participate in a succeeding offering or in any similar plan which may hereafter be adopted by the Company.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  No interest shall accrue on the Contributions of a participant in the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.7pt">The maximum number of shares of Common Stock which shall be made available for sale under the Plan shall be 300,000 shares, subject to adjustment upon changes in capitalization of the Company as provided in Section 18.  If the total number of shares which would otherwise be subject to options granted pursuant to Section 7(a) on the Offering Date of an Offering Period exceeds the number of shares then available under the Plan (after deduction of all shares for which options have been exercised), the Company shall make a pro rata allocation of the shares remaining available for option grants in as uniform a manner as shall be practicable and as it shall determine to be equitable.  Any amounts remaining in an Employee&#8217;s account not applied to the purchase of shares pursuant to this Section 12 shall be refunded on or promptly after the Exercise Date.  In such event, the Company shall give written notice of such reduction of the number of shares subject to the option to each Employee affected thereby and shall similarly reduce the rate of Contributions, if necessary.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.02pt">The participant will have no interest or voting right in shares covered by his or her option until such option has been exercised.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Board shall supervise and administer the Plan and shall have full power to adopt, amend and rescind any rules deemed desirable and appropriate for the administration of the Plan and not inconsistent with the Plan, to construe and interpret the Plan, to correct any defect or supply any omission or reconcile any inconsistency or ambiguity in the Plan and to make all other determinations necessary or advisable for the administration of the Plan, including without limitation, adopting subplans applicable to particular Designated Subsidiaries or locations, which subplans may be designed to be outside the scope of Section 423 of the Code..</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Designation of Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  A participant may designate a beneficiary who is to receive any shares and cash, if any, from the participant&#8217;s account under the Plan in the event of such participant&#8217;s death subsequent to the end of the Offering Period but prior to delivery to him or her of such shares and cash.  In addition, a participant may designate a beneficiary who is to receive any cash from the participant&#8217;s account under the Plan in the event of such participant&#8217;s death prior to the Exercise Date of the Offering Period.  If a participant is married and the designated beneficiary is not the spouse, spousal consent shall be required for such designation to be effective.  Beneficiary designations shall be made either in writing or by electronic delivery as directed by the Company.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.7pt">Such designation of beneficiary may be changed by the participant (and his or her spouse, if any) at any time by submission of the required notice, which may be electronic.  In the event of the death of a participant and in the absence of a beneficiary validly designated under the Plan who is living at the time of such participant&#8217;s death, the Company shall deliver such shares and&#47;or cash to the executor or administrator of the estate of the participant, or if no such executor or administrator has been appointed (to the knowledge of the Company), the Company, in its discretion, may deliver such shares and&#47;or cash to the spouse or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">to any one or more dependents or relatives of the participant, or if no spouse, dependent or relative is known to the Company, then to such other person as the Company may designate.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Neither Contributions credited to a participant&#8217;s account nor any rights with regard to the exercise of an option or to receive shares under the Plan may be assigned, transferred, pledged or otherwise disposed of in any way (other than by will, the laws of descent and distribution or as provided in Section 14) by the participant.  Any such attempt at assignment, transfer, pledge or other disposition shall be without effect, except that the Company may treat such act as an election to withdraw funds in accordance with Section 10.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Use of Funds</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  All Contributions received or held by the Company under the Plan may be used by the Company for any corporate purpose, and the Company shall not be obligated to segregate such Contributions.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Reports</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Individual accounts will be maintained for each participant in the Plan.  Statements of account will be given to participating Employees promptly following the Exercise Date, which statements will set forth the amounts of Contributions, the per share purchase price, the number of shares purchased and the remaining cash balance, if any.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Adjustments upon Changes in Capitalization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Subject to any required action by the stockholders of the Company, the number of shares of Common Stock covered by unexercised options under the Plan and the number of shares of Common Stock which have been authorized for issuance under the Plan but are not yet subject to options under Section 12(a) (collectively, the &#8220;Reserves&#8221;), the maximum number of shares of Common Stock that may be purchased by a participant in an Offering Period set forth in Section 3(b) as well as the price per share of Common Stock covered by each unexercised option under the Plan, shall be proportionately adjusted for any increase or decrease in the number of issued shares of Common Stock resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Common Stock. Such adjustment shall be made by the Board, whose determination in that respect shall be final, binding and conclusive.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In the event of the proposed dissolution or liquidation of the Company, an Offering Period then in progress will terminate immediately prior to the consummation of such proposed action, unless otherwise provided by the Board.  In the event of a proposed sale of all or substantially all of the assets of the Company, or the merger, consolidation or other capital reorganization of the Company with or into another corporation, each option outstanding under the Plan shall be assumed or an equivalent option shall be substituted by such successor corporation or a parent or subsidiary of such successor corporation, unless the Board determines, in the exercise of its sole discretion and in lieu of such assumption or substitution, to shorten the Offering Period then in progress by setting a new Exercise Date (the &#8220;New Exercise Date&#8221;).  If the Board shortens the Offering Period then in progress in lieu of assumption or substitution in the event of a merger or sale of assets, the Board shall notify each participant in writing, at least ten days prior to the New Exercise Date, that the Exercise Date for his or her option has been changed to the New Exercise Date and that his or her option will be exercised automatically on the New Exercise Date, unless prior to such date he or she has withdrawn from the Offering Period as provided in Section 10.  For purposes of this section, an option granted under the Plan shall be deemed to be assumed if, following the sale of assets, merger or other reorganization, the option confers the right to purchase, for each share of Common Stock subject to the option immediately prior to the sale of assets, merger or other reorganization, the consideration (whether stock, cash or other securities or property) received in the sale of assets, merger or other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">reorganization by holders of Common Stock for each share of Common Stock held on the effective date of such transaction (and if such holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding shares of Common Stock)&#59; provided, however, that if such consideration received in such transaction was not solely common stock of the successor corporation or its parent (as defined in Section 424(e) of the Code), the Board may, with the consent of the successor corporation, provide for the consideration to be received upon exercise of the option to be solely common stock of the successor corporation or its parent equal in fair market value to the per share consideration received by holders of Common Stock in the sale of assets, merger or other reorganization.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The Board may, if it so determines in the exercise of its sole discretion, also make provision for adjusting the Reserves, as well as the price per share of Common Stock covered by each outstanding option, in the event that the Company effects one or more reorganizations, recapitalizations, rights offerings or other increases or reductions of shares of its outstanding Common Stock, and in the event of the Company being consolidated with or merged into any other corporation.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Amendment or Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.7pt">The Board may at any time terminate or amend the Plan.  Except as provided in Section 18, no such termination may affect options previously granted, nor may an amendment make any change in any option theretofore granted which adversely affects the rights of any participant provided that an Offering Period may be terminated by the Board on an Exercise Date or by the Board&#8217;s setting a new Exercise Date with respect to an Offering Period then in progress if the Board determines that termination of the Offering Period is in the best interests of the Company and the stockholders or if continuation of the Offering Period would cause the Company to incur adverse accounting charges in the generally-accepted accounting rules applicable to the Plan.  In addition, to the extent necessary to comply with Section 423 of the Code (or any successor rule or provision or any applicable law or regulation), the Company shall obtain stockholder approval in such a manner and to such a degree as so required.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b.)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:19.02pt">Without stockholder consent and without regard to whether any participant rights may be considered to have been adversely affected, the Board shall be entitled to change the Offering Periods, limit the frequency and&#47;or number of changes in the amount withheld during an Offering Period, establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars, permit payroll withholding in excess of the amount designated by a participant in order to adjust for delays or mistakes in the Company&#8217;s processing of properly completed withholding elections, establish reasonable waiting and adjustment periods and&#47;or accounting and crediting procedures to ensure that amounts applied toward the purchase of Common Stock for each participant properly correspond with amounts withheld from the participant&#8217;s Compensation, and establish such other limitations or procedures as the Board determines in its sole discretion advisable that are consistent with the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  All notices or other communications by a participant to the Company under or in connection with the Plan shall be deemed to have been duly given when received in the form specified by the Company at the location, or by the person, designated by the Company for the receipt thereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Conditions upon Issuance of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Shares shall not be issued with respect to an option unless the exercise of such option and the issuance and delivery of such shares pursuant </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">thereto shall comply with all applicable provisions of law, domestic or foreign, including, without limitation, the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, the rules and regulations promulgated thereunder, and the requirements of any stock exchange upon which the shares may then be listed, and shall be further subject to the approval of counsel for the Company with respect to such compliance.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">As a condition to the exercise of an option, the Company may require the person exercising such option to represent and warrant at the time of any such exercise that the shares are being purchased only for investment and without any present intention to sell or distribute such shares if, in the opinion of counsel for the Company, such a representation is required by any of the aforementioned applicable provisions of law.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Information Regarding Disqualifying Dispositions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  By electing to participate in the Plan, each participant agrees to provide any information about any transfer of shares of Common Stock acquired under the Plan that occurs within two years after the first business day of the Offering Period in which such shares were acquired as may be requested by the Company or any Subsidiaries in order to assist it in complying with the tax laws.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Right to Terminate Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Nothing in the Plan or in any agreement entered into pursuant to the Plan shall confer upon any Employee the right to continue in the employment of the Company or any Subsidiary, or affect any right which the Company or any Subsidiary may have to terminate the employment of such Employee.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Rights as a Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Neither the granting of an option nor a deduction from payroll shall constitute an Employee the owner of shares covered by an option.  No Employee shall have any right as a stockholder unless and until an option has been exercised, and the shares underlying the option have been registered in the Company&#8217;s share register.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Term of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The Plan became effective</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">upon its adoption by the Board on April 22, 2021 and shall continue in effect through April 22, 2031, unless sooner terminated under Section 19. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:21pt;text-decoration:underline">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This Plan shall be governed in accordance with the laws of the State of Delaware, applied without giving effect to any conflict-of-law principles.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>sls-20210630ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib563bc4413a948ddb4ff39e52233a02a_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Angelos M. Stergiou, certify that&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of SELLAS Life Sciences Group, Inc.&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.  The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; August&#160;12, 2021</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Angelos M. Stergiou</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angelos M. Stergiou, MD, ScD h.c.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer and Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>sls-20210630ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i26347e2255a1431a8f32901bd6c4dfc8_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Angelos M. Stergiou, certify that&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of SELLAS Life Sciences Group, Inc.&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; August&#160;12, 2021 </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Angelos M. Stergiou</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angelos M. Stergiou, MD, ScD h.c.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer and Principal Financial Officer)</font></td></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>sls-20210630ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i7b4d0ce23909423b96c19caa0cd9622a_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the accompanying Quarterly Report of SELLAS Life Sciences Group, Inc., (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. The information contained in the Report fairly presents, in all material respects, the Company&#8217;s financial condition and result of operations.</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:44.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Angelos M. Stergiou</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angelos M. Stergiou, MD, ScD h.c.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer and Principal Financial Officer)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August&#160;12, 2021</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A signed original of this written statement required by&#160;Rule&#160;13a-14(b)&#160;of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section&#160;1350 has been provided to the Registrant and will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This certification accompanies the Form&#160;10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></div><div><font><br></font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>sls-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:44c0be2c-a517-445c-901f-827aacd933ea,g:c47eecba-e87d-4369-b623-d76d853819d1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sls="http://www.sellaslife.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sellaslife.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sls-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sls-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sls-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sls-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sellaslife.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.sellaslife.com/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Liquidity" roleURI="http://www.sellaslife.com/role/Liquidity">
        <link:definition>2102102 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiquidityDetails" roleURI="http://www.sellaslife.com/role/LiquidityDetails">
        <link:definition>2403401 - Disclosure - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPolicies" roleURI="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPolicies">
        <link:definition>2104103 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesPolicies" roleURI="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies">
        <link:definition>2205201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesTables" roleURI="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTables">
        <link:definition>2306301 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails" roleURI="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails">
        <link:definition>2407402 - Disclosure - Basis of Presentation and Significant Accounting Policies - Stock Subscription Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails" roleURI="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails">
        <link:definition>2408403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Time - Vested Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" roleURI="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
        <link:definition>2409404 - Disclosure - Basis of Presentation and Significant Accounting Policies - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.sellaslife.com/role/FairValueMeasurements">
        <link:definition>2110104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.sellaslife.com/role/FairValueMeasurementsTables">
        <link:definition>2311302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails" roleURI="http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails">
        <link:definition>2412405 - Disclosure - Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails" roleURI="http://www.sellaslife.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails">
        <link:definition>2413406 - Disclosure - Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2414407 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccounts" roleURI="http://www.sellaslife.com/role/BalanceSheetAccounts">
        <link:definition>2115105 - Disclosure - Balance Sheet Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsTables" roleURI="http://www.sellaslife.com/role/BalanceSheetAccountsTables">
        <link:definition>2316303 - Disclosure - Balance Sheet Accounts (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2417408 - Disclosure - Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>2418409 - Disclosure - Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.sellaslife.com/role/CommitmentsandContingencies">
        <link:definition>2119106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.sellaslife.com/role/CommitmentsandContingenciesTables">
        <link:definition>2320304 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2421410 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details" roleURI="http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details">
        <link:definition>2422411 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities - 842 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1" roleURI="http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1">
        <link:definition>2422411 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities - 842 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.sellaslife.com/role/StockholdersEquity">
        <link:definition>2123107 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.sellaslife.com/role/StockholdersEquityTables">
        <link:definition>2324305 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.sellaslife.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2425412 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityCommonStockareReservedforFutureIssuanceDetails" roleURI="http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails">
        <link:definition>2426413 - Disclosure - Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoAcquireSharesofCommonStock" roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStock">
        <link:definition>2127108 - Disclosure - Warrants to Acquire Shares of Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoAcquireSharesofCommonStockTables" roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockTables">
        <link:definition>2328306 - Disclosure - Warrants to Acquire Shares of Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails" roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails">
        <link:definition>2429414 - Disclosure - Warrants to Acquire Shares of Common Stock - Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails" roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails">
        <link:definition>2430415 - Disclosure - Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoAcquireSharesofCommonStockNarrativeDetails" roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails">
        <link:definition>2431416 - Disclosure - Warrants to Acquire Shares of Common Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails" roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails">
        <link:definition>2432417 - Disclosure - Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseRevenuewith3DMedicinesInc" roleURI="http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesInc">
        <link:definition>2133109 - Disclosure - License Revenue with 3D Medicines, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseRevenuewith3DMedicinesIncTables" roleURI="http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncTables">
        <link:definition>2334307 - Disclosure - License Revenue with 3D Medicines, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseRevenuewith3DMedicinesIncNarrativeDetails" roleURI="http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails">
        <link:definition>2435418 - Disclosure - License Revenue with 3D Medicines, Inc. - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseRevenuewith3DMedicinesIncDeferredRevenueDetails" roleURI="http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncDeferredRevenueDetails">
        <link:definition>2436419 - Disclosure - License Revenue with 3D Medicines, Inc. - Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.sellaslife.com/role/StockBasedCompensation">
        <link:definition>2137110 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.sellaslife.com/role/StockBasedCompensationTables">
        <link:definition>2338308 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2439420 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2440421 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAllocatedStockbasedCompensationDetails" roleURI="http://www.sellaslife.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails">
        <link:definition>2441422 - Disclosure - Stock-Based Compensation - Allocated Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails" roleURI="http://www.sellaslife.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails">
        <link:definition>2442423 - Disclosure - Stock-Based Compensation - Assumptions for Option Grants Issued (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRSUActivityDetails" roleURI="http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails">
        <link:definition>2443424 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.sellaslife.com/role/SubsequentEvents">
        <link:definition>2144111 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sls_SaleOfStockAgentFeePercentageOfGrossProceeds" abstract="false" name="SaleOfStockAgentFeePercentageOfGrossProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sls_SaleOfStockAuthorizedAmount" abstract="false" name="SaleOfStockAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_ContractResearchPayable" abstract="false" name="ContractResearchPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved" abstract="false" name="ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_StockIssuedDuringPeriodValuePreFundedWarrant" abstract="false" name="StockIssuedDuringPeriodValuePreFundedWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_ChangeInFairValueOfContingentPurchasePriceConsideration" abstract="false" name="ChangeInFairValueOfContingentPurchasePriceConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_DividendArisingFromWarrantModifications" abstract="false" name="DividendArisingFromWarrantModifications" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_NonCashCharges" abstract="false" name="NonCashCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_July2020PIPEOfferingMember" abstract="true" name="July2020PIPEOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" abstract="false" name="FairValueOfWarrantLiabilityAssumptionsExpectedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sls_ChangeInFairValueOfContingentPurchaseConsideration" abstract="false" name="ChangeInFairValueOfContingentPurchaseConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_TwoThousandAndSeventeenEquityIncentivePlanMember" abstract="true" name="TwoThousandAndSeventeenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_July2018OfferingMember" abstract="true" name="July2018OfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfWarrantValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sls_WarrantsFairValueAssumptionsRiskFreeInterestRate" abstract="false" name="WarrantsFairValueAssumptionsRiskFreeInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sls_A2017EmployeeStockPurchasePlanMember" abstract="true" name="A2017EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_StockIssuedDuringPeriodValueCommonStockandWarrants" abstract="false" name="StockIssuedDuringPeriodValueCommonStockandWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion" abstract="false" name="ContingentPurchasePriceConsiderationNetOfCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_ClassofWarrantorRightOutstandingRollForward" abstract="true" name="ClassofWarrantorRightOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" abstract="false" name="EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sls_TwoThousandAndNineteenEquityIncentivePlanMember" abstract="true" name="TwoThousandAndNineteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_ClassOfWarrantOrRightNumberOfWarrantsExercised" abstract="false" name="ClassOfWarrantOrRightNumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sls_ClassOfWarrantOrRightNumberOfWarrantsIssued" abstract="false" name="ClassOfWarrantOrRightNumberOfWarrantsIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sls_MeasurementInputWeightedAverageCostOfCapitalMember" abstract="true" name="MeasurementInputWeightedAverageCostOfCapitalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_WarrantStrikePrice" abstract="false" name="WarrantStrikePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock" abstract="false" name="ChangesInFairValueOfWarrantLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" abstract="false" name="RestrictedCashAndCashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_A2021EmployeeStockPurchasePlanMember" abstract="true" name="A2021EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_StockIssuedDuringPeriodSharesPrefundedWarrant" abstract="false" name="StockIssuedDuringPeriodSharesPrefundedWarrant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sls_A2019EquityIncentivePlanMember" abstract="true" name="A2019EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_FairValueOfWarrantsLiabilities" abstract="false" name="FairValueOfWarrantsLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived" abstract="false" name="ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_OtherLiabilityClassifiedMember" abstract="true" name="OtherLiabilityClassifiedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_ChangeInOperatingLeaseRightOfUseAssets" abstract="false" name="ChangeInOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_ProceedsFromStockSubscriptionReceivable" abstract="false" name="ProceedsFromStockSubscriptionReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_InProcessResearchDevelopment" abstract="false" name="InProcessResearchDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_January2020OfferingMember" abstract="true" name="January2020OfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_OtherWarrantIssuesMember" abstract="true" name="OtherWarrantIssuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum" abstract="false" name="ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_ChangeInFairValueOfWarrantLiabilities" abstract="false" name="ChangeInFairValueOfWarrantLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_ContractWithCustomerLiabilityNewContractRevenueRecognized" abstract="false" name="ContractWithCustomerLiabilityNewContractRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_PrepaidProfessionalServices" abstract="false" name="PrepaidProfessionalServices" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sls_MeasurementInputCostOfDebtMember" abstract="true" name="MeasurementInputCostOfDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_OfficeSpaceLeaseExpiringDecember312024Member" abstract="true" name="OfficeSpaceLeaseExpiringDecember312024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_July2019OfferingMember" abstract="true" name="July2019OfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_IncreaseDecreaseInContractWithCustomerLiabilityNet" abstract="false" name="IncreaseDecreaseInContractWithCustomerLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments" abstract="false" name="ProceedsFromResearchAndDevelopmentArrangementMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_AptheraInc.Member" abstract="true" name="AptheraInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_ClosingPriceOfCommonStock" abstract="false" name="ClosingPriceOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sls_PrepaidResearchAndDevelopment" abstract="false" name="PrepaidResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_StockIssuedDuringPeriodSharesCommonStockandWarrants" abstract="false" name="StockIssuedDuringPeriodSharesCommonStockandWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sls_ResearchAndDevelopmentArrangementCashPaymentReceived" abstract="false" name="ResearchAndDevelopmentArrangementCashPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_ScheduleOfWarrantActivityTableTextBlock" abstract="false" name="ScheduleOfWarrantActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" abstract="false" name="ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_OperatingLeaseRemainingLeaseTerm" abstract="false" name="OperatingLeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sls_WarrantExerciseAgreementMember" abstract="true" name="WarrantExerciseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_NoncashOfferingExpense" abstract="false" name="NoncashOfferingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_CommonStockAreReservedForFutureIssuanceTableTextBlock" abstract="false" name="CommonStockAreReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sls_StockSubscriptionReceivable" abstract="false" name="StockSubscriptionReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_ClassofWarrantorRightFairValueRollForward" abstract="true" name="ClassofWarrantorRightFairValueRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm" abstract="false" name="ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sls_FairValueOfWarrantsPotentiallySettleableInCash" abstract="false" name="FairValueOfWarrantsPotentiallySettleableInCash" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sls_SalesAgreementMember" abstract="true" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sls_ClassofWarrantorRightCanceledOrExpired" abstract="false" name="ClassofWarrantorRightCanceledOrExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sls_WarrantsFairValueAssumptionsExpectedVolatility" abstract="false" name="WarrantsFairValueAssumptionsExpectedVolatility" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm" abstract="false" name="ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sls_StockSubscriptionReceivableCurrent" abstract="false" name="StockSubscriptionReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>sls-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:44c0be2c-a517-445c-901f-827aacd933ea,g:c47eecba-e87d-4369-b623-d76d853819d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sls-20210630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9e99b7c6-ffdd-4fbd-8cf0-83bd43eb9e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_69cc4d01-ed66-444d-a6f8-47350561842b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9e99b7c6-ffdd-4fbd-8cf0-83bd43eb9e9f" xlink:to="loc_us-gaap_AccountsPayableCurrent_69cc4d01-ed66-444d-a6f8-47350561842b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_31e721de-3f25-42e9-ad7a-06f57dd45233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9e99b7c6-ffdd-4fbd-8cf0-83bd43eb9e9f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_31e721de-3f25-42e9-ad7a-06f57dd45233" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ad1bcc2d-2455-4f58-b91c-62717bbe4801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9e99b7c6-ffdd-4fbd-8cf0-83bd43eb9e9f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ad1bcc2d-2455-4f58-b91c-62717bbe4801" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_44123fc5-6c34-4c6a-b980-0299d8eec186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9e99b7c6-ffdd-4fbd-8cf0-83bd43eb9e9f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_44123fc5-6c34-4c6a-b980-0299d8eec186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f15e8b16-ad34-4b4c-8506-45d28857e71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_695dee0f-3a0c-4a49-964b-a2537dfc44c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f15e8b16-ad34-4b4c-8506-45d28857e71f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_695dee0f-3a0c-4a49-964b-a2537dfc44c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_93e6782a-c9c8-4e0f-b3ae-af13a59213be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f15e8b16-ad34-4b4c-8506-45d28857e71f" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_93e6782a-c9c8-4e0f-b3ae-af13a59213be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockSubscriptionReceivableCurrent_cd0224a5-259f-4a34-b950-b37b3a438e3b" xlink:href="sls-20210630.xsd#sls_StockSubscriptionReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f15e8b16-ad34-4b4c-8506-45d28857e71f" xlink:to="loc_sls_StockSubscriptionReceivableCurrent_cd0224a5-259f-4a34-b950-b37b3a438e3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent_891f2f88-d474-4ec2-a756-f040d658474b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f15e8b16-ad34-4b4c-8506-45d28857e71f" xlink:to="loc_us-gaap_CapitalizedContractCostNetCurrent_891f2f88-d474-4ec2-a756-f040d658474b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a30c4d9-848a-4e15-9617-127dbd1a9768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f15e8b16-ad34-4b4c-8506-45d28857e71f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a30c4d9-848a-4e15-9617-127dbd1a9768" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_399b89e8-12f0-4543-a202-f0982b740123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9c288a32-0714-40aa-b97d-0a7af2dcea16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_399b89e8-12f0-4543-a202-f0982b740123" xlink:to="loc_us-gaap_Liabilities_9c288a32-0714-40aa-b97d-0a7af2dcea16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5d2b9c2e-5e51-4268-bd69-b00ba754e7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_399b89e8-12f0-4543-a202-f0982b740123" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5d2b9c2e-5e51-4268-bd69-b00ba754e7f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_69ca1a93-85a0-4d3f-b805-93728709c8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_399b89e8-12f0-4543-a202-f0982b740123" xlink:to="loc_us-gaap_StockholdersEquity_69ca1a93-85a0-4d3f-b805-93728709c8ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_08b24efa-21a4-4070-993d-3ddd491f48e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4d6fb2ff-4b10-4a78-a3fe-6a3ba0d686b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08b24efa-21a4-4070-993d-3ddd491f48e2" xlink:to="loc_us-gaap_AssetsCurrent_4d6fb2ff-4b10-4a78-a3fe-6a3ba0d686b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_acbf0568-9268-4209-b2fc-35a863f74611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08b24efa-21a4-4070-993d-3ddd491f48e2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_acbf0568-9268-4209-b2fc-35a863f74611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_InProcessResearchDevelopment_b2212a97-cede-4bd5-8413-266d269521ac" xlink:href="sls-20210630.xsd#sls_InProcessResearchDevelopment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08b24efa-21a4-4070-993d-3ddd491f48e2" xlink:to="loc_sls_InProcessResearchDevelopment_b2212a97-cede-4bd5-8413-266d269521ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9bf68d61-3337-42b3-86fe-178cc1f58b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08b24efa-21a4-4070-993d-3ddd491f48e2" xlink:to="loc_us-gaap_Goodwill_9bf68d61-3337-42b3-86fe-178cc1f58b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_8420f4f0-7db1-48bf-9334-b60743206186" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08b24efa-21a4-4070-993d-3ddd491f48e2" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_8420f4f0-7db1-48bf-9334-b60743206186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_942e9995-f84e-4abd-a6cc-30c636df41f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3055dc44-82c5-4306-9ab3-d1901b8fe971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_942e9995-f84e-4abd-a6cc-30c636df41f7" xlink:to="loc_us-gaap_LiabilitiesCurrent_3055dc44-82c5-4306-9ab3-d1901b8fe971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0404daf0-bbbc-4eb9-afa1-eca3eb023375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_942e9995-f84e-4abd-a6cc-30c636df41f7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0404daf0-bbbc-4eb9-afa1-eca3eb023375" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_761c180a-7bbf-490a-9ac6-73917752df14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_942e9995-f84e-4abd-a6cc-30c636df41f7" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_761c180a-7bbf-490a-9ac6-73917752df14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_FairValueOfWarrantsPotentiallySettleableInCash_da2125e4-672b-4bac-b765-c0fb276b9d9f" xlink:href="sls-20210630.xsd#sls_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_942e9995-f84e-4abd-a6cc-30c636df41f7" xlink:to="loc_sls_FairValueOfWarrantsPotentiallySettleableInCash_da2125e4-672b-4bac-b765-c0fb276b9d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion_33ded739-fa3a-4e2e-970b-ba3c813a6e98" xlink:href="sls-20210630.xsd#sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_942e9995-f84e-4abd-a6cc-30c636df41f7" xlink:to="loc_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion_33ded739-fa3a-4e2e-970b-ba3c813a6e98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bcae9e8b-452b-48af-8b17-8ba9832e1814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b1452c07-5590-4fbd-81e3-4c80831d393a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bcae9e8b-452b-48af-8b17-8ba9832e1814" xlink:to="loc_us-gaap_PreferredStockValue_b1452c07-5590-4fbd-81e3-4c80831d393a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_901e294d-dbca-4812-a94d-fae4d0c63ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bcae9e8b-452b-48af-8b17-8ba9832e1814" xlink:to="loc_us-gaap_CommonStockValue_901e294d-dbca-4812-a94d-fae4d0c63ec0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f4b4e7b2-244c-4643-a015-4e35f8d129b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bcae9e8b-452b-48af-8b17-8ba9832e1814" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f4b4e7b2-244c-4643-a015-4e35f8d129b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_69599298-49bf-485a-bd17-947df9456a78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bcae9e8b-452b-48af-8b17-8ba9832e1814" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_69599298-49bf-485a-bd17-947df9456a78" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sls-20210630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_080c931b-c29e-4158-bb03-a6803c9c6919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_16aa5741-5306-49a8-8bc3-4f3f83bbc513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_080c931b-c29e-4158-bb03-a6803c9c6919" xlink:to="loc_us-gaap_NetIncomeLoss_16aa5741-5306-49a8-8bc3-4f3f83bbc513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_DividendArisingFromWarrantModifications_91f6f2f0-de62-4fe3-8945-cb3b61335f88" xlink:href="sls-20210630.xsd#sls_DividendArisingFromWarrantModifications"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_080c931b-c29e-4158-bb03-a6803c9c6919" xlink:to="loc_sls_DividendArisingFromWarrantModifications_91f6f2f0-de62-4fe3-8945-cb3b61335f88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_bba434b2-44a4-455b-8a85-a8b54c2e722b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_dbefb008-9b3a-4970-b16b-71ef8e23bbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bba434b2-44a4-455b-8a85-a8b54c2e722b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_dbefb008-9b3a-4970-b16b-71ef8e23bbc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c6fe1750-8b9d-47a5-9f63-b30abb05d676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bba434b2-44a4-455b-8a85-a8b54c2e722b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c6fe1750-8b9d-47a5-9f63-b30abb05d676" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fcc844e4-ef3c-45d8-a105-27c0d821853d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_bba434b2-44a4-455b-8a85-a8b54c2e722b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fcc844e4-ef3c-45d8-a105-27c0d821853d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_8468f0bb-4faa-44ee-91c4-bd971bdf7516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_091b0a2d-c376-49b9-b3b8-39b268198b98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_8468f0bb-4faa-44ee-91c4-bd971bdf7516" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_091b0a2d-c376-49b9-b3b8-39b268198b98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangeInFairValueOfContingentPurchasePriceConsideration_ed0b14c0-3322-4305-b864-70390e478f4f" xlink:href="sls-20210630.xsd#sls_ChangeInFairValueOfContingentPurchasePriceConsideration"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_8468f0bb-4faa-44ee-91c4-bd971bdf7516" xlink:to="loc_sls_ChangeInFairValueOfContingentPurchasePriceConsideration_ed0b14c0-3322-4305-b864-70390e478f4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_2b5cd1e1-afbf-42f1-b2fc-d51f563ba7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_8468f0bb-4faa-44ee-91c4-bd971bdf7516" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_2b5cd1e1-afbf-42f1-b2fc-d51f563ba7fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_89398aae-a40a-4e61-9d3a-9dbb1843cf75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f85c0d84-dc99-4dc9-b86c-de932e9d3839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_89398aae-a40a-4e61-9d3a-9dbb1843cf75" xlink:to="loc_us-gaap_OperatingIncomeLoss_f85c0d84-dc99-4dc9-b86c-de932e9d3839" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_4aed720d-6e8f-4500-8e74-d089dc57a7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_89398aae-a40a-4e61-9d3a-9dbb1843cf75" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_4aed720d-6e8f-4500-8e74-d089dc57a7a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7eb69136-bdd7-4edd-9809-5e985c6f8343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_245a29ba-5591-4af6-b760-d54e6460310d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7eb69136-bdd7-4edd-9809-5e985c6f8343" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_245a29ba-5591-4af6-b760-d54e6460310d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e7cbf000-004f-4203-94b3-406745537b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7eb69136-bdd7-4edd-9809-5e985c6f8343" xlink:to="loc_us-gaap_CostsAndExpenses_e7cbf000-004f-4203-94b3-406745537b79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7835f149-4351-412f-ab0d-8e7815e3f00d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1dc582fc-96d8-4686-a9f6-e6040cd9d9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7835f149-4351-412f-ab0d-8e7815e3f00d" xlink:to="loc_us-gaap_NetIncomeLoss_1dc582fc-96d8-4686-a9f6-e6040cd9d9c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_DividendArisingFromWarrantModifications_2bdb8034-08be-4ee5-a897-5c76d7560bc6" xlink:href="sls-20210630.xsd#sls_DividendArisingFromWarrantModifications"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_7835f149-4351-412f-ab0d-8e7815e3f00d" xlink:to="loc_sls_DividendArisingFromWarrantModifications_2bdb8034-08be-4ee5-a897-5c76d7560bc6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sls-20210630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b013027-2474-42a1-8adf-886a56569b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a9480cce-cb7a-4b3c-9d8a-4b9f9fb33f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b013027-2474-42a1-8adf-886a56569b5a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a9480cce-cb7a-4b3c-9d8a-4b9f9fb33f35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ProceedsFromStockSubscriptionReceivable_3b37a58f-0170-42a0-8759-6594b6c74a27" xlink:href="sls-20210630.xsd#sls_ProceedsFromStockSubscriptionReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b013027-2474-42a1-8adf-886a56569b5a" xlink:to="loc_sls_ProceedsFromStockSubscriptionReceivable_3b37a58f-0170-42a0-8759-6594b6c74a27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_eadb9468-093b-4c79-b35c-0cabe3b222cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3b013027-2474-42a1-8adf-886a56569b5a" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_eadb9468-093b-4c79-b35c-0cabe3b222cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_48d58c91-9c76-4ae8-953d-7f8f6313555e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77bdfac8-c4eb-41d1-99b8-20dd63887cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_48d58c91-9c76-4ae8-953d-7f8f6313555e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_77bdfac8-c4eb-41d1-99b8-20dd63887cc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_47a791d7-4315-49f0-a6de-a256913d15f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_48d58c91-9c76-4ae8-953d-7f8f6313555e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_47a791d7-4315-49f0-a6de-a256913d15f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96eac351-9624-496a-8149-a5c524d12108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bd0636f4-b2df-42f7-ba37-48e0a74027be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96eac351-9624-496a-8149-a5c524d12108" xlink:to="loc_us-gaap_NetIncomeLoss_bd0636f4-b2df-42f7-ba37-48e0a74027be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d38a7ac3-6996-4b97-9e89-b34be7d490b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96eac351-9624-496a-8149-a5c524d12108" xlink:to="loc_us-gaap_ShareBasedCompensation_d38a7ac3-6996-4b97-9e89-b34be7d490b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangeInOperatingLeaseRightOfUseAssets_f434b6f3-1f20-41ba-bf0d-f19d63797d90" xlink:href="sls-20210630.xsd#sls_ChangeInOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96eac351-9624-496a-8149-a5c524d12108" xlink:to="loc_sls_ChangeInOperatingLeaseRightOfUseAssets_f434b6f3-1f20-41ba-bf0d-f19d63797d90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_c21b4b3b-fda2-435e-82c5-02e7cc18ecf5" xlink:href="sls-20210630.xsd#sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96eac351-9624-496a-8149-a5c524d12108" xlink:to="loc_sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_c21b4b3b-fda2-435e-82c5-02e7cc18ecf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangeInFairValueOfContingentPurchaseConsideration_0f6634d3-f049-4377-8fab-4a06a91a2bf1" xlink:href="sls-20210630.xsd#sls_ChangeInFairValueOfContingentPurchaseConsideration"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96eac351-9624-496a-8149-a5c524d12108" xlink:to="loc_sls_ChangeInFairValueOfContingentPurchaseConsideration_0f6634d3-f049-4377-8fab-4a06a91a2bf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_69cbb1f1-e958-4777-b528-35a29c523025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96eac351-9624-496a-8149-a5c524d12108" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_69cbb1f1-e958-4777-b528-35a29c523025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19c12788-508f-4f83-91e2-a3161478a68f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96eac351-9624-496a-8149-a5c524d12108" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_19c12788-508f-4f83-91e2-a3161478a68f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8f201b68-d035-4f24-acaa-1b39475b50cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96eac351-9624-496a-8149-a5c524d12108" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_8f201b68-d035-4f24-acaa-1b39475b50cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8392910-c85d-4021-8a3c-1f5296bd9654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96eac351-9624-496a-8149-a5c524d12108" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8392910-c85d-4021-8a3c-1f5296bd9654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_IncreaseDecreaseInContractWithCustomerLiabilityNet_cd0bc285-5717-4040-bef7-1a58a9cc44da" xlink:href="sls-20210630.xsd#sls_IncreaseDecreaseInContractWithCustomerLiabilityNet"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_96eac351-9624-496a-8149-a5c524d12108" xlink:to="loc_sls_IncreaseDecreaseInContractWithCustomerLiabilityNet_cd0bc285-5717-4040-bef7-1a58a9cc44da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e21b3cdb-14cc-4b32-af85-5499a3f3aa07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0ff89927-ad1b-472d-a47b-84f554df944b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e21b3cdb-14cc-4b32-af85-5499a3f3aa07" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0ff89927-ad1b-472d-a47b-84f554df944b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure_04523295-aed0-4723-9f26-981612a4f3b8" xlink:href="sls-20210630.xsd#sls_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e21b3cdb-14cc-4b32-af85-5499a3f3aa07" xlink:to="loc_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure_04523295-aed0-4723-9f26-981612a4f3b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_87697c2e-bb5d-4126-904b-8d48b01068a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_FairValueOfWarrantsPotentiallySettleableInCash_3ea86f0c-2eee-492d-bcff-784cd75afa10" xlink:href="sls-20210630.xsd#sls_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_87697c2e-bb5d-4126-904b-8d48b01068a9" xlink:to="loc_sls_FairValueOfWarrantsPotentiallySettleableInCash_3ea86f0c-2eee-492d-bcff-784cd75afa10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_12526b3a-397f-454c-b5bc-0ea9e4d853f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_87697c2e-bb5d-4126-904b-8d48b01068a9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_12526b3a-397f-454c-b5bc-0ea9e4d853f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cea5020b-478c-473b-9afd-456d177e122d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_80524588-c1da-4b36-8de5-269f632eec21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cea5020b-478c-473b-9afd-456d177e122d" xlink:to="loc_us-gaap_PrepaidInsurance_80524588-c1da-4b36-8de5-269f632eec21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_PrepaidResearchAndDevelopment_5e56b404-c05e-4a76-bb27-d67a38c1227f" xlink:href="sls-20210630.xsd#sls_PrepaidResearchAndDevelopment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cea5020b-478c-473b-9afd-456d177e122d" xlink:to="loc_sls_PrepaidResearchAndDevelopment_5e56b404-c05e-4a76-bb27-d67a38c1227f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_PrepaidProfessionalServices_a76e075f-eb01-43f1-b0df-3136370bc548" xlink:href="sls-20210630.xsd#sls_PrepaidProfessionalServices"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cea5020b-478c-473b-9afd-456d177e122d" xlink:to="loc_sls_PrepaidProfessionalServices_a76e075f-eb01-43f1-b0df-3136370bc548" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_83996953-6348-47db-b60c-8c2c0bf732d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cea5020b-478c-473b-9afd-456d177e122d" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_83996953-6348-47db-b60c-8c2c0bf732d9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8adac35e-fc1f-4676-9fd3-0b845b99309e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ContractResearchPayable_599f8513-61ec-4fcb-8e07-457cbaefc567" xlink:href="sls-20210630.xsd#sls_ContractResearchPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8adac35e-fc1f-4676-9fd3-0b845b99309e" xlink:to="loc_sls_ContractResearchPayable_599f8513-61ec-4fcb-8e07-457cbaefc567" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_160ed429-5a26-4a57-a68b-ab9033ed58f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8adac35e-fc1f-4676-9fd3-0b845b99309e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_160ed429-5a26-4a57-a68b-ab9033ed58f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_c5502a9d-9a76-4707-8438-318cfcf69728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8adac35e-fc1f-4676-9fd3-0b845b99309e" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_c5502a9d-9a76-4707-8438-318cfcf69728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f0e570f7-d4f9-43fb-b8b2-b86eb15cefe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_8adac35e-fc1f-4676-9fd3-0b845b99309e" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f0e570f7-d4f9-43fb-b8b2-b86eb15cefe2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details" xlink:type="simple" xlink:href="sls-20210630.xsd#CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"/>
  <link:calculationLink xlink:role="http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae7d1084-500d-43bf-a418-f4d065449713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_dd9119bb-1f80-4cd8-aefd-d210d2ca0a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae7d1084-500d-43bf-a418-f4d065449713" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_dd9119bb-1f80-4cd8-aefd-d210d2ca0a44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_56b6185c-efa6-435d-b193-c4d71926355b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae7d1084-500d-43bf-a418-f4d065449713" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_56b6185c-efa6-435d-b193-c4d71926355b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ef685d38-1391-4059-8449-6668cdb69ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae7d1084-500d-43bf-a418-f4d065449713" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ef685d38-1391-4059-8449-6668cdb69ed9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4c6ea1b8-b7b7-4336-992d-6607721ed34e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ae7d1084-500d-43bf-a418-f4d065449713" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4c6ea1b8-b7b7-4336-992d-6607721ed34e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1" xlink:type="simple" xlink:href="sls-20210630.xsd#CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1"/>
  <link:calculationLink xlink:role="http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6ca7d60b-dc00-434c-8efd-2df44565ceb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a95ba212-f130-49c9-860c-ce239697ecdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6ca7d60b-dc00-434c-8efd-2df44565ceb9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a95ba212-f130-49c9-860c-ce239697ecdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d0df040b-756c-4c6c-b64c-9c4ee440ac66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6ca7d60b-dc00-434c-8efd-2df44565ceb9" xlink:to="loc_us-gaap_OperatingLeaseLiability_d0df040b-756c-4c6c-b64c-9c4ee440ac66" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"/>
  <link:calculationLink xlink:role="http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_cd73f3ca-8a45-4e63-aa89-7c88554ed3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_40c54dfd-95d2-48cd-901b-aad52d4de2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_cd73f3ca-8a45-4e63-aa89-7c88554ed3bc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_40c54dfd-95d2-48cd-901b-aad52d4de2fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25f0f4ec-b31f-4d5c-b8c7-987c406ab097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_cd73f3ca-8a45-4e63-aa89-7c88554ed3bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25f0f4ec-b31f-4d5c-b8c7-987c406ab097" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_61ac42f8-8a1c-4b94-a5ad-865f95cb944e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_cd73f3ca-8a45-4e63-aa89-7c88554ed3bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_61ac42f8-8a1c-4b94-a5ad-865f95cb944e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_43fcc956-a0ee-4628-bf9b-cfc6ece34e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_cd73f3ca-8a45-4e63-aa89-7c88554ed3bc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_43fcc956-a0ee-4628-bf9b-cfc6ece34e69" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>sls-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:44c0be2c-a517-445c-901f-827aacd933ea,g:c47eecba-e87d-4369-b623-d76d853819d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sls-20210630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i22f40718f99c4ede92c33a622f67159b_CONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_809bca3f-55c7-476e-9436-79ac22be6ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_809bca3f-55c7-476e-9436-79ac22be6ad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9042991e-196f-41ea-8d77-47da249d83bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9042991e-196f-41ea-8d77-47da249d83bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_18cc0401-3b07-465b-97ee-4fd62fc99670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_PreferredStockSharesIssued_18cc0401-3b07-465b-97ee-4fd62fc99670" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3461169a-f39c-4a6a-9621-b8bb9f915159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3461169a-f39c-4a6a-9621-b8bb9f915159" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5fccff37-371c-48d5-b2d3-b55674c37b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5fccff37-371c-48d5-b2d3-b55674c37b6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7e6cb5cc-a96a-46dd-82ec-4c948232604f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7e6cb5cc-a96a-46dd-82ec-4c948232604f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ab94c44e-5878-4bc1-86f3-ca84c1e4e469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_CommonStockSharesIssued_ab94c44e-5878-4bc1-86f3-ca84c1e4e469" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cbda0763-7b11-4e7f-90ab-f2be9f1406f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cbda0763-7b11-4e7f-90ab-f2be9f1406f0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1ab399c7-d122-47d4-8d8f-e5e620e961df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_StatementTable_1ab399c7-d122-47d4-8d8f-e5e620e961df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9d786895-2c4d-49f0-bc75-6c32f27bfeff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1ab399c7-d122-47d4-8d8f-e5e620e961df" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9d786895-2c4d-49f0-bc75-6c32f27bfeff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9d786895-2c4d-49f0-bc75-6c32f27bfeff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9d786895-2c4d-49f0-bc75-6c32f27bfeff" xlink:to="loc_us-gaap_ClassOfStockDomain_9d786895-2c4d-49f0-bc75-6c32f27bfeff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b55fec9d-3bd4-4525-9a82-33e768eaefca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9d786895-2c4d-49f0-bc75-6c32f27bfeff" xlink:to="loc_us-gaap_ClassOfStockDomain_b55fec9d-3bd4-4525-9a82-33e768eaefca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2afd0c0f-5aef-4b54-b7f1-2eaf6e841c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b55fec9d-3bd4-4525-9a82-33e768eaefca" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2afd0c0f-5aef-4b54-b7f1-2eaf6e841c37" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sls-20210630.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="ie14a850d4491492890d5b4406a893a93_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bdd6c731-5461-483b-b46d-53aadcf2d065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bdd6c731-5461-483b-b46d-53aadcf2d065" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_163c778a-ac26-4a35-b868-60aa4bffbeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_us-gaap_SharesOutstanding_163c778a-ac26-4a35-b868-60aa4bffbeb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_330c319c-3ee1-4b7d-b2e0-6e654770e15d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_us-gaap_StockholdersEquity_330c319c-3ee1-4b7d-b2e0-6e654770e15d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants_8bc3572a-dc72-47ca-9980-709c5f43e347" xlink:href="sls-20210630.xsd#sls_StockIssuedDuringPeriodSharesCommonStockandWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants_8bc3572a-dc72-47ca-9980-709c5f43e347" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockIssuedDuringPeriodValueCommonStockandWarrants_3697e7fc-409f-4e47-970f-77691f936d39" xlink:href="sls-20210630.xsd#sls_StockIssuedDuringPeriodValueCommonStockandWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_sls_StockIssuedDuringPeriodValueCommonStockandWarrants_3697e7fc-409f-4e47-970f-77691f936d39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e8f4638b-2703-49af-bfd1-26c74d3967f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e8f4638b-2703-49af-bfd1-26c74d3967f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_231087dd-93bd-4c18-b935-932e8ae9b6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_231087dd-93bd-4c18-b935-932e8ae9b6ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockIssuedDuringPeriodSharesPrefundedWarrant_60ccd6c0-eef6-4fce-9123-af6d622c9fd1" xlink:href="sls-20210630.xsd#sls_StockIssuedDuringPeriodSharesPrefundedWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_sls_StockIssuedDuringPeriodSharesPrefundedWarrant_60ccd6c0-eef6-4fce-9123-af6d622c9fd1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockIssuedDuringPeriodValuePreFundedWarrant_09dfeecc-2276-4808-8bf4-e0c9941bb57d" xlink:href="sls-20210630.xsd#sls_StockIssuedDuringPeriodValuePreFundedWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_sls_StockIssuedDuringPeriodValuePreFundedWarrant_09dfeecc-2276-4808-8bf4-e0c9941bb57d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f3e6a575-1929-4b24-b1bd-cf670b84988a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f3e6a575-1929-4b24-b1bd-cf670b84988a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d9c6d9c7-e2e5-474b-b2ee-e7134f586412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_us-gaap_NetIncomeLoss_d9c6d9c7-e2e5-474b-b2ee-e7134f586412" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e90682f9-2fe5-4269-afd0-0ff4c16b9e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3c19b6c6-cefd-4e13-9594-6cb91ef28a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_08d043c3-005a-4b87-9510-d1b051e2f557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bdd6c731-5461-483b-b46d-53aadcf2d065" xlink:to="loc_us-gaap_StatementTable_08d043c3-005a-4b87-9510-d1b051e2f557" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_83074622-b249-464f-adaf-a065a6591614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_08d043c3-005a-4b87-9510-d1b051e2f557" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_83074622-b249-464f-adaf-a065a6591614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_83074622-b249-464f-adaf-a065a6591614_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_83074622-b249-464f-adaf-a065a6591614" xlink:to="loc_us-gaap_EquityComponentDomain_83074622-b249-464f-adaf-a065a6591614_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ceb8228f-444a-4a4a-b3b7-71bea0df62d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_83074622-b249-464f-adaf-a065a6591614" xlink:to="loc_us-gaap_EquityComponentDomain_ceb8228f-444a-4a4a-b3b7-71bea0df62d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_89ed2246-9b6c-4fb5-8313-1f94c0e0647a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ceb8228f-444a-4a4a-b3b7-71bea0df62d0" xlink:to="loc_us-gaap_CommonStockMember_89ed2246-9b6c-4fb5-8313-1f94c0e0647a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8d66e6a9-7de6-4c85-9cc9-5cffbd25f039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ceb8228f-444a-4a4a-b3b7-71bea0df62d0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8d66e6a9-7de6-4c85-9cc9-5cffbd25f039" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_87042f6f-6568-44be-a00f-86dea1ffbdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ceb8228f-444a-4a4a-b3b7-71bea0df62d0" xlink:to="loc_us-gaap_RetainedEarningsMember_87042f6f-6568-44be-a00f-86dea1ffbdf9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/LiquidityDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#LiquidityDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/LiquidityDetails" xlink:type="extended" id="i168ff07664c8443c92e5b91b1e4fe3d6_LiquidityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_944dbc57-4ae6-4723-b75a-86a521d886b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_944dbc57-4ae6-4723-b75a-86a521d886b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e309a0f0-9ec9-48db-b0d0-2d820362b912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_NetIncomeLoss_e309a0f0-9ec9-48db-b0d0-2d820362b912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf4a5bb5-7bc8-4983-b175-be9515d2d7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf4a5bb5-7bc8-4983-b175-be9515d2d7a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2d89550a-1e1e-4c5e-9ce1-c2cbe2940699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2d89550a-1e1e-4c5e-9ce1-c2cbe2940699" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d58a45a5-8a2c-4e70-a6a0-1f947cb1fdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d58a45a5-8a2c-4e70-a6a0-1f947cb1fdf9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_094ba92c-8f84-4803-9885-35341ba5e94b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_094ba92c-8f84-4803-9885-35341ba5e94b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_af4f919c-3651-4abe-a5b8-f65f40d7b45d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_af4f919c-3651-4abe-a5b8-f65f40d7b45d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_NonCashCharges_313637f5-51f3-4fc2-a3a1-c67a032fcd4c" xlink:href="sls-20210630.xsd#sls_NonCashCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_sls_NonCashCharges_313637f5-51f3-4fc2-a3a1-c67a032fcd4c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_SaleOfStockAuthorizedAmount_baaeb34a-2c20-42dc-8a53-1b5fa5ffc4d8" xlink:href="sls-20210630.xsd#sls_SaleOfStockAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_sls_SaleOfStockAuthorizedAmount_baaeb34a-2c20-42dc-8a53-1b5fa5ffc4d8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_SaleOfStockAgentFeePercentageOfGrossProceeds_6ab8c82d-c5e0-4209-9501-d6cab730d2bd" xlink:href="sls-20210630.xsd#sls_SaleOfStockAgentFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_sls_SaleOfStockAgentFeePercentageOfGrossProceeds_6ab8c82d-c5e0-4209-9501-d6cab730d2bd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_293f85b6-8478-48f9-a9d8-ebdc62decf15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_293f85b6-8478-48f9-a9d8-ebdc62decf15" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_9900f8f0-52ce-4b97-8b96-29bcd816bc02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_9900f8f0-52ce-4b97-8b96-29bcd816bc02" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_764eed43-a643-4c7c-891c-bc4aba9eae8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_764eed43-a643-4c7c-891c-bc4aba9eae8b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments_e76ce593-19e7-4107-955a-58fd87b09e40" xlink:href="sls-20210630.xsd#sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments_e76ce593-19e7-4107-955a-58fd87b09e40" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived_b779e860-e8bd-4b25-a976-2d80b1da447e" xlink:href="sls-20210630.xsd#sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived_b779e860-e8bd-4b25-a976-2d80b1da447e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a963b40-16c4-4cce-aed4-5100df2df950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a963b40-16c4-4cce-aed4-5100df2df950" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_bb4ca061-858d-4e20-93bb-e606fadf3b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_bb4ca061-858d-4e20-93bb-e606fadf3b1f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockSubscriptionReceivableCurrent_506f5682-087b-43ad-b12d-10e6e1a8f7ab" xlink:href="sls-20210630.xsd#sls_StockSubscriptionReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_sls_StockSubscriptionReceivableCurrent_506f5682-087b-43ad-b12d-10e6e1a8f7ab" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7562828-b229-4262-87f1-bd0f5cf54ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7562828-b229-4262-87f1-bd0f5cf54ea9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_112882fa-d605-4677-83a1-acd15cdd6034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7562828-b229-4262-87f1-bd0f5cf54ea9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_112882fa-d605-4677-83a1-acd15cdd6034" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_112882fa-d605-4677-83a1-acd15cdd6034_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_112882fa-d605-4677-83a1-acd15cdd6034" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_112882fa-d605-4677-83a1-acd15cdd6034_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3aecc25-e191-494e-a644-3528343fd9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_112882fa-d605-4677-83a1-acd15cdd6034" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3aecc25-e191-494e-a644-3528343fd9c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_SalesAgreementMember_c7eae009-df74-4d98-8efa-d180c917de1b" xlink:href="sls-20210630.xsd#sls_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3aecc25-e191-494e-a644-3528343fd9c2" xlink:to="loc_sls_SalesAgreementMember_c7eae009-df74-4d98-8efa-d180c917de1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_61e2a020-ee72-4eef-9634-79add2c4c5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7562828-b229-4262-87f1-bd0f5cf54ea9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_61e2a020-ee72-4eef-9634-79add2c4c5a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_61e2a020-ee72-4eef-9634-79add2c4c5a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_61e2a020-ee72-4eef-9634-79add2c4c5a9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_61e2a020-ee72-4eef-9634-79add2c4c5a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e078a494-b98a-40b0-9e8a-112bdf6b2137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_61e2a020-ee72-4eef-9634-79add2c4c5a9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e078a494-b98a-40b0-9e8a-112bdf6b2137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c4ec7c66-2bba-41a6-9ae0-9fdc9b112e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e078a494-b98a-40b0-9e8a-112bdf6b2137" xlink:to="loc_us-gaap_SubsequentEventMember_c4ec7c66-2bba-41a6-9ae0-9fdc9b112e70" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails" xlink:type="extended" id="i4b4bcb24d9d049f6b565b3483514c787_BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3748b5fd-2412-4f15-aefa-9be6e5c5b16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8555103d-76b3-4145-826f-8b5448c6b6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3748b5fd-2412-4f15-aefa-9be6e5c5b16d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8555103d-76b3-4145-826f-8b5448c6b6a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_30809d03-bdf8-4fe5-972c-cd4618fe832b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3748b5fd-2412-4f15-aefa-9be6e5c5b16d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_30809d03-bdf8-4fe5-972c-cd4618fe832b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_22e895a8-5fea-4d05-b934-637a48dac60a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3748b5fd-2412-4f15-aefa-9be6e5c5b16d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_22e895a8-5fea-4d05-b934-637a48dac60a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cd031602-eeba-4dfb-9151-a41c3e8c19dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_22e895a8-5fea-4d05-b934-637a48dac60a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cd031602-eeba-4dfb-9151-a41c3e8c19dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cd031602-eeba-4dfb-9151-a41c3e8c19dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cd031602-eeba-4dfb-9151-a41c3e8c19dd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cd031602-eeba-4dfb-9151-a41c3e8c19dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9fece5a7-4c85-46e8-b0ff-5f6ad2ac99c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cd031602-eeba-4dfb-9151-a41c3e8c19dd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9fece5a7-4c85-46e8-b0ff-5f6ad2ac99c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6fad2d5d-85d7-460f-8403-1f7fc0335ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9fece5a7-4c85-46e8-b0ff-5f6ad2ac99c1" xlink:to="loc_us-gaap_SubsequentEventMember_6fad2d5d-85d7-460f-8403-1f7fc0335ef4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails" xlink:type="extended" id="ie2014269b6af4b6598d025ebe21c7fe0_BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_68d17815-6737-41c7-9b9b-9e694d44cd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5d48d8c1-e755-4bae-a17d-faef031f3eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_68d17815-6737-41c7-9b9b-9e694d44cd9a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5d48d8c1-e755-4bae-a17d-faef031f3eeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f90a549-a676-473d-a6e5-719dbddf89c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_68d17815-6737-41c7-9b9b-9e694d44cd9a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f90a549-a676-473d-a6e5-719dbddf89c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d832f9be-3552-4f8b-98e5-08299949d2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f90a549-a676-473d-a6e5-719dbddf89c5" xlink:to="loc_us-gaap_AwardTypeAxis_d832f9be-3552-4f8b-98e5-08299949d2ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d832f9be-3552-4f8b-98e5-08299949d2ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d832f9be-3552-4f8b-98e5-08299949d2ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d832f9be-3552-4f8b-98e5-08299949d2ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c38d8f-a769-4152-9568-60b1e7bb4611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d832f9be-3552-4f8b-98e5-08299949d2ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c38d8f-a769-4152-9568-60b1e7bb4611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6048c336-18f9-4488-9e29-b0359593d1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c38d8f-a769-4152-9568-60b1e7bb4611" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6048c336-18f9-4488-9e29-b0359593d1f4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended" id="i7aec18da26f14af2b9c947bc0688e0b9_BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_46f94bf5-790f-44cf-873d-aec1df36fdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_38103899-dd59-4ce6-9250-ac740d2b8000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_46f94bf5-790f-44cf-873d-aec1df36fdf9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_38103899-dd59-4ce6-9250-ac740d2b8000" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64ce8f22-b093-4e76-8800-51a05e1d6a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_46f94bf5-790f-44cf-873d-aec1df36fdf9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64ce8f22-b093-4e76-8800-51a05e1d6a40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b2ee1824-d12c-4299-bb53-777fd7e29c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64ce8f22-b093-4e76-8800-51a05e1d6a40" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b2ee1824-d12c-4299-bb53-777fd7e29c4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b2ee1824-d12c-4299-bb53-777fd7e29c4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b2ee1824-d12c-4299-bb53-777fd7e29c4d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b2ee1824-d12c-4299-bb53-777fd7e29c4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1783c839-f577-49f0-928e-6f98fcbeda33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b2ee1824-d12c-4299-bb53-777fd7e29c4d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1783c839-f577-49f0-928e-6f98fcbeda33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_5879e1ff-e3e7-46e0-a847-b1b64158a658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1783c839-f577-49f0-928e-6f98fcbeda33" xlink:to="loc_us-gaap_WarrantMember_5879e1ff-e3e7-46e0-a847-b1b64158a658" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fb3c0138-0763-47b4-9ce4-19cf1a92a7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1783c839-f577-49f0-928e-6f98fcbeda33" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fb3c0138-0763-47b4-9ce4-19cf1a92a7cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4c6e2567-6710-4983-a918-2ea9155e487d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1783c839-f577-49f0-928e-6f98fcbeda33" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4c6e2567-6710-4983-a918-2ea9155e487d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails" xlink:type="extended" id="ia94193f9ff2f479087ec0606b0bbd932_FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da69f0f4-ce4a-41d8-b04e-baa8c65c7214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_f663906f-b269-49cd-85bf-ecf42f761a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da69f0f4-ce4a-41d8-b04e-baa8c65c7214" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_f663906f-b269-49cd-85bf-ecf42f761a95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_13035071-8acb-4223-9717-bad25a13569c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f663906f-b269-49cd-85bf-ecf42f761a95" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_13035071-8acb-4223-9717-bad25a13569c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure_5b4950b2-74dc-4675-99c1-0be8c549ee8c" xlink:href="sls-20210630.xsd#sls_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f663906f-b269-49cd-85bf-ecf42f761a95" xlink:to="loc_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure_5b4950b2-74dc-4675-99c1-0be8c549ee8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_999c98bc-6155-4765-b2ac-8232cb67ae0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f663906f-b269-49cd-85bf-ecf42f761a95" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_999c98bc-6155-4765-b2ac-8232cb67ae0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_277b68e1-ff19-4ad7-a9c9-ee965c9d55c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da69f0f4-ce4a-41d8-b04e-baa8c65c7214" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_277b68e1-ff19-4ad7-a9c9-ee965c9d55c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_FairValueOfWarrantsPotentiallySettleableInCash_c51cb364-579d-43f5-931a-0670d15d6778" xlink:href="sls-20210630.xsd#sls_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_277b68e1-ff19-4ad7-a9c9-ee965c9d55c6" xlink:to="loc_sls_FairValueOfWarrantsPotentiallySettleableInCash_c51cb364-579d-43f5-931a-0670d15d6778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0152362a-3acf-4718-af8a-01283ea01567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_277b68e1-ff19-4ad7-a9c9-ee965c9d55c6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0152362a-3acf-4718-af8a-01283ea01567" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_de99bf15-954c-4e7e-aac5-d5c99ea6db6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_277b68e1-ff19-4ad7-a9c9-ee965c9d55c6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_de99bf15-954c-4e7e-aac5-d5c99ea6db6d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_47b8e1cf-a17e-4c38-83e6-a88668accd63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da69f0f4-ce4a-41d8-b04e-baa8c65c7214" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_47b8e1cf-a17e-4c38-83e6-a88668accd63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ad72128-2f2e-449b-876f-3eb119407a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_47b8e1cf-a17e-4c38-83e6-a88668accd63" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ad72128-2f2e-449b-876f-3eb119407a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5ad72128-2f2e-449b-876f-3eb119407a04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ad72128-2f2e-449b-876f-3eb119407a04" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5ad72128-2f2e-449b-876f-3eb119407a04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ce010e3c-9111-4ad2-b3ee-cd9c42b1f942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ad72128-2f2e-449b-876f-3eb119407a04" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ce010e3c-9111-4ad2-b3ee-cd9c42b1f942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9c293467-ee27-4727-9730-9322c966b888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ce010e3c-9111-4ad2-b3ee-cd9c42b1f942" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9c293467-ee27-4727-9730-9322c966b888" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7d6bae0d-f5d7-4f24-8336-a8b9569baef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_47b8e1cf-a17e-4c38-83e6-a88668accd63" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7d6bae0d-f5d7-4f24-8336-a8b9569baef4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d6bae0d-f5d7-4f24-8336-a8b9569baef4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7d6bae0d-f5d7-4f24-8336-a8b9569baef4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7d6bae0d-f5d7-4f24-8336-a8b9569baef4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e464a50e-efc8-489a-8c21-c997ae2d1520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7d6bae0d-f5d7-4f24-8336-a8b9569baef4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e464a50e-efc8-489a-8c21-c997ae2d1520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c5642967-8d8f-4ac6-aafc-8e4455a91c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e464a50e-efc8-489a-8c21-c997ae2d1520" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c5642967-8d8f-4ac6-aafc-8e4455a91c94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_13e44bd9-fce4-4327-9688-b0d1f3bc3eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e464a50e-efc8-489a-8c21-c997ae2d1520" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_13e44bd9-fce4-4327-9688-b0d1f3bc3eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a4f5034f-bfd7-4d21-8d4e-a8d96778dee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e464a50e-efc8-489a-8c21-c997ae2d1520" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a4f5034f-bfd7-4d21-8d4e-a8d96778dee0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails" xlink:type="extended" id="id215e7eb638c4615a619ddc84f792c47_FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a66f1fe3-cd7a-4a4b-983d-415cfdaa110e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db3b9c56-8bdc-4ba5-b9be-16a3a7b98a41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a66f1fe3-cd7a-4a4b-983d-415cfdaa110e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db3b9c56-8bdc-4ba5-b9be-16a3a7b98a41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f019707d-3a7d-4815-a32f-341944844cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db3b9c56-8bdc-4ba5-b9be-16a3a7b98a41" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f019707d-3a7d-4815-a32f-341944844cc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_fa0f3761-f319-4bb8-8499-96f5463d105b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db3b9c56-8bdc-4ba5-b9be-16a3a7b98a41" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_fa0f3761-f319-4bb8-8499-96f5463d105b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5c74500d-9212-4ed5-bdbf-1b72a8816512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c7ec2fe7-f507-4372-bd3a-8c9bbfb33a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a66f1fe3-cd7a-4a4b-983d-415cfdaa110e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c7ec2fe7-f507-4372-bd3a-8c9bbfb33a14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dafc9f6a-7dea-437b-ba78-b4afb3e4946c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c7ec2fe7-f507-4372-bd3a-8c9bbfb33a14" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dafc9f6a-7dea-437b-ba78-b4afb3e4946c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dafc9f6a-7dea-437b-ba78-b4afb3e4946c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dafc9f6a-7dea-437b-ba78-b4afb3e4946c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dafc9f6a-7dea-437b-ba78-b4afb3e4946c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_393697e3-f1d4-4807-a1d5-44feda7006cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dafc9f6a-7dea-437b-ba78-b4afb3e4946c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_393697e3-f1d4-4807-a1d5-44feda7006cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9d2d99aa-1273-4971-90bf-6a2426a93693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_393697e3-f1d4-4807-a1d5-44feda7006cc" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9d2d99aa-1273-4971-90bf-6a2426a93693" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="ie22885324fe04942a5f174c4a93978d6_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_40e075bf-e191-4195-911c-a9a6d4e6d780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_40e075bf-e191-4195-911c-a9a6d4e6d780" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_8c19b57f-c415-4af8-b46d-993e51677049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_8c19b57f-c415-4af8-b46d-993e51677049" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d6effe47-161c-4242-9675-02b4b06d34a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d6effe47-161c-4242-9675-02b4b06d34a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow_91506191-abcd-4a11-954d-e38c6a4d140c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow_91506191-abcd-4a11-954d-e38c6a4d140c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7f503413-620b-485e-8a20-36efebac8a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7f503413-620b-485e-8a20-36efebac8a16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones_79525700-ca84-4906-a513-22d774054d54" xlink:href="sls-20210630.xsd#sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:to="loc_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones_79525700-ca84-4906-a513-22d774054d54" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1bc95bb6-7998-40e2-8cc5-7a4a22805f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1bc95bb6-7998-40e2-8cc5-7a4a22805f5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d85344f2-6cfd-415a-b205-ba09af48d003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1bc95bb6-7998-40e2-8cc5-7a4a22805f5e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d85344f2-6cfd-415a-b205-ba09af48d003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d85344f2-6cfd-415a-b205-ba09af48d003_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d85344f2-6cfd-415a-b205-ba09af48d003" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d85344f2-6cfd-415a-b205-ba09af48d003_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5f0a037-88b0-457d-b7df-a3c0e4a1843b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d85344f2-6cfd-415a-b205-ba09af48d003" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5f0a037-88b0-457d-b7df-a3c0e4a1843b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_AptheraInc.Member_9650fd2e-7565-4816-8101-62ac4d9c4227" xlink:href="sls-20210630.xsd#sls_AptheraInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5f0a037-88b0-457d-b7df-a3c0e4a1843b" xlink:to="loc_sls_AptheraInc.Member_9650fd2e-7565-4816-8101-62ac4d9c4227" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7f82e052-398e-45d3-8022-0085b2df160a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1bc95bb6-7998-40e2-8cc5-7a4a22805f5e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7f82e052-398e-45d3-8022-0085b2df160a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7f82e052-398e-45d3-8022-0085b2df160a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7f82e052-398e-45d3-8022-0085b2df160a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7f82e052-398e-45d3-8022-0085b2df160a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b1c0172f-9ebb-45fd-ace3-b8b2614b8395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7f82e052-398e-45d3-8022-0085b2df160a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b1c0172f-9ebb-45fd-ace3-b8b2614b8395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_MeasurementInputWeightedAverageCostOfCapitalMember_d181ea64-b202-4945-b40b-9cc253ca0a09" xlink:href="sls-20210630.xsd#sls_MeasurementInputWeightedAverageCostOfCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b1c0172f-9ebb-45fd-ace3-b8b2614b8395" xlink:to="loc_sls_MeasurementInputWeightedAverageCostOfCapitalMember_d181ea64-b202-4945-b40b-9cc253ca0a09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_MeasurementInputCostOfDebtMember_827de0d6-2cf0-46e0-b296-af2ea9b2ed04" xlink:href="sls-20210630.xsd#sls_MeasurementInputCostOfDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b1c0172f-9ebb-45fd-ace3-b8b2614b8395" xlink:to="loc_sls_MeasurementInputCostOfDebtMember_827de0d6-2cf0-46e0-b296-af2ea9b2ed04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c1d09fe0-85ef-4f6a-9590-562e10954f99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1bc95bb6-7998-40e2-8cc5-7a4a22805f5e" xlink:to="loc_srt_RangeAxis_c1d09fe0-85ef-4f6a-9590-562e10954f99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c1d09fe0-85ef-4f6a-9590-562e10954f99_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c1d09fe0-85ef-4f6a-9590-562e10954f99" xlink:to="loc_srt_RangeMember_c1d09fe0-85ef-4f6a-9590-562e10954f99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_903e55e7-ebe7-436c-b7cd-f3657da34378" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c1d09fe0-85ef-4f6a-9590-562e10954f99" xlink:to="loc_srt_RangeMember_903e55e7-ebe7-436c-b7cd-f3657da34378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_46480755-062c-46a4-b04f-46b4955eaf48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_903e55e7-ebe7-436c-b7cd-f3657da34378" xlink:to="loc_srt_MinimumMember_46480755-062c-46a4-b04f-46b4955eaf48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dad71ef7-182d-4922-a2cc-7e6140bb9bd9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_903e55e7-ebe7-436c-b7cd-f3657da34378" xlink:to="loc_srt_MaximumMember_dad71ef7-182d-4922-a2cc-7e6140bb9bd9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="ifae4a92c8fb84445933df6dc6e8cbfe8_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9f381485-59b7-4ff7-a703-a4138c4a1b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d5455df8-e8d0-4891-abc9-9af437f3ac06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9f381485-59b7-4ff7-a703-a4138c4a1b70" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d5455df8-e8d0-4891-abc9-9af437f3ac06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_OperatingLeaseRemainingLeaseTerm_b5306808-83ed-45b5-add0-c6612cc5fc3f" xlink:href="sls-20210630.xsd#sls_OperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9f381485-59b7-4ff7-a703-a4138c4a1b70" xlink:to="loc_sls_OperatingLeaseRemainingLeaseTerm_b5306808-83ed-45b5-add0-c6612cc5fc3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_c108a83c-fc56-402c-814b-1084c22cea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9f381485-59b7-4ff7-a703-a4138c4a1b70" xlink:to="loc_us-gaap_OperatingLeaseExpense_c108a83c-fc56-402c-814b-1084c22cea5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_0d6a5a98-b9f8-4e49-8bc1-a0f3ac5a36d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9f381485-59b7-4ff7-a703-a4138c4a1b70" xlink:to="loc_us-gaap_OperatingLeasePayments_0d6a5a98-b9f8-4e49-8bc1-a0f3ac5a36d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_510daa2c-77f8-49bd-883a-0f26b892fa99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9f381485-59b7-4ff7-a703-a4138c4a1b70" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_510daa2c-77f8-49bd-883a-0f26b892fa99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ef3a861d-e411-4964-b2e8-819e51fd3657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9f381485-59b7-4ff7-a703-a4138c4a1b70" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ef3a861d-e411-4964-b2e8-819e51fd3657" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_807054d7-3503-4eb9-b4d2-74c4208ea6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ef3a861d-e411-4964-b2e8-819e51fd3657" xlink:to="loc_us-gaap_LeaseContractualTermAxis_807054d7-3503-4eb9-b4d2-74c4208ea6d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_807054d7-3503-4eb9-b4d2-74c4208ea6d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_807054d7-3503-4eb9-b4d2-74c4208ea6d9" xlink:to="loc_us-gaap_LeaseContractualTermDomain_807054d7-3503-4eb9-b4d2-74c4208ea6d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_57371f31-2e9e-41a5-8103-0c23977c5a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_807054d7-3503-4eb9-b4d2-74c4208ea6d9" xlink:to="loc_us-gaap_LeaseContractualTermDomain_57371f31-2e9e-41a5-8103-0c23977c5a00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_OfficeSpaceLeaseExpiringDecember312024Member_03549699-2fde-4b98-b161-632fb122ef69" xlink:href="sls-20210630.xsd#sls_OfficeSpaceLeaseExpiringDecember312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_57371f31-2e9e-41a5-8103-0c23977c5a00" xlink:to="loc_sls_OfficeSpaceLeaseExpiringDecember312024Member_03549699-2fde-4b98-b161-632fb122ef69" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails" xlink:type="extended" id="i8b5cc4fe67ab49bb8579940dede276f4_StockholdersEquityCommonStockareReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1231436-2f59-46e5-84e6-ee55bb747789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d73aa6e7-09d7-4c92-ae46-527e70e7ec7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1231436-2f59-46e5-84e6-ee55bb747789" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d73aa6e7-09d7-4c92-ae46-527e70e7ec7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_886c1dab-e369-4b0e-b4cb-952b214d5348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1231436-2f59-46e5-84e6-ee55bb747789" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_886c1dab-e369-4b0e-b4cb-952b214d5348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fd9438dc-35a8-4f9f-aeba-22c895a4b854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1231436-2f59-46e5-84e6-ee55bb747789" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fd9438dc-35a8-4f9f-aeba-22c895a4b854" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4aa8c9f9-72bc-4cbf-8f32-ab0418bf1541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1231436-2f59-46e5-84e6-ee55bb747789" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4aa8c9f9-72bc-4cbf-8f32-ab0418bf1541" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_15d513e8-84d5-49e7-9732-b9143cbd3297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1231436-2f59-46e5-84e6-ee55bb747789" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_15d513e8-84d5-49e7-9732-b9143cbd3297" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca225fb7-9cfe-4155-b94e-2d974c0c7808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1231436-2f59-46e5-84e6-ee55bb747789" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca225fb7-9cfe-4155-b94e-2d974c0c7808" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5c20db70-f2ed-4dc7-9afd-4594a76c33a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca225fb7-9cfe-4155-b94e-2d974c0c7808" xlink:to="loc_us-gaap_AwardTypeAxis_5c20db70-f2ed-4dc7-9afd-4594a76c33a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c20db70-f2ed-4dc7-9afd-4594a76c33a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5c20db70-f2ed-4dc7-9afd-4594a76c33a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c20db70-f2ed-4dc7-9afd-4594a76c33a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7b62f46-4181-4fc6-8470-73f538e137bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5c20db70-f2ed-4dc7-9afd-4594a76c33a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7b62f46-4181-4fc6-8470-73f538e137bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a1f84d11-cafd-4897-8524-f9afe82326dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7b62f46-4181-4fc6-8470-73f538e137bc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a1f84d11-cafd-4897-8524-f9afe82326dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bf2293c6-9e45-40a6-b2f4-c1942ed90283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca225fb7-9cfe-4155-b94e-2d974c0c7808" xlink:to="loc_us-gaap_PlanNameAxis_bf2293c6-9e45-40a6-b2f4-c1942ed90283" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bf2293c6-9e45-40a6-b2f4-c1942ed90283_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_bf2293c6-9e45-40a6-b2f4-c1942ed90283" xlink:to="loc_us-gaap_PlanNameDomain_bf2293c6-9e45-40a6-b2f4-c1942ed90283_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d8939a25-ff4b-46c4-a62a-4d03813b4dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_bf2293c6-9e45-40a6-b2f4-c1942ed90283" xlink:to="loc_us-gaap_PlanNameDomain_d8939a25-ff4b-46c4-a62a-4d03813b4dc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_A2019EquityIncentivePlanMember_c257091e-9da1-4a2b-903d-0d744d80d9d5" xlink:href="sls-20210630.xsd#sls_A2019EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d8939a25-ff4b-46c4-a62a-4d03813b4dc6" xlink:to="loc_sls_A2019EquityIncentivePlanMember_c257091e-9da1-4a2b-903d-0d744d80d9d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_A2021EmployeeStockPurchasePlanMember_2de1ad68-1393-43a1-8c9d-0936f77c6399" xlink:href="sls-20210630.xsd#sls_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d8939a25-ff4b-46c4-a62a-4d03813b4dc6" xlink:to="loc_sls_A2021EmployeeStockPurchasePlanMember_2de1ad68-1393-43a1-8c9d-0936f77c6399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_A2017EmployeeStockPurchasePlanMember_cbf4287e-4ad4-4af7-a677-7d4025618937" xlink:href="sls-20210630.xsd#sls_A2017EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d8939a25-ff4b-46c4-a62a-4d03813b4dc6" xlink:to="loc_sls_A2017EmployeeStockPurchasePlanMember_cbf4287e-4ad4-4af7-a677-7d4025618937" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails" xlink:type="extended" id="id2dc279b1f7d430394751ebe805efa36_WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_4b754f30-7f8a-421c-a1a8-a809389b6d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClassofWarrantorRightOutstandingRollForward_a975a5b8-9a3f-4173-996e-7d3b1090ffcb" xlink:href="sls-20210630.xsd#sls_ClassofWarrantorRightOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4b754f30-7f8a-421c-a1a8-a809389b6d93" xlink:to="loc_sls_ClassofWarrantorRightOutstandingRollForward_a975a5b8-9a3f-4173-996e-7d3b1090ffcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_71cc816a-ac4d-48bb-876b-a76ab0673bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sls_ClassofWarrantorRightOutstandingRollForward_a975a5b8-9a3f-4173-996e-7d3b1090ffcb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_71cc816a-ac4d-48bb-876b-a76ab0673bcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued_dc802a11-d554-42da-ac60-2c6e82b4b193" xlink:href="sls-20210630.xsd#sls_ClassOfWarrantOrRightNumberOfWarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sls_ClassofWarrantorRightOutstandingRollForward_a975a5b8-9a3f-4173-996e-7d3b1090ffcb" xlink:to="loc_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued_dc802a11-d554-42da-ac60-2c6e82b4b193" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised_3ed31956-1853-46c5-b725-179714e2a06e" xlink:href="sls-20210630.xsd#sls_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sls_ClassofWarrantorRightOutstandingRollForward_a975a5b8-9a3f-4173-996e-7d3b1090ffcb" xlink:to="loc_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised_3ed31956-1853-46c5-b725-179714e2a06e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClassofWarrantorRightCanceledOrExpired_97f57f73-a478-4162-b6bc-8cb2ce60cf8f" xlink:href="sls-20210630.xsd#sls_ClassofWarrantorRightCanceledOrExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sls_ClassofWarrantorRightOutstandingRollForward_a975a5b8-9a3f-4173-996e-7d3b1090ffcb" xlink:to="loc_sls_ClassofWarrantorRightCanceledOrExpired_97f57f73-a478-4162-b6bc-8cb2ce60cf8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_adf6af05-09d3-4783-8f28-44b3e3c9b41f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_11a97fe5-28c4-4367-a177-b9b37feeeb68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4b754f30-7f8a-421c-a1a8-a809389b6d93" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_11a97fe5-28c4-4367-a177-b9b37feeeb68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b6f2dcdd-3a48-4195-a1dc-0a7c580d699a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_11a97fe5-28c4-4367-a177-b9b37feeeb68" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b6f2dcdd-3a48-4195-a1dc-0a7c580d699a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b6f2dcdd-3a48-4195-a1dc-0a7c580d699a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b6f2dcdd-3a48-4195-a1dc-0a7c580d699a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b6f2dcdd-3a48-4195-a1dc-0a7c580d699a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b6f2dcdd-3a48-4195-a1dc-0a7c580d699a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_July2020PIPEOfferingMember_2bd7a004-bd85-4b77-936a-2e39da441c61" xlink:href="sls-20210630.xsd#sls_July2020PIPEOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:to="loc_sls_July2020PIPEOfferingMember_2bd7a004-bd85-4b77-936a-2e39da441c61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_January2020OfferingMember_22478612-f3f8-4a7c-a900-5a30c8bdd1d3" xlink:href="sls-20210630.xsd#sls_January2020OfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:to="loc_sls_January2020OfferingMember_22478612-f3f8-4a7c-a900-5a30c8bdd1d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_July2019OfferingMember_db076802-ad6b-452d-ba04-0d9d40bd159f" xlink:href="sls-20210630.xsd#sls_July2019OfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:to="loc_sls_July2019OfferingMember_db076802-ad6b-452d-ba04-0d9d40bd159f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_WarrantExerciseAgreementMember_cdfeb5b3-5216-4d2c-8616-9e39c5279d8a" xlink:href="sls-20210630.xsd#sls_WarrantExerciseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:to="loc_sls_WarrantExerciseAgreementMember_cdfeb5b3-5216-4d2c-8616-9e39c5279d8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_July2018OfferingMember_9b860ff0-1d0a-468f-8047-8ee062405769" xlink:href="sls-20210630.xsd#sls_July2018OfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:to="loc_sls_July2018OfferingMember_9b860ff0-1d0a-468f-8047-8ee062405769" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_OtherWarrantIssuesMember_d66e731f-903d-4960-b1f9-73ec6fd50f35" xlink:href="sls-20210630.xsd#sls_OtherWarrantIssuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:to="loc_sls_OtherWarrantIssuesMember_d66e731f-903d-4960-b1f9-73ec6fd50f35" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended" id="ide29e2109d1f448396c376c8a02bf2cf_WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_5b040d4e-44d9-40c9-89c7-b6b73488404c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6ab35b70-9895-428f-b524-74e33452638f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5b040d4e-44d9-40c9-89c7-b6b73488404c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6ab35b70-9895-428f-b524-74e33452638f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_WarrantStrikePrice_0a0483e4-941d-4f19-8661-520806ddb30c" xlink:href="sls-20210630.xsd#sls_WarrantStrikePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5b040d4e-44d9-40c9-89c7-b6b73488404c" xlink:to="loc_sls_WarrantStrikePrice_0a0483e4-941d-4f19-8661-520806ddb30c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_c1071423-7d2a-4f19-aa10-60067d03c1cf" xlink:href="sls-20210630.xsd#sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5b040d4e-44d9-40c9-89c7-b6b73488404c" xlink:to="loc_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_c1071423-7d2a-4f19-aa10-60067d03c1cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_WarrantsFairValueAssumptionsExpectedVolatility_2fc374af-2b38-417a-bd29-0c970116998a" xlink:href="sls-20210630.xsd#sls_WarrantsFairValueAssumptionsExpectedVolatility"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5b040d4e-44d9-40c9-89c7-b6b73488404c" xlink:to="loc_sls_WarrantsFairValueAssumptionsExpectedVolatility_2fc374af-2b38-417a-bd29-0c970116998a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate_896650c2-f116-4abd-af75-49fe7fa167d0" xlink:href="sls-20210630.xsd#sls_WarrantsFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5b040d4e-44d9-40c9-89c7-b6b73488404c" xlink:to="loc_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate_896650c2-f116-4abd-af75-49fe7fa167d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_913f6486-b9e6-4121-9e4e-927d289c58da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5b040d4e-44d9-40c9-89c7-b6b73488404c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_913f6486-b9e6-4121-9e4e-927d289c58da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_11ee6eae-a5aa-497d-b5c1-b7c47bdd06d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_913f6486-b9e6-4121-9e4e-927d289c58da" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_11ee6eae-a5aa-497d-b5c1-b7c47bdd06d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_11ee6eae-a5aa-497d-b5c1-b7c47bdd06d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_11ee6eae-a5aa-497d-b5c1-b7c47bdd06d4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_11ee6eae-a5aa-497d-b5c1-b7c47bdd06d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_bc07299b-9e97-496c-bbc5-4228a0271287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_11ee6eae-a5aa-497d-b5c1-b7c47bdd06d4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_bc07299b-9e97-496c-bbc5-4228a0271287" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_OtherLiabilityClassifiedMember_70c75ec9-e828-4a94-a72e-0c0f6271b160" xlink:href="sls-20210630.xsd#sls_OtherLiabilityClassifiedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bc07299b-9e97-496c-bbc5-4228a0271287" xlink:to="loc_sls_OtherLiabilityClassifiedMember_70c75ec9-e828-4a94-a72e-0c0f6271b160" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#WarrantstoAcquireSharesofCommonStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails" xlink:type="extended" id="i7a770dae384e4646979dd2b43fbd1016_WarrantstoAcquireSharesofCommonStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_5889e047-6f76-407a-93c9-5627147054eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_4af16d77-5581-4b55-a130-357e2ea49975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5889e047-6f76-407a-93c9-5627147054eb" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_4af16d77-5581-4b55-a130-357e2ea49975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_d795b9d0-6bce-4424-8fb2-fcbed529b374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5889e047-6f76-407a-93c9-5627147054eb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_d795b9d0-6bce-4424-8fb2-fcbed529b374" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a5576b26-6ebd-4138-82d7-b670c63b910d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d795b9d0-6bce-4424-8fb2-fcbed529b374" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a5576b26-6ebd-4138-82d7-b670c63b910d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a5576b26-6ebd-4138-82d7-b670c63b910d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a5576b26-6ebd-4138-82d7-b670c63b910d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a5576b26-6ebd-4138-82d7-b670c63b910d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_72f31366-b86a-4a3f-bdb6-0c636203c289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a5576b26-6ebd-4138-82d7-b670c63b910d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_72f31366-b86a-4a3f-bdb6-0c636203c289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_7c14d0c2-5c27-4a43-80b3-5a01e417336f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_72f31366-b86a-4a3f-bdb6-0c636203c289" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_7c14d0c2-5c27-4a43-80b3-5a01e417336f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8a5d6b80-f0b2-40d2-aefa-15a7d0957a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_72f31366-b86a-4a3f-bdb6-0c636203c289" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8a5d6b80-f0b2-40d2-aefa-15a7d0957a1d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails" xlink:type="extended" id="i5ae14e9f71834fed9244fd91ebd5bb75_WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_bbc6100b-6bc5-4805-8ed8-4a52f0a71309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClassofWarrantorRightFairValueRollForward_de2d118e-bbf7-4001-9920-048cd2db693f" xlink:href="sls-20210630.xsd#sls_ClassofWarrantorRightFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bbc6100b-6bc5-4805-8ed8-4a52f0a71309" xlink:to="loc_sls_ClassofWarrantorRightFairValueRollForward_de2d118e-bbf7-4001-9920-048cd2db693f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_FairValueOfWarrantsLiabilities_4898a948-da68-4e91-b9ab-b38cc1b8a3a4" xlink:href="sls-20210630.xsd#sls_FairValueOfWarrantsLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sls_ClassofWarrantorRightFairValueRollForward_de2d118e-bbf7-4001-9920-048cd2db693f" xlink:to="loc_sls_FairValueOfWarrantsLiabilities_4898a948-da68-4e91-b9ab-b38cc1b8a3a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangeInFairValueOfWarrantLiabilities_3b5d1400-8210-4feb-93cc-2f367c8cdc7b" xlink:href="sls-20210630.xsd#sls_ChangeInFairValueOfWarrantLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sls_ClassofWarrantorRightFairValueRollForward_de2d118e-bbf7-4001-9920-048cd2db693f" xlink:to="loc_sls_ChangeInFairValueOfWarrantLiabilities_3b5d1400-8210-4feb-93cc-2f367c8cdc7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_FairValueOfWarrantsLiabilities_49d578f1-d231-412b-a895-9c4cc678db92" xlink:href="sls-20210630.xsd#sls_FairValueOfWarrantsLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_0889193b-28c2-41d5-9344-6d58e6d7f595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bbc6100b-6bc5-4805-8ed8-4a52f0a71309" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_0889193b-28c2-41d5-9344-6d58e6d7f595" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a2029740-d525-41e7-97ea-7d742bb9498d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0889193b-28c2-41d5-9344-6d58e6d7f595" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a2029740-d525-41e7-97ea-7d742bb9498d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a2029740-d525-41e7-97ea-7d742bb9498d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a2029740-d525-41e7-97ea-7d742bb9498d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a2029740-d525-41e7-97ea-7d742bb9498d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f523de7a-e604-4ea4-a787-67f53dd6ef7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a2029740-d525-41e7-97ea-7d742bb9498d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f523de7a-e604-4ea4-a787-67f53dd6ef7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_OtherLiabilityClassifiedMember_2832df28-2ba2-4c27-9ecb-acedbf25a6a2" xlink:href="sls-20210630.xsd#sls_OtherLiabilityClassifiedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f523de7a-e604-4ea4-a787-67f53dd6ef7d" xlink:to="loc_sls_OtherLiabilityClassifiedMember_2832df28-2ba2-4c27-9ecb-acedbf25a6a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="ia1ac08c7184042cb8ae77fb33adaf2fd_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_164940bf-c6bd-4d75-8e9a-fe40d998249c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_164940bf-c6bd-4d75-8e9a-fe40d998249c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_51a49bcb-d9e5-4e2c-964a-48fcc297e733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_51a49bcb-d9e5-4e2c-964a-48fcc297e733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f00d4dd8-a8bc-4b50-bfdf-6e1589412625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f00d4dd8-a8bc-4b50-bfdf-6e1589412625" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_efafce58-e170-4a7e-b834-3d5fd859a481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_efafce58-e170-4a7e-b834-3d5fd859a481" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClosingPriceOfCommonStock_83461034-eaa3-4fa0-b501-083cfdd57807" xlink:href="sls-20210630.xsd#sls_ClosingPriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_sls_ClosingPriceOfCommonStock_83461034-eaa3-4fa0-b501-083cfdd57807" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_995d9250-6501-4186-88de-91d0854bdfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_995d9250-6501-4186-88de-91d0854bdfa0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_9338cb26-a144-47bf-adbb-b6366c25a873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_9338cb26-a144-47bf-adbb-b6366c25a873" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_49b66512-22be-4d0d-93d4-5caa4e17c5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_49b66512-22be-4d0d-93d4-5caa4e17c5dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_817a11b9-3700-4a66-805a-6a95485ab5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_817a11b9-3700-4a66-805a-6a95485ab5dc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_895c04db-d98a-42bd-94e6-574c631d8b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_895c04db-d98a-42bd-94e6-574c631d8b8a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_a9bfbc9e-b746-4359-8607-975248952ec7" xlink:href="sls-20210630.xsd#sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_a9bfbc9e-b746-4359-8607-975248952ec7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3853e8b3-b592-455e-83cf-f3211fa12325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3853e8b3-b592-455e-83cf-f3211fa12325" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_34a98fa9-aa6a-479b-9f64-aba2cfa1e6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_34a98fa9-aa6a-479b-9f64-aba2cfa1e6ba" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8cbf2aaf-fdbc-4990-a79b-64befcb0e93b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8cbf2aaf-fdbc-4990-a79b-64befcb0e93b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0f859128-af2f-4683-8725-1afede607fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0f859128-af2f-4683-8725-1afede607fce" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e704b84-c1dd-474d-8d63-ca63bdccfb16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e704b84-c1dd-474d-8d63-ca63bdccfb16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9b3a69a8-7304-4721-ac93-e44c245e1970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e704b84-c1dd-474d-8d63-ca63bdccfb16" xlink:to="loc_us-gaap_PlanNameAxis_9b3a69a8-7304-4721-ac93-e44c245e1970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9b3a69a8-7304-4721-ac93-e44c245e1970_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9b3a69a8-7304-4721-ac93-e44c245e1970" xlink:to="loc_us-gaap_PlanNameDomain_9b3a69a8-7304-4721-ac93-e44c245e1970_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8309b9f3-5507-4915-bbe6-87953597624b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9b3a69a8-7304-4721-ac93-e44c245e1970" xlink:to="loc_us-gaap_PlanNameDomain_8309b9f3-5507-4915-bbe6-87953597624b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_TwoThousandAndSeventeenEquityIncentivePlanMember_4033a1a0-ab94-41c7-a6ca-c491c691dbfb" xlink:href="sls-20210630.xsd#sls_TwoThousandAndSeventeenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8309b9f3-5507-4915-bbe6-87953597624b" xlink:to="loc_sls_TwoThousandAndSeventeenEquityIncentivePlanMember_4033a1a0-ab94-41c7-a6ca-c491c691dbfb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_TwoThousandAndNineteenEquityIncentivePlanMember_a789d893-32b8-431b-9cdb-efa1ce2b553f" xlink:href="sls-20210630.xsd#sls_TwoThousandAndNineteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8309b9f3-5507-4915-bbe6-87953597624b" xlink:to="loc_sls_TwoThousandAndNineteenEquityIncentivePlanMember_a789d893-32b8-431b-9cdb-efa1ce2b553f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_A2021EmployeeStockPurchasePlanMember_5e4e7254-8550-4ca6-9263-9786edba5c8d" xlink:href="sls-20210630.xsd#sls_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8309b9f3-5507-4915-bbe6-87953597624b" xlink:to="loc_sls_A2021EmployeeStockPurchasePlanMember_5e4e7254-8550-4ca6-9263-9786edba5c8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3790f4fa-1dc3-43bf-9d3b-1592e8fcb704" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e704b84-c1dd-474d-8d63-ca63bdccfb16" xlink:to="loc_srt_RangeAxis_3790f4fa-1dc3-43bf-9d3b-1592e8fcb704" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3790f4fa-1dc3-43bf-9d3b-1592e8fcb704_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3790f4fa-1dc3-43bf-9d3b-1592e8fcb704" xlink:to="loc_srt_RangeMember_3790f4fa-1dc3-43bf-9d3b-1592e8fcb704_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8c7ddcfa-3e81-44ad-9afb-a7e0b86fd92b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3790f4fa-1dc3-43bf-9d3b-1592e8fcb704" xlink:to="loc_srt_RangeMember_8c7ddcfa-3e81-44ad-9afb-a7e0b86fd92b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6694ef12-cce5-4747-bbf5-b876410115f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8c7ddcfa-3e81-44ad-9afb-a7e0b86fd92b" xlink:to="loc_srt_MaximumMember_6694ef12-cce5-4747-bbf5-b876410115f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9fbf151a-0524-439a-9c06-806403e09472" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8c7ddcfa-3e81-44ad-9afb-a7e0b86fd92b" xlink:to="loc_srt_MinimumMember_9fbf151a-0524-439a-9c06-806403e09472" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8798f5b8-d43c-49c2-bba0-3306cb59983d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e704b84-c1dd-474d-8d63-ca63bdccfb16" xlink:to="loc_us-gaap_AwardTypeAxis_8798f5b8-d43c-49c2-bba0-3306cb59983d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8798f5b8-d43c-49c2-bba0-3306cb59983d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8798f5b8-d43c-49c2-bba0-3306cb59983d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8798f5b8-d43c-49c2-bba0-3306cb59983d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_38f996b0-11c3-4c67-86a4-8818795b6395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8798f5b8-d43c-49c2-bba0-3306cb59983d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_38f996b0-11c3-4c67-86a4-8818795b6395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_490cd849-4a2e-44b4-9fea-cd9c8a3ef435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_38f996b0-11c3-4c67-86a4-8818795b6395" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_490cd849-4a2e-44b4-9fea-cd9c8a3ef435" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2806177c-5c4e-43f6-8bbf-81952bcffc08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_38f996b0-11c3-4c67-86a4-8818795b6395" xlink:to="loc_us-gaap_EmployeeStockMember_2806177c-5c4e-43f6-8bbf-81952bcffc08" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#StockBasedCompensationAllocatedStockbasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails" xlink:type="extended" id="i89e44d5211c64307a36c43a4db83f70d_StockBasedCompensationAllocatedStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_32b25edc-be28-47ff-b171-86acb2a26084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e9e981cf-8cbe-450c-991a-2702b27c5523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_32b25edc-be28-47ff-b171-86acb2a26084" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e9e981cf-8cbe-450c-991a-2702b27c5523" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7898dc85-3089-4f88-80de-5505d1453608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_32b25edc-be28-47ff-b171-86acb2a26084" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7898dc85-3089-4f88-80de-5505d1453608" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f37fa56b-bc1e-44c6-bd02-67530d4ff161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7898dc85-3089-4f88-80de-5505d1453608" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f37fa56b-bc1e-44c6-bd02-67530d4ff161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f37fa56b-bc1e-44c6-bd02-67530d4ff161_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f37fa56b-bc1e-44c6-bd02-67530d4ff161" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f37fa56b-bc1e-44c6-bd02-67530d4ff161_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4dbef4c3-687c-42b8-86f4-ba0879e608ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f37fa56b-bc1e-44c6-bd02-67530d4ff161" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4dbef4c3-687c-42b8-86f4-ba0879e608ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0c5aa457-125f-4c18-a230-7bd1726bd359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4dbef4c3-687c-42b8-86f4-ba0879e608ea" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0c5aa457-125f-4c18-a230-7bd1726bd359" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ec1bc0bf-4d7e-42cd-bddc-b71684846c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4dbef4c3-687c-42b8-86f4-ba0879e608ea" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ec1bc0bf-4d7e-42cd-bddc-b71684846c29" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#StockBasedCompensationSummaryofRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails" xlink:type="extended" id="id30d6f04e62f4d24af9785e9f71e8f1c_StockBasedCompensationSummaryofRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d47f54-79d1-4a15-b150-17c16ac2f079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2f43dd32-b830-4755-8e80-461c08cf024e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d47f54-79d1-4a15-b150-17c16ac2f079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2f43dd32-b830-4755-8e80-461c08cf024e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f137f2ff-4b5e-4af0-a904-6cb5e1c051eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2f43dd32-b830-4755-8e80-461c08cf024e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f137f2ff-4b5e-4af0-a904-6cb5e1c051eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5b0d96f2-63f8-4835-887b-30a395adc302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2f43dd32-b830-4755-8e80-461c08cf024e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5b0d96f2-63f8-4835-887b-30a395adc302" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_aebbba9e-66f5-49be-96f4-b9920d7e93e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2f43dd32-b830-4755-8e80-461c08cf024e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_aebbba9e-66f5-49be-96f4-b9920d7e93e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a551557d-f439-40dd-9784-832519945e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_697b33a9-75d3-4d53-afbd-d0e6c9b21c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d47f54-79d1-4a15-b150-17c16ac2f079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_697b33a9-75d3-4d53-afbd-d0e6c9b21c25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1bdcd6c1-65a7-486d-ac08-53eff464e34a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_697b33a9-75d3-4d53-afbd-d0e6c9b21c25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1bdcd6c1-65a7-486d-ac08-53eff464e34a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_89500d63-1b1e-4abc-a6a6-668c16c34927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_697b33a9-75d3-4d53-afbd-d0e6c9b21c25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_89500d63-1b1e-4abc-a6a6-668c16c34927" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_98f0c6d8-bf8c-480c-a996-3ab002bbaa98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_697b33a9-75d3-4d53-afbd-d0e6c9b21c25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_98f0c6d8-bf8c-480c-a996-3ab002bbaa98" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_cb72d9e5-c662-4fa1-a962-64dd170c0b52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a405e2df-81c9-4a10-b8b0-725da865c8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d47f54-79d1-4a15-b150-17c16ac2f079" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a405e2df-81c9-4a10-b8b0-725da865c8ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b60392ae-39d7-4b45-9d61-83d6cfcaf01d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a405e2df-81c9-4a10-b8b0-725da865c8ae" xlink:to="loc_us-gaap_AwardTypeAxis_b60392ae-39d7-4b45-9d61-83d6cfcaf01d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b60392ae-39d7-4b45-9d61-83d6cfcaf01d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b60392ae-39d7-4b45-9d61-83d6cfcaf01d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b60392ae-39d7-4b45-9d61-83d6cfcaf01d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26aee7ba-e87e-45df-a4ba-d5f5a6332ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b60392ae-39d7-4b45-9d61-83d6cfcaf01d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26aee7ba-e87e-45df-a4ba-d5f5a6332ef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e03c23ca-ea4d-41d1-98bd-dbad70780e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26aee7ba-e87e-45df-a4ba-d5f5a6332ef1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e03c23ca-ea4d-41d1-98bd-dbad70780e50" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>sls-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:44c0be2c-a517-445c-901f-827aacd933ea,g:c47eecba-e87d-4369-b623-d76d853819d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_94295f0b-2f07-42c8-a29e-e2eee9ffc061_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate_8d9a07a8-06f7-4526-b006-9e7a4b66942d_terseLabel_en-US" xlink:label="lab_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate %</link:label>
    <link:label id="lab_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label id="lab_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate_documentation_en-US" xlink:label="lab_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:href="sls-20210630.xsd#sls_WarrantsFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_34f15a11-af6f-489b-aa7a-15dcb3b14d5c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_73fd1bf9-b570-42f0-a1cb-7c071adffe66_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_9194dcdb-0a91-46f5-828e-dc8bdb2df862_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_43553fe0-b3ae-45b2-af09-40cc8b67eaaa_terseLabel_en-US" xlink:label="lab_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_label_en-US" xlink:label="lab_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrant Liability Assumptions Expected Term</link:label>
    <link:label id="lab_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_documentation_en-US" xlink:label="lab_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Warrant Liability Assumptions Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:href="sls-20210630.xsd#sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:to="lab_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_e29d8fa9-e23e-4370-91c4-30a016113b97_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_bb247c09-0186-439e-9ccd-2b2e7f97b7ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ba4d5314-d9f4-42c8-92b7-e030f20ffaea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3eef4f1c-df07-4f14-a37b-82badc4501a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a592a34d-be5f-4172-a2b6-7f1499a9719f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5f012d04-5737-40ac-a031-708bdac49950_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bb6bb19e-3d3e-4c19-8b59-a8a9b0b5bf94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d3ba72a0-3ddf-47d5-a0f3-8198f8a91d5e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8ccdaa84-a943-4be6-b55d-b160f2df44d2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_321dd8f7-54c3-4390-a6e5-c420b4d50128_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_254ed741-5116-4575-883d-970f4e760608_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_2b914378-019c-47c8-a392-8ddb89f6ab3f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract asset</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bf9b6de2-4f0f-4444-8521-7158a482af7e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8af5706e-1258-4df3-aa59-f898a69ddb0d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones_e561f3ca-1b9c-4387-82d6-627cc72ec49b_terseLabel_en-US" xlink:label="lab_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration, timing of development milestones</link:label>
    <link:label id="lab_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones_label_en-US" xlink:label="lab_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Timing Of Milestones</link:label>
    <link:label id="lab_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones_documentation_en-US" xlink:label="lab_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Timing Of Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" xlink:href="sls-20210630.xsd#sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" xlink:to="lab_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_67ce926b-9284-4875-9d6c-a777bf81b5c4_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e3560df6-be92-4506-8527-13fd6b9e6f07_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_fe3e4c40-44d2-40f9-ad18-5c744c546b6b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d67a2f89-c015-47a8-9ff7-1fdaefd89b2e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c6811aa0-218f-41d3-b30c-5bf34b0a5a8f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized_9759de65-40a2-46bd-9e90-aa812a87d233_terseLabel_en-US" xlink:label="lab_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing revenue</link:label>
    <link:label id="lab_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized_0c9b5edf-022a-4911-872c-0d8b8bea5d6d_negatedTerseLabel_en-US" xlink:label="lab_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognized</link:label>
    <link:label id="lab_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized_label_en-US" xlink:label="lab_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, New Contract Revenue, Recognized</link:label>
    <link:label id="lab_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized_documentation_en-US" xlink:label="lab_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, New Contract Revenue, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized" xlink:href="sls-20210630.xsd#sls_ContractWithCustomerLiabilityNewContractRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized" xlink:to="lab_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_081d7376-d250-4e6a-adb8-2f6b1699db6c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_82a0b586-23ef-4a45-bc5c-b5964d645cb7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract asset</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_77d202e6-78b8-4011-89b5-1f723a1eddfd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_OperatingLeaseRemainingLeaseTerm_8b5fd6d4-ced2-4500-aa08-e31551a77a79_terseLabel_en-US" xlink:label="lab_sls_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, remaining term</link:label>
    <link:label id="lab_sls_OperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_sls_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Remaining Lease Term</link:label>
    <link:label id="lab_sls_OperatingLeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_sls_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_OperatingLeaseRemainingLeaseTerm" xlink:href="sls-20210630.xsd#sls_OperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_OperatingLeaseRemainingLeaseTerm" xlink:to="lab_sls_OperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cf209bf1-b6b2-4502-80dd-c9ae628103b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_148942c5-f8b0-47da-bb9c-781a6a7f6240_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_291de689-3983-497a-8cb6-eab6da58356f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_29a62164-9755-413d-947c-81d024d9eb88_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue, Related to Upfront Cash Payment Received</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_d4266d82-6f0e-412c-ac02-0eb0469f5064_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration paid</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_682d683c-f3d4-436a-a01d-f4a79684c826_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_25e238d9-c76e-48e8-8446-d54fed7cc48e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved_623e0971-eb69-4473-8578-679a342b11d5_terseLabel_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestones probable of being achieved</link:label>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved_label_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Milestones Probable Of Being Achieved</link:label>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved_documentation_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Milestones Probable Of Being Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved" xlink:href="sls-20210630.xsd#sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved" xlink:to="lab_sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_cbbfa870-f950-4460-8005-fb54692d9222_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Level 3 Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b991f586-d4de-40c4-a0bc-b347b447b829_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e3572d06-5774-4a01-a965-d53b254f1ebd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_52559cde-4480-4705-a305-30acd1a2bf2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_cd506562-ac77-492c-b589-33749d090210_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_July2020PIPEOfferingMember_5aaaecb7-1584-4ade-b2a3-dbdd9f834019_terseLabel_en-US" xlink:label="lab_sls_July2020PIPEOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2020 PIPE Offering</link:label>
    <link:label id="lab_sls_July2020PIPEOfferingMember_label_en-US" xlink:label="lab_sls_July2020PIPEOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2020 PIPE Offering [Member]</link:label>
    <link:label id="lab_sls_July2020PIPEOfferingMember_documentation_en-US" xlink:label="lab_sls_July2020PIPEOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2020 PIPE Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_July2020PIPEOfferingMember" xlink:href="sls-20210630.xsd#sls_July2020PIPEOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_July2020PIPEOfferingMember" xlink:to="lab_sls_July2020PIPEOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bbbf670b-2099-4427-ab2f-904136258d86_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_59c231d8-d24f-456c-85b9-5b51705bcb1a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1f3c6f1f-e3ae-4306-8e70-8ad82499e056_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_c464d7d5-90a3-4cf5-97e7-6dadc1eabcce_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_53eb541d-06db-4e0c-8a07-d74dcf1635b7_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims which the Company filed motions to dismiss</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5b596f84-235f-4e8b-b460-501500d52abb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_9da237de-f6be-403e-ae53-5c5a0803a691_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_865c2a46-ce67-4618-a39e-2b71d9089883_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ba804d3d-7e20-4ac4-9026-4ce8fd6bba5b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0e336dfa-a99e-463f-8f78-a451720f95ec_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1cd4dbd8-6d5d-443a-8a01-423e68034f60_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_15971047-53b2-4504-8a14-2dce7ce96dfa_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_MeasurementInputCostOfDebtMember_5ae2c485-5b23-4c60-bd09-9efd250e38d7_terseLabel_en-US" xlink:label="lab_sls_MeasurementInputCostOfDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of debt</link:label>
    <link:label id="lab_sls_MeasurementInputCostOfDebtMember_label_en-US" xlink:label="lab_sls_MeasurementInputCostOfDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Cost Of Debt [Member]</link:label>
    <link:label id="lab_sls_MeasurementInputCostOfDebtMember_documentation_en-US" xlink:label="lab_sls_MeasurementInputCostOfDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Cost Of Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_MeasurementInputCostOfDebtMember" xlink:href="sls-20210630.xsd#sls_MeasurementInputCostOfDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_MeasurementInputCostOfDebtMember" xlink:to="lab_sls_MeasurementInputCostOfDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_888be301-01b8-46fb-a726-0730dc138b88_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_95aa6702-3217-477a-aeb5-bb64368fc71e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf23718c-8ee1-4a6a-b676-a4314bf8df07_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_24171fab-f9ef-49ed-8b2f-8f32fdb8ea92_negatedTerseLabel_en-US" xlink:label="lab_sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
    <link:label id="lab_sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_label_en-US" xlink:label="lab_sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings</link:label>
    <link:label id="lab_sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_documentation_en-US" xlink:label="lab_sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of common stock warrants issued in connection with various equity financings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:href="sls-20210630.xsd#sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:to="lab_sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_54a09820-6703-4b8d-af6f-beb0dc8232b8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0e78fb1f-cc98-404e-ab12-d9b0bff63388_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-Vested Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7253a49d-5f2b-49b4-a2f2-30c4dbb769f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_8efa0afa-4eae-456f-9a5b-a4979bb804d9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_87acbc9a-8ca8-46ea-aff9-4e0de70f262c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_77fa54c3-f7ee-4627-9af6-7d410bf7470c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_84711441-b7de-4d81-abf3-42c19e780a63_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_c090b097-0e36-4265-b02c-25c1013aa339_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_280100b3-1f2f-4289-a980-bbe9e7bea0a6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_PrepaidResearchAndDevelopment_4b5a7942-ece8-4b43-a1fa-d938387aeb85_terseLabel_en-US" xlink:label="lab_sls_PrepaidResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial costs</link:label>
    <link:label id="lab_sls_PrepaidResearchAndDevelopment_label_en-US" xlink:label="lab_sls_PrepaidResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development</link:label>
    <link:label id="lab_sls_PrepaidResearchAndDevelopment_documentation_en-US" xlink:label="lab_sls_PrepaidResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_PrepaidResearchAndDevelopment" xlink:href="sls-20210630.xsd#sls_PrepaidResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_PrepaidResearchAndDevelopment" xlink:to="lab_sls_PrepaidResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_5b43604b-ae3c-460f-9909-239300a22d03_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d25ac9d4-7004-48fe-8ac0-5e2d889d2756_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_88f56c22-5337-40bd-945d-d608eeab26ae_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_OfficeSpaceLeaseExpiringDecember312024Member_b6aaf92f-b16d-4412-b7b0-1ebe71d2b60e_terseLabel_en-US" xlink:label="lab_sls_OfficeSpaceLeaseExpiringDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space Lease Expiring December 31, 2024</link:label>
    <link:label id="lab_sls_OfficeSpaceLeaseExpiringDecember312024Member_label_en-US" xlink:label="lab_sls_OfficeSpaceLeaseExpiringDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space Lease Expiring December 31, 2024 [Member]</link:label>
    <link:label id="lab_sls_OfficeSpaceLeaseExpiringDecember312024Member_documentation_en-US" xlink:label="lab_sls_OfficeSpaceLeaseExpiringDecember312024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Space Lease Expiring December 31, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_OfficeSpaceLeaseExpiringDecember312024Member" xlink:href="sls-20210630.xsd#sls_OfficeSpaceLeaseExpiringDecember312024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_OfficeSpaceLeaseExpiringDecember312024Member" xlink:to="lab_sls_OfficeSpaceLeaseExpiringDecember312024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b920d1a6-4474-4a35-a959-fe925a4e3f99_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_b0225f2d-7311-4acf-809d-d069f0527f3c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_01286fea-2135-420f-95a5-a4ecf050af12_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_62f2f7a3-b25d-425a-a520-a02d06e6f04d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_9dcbfe70-7f28-46e7-8f53-f4457f8c7800_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9eb5fa41-9e85-45bf-88b1-11e2931d2ddc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_31ffcca3-20a4-48f0-b3b8-f614d2a2b052_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_12141179-8388-409c-b2d7-e1cc0f1ed9a1_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_811be741-7f79-4ac2-b833-84ec1ff612d3_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_efb4f8cf-b550-4351-a660-d3c342a650bc_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_795182f3-71d7-4321-bf21-e69c51a64eea_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9303dce-873d-465a-9f7a-208a177be2a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_bfd8ab45-28f7-448e-8c7f-6a7a53fcb933_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2fd65724-d0f4-4a0c-ae34-90925feb3b06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementCashPaymentReceived_d237e77b-690f-4752-b033-602e078e1e56_terseLabel_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementCashPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payment received</link:label>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementCashPaymentReceived_label_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementCashPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Cash Payment Received</link:label>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementCashPaymentReceived_documentation_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementCashPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Cash Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ResearchAndDevelopmentArrangementCashPaymentReceived" xlink:href="sls-20210630.xsd#sls_ResearchAndDevelopmentArrangementCashPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ResearchAndDevelopmentArrangementCashPaymentReceived" xlink:to="lab_sls_ResearchAndDevelopmentArrangementCashPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_4bfb5e54-22da-416e-9bb9-a809e8a783cf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_365c2556-589b-4958-99c4-168a9911fe6d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_77090ecc-380d-46a7-ab9e-1a3b303415e4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0d5c73b8-fdc2-4a19-be98-6f19cc02793c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_44f08d7b-b213-4a87-8e53-7ce4fca7e5b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12407a39-1e00-4614-b880-2910c697bd0a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_08a65f8d-c61c-4ce6-80aa-18a3c76fd4a3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_530fadcf-1462-4f64-a10c-70c6bfdf046c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001&#160;par value; 5,000,000&#160;shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at June 30, 2021 and December 31, 2020</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm_15d6df24-4c03-4571-b638-6cf6786fc4d8_terseLabel_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties payable, maximum term</link:label>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm_label_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Royalties Payable, Maximum Term</link:label>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm_documentation_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Royalties Payable, Maximum Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm" xlink:href="sls-20210630.xsd#sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm" xlink:to="lab_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_87e18ae3-dba7-451c-9848-f913317297ac_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f6387f4f-fac4-4c57-92f5-4e9b54df8e06_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_18751f36-f7b7-4abb-bb4f-ce31195e8aaf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1b50949c-8c65-4ba9-b734-6cff05fd9414_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_fd6c7c65-d1db-41e5-8c3d-023898b43607_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_StockSubscriptionReceivableCurrent_c5b95ca8-ab6c-49c6-881a-1c8390713db2_terseLabel_en-US" xlink:label="lab_sls_StockSubscriptionReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription receivable</link:label>
    <link:label id="lab_sls_StockSubscriptionReceivableCurrent_label_en-US" xlink:label="lab_sls_StockSubscriptionReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subscription Receivable, Current</link:label>
    <link:label id="lab_sls_StockSubscriptionReceivableCurrent_documentation_en-US" xlink:label="lab_sls_StockSubscriptionReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subscription Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockSubscriptionReceivableCurrent" xlink:href="sls-20210630.xsd#sls_StockSubscriptionReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_StockSubscriptionReceivableCurrent" xlink:to="lab_sls_StockSubscriptionReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_144a3c06-8139-4205-8a0a-1f76bf106062_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable, maximum amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_0cea0b96-1cfd-4ff6-9cb6-9907430e6db0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b57d0438-0597-428f-955a-73622fadd7da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_11baf8ff-bcd7-4980-9af3-f30e9dbef1e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_70e647b6-b84f-4f34-a4df-54de6daa4e7d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_60b0d777-c5e0-4b7c-87a9-d6fbcb851294_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8c60bbd5-6fb7-4059-ad8b-d37441c46019_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_3b1edd79-2ad6-4652-813e-56a281b519b3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant&#160;Other Observable&#160; Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised_85a92e0f-1541-46cb-bf78-db4d168f25f1_negatedLabel_en-US" xlink:label="lab_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised_label_en-US" xlink:label="lab_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Exercised</link:label>
    <link:label id="lab_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:href="sls-20210630.xsd#sls_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:to="lab_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_2e78f125-872e-4fa2-9a98-ef0bd2adbdca_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_2ed3986e-4cb1-43c5-81cf-e89ed0f3c52e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_9e7367c3-59e2-4c0f-ba12-589f7059cd2f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_288b88bd-2408-40ae-a6e5-1062338befbd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration, measurement input (as a percent)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_642e13b5-9141-41ca-96b8-6c5991c103b6_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating right of use asset and current and non-current lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_660b1e57-96c4-4ed5-b7a5-639e7a4baad0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c7e74b20-4283-446f-b829-cf7dcc6291ea_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f2247821-1d67-4362-81e3-7dd3d75d791c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash earnings contributed per year</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b1419bc6-78c0-4ea7-b8dd-4811ad29425a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2caab625-11c5-4e5d-a379-3e0402ce91ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_daec9ce4-5375-4c1c-a6aa-a6ca9d7b05ae_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the estimated fair value of the contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_de262538-8977-4eb1-bef0-d855fee98ac9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_5282af11-c33e-4652-97d9-c1f99f51cbc9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b1bfaf2b-e3b2-46a1-88a3-ad5ac53445fc_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_CommonStockAreReservedForFutureIssuanceTableTextBlock_a1991a7e-f66e-4384-8967-6cd767a284d6_terseLabel_en-US" xlink:label="lab_sls_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_sls_CommonStockAreReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_sls_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Are Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_sls_CommonStockAreReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_sls_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock are reserved for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:href="sls-20210630.xsd#sls_CommonStockAreReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:to="lab_sls_CommonStockAreReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_SaleOfStockAuthorizedAmount_20066cb5-cb45-4d98-ba69-24bd449e82bd_terseLabel_en-US" xlink:label="lab_sls_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of shares, common stock gross proceeds</link:label>
    <link:label id="lab_sls_SaleOfStockAuthorizedAmount_label_en-US" xlink:label="lab_sls_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Authorized Amount</link:label>
    <link:label id="lab_sls_SaleOfStockAuthorizedAmount_documentation_en-US" xlink:label="lab_sls_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_SaleOfStockAuthorizedAmount" xlink:href="sls-20210630.xsd#sls_SaleOfStockAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_SaleOfStockAuthorizedAmount" xlink:to="lab_sls_SaleOfStockAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_fe65c3e3-a700-4c63-a4de-f642eb0fb867_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c58eaa33-92e9-4587-b8b9-9188fc49e6db_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_692c69e6-138e-46f4-bb4c-488c68d38272_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_00953cea-03c2-4e1a-8dd6-4eddbf3a7196_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_346e2336-7b78-4ce3-8782-ba86f4a20a08_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average vesting term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7b02b842-3ae2-4f0f-a935-1257e7ef395d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0fa382c8-29b1-4b64-9ca4-11190cb3005a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share attributable to common stockholders, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_222abe54-eb6f-4b7b-a432-0baae12bdbf5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_8dd787c2-8ecd-4699-8e2e-dae52ffc8588_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders, diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ac8af340-3346-487d-aef6-43d406ce859f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_4028e8d4-9c66-4db1-bbce-7cffc67bcb15_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders, basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_f7354ee4-4782-4c20-86d2-4b390e052ba9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Revenue with 3D Medicines, Inc.</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ca9fb993-4fb1-435a-8748-ab5bc0b1dfb5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_e5d91499-ded5-4790-82c0-4b1089861a35_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Accounts</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c178b5f1-87b8-4e83-944f-ef24cf30e0e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_11cd40e6-5ca7-41cb-9321-f7f25539cbc5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_264183d8-09d6-400d-b95f-f4e5ce54a6f7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6e1a0bd1-3598-440e-89b3-66b6c29a1621_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, December 31, 2020</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_33a1bd1f-c7e7-455f-9321-468fd47e2f43_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, June 30, 2021</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b6174559-6f88-4306-9a0f-43f0dee259bc_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_July2019OfferingMember_e20da4ef-39cb-4f93-a041-dfee1a0a29fc_terseLabel_en-US" xlink:label="lab_sls_July2019OfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">June 2019 Offering</link:label>
    <link:label id="lab_sls_July2019OfferingMember_label_en-US" xlink:label="lab_sls_July2019OfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2019 Offering [Member]</link:label>
    <link:label id="lab_sls_July2019OfferingMember_documentation_en-US" xlink:label="lab_sls_July2019OfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2019 Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_July2019OfferingMember" xlink:href="sls-20210630.xsd#sls_July2019OfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_July2019OfferingMember" xlink:to="lab_sls_July2019OfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_ab04d057-7205-449e-9992-9e70336a5458_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fc2e3e15-7cdf-40ee-bc9c-6853de0aa279_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_ffed3fb4-c788-4c82-93db-38049e00d854_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_bf113059-730f-41ca-a4b8-a7429ca46622_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2efbbf2c-d508-4eb0-baea-30a6a7750e9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8fc909-c482-49f9-a87e-d3d4fe5bdaf2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_8c7160d4-1ab5-4cdf-93d0-278d5b977e45_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b76e8281-124c-4ab2-b284-90a760dfd6b7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_660d6339-f447-478b-aa15-9c06212db512_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_94f771d2-95a6-4f18-aa9e-6aec440f3418_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_c53d3353-6f15-4852-b7a4-c761841e7416_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments related to operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow_50cd742b-9cf3-4c0f-82f6-f70810c898fa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable, minimum amount</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_StockSubscriptionReceivable_35ae0d6c-6db1-49e9-8049-55bbc11efcc7_terseLabel_en-US" xlink:label="lab_sls_StockSubscriptionReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription receivable</link:label>
    <link:label id="lab_sls_StockSubscriptionReceivable_label_en-US" xlink:label="lab_sls_StockSubscriptionReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subscription Receivable</link:label>
    <link:label id="lab_sls_StockSubscriptionReceivable_documentation_en-US" xlink:label="lab_sls_StockSubscriptionReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Subscription Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockSubscriptionReceivable" xlink:href="sls-20210630.xsd#sls_StockSubscriptionReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_StockSubscriptionReceivable" xlink:to="lab_sls_StockSubscriptionReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_bd829a82-decf-4a74-8bf8-b2bcd8921d52_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per share information:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_41eb0458-ed3f-4f96-a75f-374f34c0569c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4ddcf4b8-a753-4f81-985f-8bf42b912742_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_42d66625-6357-4620-8b1b-bb899b1ab490_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share attributable to common stockholders, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_b13e1ab5-7b54-47d7-a09a-a3108ab65415_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_TwoThousandAndNineteenEquityIncentivePlanMember_d2af685f-5143-436e-afdf-3e01999cafe8_terseLabel_en-US" xlink:label="lab_sls_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Incentive Plan</link:label>
    <link:label id="lab_sls_TwoThousandAndNineteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_sls_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Nineteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_sls_TwoThousandAndNineteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_sls_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Nineteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:href="sls-20210630.xsd#sls_TwoThousandAndNineteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:to="lab_sls_TwoThousandAndNineteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_4268c23b-e9b9-4e87-b3fa-937dedbeb2fd_terseLabel_en-US" xlink:label="lab_sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]</link:label>
    <link:label id="lab_sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_label_en-US" xlink:label="lab_sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]</link:label>
    <link:label id="lab_sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_documentation_en-US" xlink:label="lab_sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:href="sls-20210630.xsd#sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:to="lab_sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_7900cad4-fa10-43f8-860e-f8f763f57029_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract acquisition costs</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostGross" xlink:to="lab_us-gaap_CapitalizedContractCostGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_3077d5a0-43bf-4057-b4dd-c7b351d8ecaa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_2ea8dddf-aa8b-4138-b64c-40ad3d25ce67_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_3eadd1d1-0774-4bab-a677-8b302ba9dd76_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_7328ce1e-5d5b-4275-95d7-fde063f8af29_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured and recorded at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5482c3d1-5c94-4edd-a200-9016f9e57b75_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Prices&#160;In Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_40143109-0709-4c3f-9ff4-e73e72ac8c2a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a0e169fb-eaf0-48e8-a0ba-cb09d853268f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ContractResearchPayable_7ae9b2ae-33bf-443a-a840-d6798a34fc85_terseLabel_en-US" xlink:label="lab_sls_ContractResearchPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial costs</link:label>
    <link:label id="lab_sls_ContractResearchPayable_label_en-US" xlink:label="lab_sls_ContractResearchPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Research Payable</link:label>
    <link:label id="lab_sls_ContractResearchPayable_documentation_en-US" xlink:label="lab_sls_ContractResearchPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Research Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ContractResearchPayable" xlink:href="sls-20210630.xsd#sls_ContractResearchPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ContractResearchPayable" xlink:to="lab_sls_ContractResearchPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_A2021EmployeeStockPurchasePlanMember_b6368835-5103-4139-acd0-55618c7fa421_terseLabel_en-US" xlink:label="lab_sls_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 ESPP</link:label>
    <link:label id="lab_sls_A2021EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_sls_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sls_A2021EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_sls_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_A2021EmployeeStockPurchasePlanMember" xlink:href="sls-20210630.xsd#sls_A2021EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_A2021EmployeeStockPurchasePlanMember" xlink:to="lab_sls_A2021EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_bd34bf8b-e8fd-41e5-bfda-2716e857dad2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9e8d17ef-f556-40bd-b141-ea3a32ed99e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock unit award vested period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_aa14b6ee-8197-490b-b576-c9664b95cec4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_27b79d70-3cde-45aa-86d3-9c44c3f1a724_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_85cea143-0a73-4221-a5d9-8b60a4dc5a2a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ChangeInFairValueOfContingentPurchasePriceConsideration_3babdb6a-90f3-4abe-ac6b-0dbbcf962152_terseLabel_en-US" xlink:label="lab_sls_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_sls_ChangeInFairValueOfContingentPurchasePriceConsideration_label_en-US" xlink:label="lab_sls_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Price Consideration</link:label>
    <link:label id="lab_sls_ChangeInFairValueOfContingentPurchasePriceConsideration_documentation_en-US" xlink:label="lab_sls_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the fair value of contingent purchase price consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:href="sls-20210630.xsd#sls_ChangeInFairValueOfContingentPurchasePriceConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:to="lab_sls_ChangeInFairValueOfContingentPurchasePriceConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_b310682f-4bd0-41c0-939a-01079006430b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_009e6b38-2a27-46e0-bbd8-c78418d4f003_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_41bfbb33-5aed-45ca-a6fb-98712b71bfc6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiquidationBasisOfAccountingTextBlock_256d7aac-c07b-46c9-91ec-148b106a5386_terseLabel_en-US" xlink:label="lab_us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_us-gaap_LiquidationBasisOfAccountingTextBlock_label_en-US" xlink:label="lab_us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:to="lab_us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b98e0e45-8ba3-42c4-bce8-5db2ad5d3b5d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_StockIssuedDuringPeriodSharesPrefundedWarrant_1cddc092-c540-4a81-a536-46852944726b_terseLabel_en-US" xlink:label="lab_sls_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of pre-funded warrants (in shares)</link:label>
    <link:label id="lab_sls_StockIssuedDuringPeriodSharesPrefundedWarrant_label_en-US" xlink:label="lab_sls_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Pre-funded Warrant</link:label>
    <link:label id="lab_sls_StockIssuedDuringPeriodSharesPrefundedWarrant_documentation_en-US" xlink:label="lab_sls_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Pre-funded Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:href="sls-20210630.xsd#sls_StockIssuedDuringPeriodSharesPrefundedWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:to="lab_sls_StockIssuedDuringPeriodSharesPrefundedWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_63286ffc-dda4-412a-ad9b-f6c8aa4352a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_91c158c8-71ce-4b30-8357-67b6a78c0281_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_WarrantStrikePrice_29b2cb02-b6ce-4214-af76-600d58aca4f0_terseLabel_en-US" xlink:label="lab_sls_WarrantStrikePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strike price (in dollars per share)</link:label>
    <link:label id="lab_sls_WarrantStrikePrice_label_en-US" xlink:label="lab_sls_WarrantStrikePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:label id="lab_sls_WarrantStrikePrice_documentation_en-US" xlink:label="lab_sls_WarrantStrikePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Strike Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_WarrantStrikePrice" xlink:href="sls-20210630.xsd#sls_WarrantStrikePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_WarrantStrikePrice" xlink:to="lab_sls_WarrantStrikePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants_0a8c0fb4-2d05-426c-9545-ab81c95d30a2_terseLabel_en-US" xlink:label="lab_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</link:label>
    <link:label id="lab_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants_label_en-US" xlink:label="lab_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Common Stock and Warrants</link:label>
    <link:label id="lab_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants_documentation_en-US" xlink:label="lab_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Common Stock and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants" xlink:href="sls-20210630.xsd#sls_StockIssuedDuringPeriodSharesCommonStockandWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants" xlink:to="lab_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_4b086f5c-a295-4bee-a61a-2a228155e054_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_SalesAgreementMember_003558dc-a6de-4f4e-8de9-869b0e6d322c_terseLabel_en-US" xlink:label="lab_sls_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement</link:label>
    <link:label id="lab_sls_SalesAgreementMember_label_en-US" xlink:label="lab_sls_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:label id="lab_sls_SalesAgreementMember_documentation_en-US" xlink:label="lab_sls_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_SalesAgreementMember" xlink:href="sls-20210630.xsd#sls_SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_SalesAgreementMember" xlink:to="lab_sls_SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_199753e2-0812-49f3-a0d1-562f6894bcee_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_d87011fa-85ed-4da8-adab-ab971b2a5529_totalLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-operating expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_e1cfe61d-d4c9-421d-8dd5-1eba94edeb58_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_July2018OfferingMember_a45e1d92-f649-4084-9870-7ca56b661208_verboseLabel_en-US" xlink:label="lab_sls_July2018OfferingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2018 Offering</link:label>
    <link:label id="lab_sls_July2018OfferingMember_label_en-US" xlink:label="lab_sls_July2018OfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2018 Offering [Member]</link:label>
    <link:label id="lab_sls_July2018OfferingMember_documentation_en-US" xlink:label="lab_sls_July2018OfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2018 Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_July2018OfferingMember" xlink:href="sls-20210630.xsd#sls_July2018OfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_July2018OfferingMember" xlink:to="lab_sls_July2018OfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_NonCashCharges_2cf4ef46-3e3c-400b-a579-c4559cf54c10_terseLabel_en-US" xlink:label="lab_sls_NonCashCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash charges</link:label>
    <link:label id="lab_sls_NonCashCharges_label_en-US" xlink:label="lab_sls_NonCashCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Charges</link:label>
    <link:label id="lab_sls_NonCashCharges_documentation_en-US" xlink:label="lab_sls_NonCashCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_NonCashCharges" xlink:href="sls-20210630.xsd#sls_NonCashCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_NonCashCharges" xlink:to="lab_sls_NonCashCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_f840cd4a-80ef-4668-b981-b008427a79b7_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of licensing revenue</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3e784582-f9be-47bd-95bb-8aef717ae25a_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion_c32c6dd2-ba47-44dc-a037-e84e5b953101_terseLabel_en-US" xlink:label="lab_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion_label_en-US" xlink:label="lab_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Purchase Price Consideration Net Of Current Portion</link:label>
    <link:label id="lab_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion_documentation_en-US" xlink:label="lab_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent purchase price consideration, net of current portion.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:href="sls-20210630.xsd#sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:to="lab_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_a0472ac8-ae7e-4d0d-b2f7-42fa2b98c629_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure_6f4f9f63-80cb-4410-92a6-78d670e8d7c3_terseLabel_en-US" xlink:label="lab_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash equivalents</link:label>
    <link:label id="lab_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:href="sls-20210630.xsd#sls_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInDeferredRevenueRollForward_5ed88609-5dbd-4040-a5f5-fb28de7c704f_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInDeferredRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Deferred Revenue [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInDeferredRevenueRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInDeferredRevenueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Deferred Revenue [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInDeferredRevenueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward" xlink:to="lab_us-gaap_MovementInDeferredRevenueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ec524b36-b7b2-4bd2-b3a6-328ca152f2bd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b2b13925-b002-47b1-b1d7-b5eef6bbc485_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a0f22944-5f9a-4c6a-b457-87054ebe201f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ab3cf58e-76d3-44aa-81b2-3d925f044d78_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares (In Thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_6bcfe581-f812-4693-b0d1-925b46888008_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities measured and recorded at fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_071c3d6e-8b14-453c-ba5a-5bbf9f83e380_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_f539755e-5e38-4771-b9b2-540615f3f730_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ChangeInFairValueOfWarrantLiabilities_5ed3b4a5-1ae6-4e81-bfd3-7e0e8fae77cf_terseLabel_en-US" xlink:label="lab_sls_ChangeInFairValueOfWarrantLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrants</link:label>
    <link:label id="lab_sls_ChangeInFairValueOfWarrantLiabilities_label_en-US" xlink:label="lab_sls_ChangeInFairValueOfWarrantLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:label id="lab_sls_ChangeInFairValueOfWarrantLiabilities_documentation_en-US" xlink:label="lab_sls_ChangeInFairValueOfWarrantLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Warrant Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangeInFairValueOfWarrantLiabilities" xlink:href="sls-20210630.xsd#sls_ChangeInFairValueOfWarrantLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ChangeInFairValueOfWarrantLiabilities" xlink:to="lab_sls_ChangeInFairValueOfWarrantLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_e87e67e5-d544-42fb-a2e8-c14dc3a8024d_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_fa4a201d-a83f-4b1c-975a-f84155106ab5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_NoncashOfferingExpense_68ba3c57-8ed7-4bcd-9317-2f1786344bff_terseLabel_en-US" xlink:label="lab_sls_NoncashOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering expenses in accounts payable and accrued expenses and other current liabilities</link:label>
    <link:label id="lab_sls_NoncashOfferingExpense_label_en-US" xlink:label="lab_sls_NoncashOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Offering Expense</link:label>
    <link:label id="lab_sls_NoncashOfferingExpense_documentation_en-US" xlink:label="lab_sls_NoncashOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Offering Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_NoncashOfferingExpense" xlink:href="sls-20210630.xsd#sls_NoncashOfferingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_NoncashOfferingExpense" xlink:to="lab_sls_NoncashOfferingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_130a9db9-21ad-4204-871c-38873073da38_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_807fd690-7acc-4294-bb90-e427055b95f1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3068525e-1f71-46c7-a2f7-ff3931b8a49e_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_MeasurementInputWeightedAverageCostOfCapitalMember_f6f04e8e-4c0b-427e-9309-f2104e74159e_terseLabel_en-US" xlink:label="lab_sls_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average cost of capital</link:label>
    <link:label id="lab_sls_MeasurementInputWeightedAverageCostOfCapitalMember_label_en-US" xlink:label="lab_sls_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted Average Cost Of Capital [Member]</link:label>
    <link:label id="lab_sls_MeasurementInputWeightedAverageCostOfCapitalMember_documentation_en-US" xlink:label="lab_sls_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted Average Cost Of Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:href="sls-20210630.xsd#sls_MeasurementInputWeightedAverageCostOfCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:to="lab_sls_MeasurementInputWeightedAverageCostOfCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8c874c38-726a-4b6a-b966-12e9ba04c370_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock_6d75e6a6-b8e1-479d-9d63-c46e7e64a60e_terseLabel_en-US" xlink:label="lab_sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Warrant Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:href="sls-20210630.xsd#sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:to="lab_sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_0bd455de-4be0-445f-a60b-67693d7ef83c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued_777d5781-00b9-4135-9d08-ce45ac3d191c_terseLabel_en-US" xlink:label="lab_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued_label_en-US" xlink:label="lab_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Issued</link:label>
    <link:label id="lab_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued_documentation_en-US" xlink:label="lab_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:href="sls-20210630.xsd#sls_ClassOfWarrantOrRightNumberOfWarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:to="lab_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_5db8d7e5-7e7b-4b3c-a1e7-ca5d2dbe77e5_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_IncreaseDecreaseInContractWithCustomerLiabilityNet_1903ecde-e5ac-4876-8415-7b8c96ef6361_terseLabel_en-US" xlink:label="lab_sls_IncreaseDecreaseInContractWithCustomerLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_sls_IncreaseDecreaseInContractWithCustomerLiabilityNet_label_en-US" xlink:label="lab_sls_IncreaseDecreaseInContractWithCustomerLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability, Net</link:label>
    <link:label id="lab_sls_IncreaseDecreaseInContractWithCustomerLiabilityNet_documentation_en-US" xlink:label="lab_sls_IncreaseDecreaseInContractWithCustomerLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_IncreaseDecreaseInContractWithCustomerLiabilityNet" xlink:href="sls-20210630.xsd#sls_IncreaseDecreaseInContractWithCustomerLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_IncreaseDecreaseInContractWithCustomerLiabilityNet" xlink:to="lab_sls_IncreaseDecreaseInContractWithCustomerLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_36cfff74-3f52-4435-9def-6563e74d15e8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received during the period for interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInterestReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInterestReceived" xlink:to="lab_us-gaap_ProceedsFromInterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a56199b0-6312-47f6-bfc8-7f1585443030_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_16edbcbc-9408-4df0-9077-b4fc9f0bb3a1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_fe286018-036d-405c-ad0a-904e60801d1c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_46ddc904-3a19-4429-886d-c79bb61f385f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_8019207a-aaad-4442-9316-d398e0e34bc2_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_b7169393-8cdc-4827-ba67-7922faba23f9_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cff67571-4cfb-4cde-8986-c784d41c2d3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_WarrantsFairValueAssumptionsExpectedVolatility_7cbd63e2-397c-411c-af1f-304afef4c4eb_terseLabel_en-US" xlink:label="lab_sls_WarrantsFairValueAssumptionsExpectedVolatility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility %</link:label>
    <link:label id="lab_sls_WarrantsFairValueAssumptionsExpectedVolatility_label_en-US" xlink:label="lab_sls_WarrantsFairValueAssumptionsExpectedVolatility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:label id="lab_sls_WarrantsFairValueAssumptionsExpectedVolatility_documentation_en-US" xlink:label="lab_sls_WarrantsFairValueAssumptionsExpectedVolatility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Fair Value Assumptions Expected Volatility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_WarrantsFairValueAssumptionsExpectedVolatility" xlink:href="sls-20210630.xsd#sls_WarrantsFairValueAssumptionsExpectedVolatility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_WarrantsFairValueAssumptionsExpectedVolatility" xlink:to="lab_sls_WarrantsFairValueAssumptionsExpectedVolatility" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4c647aea-f2dd-4a4e-8e0b-e8fa2eef6fe5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ClassofWarrantorRightFairValueRollForward_0774031c-289f-4c3c-9dac-a7ee5a17eafc_terseLabel_en-US" xlink:label="lab_sls_ClassofWarrantorRightFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_sls_ClassofWarrantorRightFairValueRollForward_label_en-US" xlink:label="lab_sls_ClassofWarrantorRightFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:label id="lab_sls_ClassofWarrantorRightFairValueRollForward_documentation_en-US" xlink:label="lab_sls_ClassofWarrantorRightFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Fair Value [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClassofWarrantorRightFairValueRollForward" xlink:href="sls-20210630.xsd#sls_ClassofWarrantorRightFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ClassofWarrantorRightFairValueRollForward" xlink:to="lab_sls_ClassofWarrantorRightFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_WarrantExerciseAgreementMember_2f7cf999-2816-4b43-a30c-7370d80198e1_verboseLabel_en-US" xlink:label="lab_sls_WarrantExerciseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 2019 Exercise Agreement</link:label>
    <link:label id="lab_sls_WarrantExerciseAgreementMember_label_en-US" xlink:label="lab_sls_WarrantExerciseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Agreement [Member]</link:label>
    <link:label id="lab_sls_WarrantExerciseAgreementMember_documentation_en-US" xlink:label="lab_sls_WarrantExerciseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_WarrantExerciseAgreementMember" xlink:href="sls-20210630.xsd#sls_WarrantExerciseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_WarrantExerciseAgreementMember" xlink:to="lab_sls_WarrantExerciseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c9fa6aa6-2c0c-4234-8ba4-388be3eadd15_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable&#160; Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_d2bdc7dd-6ac1-4f0d-beda-965fabfb36b5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_1eb4d1e5-686b-4415-8dbc-a883da676a60_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6d06e85b-487c-42e6-ab5a-9a9622e24dfe_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dda1789a-bca6-4bab-8664-f60b39e83734_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_SaleOfStockAgentFeePercentageOfGrossProceeds_68f95a58-34a3-42a6-addd-0b05d216556e_terseLabel_en-US" xlink:label="lab_sls_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage gross proceeds from the sale of share (as a percent)</link:label>
    <link:label id="lab_sls_SaleOfStockAgentFeePercentageOfGrossProceeds_label_en-US" xlink:label="lab_sls_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Agent Fee, Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_sls_SaleOfStockAgentFeePercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_sls_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Agent Fee, Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:href="sls-20210630.xsd#sls_SaleOfStockAgentFeePercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:to="lab_sls_SaleOfStockAgentFeePercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_53a93afb-f140-4704-961c-5f396da79e84_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum_0c845e32-3890-466f-8d5e-f7041a765410_terseLabel_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future milestone payments received</link:label>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum_label_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Potential Milestone Payments To Be Received, Maximum</link:label>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum_documentation_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Potential Milestone Payments To Be Received, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum" xlink:href="sls-20210630.xsd#sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum" xlink:to="lab_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_980c8c7b-9a85-493b-a4c6-9fd464ceaf9d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current and non-current operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_4a1de7f3-eca2-4a8b-9dc3-9d5e2bbf9a19_terseLabel_en-US" xlink:label="lab_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses weighted average period</link:label>
    <link:label id="lab_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_label_en-US" xlink:label="lab_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:label id="lab_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_documentation_en-US" xlink:label="lab_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:href="sls-20210630.xsd#sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:to="lab_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c62632c3-b4d5-4bc4-9537-ff807fdc7b31_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5795f5b6-de1a-4f54-9ef3-164071e0d1f8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_66011c10-48f1-49d2-89ef-257940db9731_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ab381902-e9d5-4671-a930-91c3a2b27fae_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001&#160;par value; 350,000,000&#160;shares authorized, 15,873,941 and 14,254,554&#160;shares issued and outstanding at June 30, 2021 and December&#160;31, 2020, respectively.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_bfd0d06b-dbe6-4c9a-9aad-7347b1cdb56d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_StockIssuedDuringPeriodValueCommonStockandWarrants_4ad3a0f2-f3cb-4bfc-835f-7110132c44f8_terseLabel_en-US" xlink:label="lab_sls_StockIssuedDuringPeriodValueCommonStockandWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and common stock warrants, net of issuance costs</link:label>
    <link:label id="lab_sls_StockIssuedDuringPeriodValueCommonStockandWarrants_label_en-US" xlink:label="lab_sls_StockIssuedDuringPeriodValueCommonStockandWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Common Stock and Warrants</link:label>
    <link:label id="lab_sls_StockIssuedDuringPeriodValueCommonStockandWarrants_documentation_en-US" xlink:label="lab_sls_StockIssuedDuringPeriodValueCommonStockandWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Common Stock and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockIssuedDuringPeriodValueCommonStockandWarrants" xlink:href="sls-20210630.xsd#sls_StockIssuedDuringPeriodValueCommonStockandWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_StockIssuedDuringPeriodValueCommonStockandWarrants" xlink:to="lab_sls_StockIssuedDuringPeriodValueCommonStockandWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_bb3a35b1-b0a6-490f-95df-ca556bea9cf6_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_a4fa424f-5dc6-429d-8bd3-dc462fad10c8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 6)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_29ec527d-746a-4c48-9cbc-ee6fc0598147_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_0ec603a3-290c-46b5-825e-baea1f83c801_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dec1bb6d-82f2-4856-bf88-63d6b7d2a48c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, options exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_974d208e-780e-4da3-a103-a05b23ba98f6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ProceedsFromStockSubscriptionReceivable_48fa71e9-bd2d-416a-8409-6bf0e99c2a36_terseLabel_en-US" xlink:label="lab_sls_ProceedsFromStockSubscriptionReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collection of stock subscription receivable</link:label>
    <link:label id="lab_sls_ProceedsFromStockSubscriptionReceivable_label_en-US" xlink:label="lab_sls_ProceedsFromStockSubscriptionReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Subscription Receivable</link:label>
    <link:label id="lab_sls_ProceedsFromStockSubscriptionReceivable_documentation_en-US" xlink:label="lab_sls_ProceedsFromStockSubscriptionReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Subscription Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ProceedsFromStockSubscriptionReceivable" xlink:href="sls-20210630.xsd#sls_ProceedsFromStockSubscriptionReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ProceedsFromStockSubscriptionReceivable" xlink:to="lab_sls_ProceedsFromStockSubscriptionReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_January2020OfferingMember_0d37f49e-a126-49ba-8740-da11003ed84d_terseLabel_en-US" xlink:label="lab_sls_January2020OfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2020 Offering</link:label>
    <link:label id="lab_sls_January2020OfferingMember_label_en-US" xlink:label="lab_sls_January2020OfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2020 Offering [Member]</link:label>
    <link:label id="lab_sls_January2020OfferingMember_documentation_en-US" xlink:label="lab_sls_January2020OfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2020 Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_January2020OfferingMember" xlink:href="sls-20210630.xsd#sls_January2020OfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_January2020OfferingMember" xlink:to="lab_sls_January2020OfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ba246dac-da29-48a1-8850-599f14c138ec_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 (remaining)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ec8f0b9e-18ed-47fb-b965-548537eaef9f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_e59ac9ea-d406-4f93-a861-70f963877ec9_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_DividendArisingFromWarrantModifications_9d701c3c-a91b-45b3-a1ae-49ca67f9cdcc_negatedLabel_en-US" xlink:label="lab_sls_DividendArisingFromWarrantModifications" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend arising from warrant modifications</link:label>
    <link:label id="lab_sls_DividendArisingFromWarrantModifications_label_en-US" xlink:label="lab_sls_DividendArisingFromWarrantModifications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Arising From Warrant Modifications</link:label>
    <link:label id="lab_sls_DividendArisingFromWarrantModifications_documentation_en-US" xlink:label="lab_sls_DividendArisingFromWarrantModifications" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Arising From Warrant Modifications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_DividendArisingFromWarrantModifications" xlink:href="sls-20210630.xsd#sls_DividendArisingFromWarrantModifications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_DividendArisingFromWarrantModifications" xlink:to="lab_sls_DividendArisingFromWarrantModifications" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_61db78a0-72b4-4510-b5f4-eace86760daa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions for Option Grants Issued</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_45577d4e-703f-460e-b651-9daa007e2b7a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ce2d7684-f56e-4bc4-829c-07e756ebb5a6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_c4e5ba23-ccf4-435a-af5f-b2c0b65a390f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_FairValueOfWarrantsLiabilities_3033199b-c0a3-4fb6-b511-25c6411e91c6_periodStartLabel_en-US" xlink:label="lab_sls_FairValueOfWarrantsLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability, beginning balance</link:label>
    <link:label id="lab_sls_FairValueOfWarrantsLiabilities_a979a463-2b1c-4f75-976a-8f9004152525_periodEndLabel_en-US" xlink:label="lab_sls_FairValueOfWarrantsLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability, ending balance</link:label>
    <link:label id="lab_sls_FairValueOfWarrantsLiabilities_label_en-US" xlink:label="lab_sls_FairValueOfWarrantsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrants Liabilities</link:label>
    <link:label id="lab_sls_FairValueOfWarrantsLiabilities_documentation_en-US" xlink:label="lab_sls_FairValueOfWarrantsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrant liabilities as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_FairValueOfWarrantsLiabilities" xlink:href="sls-20210630.xsd#sls_FairValueOfWarrantsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_FairValueOfWarrantsLiabilities" xlink:to="lab_sls_FairValueOfWarrantsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ClosingPriceOfCommonStock_38ea87ba-6668-4e95-8c4c-11d186e900da_terseLabel_en-US" xlink:label="lab_sls_ClosingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing price of the Company's common stock (in dollars per share)</link:label>
    <link:label id="lab_sls_ClosingPriceOfCommonStock_label_en-US" xlink:label="lab_sls_ClosingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing Price Of Common Stock</link:label>
    <link:label id="lab_sls_ClosingPriceOfCommonStock_documentation_en-US" xlink:label="lab_sls_ClosingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing price of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClosingPriceOfCommonStock" xlink:href="sls-20210630.xsd#sls_ClosingPriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ClosingPriceOfCommonStock" xlink:to="lab_sls_ClosingPriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_f0ca4e69-9af3-4ecb-bd7d-b4fb1997d393_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49c9b2d5-dc83-4465-a620-196e4dbe7542_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_247731b1-cab2-42a6-b2a6-8c103f89db66_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_0004905d-7537-48fe-a5ec-7c1a9bdcdf2e_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_ef17abe2-2eae-498a-8984-7ad3290df0b6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_23f6f845-b35c-4e6f-97d7-88596f0db007_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ef25a97f-1c49-40f0-88be-4852edc63597_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5864f790-6467-4033-9cb7-f744ef26480d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_A2017EmployeeStockPurchasePlanMember_d133a29b-da1f-4bb7-a8aa-2efe6e64676e_terseLabel_en-US" xlink:label="lab_sls_A2017EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 ESPP</link:label>
    <link:label id="lab_sls_A2017EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_sls_A2017EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sls_A2017EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_sls_A2017EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_A2017EmployeeStockPurchasePlanMember" xlink:href="sls-20210630.xsd#sls_A2017EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_A2017EmployeeStockPurchasePlanMember" xlink:to="lab_sls_A2017EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_9bbbdfb6-1427-477a-905d-4b49705b2fe4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d45dcb7a-6228-4182-b4f4-b2d268a01689_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_e09fedb1-90e0-4722-b242-f4ea0f8cc809_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_33491d10-d251-4c9f-aeb3-733a556d2e43_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7a0383f1-8776-4af1-bd6a-8591b78badfe_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_50e571a9-ac1a-42b5-adb5-2613e55a7964_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_64188b43-6960-4708-bba0-4b72cc7bac50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3b4f81ab-8f12-4053-a8b1-20b40012c26a_totalLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6959d057-6159-4c7f-ae73-282868addb23_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0202a1a2-fff3-43ec-8e68-55e0d5de7b8f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_79c6a7b6-af74-4971-b3fb-31c9ad28bb3b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds of common stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e10630a7-e3aa-4d26-a202-b0320ab9f793_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_12c8fdd3-6c72-45e9-8227-4337d5e005cf_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_32fee202-ac1d-4e32-a860-1db71dd1c64b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eb530401-0582-4a0f-813c-6771bcf5787a_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9a83cfaf-fe04-4421-a503-9d669eb184d6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f6ca3135-3bc2-4190-9810-46707421f7b2_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock_8f402834-cbb0-4294-a13e-1af59dd62448_terseLabel_en-US" xlink:label="lab_sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Warrant Liability</link:label>
    <link:label id="lab_sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock_label_en-US" xlink:label="lab_sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Fair Value Of Warrant Liability [Table Text Block]</link:label>
    <link:label id="lab_sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Fair Value Of Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:href="sls-20210630.xsd#sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:to="lab_sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f609fdf5-172d-4832-b74d-6d48cbdc4a8c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_308ee5bd-13ef-47af-a10e-ebea445b37b7_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f691dd4f-02c8-4436-b934-537256595bc4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e04fc1e4-80b4-479c-a4bc-6d17c52d9753_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1910686d-3e05-4c57-95db-7c00be37313d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Averages contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_StockIssuedDuringPeriodValuePreFundedWarrant_85147545-c224-43a1-93fe-605153941da4_terseLabel_en-US" xlink:label="lab_sls_StockIssuedDuringPeriodValuePreFundedWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of pre-funded warrants</link:label>
    <link:label id="lab_sls_StockIssuedDuringPeriodValuePreFundedWarrant_label_en-US" xlink:label="lab_sls_StockIssuedDuringPeriodValuePreFundedWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value, Pre-Funded Warrant</link:label>
    <link:label id="lab_sls_StockIssuedDuringPeriodValuePreFundedWarrant_documentation_en-US" xlink:label="lab_sls_StockIssuedDuringPeriodValuePreFundedWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value, Pre-Funded Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockIssuedDuringPeriodValuePreFundedWarrant" xlink:href="sls-20210630.xsd#sls_StockIssuedDuringPeriodValuePreFundedWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_StockIssuedDuringPeriodValuePreFundedWarrant" xlink:to="lab_sls_StockIssuedDuringPeriodValuePreFundedWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_FairValueOfWarrantsPotentiallySettleableInCash_27bff75d-d74a-4cc6-90c4-ff5ac921d2f9_terseLabel_en-US" xlink:label="lab_sls_FairValueOfWarrantsPotentiallySettleableInCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_sls_FairValueOfWarrantsPotentiallySettleableInCash_df7ff2d0-b196-47f3-bcf1-720d508bfbc4_verboseLabel_en-US" xlink:label="lab_sls_FairValueOfWarrantsPotentiallySettleableInCash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_sls_FairValueOfWarrantsPotentiallySettleableInCash_label_en-US" xlink:label="lab_sls_FairValueOfWarrantsPotentiallySettleableInCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Warrants Potentially Settleable In Cash</link:label>
    <link:label id="lab_sls_FairValueOfWarrantsPotentiallySettleableInCash_documentation_en-US" xlink:label="lab_sls_FairValueOfWarrantsPotentiallySettleableInCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants potentially settleable in cash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_FairValueOfWarrantsPotentiallySettleableInCash" xlink:href="sls-20210630.xsd#sls_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_FairValueOfWarrantsPotentiallySettleableInCash" xlink:to="lab_sls_FairValueOfWarrantsPotentiallySettleableInCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3435a7d1-72d6-4980-96f9-b47baf19e52b_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8a8dc10d-0b5f-46de-94e4-16435dc37048_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2e55bce9-1c24-4928-8693-c60017ec8bd2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2ff1569c-c538-4fd0-882c-23048b75aa1e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_15b3eda7-4555-4b32-a4de-b45ef07d9a77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Outstanding Excluded from Computation of Diluted Weighted Average Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_e176291e-6132-460d-9078-19e47db59a9e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_00a4d692-c3f9-46ab-8b0b-126b30c236af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_2c010b25-0ab6-4a4b-95c0-231271510e6d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_3c575b1f-d040-4c7b-8d2e-1efba8fc5689_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-operating income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_86227e2e-8382-4188-809a-2b9ddfd9107c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_4880a35c-5dca-4c0e-a4bc-1af6c0eff500_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_OtherLiabilityClassifiedMember_817a707e-a65a-4d87-b5ef-92062b871e67_terseLabel_en-US" xlink:label="lab_sls_OtherLiabilityClassifiedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other warrants (liability-classified)</link:label>
    <link:label id="lab_sls_OtherLiabilityClassifiedMember_label_en-US" xlink:label="lab_sls_OtherLiabilityClassifiedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liability Classified [Member]</link:label>
    <link:label id="lab_sls_OtherLiabilityClassifiedMember_documentation_en-US" xlink:label="lab_sls_OtherLiabilityClassifiedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liability Classified [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_OtherLiabilityClassifiedMember" xlink:href="sls-20210630.xsd#sls_OtherLiabilityClassifiedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_OtherLiabilityClassifiedMember" xlink:to="lab_sls_OtherLiabilityClassifiedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_6d1149c3-a275-4ee9-98e9-e96f25106ded_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_2a57d3a3-71e9-414c-a5be-75acd7579489_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9612c84d-5cd3-4cf1-b211-f8ff73f7037d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_735baf6d-ea5f-4597-ad7d-07e3a91fc7f4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_TwoThousandAndSeventeenEquityIncentivePlanMember_6ba4dca6-7b36-47e7-b569-361926aea673_terseLabel_en-US" xlink:label="lab_sls_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Equity Plan</link:label>
    <link:label id="lab_sls_TwoThousandAndSeventeenEquityIncentivePlanMember_label_en-US" xlink:label="lab_sls_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Seventeen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_sls_TwoThousandAndSeventeenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_sls_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Seventeen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:href="sls-20210630.xsd#sls_TwoThousandAndSeventeenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:to="lab_sls_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments_fabfaa22-7b20-441d-98c7-3b8422a783a9_terseLabel_en-US" xlink:label="lab_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received</link:label>
    <link:label id="lab_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments_label_en-US" xlink:label="lab_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Research And Development Arrangement, Milestone Payments</link:label>
    <link:label id="lab_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments_documentation_en-US" xlink:label="lab_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Research And Development Arrangement, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments" xlink:href="sls-20210630.xsd#sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments" xlink:to="lab_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_21c8cad7-c369-4212-b67a-2e9243b6770f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_197b0128-6ef1-4584-9562-81b8f0cb4937_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_7e705644-64f8-4011-a529-0834ca1966b9_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4f8d47c7-84ad-4f97-8fae-1dc803f6f759_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_5d57a750-504d-4177-856c-13b2aa785b32_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_26574bfe-0e2f-4e34-a72c-98e8e0602e8d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected lives (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ChangeInFairValueOfContingentPurchaseConsideration_7647c73c-a9db-4918-82a0-b499f8167397_negatedTerseLabel_en-US" xlink:label="lab_sls_ChangeInFairValueOfContingentPurchaseConsideration" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_sls_ChangeInFairValueOfContingentPurchaseConsideration_label_en-US" xlink:label="lab_sls_ChangeInFairValueOfContingentPurchaseConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Fair Value Of Contingent Purchase Consideration</link:label>
    <link:label id="lab_sls_ChangeInFairValueOfContingentPurchaseConsideration_documentation_en-US" xlink:label="lab_sls_ChangeInFairValueOfContingentPurchaseConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent purchase consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangeInFairValueOfContingentPurchaseConsideration" xlink:href="sls-20210630.xsd#sls_ChangeInFairValueOfContingentPurchaseConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ChangeInFairValueOfContingentPurchaseConsideration" xlink:to="lab_sls_ChangeInFairValueOfContingentPurchaseConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_554b1dc9-72e1-41f5-a1ed-9e2338b50fe4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_ec598586-11d1-465f-b7b0-9a0a3c47cc73_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f2f16690-088a-41fd-ad1b-d31a45c13e9d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_c3ce9ad5-7b57-4ca9-b390-5bdb9ce07e49_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4e8b9bbe-62a9-471e-b3e0-089f27fbc313_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_503941e0-d463-407a-b86a-1c368aa8c91b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5a506ef4-b346-4aad-8377-33fd356dc022_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2391deeb-7358-4469-aaab-15a6b047e21b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7a2b98dc-542c-43a7-9552-ce41622021ba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_558d4e91-28b7-4242-9c72-c442ce3f4a62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares available for future issuance under stock based awards (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_394f3de4-ed0b-4840-ac7d-596b4aafed48_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_a92b7438-796d-44c3-8ec3-127e5df119a3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e87983b2-d790-4f04-bd30-881c5e6d1bd8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c06df493-a03b-4463-8607-476bffc5c486_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_efe6dfa2-6491-496e-911c-b733d6ea3712_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ClassofWarrantorRightOutstandingRollForward_6065a925-3b7d-4a20-83e7-529ca8f2cb8f_terseLabel_en-US" xlink:label="lab_sls_ClassofWarrantorRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_sls_ClassofWarrantorRightOutstandingRollForward_label_en-US" xlink:label="lab_sls_ClassofWarrantorRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_sls_ClassofWarrantorRightOutstandingRollForward_documentation_en-US" xlink:label="lab_sls_ClassofWarrantorRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClassofWarrantorRightOutstandingRollForward" xlink:href="sls-20210630.xsd#sls_ClassofWarrantorRightOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ClassofWarrantorRightOutstandingRollForward" xlink:to="lab_sls_ClassofWarrantorRightOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ScheduleOfWarrantActivityTableTextBlock_43ef717a-523d-4634-ad25-a86dc95f80cd_terseLabel_en-US" xlink:label="lab_sls_ScheduleOfWarrantActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrant Activity</link:label>
    <link:label id="lab_sls_ScheduleOfWarrantActivityTableTextBlock_label_en-US" xlink:label="lab_sls_ScheduleOfWarrantActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Warrant Activity [Table Text Block]</link:label>
    <link:label id="lab_sls_ScheduleOfWarrantActivityTableTextBlock_documentation_en-US" xlink:label="lab_sls_ScheduleOfWarrantActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Warrant Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ScheduleOfWarrantActivityTableTextBlock" xlink:href="sls-20210630.xsd#sls_ScheduleOfWarrantActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ScheduleOfWarrantActivityTableTextBlock" xlink:to="lab_sls_ScheduleOfWarrantActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_AptheraInc.Member_0f230635-1451-4cc7-8dbd-7416576efb0e_terseLabel_en-US" xlink:label="lab_sls_AptheraInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apthera, Inc.</link:label>
    <link:label id="lab_sls_AptheraInc.Member_label_en-US" xlink:label="lab_sls_AptheraInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apthera, Inc. [Member]</link:label>
    <link:label id="lab_sls_AptheraInc.Member_documentation_en-US" xlink:label="lab_sls_AptheraInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apthera, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_AptheraInc.Member" xlink:href="sls-20210630.xsd#sls_AptheraInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_AptheraInc.Member" xlink:to="lab_sls_AptheraInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f02b39d5-da8b-4264-ba42-3786e87b4b80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6de62a81-e138-4cf0-a661-6ff30d4e1a72_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Standards Adopted and Recent Accounting Standards Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_815cf0e9-91ea-4f8f-9ecf-20eedf8d812b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_589ad91c-55e6-4b00-b113-266d032aaef7_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_45f58505-d00b-4856-94d2-3499eb28dc9c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b2300ef9-c2cc-4863-9d5c-0e7852bea339_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_InProcessResearchDevelopment_b4cc3aa4-961e-4b7b-b15d-073cd1fb3da3_terseLabel_en-US" xlink:label="lab_sls_InProcessResearchDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_sls_InProcessResearchDevelopment_label_en-US" xlink:label="lab_sls_InProcessResearchDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research Development</link:label>
    <link:label id="lab_sls_InProcessResearchDevelopment_documentation_en-US" xlink:label="lab_sls_InProcessResearchDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_InProcessResearchDevelopment" xlink:href="sls-20210630.xsd#sls_InProcessResearchDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_InProcessResearchDevelopment" xlink:to="lab_sls_InProcessResearchDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d5c7a145-04ff-4b9d-b2e5-a82d398227bc_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_04d274db-2eab-41b9-83b7-e3321d71954f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_85bef540-acf9-4f98-bc92-a7136cbd69c0_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_67e663df-e680-412a-9b8b-ca955515de58_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits and other assets</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsNoncurrent" xlink:to="lab_us-gaap_DepositsAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_f79d6275-901d-4132-a866-a34cfc73f47c_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to Acquire Shares of Common Stock</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Indexed to Issuer's Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_069ac0a6-c067-4020-8da7-8e5b1bbde938_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_57400f1b-7af8-4880-9834-f6183ccca6ec_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f75784be-352f-4ca8-9a81-d7a87d8932d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2ee259cb-7182-4435-8892-43e1112f5ef8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_94a4b0a1-e2ce-4f3b-beef-179a129dc7b6_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ea770711-d6c0-42f1-8a09-fab50406cd31_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_278354e8-d447-4e06-94e8-ed8e47c61ca0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm_1d0e0790-ef57-4de9-965c-539e430abf43_terseLabel_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties payable, minimum term</link:label>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm_label_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Royalties Payable, Minimum Term</link:label>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm_documentation_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Royalties Payable, Minimum Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm" xlink:href="sls-20210630.xsd#sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm" xlink:to="lab_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1bcff17c-6c70-490d-b4aa-aaf31a08e72d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_af908d21-4cff-40f2-9ae6-4d92d5819a6c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_039c4444-ef58-46d8-9b1d-cb75302dd64d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ee3157f7-9811-4d96-a995-17ebf8048832_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_f5a987e9-3e79-4cde-bd2d-eaa16a342c29_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ChangeInOperatingLeaseRightOfUseAssets_c9564514-48f0-401e-be31-717a3699ae1f_terseLabel_en-US" xlink:label="lab_sls_ChangeInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating lease right of use assets</link:label>
    <link:label id="lab_sls_ChangeInOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_sls_ChangeInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Operating Lease Right Of Use Assets</link:label>
    <link:label id="lab_sls_ChangeInOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_sls_ChangeInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Operating Lease Right of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangeInOperatingLeaseRightOfUseAssets" xlink:href="sls-20210630.xsd#sls_ChangeInOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="lab_sls_ChangeInOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5619e0ff-ba4c-4060-b9d8-0bef9f90f8d5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_a5bc7bce-fd1a-4afa-9989-674b40075250_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and rights outstanding, measurement input coupon rate</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_3d0764a2-be8a-41e5-88a5-50bae9ad72b7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_469ff669-5b85-4280-a17f-f276b541f005_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_9f2b97bf-34d0-49e8-b999-2e0f554a058e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c17bcfcf-725a-4412-86f9-90a26a80553b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_2580ea3d-1b3a-46dc-a5ef-6e982c4c8ddc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_OtherWarrantIssuesMember_eb112791-8cc3-4555-8d9c-95e313d8541d_terseLabel_en-US" xlink:label="lab_sls_OtherWarrantIssuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_sls_OtherWarrantIssuesMember_label_en-US" xlink:label="lab_sls_OtherWarrantIssuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Warrant Issues [Member]</link:label>
    <link:label id="lab_sls_OtherWarrantIssuesMember_documentation_en-US" xlink:label="lab_sls_OtherWarrantIssuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Warrant Issues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_OtherWarrantIssuesMember" xlink:href="sls-20210630.xsd#sls_OtherWarrantIssuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_OtherWarrantIssuesMember" xlink:to="lab_sls_OtherWarrantIssuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_A2019EquityIncentivePlanMember_ef3714eb-c27f-406a-a6d4-a39c8c712343_terseLabel_en-US" xlink:label="lab_sls_A2019EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan</link:label>
    <link:label id="lab_sls_A2019EquityIncentivePlanMember_label_en-US" xlink:label="lab_sls_A2019EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_sls_A2019EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_sls_A2019EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_A2019EquityIncentivePlanMember" xlink:href="sls-20210630.xsd#sls_A2019EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_A2019EquityIncentivePlanMember" xlink:to="lab_sls_A2019EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetCurrent_2314fdda-fe11-4040-ab50-e659a984762d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract asset</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetCurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetCurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_PrepaidProfessionalServices_3deb8265-bd72-4056-bace-b7f893ea6512_terseLabel_en-US" xlink:label="lab_sls_PrepaidProfessionalServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_sls_PrepaidProfessionalServices_label_en-US" xlink:label="lab_sls_PrepaidProfessionalServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Professional Services</link:label>
    <link:label id="lab_sls_PrepaidProfessionalServices_documentation_en-US" xlink:label="lab_sls_PrepaidProfessionalServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Professional Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_PrepaidProfessionalServices" xlink:href="sls-20210630.xsd#sls_PrepaidProfessionalServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_PrepaidProfessionalServices" xlink:to="lab_sls_PrepaidProfessionalServices" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ClassofWarrantorRightCanceledOrExpired_692d191d-54d1-48e5-90d6-b4086be2ba53_negatedTerseLabel_en-US" xlink:label="lab_sls_ClassofWarrantorRightCanceledOrExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/Expired (in shares)</link:label>
    <link:label id="lab_sls_ClassofWarrantorRightCanceledOrExpired_label_en-US" xlink:label="lab_sls_ClassofWarrantorRightCanceledOrExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Canceled Or Expired</link:label>
    <link:label id="lab_sls_ClassofWarrantorRightCanceledOrExpired_documentation_en-US" xlink:label="lab_sls_ClassofWarrantorRightCanceledOrExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Canceled Or Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClassofWarrantorRightCanceledOrExpired" xlink:href="sls-20210630.xsd#sls_ClassofWarrantorRightCanceledOrExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ClassofWarrantorRightCanceledOrExpired" xlink:to="lab_sls_ClassofWarrantorRightCanceledOrExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_243f27a7-1427-4dbe-aff9-ded5f22ed27a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived_880f32b6-2c1e-41df-945e-687f5e67a206_terseLabel_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments to be received</link:label>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived_label_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Potential Milestone Payments To Be Received</link:label>
    <link:label id="lab_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived_documentation_en-US" xlink:label="lab_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Arrangement, Potential Milestone Payments To Be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived" xlink:href="sls-20210630.xsd#sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived" xlink:to="lab_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a5e4b54e-9531-44cf-a9a2-d8ba5e421bd5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>sls-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:44c0be2c-a517-445c-901f-827aacd933ea,g:c47eecba-e87d-4369-b623-d76d853819d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sellaslife.com/role/Cover" xlink:type="simple" xlink:href="sls-20210630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_715a3f80-a229-4fff-9e2b-18faf6a76565" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_DocumentType_715a3f80-a229-4fff-9e2b-18faf6a76565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d96dfbdf-e512-49d5-adaf-3121a867de11" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_DocumentQuarterlyReport_d96dfbdf-e512-49d5-adaf-3121a867de11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e5beef1b-14f7-4eea-9e80-729b2a9d3d7c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_DocumentPeriodEndDate_e5beef1b-14f7-4eea-9e80-729b2a9d3d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_fa67922e-cb15-4e22-8863-eb21cafb1cd9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_DocumentTransitionReport_fa67922e-cb15-4e22-8863-eb21cafb1cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f5dd41e8-d03d-43cc-8a2d-587e773ac0b5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntityFileNumber_f5dd41e8-d03d-43cc-8a2d-587e773ac0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_70bae9b1-0306-4fe3-8342-a19b6623d5ad" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntityRegistrantName_70bae9b1-0306-4fe3-8342-a19b6623d5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_cd8d758d-43b5-469c-903f-15568199bce0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntityIncorporationStateCountryCode_cd8d758d-43b5-469c-903f-15568199bce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9b4af8f5-0037-4baf-a337-f36aac5b407d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntityTaxIdentificationNumber_9b4af8f5-0037-4baf-a337-f36aac5b407d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b2315c57-03b1-4861-b1dc-009817575a40" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntityAddressAddressLine1_b2315c57-03b1-4861-b1dc-009817575a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_773532ab-f2cc-4d4d-a98b-debe3a27696e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntityAddressCityOrTown_773532ab-f2cc-4d4d-a98b-debe3a27696e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_7820cdf8-a837-4a06-bc8c-e397a8bf39f2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntityAddressStateOrProvince_7820cdf8-a837-4a06-bc8c-e397a8bf39f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fb260d9f-f393-4bf0-8225-d2b78edf6f85" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntityAddressPostalZipCode_fb260d9f-f393-4bf0-8225-d2b78edf6f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_dfcd910b-8fa3-4d45-b654-102b88c387a0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_CityAreaCode_dfcd910b-8fa3-4d45-b654-102b88c387a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_71e817f4-d02d-43dc-a37c-20103974329d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_LocalPhoneNumber_71e817f4-d02d-43dc-a37c-20103974329d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d125cd32-a110-41bc-a402-730a3c25b4ae" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_Security12bTitle_d125cd32-a110-41bc-a402-730a3c25b4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0118b444-b381-4561-9fbc-6ab721030b09" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_TradingSymbol_0118b444-b381-4561-9fbc-6ab721030b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c941c76f-f5e8-4e76-875e-996d1ef3f743" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_SecurityExchangeName_c941c76f-f5e8-4e76-875e-996d1ef3f743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_621d5fbe-daa1-4ddc-a47f-6832833f823c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntityCurrentReportingStatus_621d5fbe-daa1-4ddc-a47f-6832833f823c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_64b429be-bc4a-493d-8a08-66995faad782" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntityInteractiveDataCurrent_64b429be-bc4a-493d-8a08-66995faad782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_185ad21d-9e18-4459-844a-13c6d9023aea" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntityFilerCategory_185ad21d-9e18-4459-844a-13c6d9023aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5da60bce-e135-44bf-b154-22708304809c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntitySmallBusiness_5da60bce-e135-44bf-b154-22708304809c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e3526da7-a3dc-4671-951a-23be1baeb674" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntityEmergingGrowthCompany_e3526da7-a3dc-4671-951a-23be1baeb674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_faa219cb-2948-49c2-a6f2-5c610a6058f1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntityShellCompany_faa219cb-2948-49c2-a6f2-5c610a6058f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a13db49d-7b4c-4d30-b38a-98e8e094d963" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a13db49d-7b4c-4d30-b38a-98e8e094d963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_09d16db6-3299-43fb-a1f2-970ba01911a3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_EntityCentralIndexKey_09d16db6-3299-43fb-a1f2-970ba01911a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_e326279f-3816-46d8-b503-a644e687cd5d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_CurrentFiscalYearEndDate_e326279f-3816-46d8-b503-a644e687cd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a3a134f0-4884-4655-bdf9-c9b3dda40196" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_DocumentFiscalYearFocus_a3a134f0-4884-4655-bdf9-c9b3dda40196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_efd50a07-6f36-47aa-b1ab-aa4fdc665f8f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_DocumentFiscalPeriodFocus_efd50a07-6f36-47aa-b1ab-aa4fdc665f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_18faa046-ff24-4cd7-a220-92b5615903eb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30058bbf-89a7-4aa5-b3f0-487626b897db" xlink:to="loc_dei_AmendmentFlag_18faa046-ff24-4cd7-a220-92b5615903eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sls-20210630.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_55feff2d-20d1-4bf7-acef-5af86a7875f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1a2e16a8-9763-40e7-9eda-9da9c1ad9637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_55feff2d-20d1-4bf7-acef-5af86a7875f1" xlink:to="loc_us-gaap_AssetsAbstract_1a2e16a8-9763-40e7-9eda-9da9c1ad9637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_dc1feb9a-59ad-4cc8-a29e-a3656b58f7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a2e16a8-9763-40e7-9eda-9da9c1ad9637" xlink:to="loc_us-gaap_AssetsCurrentAbstract_dc1feb9a-59ad-4cc8-a29e-a3656b58f7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_545ab21d-232e-43bb-bf2a-5682b10f91f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dc1feb9a-59ad-4cc8-a29e-a3656b58f7d7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_545ab21d-232e-43bb-bf2a-5682b10f91f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3640a9bd-4805-4c3b-b846-941f797568eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dc1feb9a-59ad-4cc8-a29e-a3656b58f7d7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_3640a9bd-4805-4c3b-b846-941f797568eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockSubscriptionReceivableCurrent_a15ff2bd-d949-4b06-82a0-5f7c23569ccc" xlink:href="sls-20210630.xsd#sls_StockSubscriptionReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dc1feb9a-59ad-4cc8-a29e-a3656b58f7d7" xlink:to="loc_sls_StockSubscriptionReceivableCurrent_a15ff2bd-d949-4b06-82a0-5f7c23569ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetCurrent_5b2701ac-9ff4-4049-b544-370820591c04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dc1feb9a-59ad-4cc8-a29e-a3656b58f7d7" xlink:to="loc_us-gaap_CapitalizedContractCostNetCurrent_5b2701ac-9ff4-4049-b544-370820591c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ecc1b0b-b692-44fe-8dce-a1591eab792e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dc1feb9a-59ad-4cc8-a29e-a3656b58f7d7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3ecc1b0b-b692-44fe-8dce-a1591eab792e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fe0516d1-2f17-464c-86fd-b99dca3a26ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_dc1feb9a-59ad-4cc8-a29e-a3656b58f7d7" xlink:to="loc_us-gaap_AssetsCurrent_fe0516d1-2f17-464c-86fd-b99dca3a26ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6732b310-ba66-46f4-9006-9042bb2be231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a2e16a8-9763-40e7-9eda-9da9c1ad9637" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6732b310-ba66-46f4-9006-9042bb2be231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_InProcessResearchDevelopment_b51d5087-628d-40f5-8378-0750c5a5e8a5" xlink:href="sls-20210630.xsd#sls_InProcessResearchDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a2e16a8-9763-40e7-9eda-9da9c1ad9637" xlink:to="loc_sls_InProcessResearchDevelopment_b51d5087-628d-40f5-8378-0750c5a5e8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e516427a-2ca1-4cb9-8dca-69ee96554593" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a2e16a8-9763-40e7-9eda-9da9c1ad9637" xlink:to="loc_us-gaap_Goodwill_e516427a-2ca1-4cb9-8dca-69ee96554593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_6c38c2c8-1286-4a47-af65-327201eb65d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a2e16a8-9763-40e7-9eda-9da9c1ad9637" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_6c38c2c8-1286-4a47-af65-327201eb65d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5a70e8d8-8b91-4e74-83af-78fce86fe728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1a2e16a8-9763-40e7-9eda-9da9c1ad9637" xlink:to="loc_us-gaap_Assets_5a70e8d8-8b91-4e74-83af-78fce86fe728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad34b289-d64e-4a29-905f-fb24eafde7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_55feff2d-20d1-4bf7-acef-5af86a7875f1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad34b289-d64e-4a29-905f-fb24eafde7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_991effe9-44f8-4ced-a53a-e36fbc9f946b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad34b289-d64e-4a29-905f-fb24eafde7ab" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_991effe9-44f8-4ced-a53a-e36fbc9f946b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_970f1eb8-5189-4842-b32b-9243fa88c8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_991effe9-44f8-4ced-a53a-e36fbc9f946b" xlink:to="loc_us-gaap_AccountsPayableCurrent_970f1eb8-5189-4842-b32b-9243fa88c8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3ed2ae52-ff9b-424f-b39d-1af7818060b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_991effe9-44f8-4ced-a53a-e36fbc9f946b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3ed2ae52-ff9b-424f-b39d-1af7818060b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_20e914f1-e7a0-4c8d-b349-42814b0e2d28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_991effe9-44f8-4ced-a53a-e36fbc9f946b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_20e914f1-e7a0-4c8d-b349-42814b0e2d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_83fdf44b-27cc-4b6d-b784-85b76805ff60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_991effe9-44f8-4ced-a53a-e36fbc9f946b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_83fdf44b-27cc-4b6d-b784-85b76805ff60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_12d641e9-6996-46fc-bef5-aa45a4e19356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_991effe9-44f8-4ced-a53a-e36fbc9f946b" xlink:to="loc_us-gaap_LiabilitiesCurrent_12d641e9-6996-46fc-bef5-aa45a4e19356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f7544ce1-7868-40d9-a9fd-99b609806cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad34b289-d64e-4a29-905f-fb24eafde7ab" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f7544ce1-7868-40d9-a9fd-99b609806cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_32d401e1-6bc0-49ee-b5bc-94c9e2bfbde7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad34b289-d64e-4a29-905f-fb24eafde7ab" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_32d401e1-6bc0-49ee-b5bc-94c9e2bfbde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_FairValueOfWarrantsPotentiallySettleableInCash_67b6f875-3535-40cb-80dc-02942f371ebc" xlink:href="sls-20210630.xsd#sls_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad34b289-d64e-4a29-905f-fb24eafde7ab" xlink:to="loc_sls_FairValueOfWarrantsPotentiallySettleableInCash_67b6f875-3535-40cb-80dc-02942f371ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion_e7237dbb-f84e-459c-8f08-06eb022f4da5" xlink:href="sls-20210630.xsd#sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad34b289-d64e-4a29-905f-fb24eafde7ab" xlink:to="loc_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion_e7237dbb-f84e-459c-8f08-06eb022f4da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4cff781c-2adf-4ca8-be3e-2030d3e95063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad34b289-d64e-4a29-905f-fb24eafde7ab" xlink:to="loc_us-gaap_Liabilities_4cff781c-2adf-4ca8-be3e-2030d3e95063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_07983299-3994-4c59-bc03-1b99f2325a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad34b289-d64e-4a29-905f-fb24eafde7ab" xlink:to="loc_us-gaap_CommitmentsAndContingencies_07983299-3994-4c59-bc03-1b99f2325a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9d93ca3c-c319-4d02-a0c2-40138019ba26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad34b289-d64e-4a29-905f-fb24eafde7ab" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9d93ca3c-c319-4d02-a0c2-40138019ba26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1371f677-bfe6-43df-87dd-9b077c88dde9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9d93ca3c-c319-4d02-a0c2-40138019ba26" xlink:to="loc_us-gaap_PreferredStockValue_1371f677-bfe6-43df-87dd-9b077c88dde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9772bc45-b680-45ce-a6d5-fa767fa27cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9d93ca3c-c319-4d02-a0c2-40138019ba26" xlink:to="loc_us-gaap_CommonStockValue_9772bc45-b680-45ce-a6d5-fa767fa27cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c7bbcb12-bcd1-415d-8480-d6e1c4fb81d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9d93ca3c-c319-4d02-a0c2-40138019ba26" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c7bbcb12-bcd1-415d-8480-d6e1c4fb81d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_88285de7-4486-4211-a1ac-751044e889bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9d93ca3c-c319-4d02-a0c2-40138019ba26" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_88285de7-4486-4211-a1ac-751044e889bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_316102ac-d36c-496c-832d-a6ee1098af25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9d93ca3c-c319-4d02-a0c2-40138019ba26" xlink:to="loc_us-gaap_StockholdersEquity_316102ac-d36c-496c-832d-a6ee1098af25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c562ff43-d613-4cde-b6d3-8b24ce133e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad34b289-d64e-4a29-905f-fb24eafde7ab" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c562ff43-d613-4cde-b6d3-8b24ce133e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sls-20210630.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_90468e48-41c5-4dd3-9103-beb9a3c615b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1ab399c7-d122-47d4-8d8f-e5e620e961df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_90468e48-41c5-4dd3-9103-beb9a3c615b4" xlink:to="loc_us-gaap_StatementTable_1ab399c7-d122-47d4-8d8f-e5e620e961df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9d786895-2c4d-49f0-bc75-6c32f27bfeff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1ab399c7-d122-47d4-8d8f-e5e620e961df" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9d786895-2c4d-49f0-bc75-6c32f27bfeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b55fec9d-3bd4-4525-9a82-33e768eaefca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9d786895-2c4d-49f0-bc75-6c32f27bfeff" xlink:to="loc_us-gaap_ClassOfStockDomain_b55fec9d-3bd4-4525-9a82-33e768eaefca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2afd0c0f-5aef-4b54-b7f1-2eaf6e841c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b55fec9d-3bd4-4525-9a82-33e768eaefca" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2afd0c0f-5aef-4b54-b7f1-2eaf6e841c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1ab399c7-d122-47d4-8d8f-e5e620e961df" xlink:to="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_809bca3f-55c7-476e-9436-79ac22be6ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_809bca3f-55c7-476e-9436-79ac22be6ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9042991e-196f-41ea-8d77-47da249d83bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9042991e-196f-41ea-8d77-47da249d83bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_18cc0401-3b07-465b-97ee-4fd62fc99670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_PreferredStockSharesIssued_18cc0401-3b07-465b-97ee-4fd62fc99670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3461169a-f39c-4a6a-9621-b8bb9f915159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3461169a-f39c-4a6a-9621-b8bb9f915159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5fccff37-371c-48d5-b2d3-b55674c37b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5fccff37-371c-48d5-b2d3-b55674c37b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7e6cb5cc-a96a-46dd-82ec-4c948232604f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7e6cb5cc-a96a-46dd-82ec-4c948232604f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ab94c44e-5878-4bc1-86f3-ca84c1e4e469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_CommonStockSharesIssued_ab94c44e-5878-4bc1-86f3-ca84c1e4e469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cbda0763-7b11-4e7f-90ab-f2be9f1406f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d9de47b1-2a86-4cb7-bf3b-413d8f12e701" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cbda0763-7b11-4e7f-90ab-f2be9f1406f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sls-20210630.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_66eb176e-381a-463f-a699-f235000c4f16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c88f4cf9-2fca-429b-a18f-778ec8d45e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_66eb176e-381a-463f-a699-f235000c4f16" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c88f4cf9-2fca-429b-a18f-778ec8d45e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_709f9659-848e-4047-bd55-85b2905a494a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_66eb176e-381a-463f-a699-f235000c4f16" xlink:to="loc_us-gaap_OperatingExpensesAbstract_709f9659-848e-4047-bd55-85b2905a494a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ecd26bfc-5874-4785-bd90-47e2cc6aebf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_709f9659-848e-4047-bd55-85b2905a494a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ecd26bfc-5874-4785-bd90-47e2cc6aebf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3aa67300-fac1-4dcc-a8ed-cd3933b919dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_709f9659-848e-4047-bd55-85b2905a494a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3aa67300-fac1-4dcc-a8ed-cd3933b919dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d80bd7f5-c7e5-4d00-bad6-a05ea3913eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_709f9659-848e-4047-bd55-85b2905a494a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d80bd7f5-c7e5-4d00-bad6-a05ea3913eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4a9b938d-e205-45c0-80a5-ac261a2859c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_709f9659-848e-4047-bd55-85b2905a494a" xlink:to="loc_us-gaap_CostsAndExpenses_4a9b938d-e205-45c0-80a5-ac261a2859c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_77ddb333-67f7-41dd-91b6-fe1dfdd319d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_66eb176e-381a-463f-a699-f235000c4f16" xlink:to="loc_us-gaap_OperatingIncomeLoss_77ddb333-67f7-41dd-91b6-fe1dfdd319d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_be893085-213e-4e9e-800a-6771874eead0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_66eb176e-381a-463f-a699-f235000c4f16" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_be893085-213e-4e9e-800a-6771874eead0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_37dd7da7-c89e-40d8-b435-bc2bda8df17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_be893085-213e-4e9e-800a-6771874eead0" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_37dd7da7-c89e-40d8-b435-bc2bda8df17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangeInFairValueOfContingentPurchasePriceConsideration_4e0fda48-ac5a-4f66-9f31-e631997f14fb" xlink:href="sls-20210630.xsd#sls_ChangeInFairValueOfContingentPurchasePriceConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_be893085-213e-4e9e-800a-6771874eead0" xlink:to="loc_sls_ChangeInFairValueOfContingentPurchasePriceConsideration_4e0fda48-ac5a-4f66-9f31-e631997f14fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_5708ab9e-d010-4c44-84aa-0546a38f828a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_be893085-213e-4e9e-800a-6771874eead0" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_5708ab9e-d010-4c44-84aa-0546a38f828a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_7bbe3585-657c-4bff-bc69-57c70e19d232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_be893085-213e-4e9e-800a-6771874eead0" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_7bbe3585-657c-4bff-bc69-57c70e19d232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f8755e1e-2b40-40a0-bb35-54d7f54442b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_66eb176e-381a-463f-a699-f235000c4f16" xlink:to="loc_us-gaap_NetIncomeLoss_f8755e1e-2b40-40a0-bb35-54d7f54442b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_DividendArisingFromWarrantModifications_101d408a-4861-433c-8203-e9c4984b3f88" xlink:href="sls-20210630.xsd#sls_DividendArisingFromWarrantModifications"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_66eb176e-381a-463f-a699-f235000c4f16" xlink:to="loc_sls_DividendArisingFromWarrantModifications_101d408a-4861-433c-8203-e9c4984b3f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a5852084-3583-43fc-a38e-9a11a65e1bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_66eb176e-381a-463f-a699-f235000c4f16" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a5852084-3583-43fc-a38e-9a11a65e1bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5a16f4e5-e1d6-4c39-b766-1ed9c2182f15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_66eb176e-381a-463f-a699-f235000c4f16" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5a16f4e5-e1d6-4c39-b766-1ed9c2182f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_2434ec88-6684-47b0-9afb-e9321fec3e67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_66eb176e-381a-463f-a699-f235000c4f16" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_2434ec88-6684-47b0-9afb-e9321fec3e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c5e0457b-8743-4e56-ba8c-37c6c449d413" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_2434ec88-6684-47b0-9afb-e9321fec3e67" xlink:to="loc_us-gaap_EarningsPerShareBasic_c5e0457b-8743-4e56-ba8c-37c6c449d413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_979b103e-1f7c-4813-bb97-2f1b1b377989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_2434ec88-6684-47b0-9afb-e9321fec3e67" xlink:to="loc_us-gaap_EarningsPerShareDiluted_979b103e-1f7c-4813-bb97-2f1b1b377989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0ed3cdb8-843c-4ac5-a996-3e72c0a929b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_2434ec88-6684-47b0-9afb-e9321fec3e67" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0ed3cdb8-843c-4ac5-a996-3e72c0a929b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d1243fad-5a81-4a2d-b438-5ebd5f842cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_2434ec88-6684-47b0-9afb-e9321fec3e67" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d1243fad-5a81-4a2d-b438-5ebd5f842cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sls-20210630.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d8f387e2-e6d9-487a-8b13-014029a7236a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_08d043c3-005a-4b87-9510-d1b051e2f557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d8f387e2-e6d9-487a-8b13-014029a7236a" xlink:to="loc_us-gaap_StatementTable_08d043c3-005a-4b87-9510-d1b051e2f557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_83074622-b249-464f-adaf-a065a6591614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_08d043c3-005a-4b87-9510-d1b051e2f557" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_83074622-b249-464f-adaf-a065a6591614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ceb8228f-444a-4a4a-b3b7-71bea0df62d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_83074622-b249-464f-adaf-a065a6591614" xlink:to="loc_us-gaap_EquityComponentDomain_ceb8228f-444a-4a4a-b3b7-71bea0df62d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_89ed2246-9b6c-4fb5-8313-1f94c0e0647a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ceb8228f-444a-4a4a-b3b7-71bea0df62d0" xlink:to="loc_us-gaap_CommonStockMember_89ed2246-9b6c-4fb5-8313-1f94c0e0647a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8d66e6a9-7de6-4c85-9cc9-5cffbd25f039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ceb8228f-444a-4a4a-b3b7-71bea0df62d0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8d66e6a9-7de6-4c85-9cc9-5cffbd25f039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_87042f6f-6568-44be-a00f-86dea1ffbdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ceb8228f-444a-4a4a-b3b7-71bea0df62d0" xlink:to="loc_us-gaap_RetainedEarningsMember_87042f6f-6568-44be-a00f-86dea1ffbdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bdd6c731-5461-483b-b46d-53aadcf2d065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_08d043c3-005a-4b87-9510-d1b051e2f557" xlink:to="loc_us-gaap_StatementLineItems_bdd6c731-5461-483b-b46d-53aadcf2d065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bdd6c731-5461-483b-b46d-53aadcf2d065" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_163c778a-ac26-4a35-b868-60aa4bffbeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_us-gaap_SharesOutstanding_163c778a-ac26-4a35-b868-60aa4bffbeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_330c319c-3ee1-4b7d-b2e0-6e654770e15d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_us-gaap_StockholdersEquity_330c319c-3ee1-4b7d-b2e0-6e654770e15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants_8bc3572a-dc72-47ca-9980-709c5f43e347" xlink:href="sls-20210630.xsd#sls_StockIssuedDuringPeriodSharesCommonStockandWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants_8bc3572a-dc72-47ca-9980-709c5f43e347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockIssuedDuringPeriodValueCommonStockandWarrants_3697e7fc-409f-4e47-970f-77691f936d39" xlink:href="sls-20210630.xsd#sls_StockIssuedDuringPeriodValueCommonStockandWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_sls_StockIssuedDuringPeriodValueCommonStockandWarrants_3697e7fc-409f-4e47-970f-77691f936d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e8f4638b-2703-49af-bfd1-26c74d3967f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e8f4638b-2703-49af-bfd1-26c74d3967f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_231087dd-93bd-4c18-b935-932e8ae9b6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_231087dd-93bd-4c18-b935-932e8ae9b6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockIssuedDuringPeriodSharesPrefundedWarrant_60ccd6c0-eef6-4fce-9123-af6d622c9fd1" xlink:href="sls-20210630.xsd#sls_StockIssuedDuringPeriodSharesPrefundedWarrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_sls_StockIssuedDuringPeriodSharesPrefundedWarrant_60ccd6c0-eef6-4fce-9123-af6d622c9fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockIssuedDuringPeriodValuePreFundedWarrant_09dfeecc-2276-4808-8bf4-e0c9941bb57d" xlink:href="sls-20210630.xsd#sls_StockIssuedDuringPeriodValuePreFundedWarrant"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_sls_StockIssuedDuringPeriodValuePreFundedWarrant_09dfeecc-2276-4808-8bf4-e0c9941bb57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f3e6a575-1929-4b24-b1bd-cf670b84988a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f3e6a575-1929-4b24-b1bd-cf670b84988a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d9c6d9c7-e2e5-474b-b2ee-e7134f586412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_us-gaap_NetIncomeLoss_d9c6d9c7-e2e5-474b-b2ee-e7134f586412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e90682f9-2fe5-4269-afd0-0ff4c16b9e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_us-gaap_SharesOutstanding_e90682f9-2fe5-4269-afd0-0ff4c16b9e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3c19b6c6-cefd-4e13-9594-6cb91ef28a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_92bd73c1-5a8f-412e-9b3f-56458918ac14" xlink:to="loc_us-gaap_StockholdersEquity_3c19b6c6-cefd-4e13-9594-6cb91ef28a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sls-20210630.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d8f16f2e-8c62-438c-a91b-2efe662d9896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_718f430d-5deb-44c8-ad12-1722184b1ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d8f16f2e-8c62-438c-a91b-2efe662d9896" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_718f430d-5deb-44c8-ad12-1722184b1ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a24e72c8-bc13-4008-959a-7090cfd5f841" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_718f430d-5deb-44c8-ad12-1722184b1ef2" xlink:to="loc_us-gaap_NetIncomeLoss_a24e72c8-bc13-4008-959a-7090cfd5f841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_14204fbb-19ba-42b3-b245-c974bbfa8149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_718f430d-5deb-44c8-ad12-1722184b1ef2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_14204fbb-19ba-42b3-b245-c974bbfa8149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a55b9b83-2f58-43d7-97e7-5f9e8c39f1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_14204fbb-19ba-42b3-b245-c974bbfa8149" xlink:to="loc_us-gaap_ShareBasedCompensation_a55b9b83-2f58-43d7-97e7-5f9e8c39f1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangeInOperatingLeaseRightOfUseAssets_1c13fa5c-2fae-4969-870e-087cd2655bbb" xlink:href="sls-20210630.xsd#sls_ChangeInOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_14204fbb-19ba-42b3-b245-c974bbfa8149" xlink:to="loc_sls_ChangeInOperatingLeaseRightOfUseAssets_1c13fa5c-2fae-4969-870e-087cd2655bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_8c3d96e2-caa9-4e1b-83da-754b02d7e28a" xlink:href="sls-20210630.xsd#sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_14204fbb-19ba-42b3-b245-c974bbfa8149" xlink:to="loc_sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings_8c3d96e2-caa9-4e1b-83da-754b02d7e28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangeInFairValueOfContingentPurchaseConsideration_5e048828-85a1-4647-9ec3-646cfc1a2520" xlink:href="sls-20210630.xsd#sls_ChangeInFairValueOfContingentPurchaseConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_14204fbb-19ba-42b3-b245-c974bbfa8149" xlink:to="loc_sls_ChangeInFairValueOfContingentPurchaseConsideration_5e048828-85a1-4647-9ec3-646cfc1a2520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64f6dc79-632d-4548-a61f-93a79dc18dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_14204fbb-19ba-42b3-b245-c974bbfa8149" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64f6dc79-632d-4548-a61f-93a79dc18dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_a4b7d119-fd2e-4878-858e-de3258c7a925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64f6dc79-632d-4548-a61f-93a79dc18dd4" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_a4b7d119-fd2e-4878-858e-de3258c7a925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7e949a8d-ccfd-45e3-baaf-71089216835d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64f6dc79-632d-4548-a61f-93a79dc18dd4" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7e949a8d-ccfd-45e3-baaf-71089216835d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_290ab415-f21c-48e0-8978-c25d0f2cd571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64f6dc79-632d-4548-a61f-93a79dc18dd4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_290ab415-f21c-48e0-8978-c25d0f2cd571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a790bf82-d31b-45a0-aa21-715cb8e4b597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64f6dc79-632d-4548-a61f-93a79dc18dd4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a790bf82-d31b-45a0-aa21-715cb8e4b597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_IncreaseDecreaseInContractWithCustomerLiabilityNet_845fad58-6864-45bd-a18d-2bdd3228d007" xlink:href="sls-20210630.xsd#sls_IncreaseDecreaseInContractWithCustomerLiabilityNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_64f6dc79-632d-4548-a61f-93a79dc18dd4" xlink:to="loc_sls_IncreaseDecreaseInContractWithCustomerLiabilityNet_845fad58-6864-45bd-a18d-2bdd3228d007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36bd9a1f-a52a-4e5d-a797-5fb1ba753ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_718f430d-5deb-44c8-ad12-1722184b1ef2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_36bd9a1f-a52a-4e5d-a797-5fb1ba753ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a953e00b-9545-4d3c-9d1a-09f08e06574c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d8f16f2e-8c62-438c-a91b-2efe662d9896" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a953e00b-9545-4d3c-9d1a-09f08e06574c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_45254d51-ed05-459b-b2ab-0e988069104c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a953e00b-9545-4d3c-9d1a-09f08e06574c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_45254d51-ed05-459b-b2ab-0e988069104c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ProceedsFromStockSubscriptionReceivable_e79c0724-d35d-43ed-bc07-bf754f428501" xlink:href="sls-20210630.xsd#sls_ProceedsFromStockSubscriptionReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a953e00b-9545-4d3c-9d1a-09f08e06574c" xlink:to="loc_sls_ProceedsFromStockSubscriptionReceivable_e79c0724-d35d-43ed-bc07-bf754f428501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_9b308904-1f82-4523-9661-d43a42b9c53e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a953e00b-9545-4d3c-9d1a-09f08e06574c" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_9b308904-1f82-4523-9661-d43a42b9c53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_482eb6af-ad7c-4518-8b77-be581808ee12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a953e00b-9545-4d3c-9d1a-09f08e06574c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_482eb6af-ad7c-4518-8b77-be581808ee12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_26de097b-2f22-49f3-84db-df1d42606d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d8f16f2e-8c62-438c-a91b-2efe662d9896" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_26de097b-2f22-49f3-84db-df1d42606d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_216b26aa-9a8f-41e7-94a4-0c8c24c89d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d8f16f2e-8c62-438c-a91b-2efe662d9896" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_216b26aa-9a8f-41e7-94a4-0c8c24c89d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7ad6676f-9b3d-41fe-b44e-0fe4fe6685a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d8f16f2e-8c62-438c-a91b-2efe662d9896" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7ad6676f-9b3d-41fe-b44e-0fe4fe6685a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_58b53381-2b1a-49ea-9256-6eea4587cc97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d8f16f2e-8c62-438c-a91b-2efe662d9896" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_58b53381-2b1a-49ea-9256-6eea4587cc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_e523c2fe-f0f4-48f7-811e-2556621100dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromInterestReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_58b53381-2b1a-49ea-9256-6eea4587cc97" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_e523c2fe-f0f4-48f7-811e-2556621100dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a9fc2f4b-40ca-4640-8013-84fa65e4e3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d8f16f2e-8c62-438c-a91b-2efe662d9896" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a9fc2f4b-40ca-4640-8013-84fa65e4e3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockSubscriptionReceivable_dd9c99d7-cbac-48d2-a45c-5576cf5eb89d" xlink:href="sls-20210630.xsd#sls_StockSubscriptionReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a9fc2f4b-40ca-4640-8013-84fa65e4e3aa" xlink:to="loc_sls_StockSubscriptionReceivable_dd9c99d7-cbac-48d2-a45c-5576cf5eb89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a8de35a6-dac5-4a69-8dec-62c0166dc220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a9fc2f4b-40ca-4640-8013-84fa65e4e3aa" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a8de35a6-dac5-4a69-8dec-62c0166dc220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_NoncashOfferingExpense_a63745b3-615f-402c-8687-00835f0e0a04" xlink:href="sls-20210630.xsd#sls_NoncashOfferingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a9fc2f4b-40ca-4640-8013-84fa65e4e3aa" xlink:to="loc_sls_NoncashOfferingExpense_a63745b3-615f-402c-8687-00835f0e0a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="sls-20210630.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31d082ad-dfeb-4447-bb7f-4e08572b4905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_85ef3ca9-d60b-4e9c-bc6e-8251536930c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31d082ad-dfeb-4447-bb7f-4e08572b4905" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_85ef3ca9-d60b-4e9c-bc6e-8251536930c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/Liquidity" xlink:type="simple" xlink:href="sls-20210630.xsd#Liquidity"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/Liquidity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4dfba9d-a246-4a8b-8756-af330ba8fc99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingTextBlock_f28ee109-815f-4a11-9a37-c745cfb7eb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4dfba9d-a246-4a8b-8756-af330ba8fc99" xlink:to="loc_us-gaap_LiquidationBasisOfAccountingTextBlock_f28ee109-815f-4a11-9a37-c745cfb7eb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/LiquidityDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#LiquidityDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/LiquidityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_870da4d9-a779-4caa-9641-99a91221053b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7562828-b229-4262-87f1-bd0f5cf54ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_870da4d9-a779-4caa-9641-99a91221053b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7562828-b229-4262-87f1-bd0f5cf54ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_112882fa-d605-4677-83a1-acd15cdd6034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7562828-b229-4262-87f1-bd0f5cf54ea9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_112882fa-d605-4677-83a1-acd15cdd6034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3aecc25-e191-494e-a644-3528343fd9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_112882fa-d605-4677-83a1-acd15cdd6034" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3aecc25-e191-494e-a644-3528343fd9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_SalesAgreementMember_c7eae009-df74-4d98-8efa-d180c917de1b" xlink:href="sls-20210630.xsd#sls_SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c3aecc25-e191-494e-a644-3528343fd9c2" xlink:to="loc_sls_SalesAgreementMember_c7eae009-df74-4d98-8efa-d180c917de1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_61e2a020-ee72-4eef-9634-79add2c4c5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7562828-b229-4262-87f1-bd0f5cf54ea9" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_61e2a020-ee72-4eef-9634-79add2c4c5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e078a494-b98a-40b0-9e8a-112bdf6b2137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_61e2a020-ee72-4eef-9634-79add2c4c5a9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e078a494-b98a-40b0-9e8a-112bdf6b2137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c4ec7c66-2bba-41a6-9ae0-9fdc9b112e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e078a494-b98a-40b0-9e8a-112bdf6b2137" xlink:to="loc_us-gaap_SubsequentEventMember_c4ec7c66-2bba-41a6-9ae0-9fdc9b112e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a7562828-b229-4262-87f1-bd0f5cf54ea9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_944dbc57-4ae6-4723-b75a-86a521d886b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_944dbc57-4ae6-4723-b75a-86a521d886b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e309a0f0-9ec9-48db-b0d0-2d820362b912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_NetIncomeLoss_e309a0f0-9ec9-48db-b0d0-2d820362b912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf4a5bb5-7bc8-4983-b175-be9515d2d7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf4a5bb5-7bc8-4983-b175-be9515d2d7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2d89550a-1e1e-4c5e-9ce1-c2cbe2940699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2d89550a-1e1e-4c5e-9ce1-c2cbe2940699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d58a45a5-8a2c-4e70-a6a0-1f947cb1fdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d58a45a5-8a2c-4e70-a6a0-1f947cb1fdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_094ba92c-8f84-4803-9885-35341ba5e94b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_094ba92c-8f84-4803-9885-35341ba5e94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_af4f919c-3651-4abe-a5b8-f65f40d7b45d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_af4f919c-3651-4abe-a5b8-f65f40d7b45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_NonCashCharges_313637f5-51f3-4fc2-a3a1-c67a032fcd4c" xlink:href="sls-20210630.xsd#sls_NonCashCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_sls_NonCashCharges_313637f5-51f3-4fc2-a3a1-c67a032fcd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_SaleOfStockAuthorizedAmount_baaeb34a-2c20-42dc-8a53-1b5fa5ffc4d8" xlink:href="sls-20210630.xsd#sls_SaleOfStockAuthorizedAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_sls_SaleOfStockAuthorizedAmount_baaeb34a-2c20-42dc-8a53-1b5fa5ffc4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_SaleOfStockAgentFeePercentageOfGrossProceeds_6ab8c82d-c5e0-4209-9501-d6cab730d2bd" xlink:href="sls-20210630.xsd#sls_SaleOfStockAgentFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_sls_SaleOfStockAgentFeePercentageOfGrossProceeds_6ab8c82d-c5e0-4209-9501-d6cab730d2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_293f85b6-8478-48f9-a9d8-ebdc62decf15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_293f85b6-8478-48f9-a9d8-ebdc62decf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_9900f8f0-52ce-4b97-8b96-29bcd816bc02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_9900f8f0-52ce-4b97-8b96-29bcd816bc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_764eed43-a643-4c7c-891c-bc4aba9eae8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_764eed43-a643-4c7c-891c-bc4aba9eae8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments_e76ce593-19e7-4107-955a-58fd87b09e40" xlink:href="sls-20210630.xsd#sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments_e76ce593-19e7-4107-955a-58fd87b09e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived_b779e860-e8bd-4b25-a976-2d80b1da447e" xlink:href="sls-20210630.xsd#sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived_b779e860-e8bd-4b25-a976-2d80b1da447e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a963b40-16c4-4cce-aed4-5100df2df950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a963b40-16c4-4cce-aed4-5100df2df950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_bb4ca061-858d-4e20-93bb-e606fadf3b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_bb4ca061-858d-4e20-93bb-e606fadf3b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_StockSubscriptionReceivableCurrent_506f5682-087b-43ad-b12d-10e6e1a8f7ab" xlink:href="sls-20210630.xsd#sls_StockSubscriptionReceivableCurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9f9d04ac-6e97-44eb-91a8-65c6a52c1a06" xlink:to="loc_sls_StockSubscriptionReceivableCurrent_506f5682-087b-43ad-b12d-10e6e1a8f7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="sls-20210630.xsd#BasisofPresentationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c33d853c-b479-4561-9b72-86e0530be521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_25b296d4-cef5-4d57-8210-e5d0c7034a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c33d853c-b479-4561-9b72-86e0530be521" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_25b296d4-cef5-4d57-8210-e5d0c7034a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sls-20210630.xsd#BasisofPresentationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bd24de2b-e57f-43c0-8d44-6e17ce29d475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_44c6c71c-8c28-4ca6-9f79-8571ec5be68d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd24de2b-e57f-43c0-8d44-6e17ce29d475" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_44c6c71c-8c28-4ca6-9f79-8571ec5be68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d88ff0cb-171e-445b-9b95-729b1ff31ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd24de2b-e57f-43c0-8d44-6e17ce29d475" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d88ff0cb-171e-445b-9b95-729b1ff31ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_baed6013-e242-4996-95ad-16c5e853afaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd24de2b-e57f-43c0-8d44-6e17ce29d475" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_baed6013-e242-4996-95ad-16c5e853afaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_17ad29cf-50f7-408c-b69f-a124d62493d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd24de2b-e57f-43c0-8d44-6e17ce29d475" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_17ad29cf-50f7-408c-b69f-a124d62493d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_600464d7-d10a-4488-bcf0-dc18cfa16828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd24de2b-e57f-43c0-8d44-6e17ce29d475" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_600464d7-d10a-4488-bcf0-dc18cfa16828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2bff8147-f114-4ac0-83e1-00cf98cfb5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd24de2b-e57f-43c0-8d44-6e17ce29d475" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2bff8147-f114-4ac0-83e1-00cf98cfb5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="sls-20210630.xsd#BasisofPresentationandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c9539bf0-5bec-4894-8531-96dd840b81f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_aa2ddf5a-54d7-4bb1-9dc0-593a5033a033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9539bf0-5bec-4894-8531-96dd840b81f3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_aa2ddf5a-54d7-4bb1-9dc0-593a5033a033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6f34d182-dd81-42d0-aea3-34da59df2424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_22e895a8-5fea-4d05-b934-637a48dac60a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6f34d182-dd81-42d0-aea3-34da59df2424" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_22e895a8-5fea-4d05-b934-637a48dac60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cd031602-eeba-4dfb-9151-a41c3e8c19dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_22e895a8-5fea-4d05-b934-637a48dac60a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cd031602-eeba-4dfb-9151-a41c3e8c19dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9fece5a7-4c85-46e8-b0ff-5f6ad2ac99c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cd031602-eeba-4dfb-9151-a41c3e8c19dd" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9fece5a7-4c85-46e8-b0ff-5f6ad2ac99c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_6fad2d5d-85d7-460f-8403-1f7fc0335ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9fece5a7-4c85-46e8-b0ff-5f6ad2ac99c1" xlink:to="loc_us-gaap_SubsequentEventMember_6fad2d5d-85d7-460f-8403-1f7fc0335ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3748b5fd-2412-4f15-aefa-9be6e5c5b16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_22e895a8-5fea-4d05-b934-637a48dac60a" xlink:to="loc_us-gaap_ClassOfStockLineItems_3748b5fd-2412-4f15-aefa-9be6e5c5b16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8555103d-76b3-4145-826f-8b5448c6b6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3748b5fd-2412-4f15-aefa-9be6e5c5b16d" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8555103d-76b3-4145-826f-8b5448c6b6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_30809d03-bdf8-4fe5-972c-cd4618fe832b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3748b5fd-2412-4f15-aefa-9be6e5c5b16d" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_30809d03-bdf8-4fe5-972c-cd4618fe832b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_97a3575a-0a99-4be0-a3fe-6b879f67f8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f90a549-a676-473d-a6e5-719dbddf89c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_97a3575a-0a99-4be0-a3fe-6b879f67f8d4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f90a549-a676-473d-a6e5-719dbddf89c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d832f9be-3552-4f8b-98e5-08299949d2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f90a549-a676-473d-a6e5-719dbddf89c5" xlink:to="loc_us-gaap_AwardTypeAxis_d832f9be-3552-4f8b-98e5-08299949d2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c38d8f-a769-4152-9568-60b1e7bb4611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d832f9be-3552-4f8b-98e5-08299949d2ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c38d8f-a769-4152-9568-60b1e7bb4611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6048c336-18f9-4488-9e29-b0359593d1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7c38d8f-a769-4152-9568-60b1e7bb4611" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6048c336-18f9-4488-9e29-b0359593d1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_68d17815-6737-41c7-9b9b-9e694d44cd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6f90a549-a676-473d-a6e5-719dbddf89c5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_68d17815-6737-41c7-9b9b-9e694d44cd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5d48d8c1-e755-4bae-a17d-faef031f3eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_68d17815-6737-41c7-9b9b-9e694d44cd9a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5d48d8c1-e755-4bae-a17d-faef031f3eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6d40ead1-88d7-49af-970b-f89df43f65f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64ce8f22-b093-4e76-8800-51a05e1d6a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6d40ead1-88d7-49af-970b-f89df43f65f1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64ce8f22-b093-4e76-8800-51a05e1d6a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b2ee1824-d12c-4299-bb53-777fd7e29c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64ce8f22-b093-4e76-8800-51a05e1d6a40" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b2ee1824-d12c-4299-bb53-777fd7e29c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1783c839-f577-49f0-928e-6f98fcbeda33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b2ee1824-d12c-4299-bb53-777fd7e29c4d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1783c839-f577-49f0-928e-6f98fcbeda33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_5879e1ff-e3e7-46e0-a847-b1b64158a658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1783c839-f577-49f0-928e-6f98fcbeda33" xlink:to="loc_us-gaap_WarrantMember_5879e1ff-e3e7-46e0-a847-b1b64158a658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fb3c0138-0763-47b4-9ce4-19cf1a92a7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1783c839-f577-49f0-928e-6f98fcbeda33" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fb3c0138-0763-47b4-9ce4-19cf1a92a7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4c6e2567-6710-4983-a918-2ea9155e487d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1783c839-f577-49f0-928e-6f98fcbeda33" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4c6e2567-6710-4983-a918-2ea9155e487d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_46f94bf5-790f-44cf-873d-aec1df36fdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64ce8f22-b093-4e76-8800-51a05e1d6a40" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_46f94bf5-790f-44cf-873d-aec1df36fdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_38103899-dd59-4ce6-9250-ac740d2b8000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_46f94bf5-790f-44cf-873d-aec1df36fdf9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_38103899-dd59-4ce6-9250-ac740d2b8000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="sls-20210630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e9a7fa67-9725-4d6c-9aaf-2d74a2ee1736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_09eef48c-8a82-443a-82ac-80a2e93244fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e9a7fa67-9725-4d6c-9aaf-2d74a2ee1736" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_09eef48c-8a82-443a-82ac-80a2e93244fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="sls-20210630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dbf32f55-d3b0-4e1e-854a-81fcf602fe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_18cab696-de45-4383-a618-3ac7c332334a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dbf32f55-d3b0-4e1e-854a-81fcf602fe2b" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_18cab696-de45-4383-a618-3ac7c332334a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ba1e25eb-5066-4c7b-a147-53bce530b9df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dbf32f55-d3b0-4e1e-854a-81fcf602fe2b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_ba1e25eb-5066-4c7b-a147-53bce530b9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3d7e328c-1e55-4996-974b-34fc40363143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_47b8e1cf-a17e-4c38-83e6-a88668accd63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3d7e328c-1e55-4996-974b-34fc40363143" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_47b8e1cf-a17e-4c38-83e6-a88668accd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ad72128-2f2e-449b-876f-3eb119407a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_47b8e1cf-a17e-4c38-83e6-a88668accd63" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ad72128-2f2e-449b-876f-3eb119407a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ce010e3c-9111-4ad2-b3ee-cd9c42b1f942" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_5ad72128-2f2e-449b-876f-3eb119407a04" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ce010e3c-9111-4ad2-b3ee-cd9c42b1f942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9c293467-ee27-4727-9730-9322c966b888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_ce010e3c-9111-4ad2-b3ee-cd9c42b1f942" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9c293467-ee27-4727-9730-9322c966b888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7d6bae0d-f5d7-4f24-8336-a8b9569baef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_47b8e1cf-a17e-4c38-83e6-a88668accd63" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7d6bae0d-f5d7-4f24-8336-a8b9569baef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e464a50e-efc8-489a-8c21-c997ae2d1520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7d6bae0d-f5d7-4f24-8336-a8b9569baef4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e464a50e-efc8-489a-8c21-c997ae2d1520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c5642967-8d8f-4ac6-aafc-8e4455a91c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e464a50e-efc8-489a-8c21-c997ae2d1520" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c5642967-8d8f-4ac6-aafc-8e4455a91c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_13e44bd9-fce4-4327-9688-b0d1f3bc3eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e464a50e-efc8-489a-8c21-c997ae2d1520" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_13e44bd9-fce4-4327-9688-b0d1f3bc3eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a4f5034f-bfd7-4d21-8d4e-a8d96778dee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e464a50e-efc8-489a-8c21-c997ae2d1520" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a4f5034f-bfd7-4d21-8d4e-a8d96778dee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da69f0f4-ce4a-41d8-b04e-baa8c65c7214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_47b8e1cf-a17e-4c38-83e6-a88668accd63" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da69f0f4-ce4a-41d8-b04e-baa8c65c7214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_f663906f-b269-49cd-85bf-ecf42f761a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da69f0f4-ce4a-41d8-b04e-baa8c65c7214" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_f663906f-b269-49cd-85bf-ecf42f761a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_13035071-8acb-4223-9717-bad25a13569c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f663906f-b269-49cd-85bf-ecf42f761a95" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_13035071-8acb-4223-9717-bad25a13569c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure_5b4950b2-74dc-4675-99c1-0be8c549ee8c" xlink:href="sls-20210630.xsd#sls_RestrictedCashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f663906f-b269-49cd-85bf-ecf42f761a95" xlink:to="loc_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure_5b4950b2-74dc-4675-99c1-0be8c549ee8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_999c98bc-6155-4765-b2ac-8232cb67ae0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_f663906f-b269-49cd-85bf-ecf42f761a95" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_999c98bc-6155-4765-b2ac-8232cb67ae0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_277b68e1-ff19-4ad7-a9c9-ee965c9d55c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da69f0f4-ce4a-41d8-b04e-baa8c65c7214" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_277b68e1-ff19-4ad7-a9c9-ee965c9d55c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_FairValueOfWarrantsPotentiallySettleableInCash_c51cb364-579d-43f5-931a-0670d15d6778" xlink:href="sls-20210630.xsd#sls_FairValueOfWarrantsPotentiallySettleableInCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_277b68e1-ff19-4ad7-a9c9-ee965c9d55c6" xlink:to="loc_sls_FairValueOfWarrantsPotentiallySettleableInCash_c51cb364-579d-43f5-931a-0670d15d6778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0152362a-3acf-4718-af8a-01283ea01567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_277b68e1-ff19-4ad7-a9c9-ee965c9d55c6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0152362a-3acf-4718-af8a-01283ea01567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_de99bf15-954c-4e7e-aac5-d5c99ea6db6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_277b68e1-ff19-4ad7-a9c9-ee965c9d55c6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_de99bf15-954c-4e7e-aac5-d5c99ea6db6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d34c42ac-63ca-4626-9a00-094207450635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c7ec2fe7-f507-4372-bd3a-8c9bbfb33a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d34c42ac-63ca-4626-9a00-094207450635" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c7ec2fe7-f507-4372-bd3a-8c9bbfb33a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dafc9f6a-7dea-437b-ba78-b4afb3e4946c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c7ec2fe7-f507-4372-bd3a-8c9bbfb33a14" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dafc9f6a-7dea-437b-ba78-b4afb3e4946c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_393697e3-f1d4-4807-a1d5-44feda7006cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_dafc9f6a-7dea-437b-ba78-b4afb3e4946c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_393697e3-f1d4-4807-a1d5-44feda7006cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9d2d99aa-1273-4971-90bf-6a2426a93693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_393697e3-f1d4-4807-a1d5-44feda7006cc" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9d2d99aa-1273-4971-90bf-6a2426a93693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a66f1fe3-cd7a-4a4b-983d-415cfdaa110e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_c7ec2fe7-f507-4372-bd3a-8c9bbfb33a14" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a66f1fe3-cd7a-4a4b-983d-415cfdaa110e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db3b9c56-8bdc-4ba5-b9be-16a3a7b98a41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_a66f1fe3-cd7a-4a4b-983d-415cfdaa110e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db3b9c56-8bdc-4ba5-b9be-16a3a7b98a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f019707d-3a7d-4815-a32f-341944844cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db3b9c56-8bdc-4ba5-b9be-16a3a7b98a41" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f019707d-3a7d-4815-a32f-341944844cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_fa0f3761-f319-4bb8-8499-96f5463d105b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db3b9c56-8bdc-4ba5-b9be-16a3a7b98a41" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_fa0f3761-f319-4bb8-8499-96f5463d105b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5c74500d-9212-4ed5-bdbf-1b72a8816512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_db3b9c56-8bdc-4ba5-b9be-16a3a7b98a41" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5c74500d-9212-4ed5-bdbf-1b72a8816512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2e6ff651-bc82-4dad-af54-ec0905cc7668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1bc95bb6-7998-40e2-8cc5-7a4a22805f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2e6ff651-bc82-4dad-af54-ec0905cc7668" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1bc95bb6-7998-40e2-8cc5-7a4a22805f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d85344f2-6cfd-415a-b205-ba09af48d003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1bc95bb6-7998-40e2-8cc5-7a4a22805f5e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d85344f2-6cfd-415a-b205-ba09af48d003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5f0a037-88b0-457d-b7df-a3c0e4a1843b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d85344f2-6cfd-415a-b205-ba09af48d003" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5f0a037-88b0-457d-b7df-a3c0e4a1843b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_AptheraInc.Member_9650fd2e-7565-4816-8101-62ac4d9c4227" xlink:href="sls-20210630.xsd#sls_AptheraInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5f0a037-88b0-457d-b7df-a3c0e4a1843b" xlink:to="loc_sls_AptheraInc.Member_9650fd2e-7565-4816-8101-62ac4d9c4227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7f82e052-398e-45d3-8022-0085b2df160a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1bc95bb6-7998-40e2-8cc5-7a4a22805f5e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7f82e052-398e-45d3-8022-0085b2df160a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b1c0172f-9ebb-45fd-ace3-b8b2614b8395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7f82e052-398e-45d3-8022-0085b2df160a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b1c0172f-9ebb-45fd-ace3-b8b2614b8395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_MeasurementInputWeightedAverageCostOfCapitalMember_d181ea64-b202-4945-b40b-9cc253ca0a09" xlink:href="sls-20210630.xsd#sls_MeasurementInputWeightedAverageCostOfCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b1c0172f-9ebb-45fd-ace3-b8b2614b8395" xlink:to="loc_sls_MeasurementInputWeightedAverageCostOfCapitalMember_d181ea64-b202-4945-b40b-9cc253ca0a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_MeasurementInputCostOfDebtMember_827de0d6-2cf0-46e0-b296-af2ea9b2ed04" xlink:href="sls-20210630.xsd#sls_MeasurementInputCostOfDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_b1c0172f-9ebb-45fd-ace3-b8b2614b8395" xlink:to="loc_sls_MeasurementInputCostOfDebtMember_827de0d6-2cf0-46e0-b296-af2ea9b2ed04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c1d09fe0-85ef-4f6a-9590-562e10954f99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1bc95bb6-7998-40e2-8cc5-7a4a22805f5e" xlink:to="loc_srt_RangeAxis_c1d09fe0-85ef-4f6a-9590-562e10954f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_903e55e7-ebe7-436c-b7cd-f3657da34378" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c1d09fe0-85ef-4f6a-9590-562e10954f99" xlink:to="loc_srt_RangeMember_903e55e7-ebe7-436c-b7cd-f3657da34378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_46480755-062c-46a4-b04f-46b4955eaf48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_903e55e7-ebe7-436c-b7cd-f3657da34378" xlink:to="loc_srt_MinimumMember_46480755-062c-46a4-b04f-46b4955eaf48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dad71ef7-182d-4922-a2cc-7e6140bb9bd9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_903e55e7-ebe7-436c-b7cd-f3657da34378" xlink:to="loc_srt_MaximumMember_dad71ef7-182d-4922-a2cc-7e6140bb9bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1bc95bb6-7998-40e2-8cc5-7a4a22805f5e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_40e075bf-e191-4195-911c-a9a6d4e6d780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_40e075bf-e191-4195-911c-a9a6d4e6d780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_8c19b57f-c415-4af8-b46d-993e51677049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_8c19b57f-c415-4af8-b46d-993e51677049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d6effe47-161c-4242-9675-02b4b06d34a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d6effe47-161c-4242-9675-02b4b06d34a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow_91506191-abcd-4a11-954d-e38c6a4d140c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow_91506191-abcd-4a11-954d-e38c6a4d140c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7f503413-620b-485e-8a20-36efebac8a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7f503413-620b-485e-8a20-36efebac8a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones_79525700-ca84-4906-a513-22d774054d54" xlink:href="sls-20210630.xsd#sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5106e4c-7d76-46d8-9c5d-e146b90de65b" xlink:to="loc_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones_79525700-ca84-4906-a513-22d774054d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/BalanceSheetAccounts" xlink:type="simple" xlink:href="sls-20210630.xsd#BalanceSheetAccounts"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/BalanceSheetAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_58cc4076-dd9a-4164-93eb-4ecf44a280f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_ff071a7e-fede-454b-b75d-21e29ed7f2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_58cc4076-dd9a-4164-93eb-4ecf44a280f5" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_ff071a7e-fede-454b-b75d-21e29ed7f2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/BalanceSheetAccountsTables" xlink:type="simple" xlink:href="sls-20210630.xsd#BalanceSheetAccountsTables"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/BalanceSheetAccountsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7622d98-76ea-46cd-9e79-2a800b3833ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_aecf7e1f-f33c-44b3-92a4-09d95c7d37d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7622d98-76ea-46cd-9e79-2a800b3833ad" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_aecf7e1f-f33c-44b3-92a4-09d95c7d37d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7e676b6f-7c70-4416-8a85-04a8fb534e18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d7622d98-76ea-46cd-9e79-2a800b3833ad" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7e676b6f-7c70-4416-8a85-04a8fb534e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fec731a5-f5a6-4ed4-9f2d-346605307792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_12612d51-5740-4fa6-97fd-3b6b3b017ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fec731a5-f5a6-4ed4-9f2d-346605307792" xlink:to="loc_us-gaap_PrepaidInsurance_12612d51-5740-4fa6-97fd-3b6b3b017ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_PrepaidResearchAndDevelopment_b2c0a73d-218d-4f1c-afd7-4cf67fb84d91" xlink:href="sls-20210630.xsd#sls_PrepaidResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fec731a5-f5a6-4ed4-9f2d-346605307792" xlink:to="loc_sls_PrepaidResearchAndDevelopment_b2c0a73d-218d-4f1c-afd7-4cf67fb84d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_PrepaidProfessionalServices_30de2e92-1e4f-4eb9-b38b-de94a4db5688" xlink:href="sls-20210630.xsd#sls_PrepaidProfessionalServices"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fec731a5-f5a6-4ed4-9f2d-346605307792" xlink:to="loc_sls_PrepaidProfessionalServices_30de2e92-1e4f-4eb9-b38b-de94a4db5688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_4e98d265-ac89-4848-9e6c-e22c0d95eeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fec731a5-f5a6-4ed4-9f2d-346605307792" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_4e98d265-ac89-4848-9e6c-e22c0d95eeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_724e96c1-633e-4a52-b96f-0adb287556e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fec731a5-f5a6-4ed4-9f2d-346605307792" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_724e96c1-633e-4a52-b96f-0adb287556e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_956d513f-2915-4348-9c16-25f57a9cda87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ContractResearchPayable_4781c143-07ee-4c06-84d9-3e1ca4eae33e" xlink:href="sls-20210630.xsd#sls_ContractResearchPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_956d513f-2915-4348-9c16-25f57a9cda87" xlink:to="loc_sls_ContractResearchPayable_4781c143-07ee-4c06-84d9-3e1ca4eae33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_50632396-fa1a-4252-834c-20fe1f323c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_956d513f-2915-4348-9c16-25f57a9cda87" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_50632396-fa1a-4252-834c-20fe1f323c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_1254d4c8-f80e-4ab0-9ef1-3a0db981ed40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_956d513f-2915-4348-9c16-25f57a9cda87" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_1254d4c8-f80e-4ab0-9ef1-3a0db981ed40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0fa4a054-b4d6-43ee-9a06-883feef2b111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_956d513f-2915-4348-9c16-25f57a9cda87" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0fa4a054-b4d6-43ee-9a06-883feef2b111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_793b1c4f-f60c-4ba3-a6e5-054a8572d702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_956d513f-2915-4348-9c16-25f57a9cda87" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_793b1c4f-f60c-4ba3-a6e5-054a8572d702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sls-20210630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5cb92951-b3f3-4d9b-9d75-98f6aa73a2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a757471a-0e1f-464a-b33c-1c4f9da4a822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5cb92951-b3f3-4d9b-9d75-98f6aa73a2bc" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a757471a-0e1f-464a-b33c-1c4f9da4a822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="sls-20210630.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9597fbc8-2c6e-4516-9373-0d711d284650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b21c37ee-6dc1-42ad-80af-f5f86fae150d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9597fbc8-2c6e-4516-9373-0d711d284650" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b21c37ee-6dc1-42ad-80af-f5f86fae150d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_29bfcedd-7a1f-4fe7-9d32-1fb67b0385b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ef3a861d-e411-4964-b2e8-819e51fd3657" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_29bfcedd-7a1f-4fe7-9d32-1fb67b0385b3" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ef3a861d-e411-4964-b2e8-819e51fd3657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_807054d7-3503-4eb9-b4d2-74c4208ea6d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ef3a861d-e411-4964-b2e8-819e51fd3657" xlink:to="loc_us-gaap_LeaseContractualTermAxis_807054d7-3503-4eb9-b4d2-74c4208ea6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_57371f31-2e9e-41a5-8103-0c23977c5a00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_807054d7-3503-4eb9-b4d2-74c4208ea6d9" xlink:to="loc_us-gaap_LeaseContractualTermDomain_57371f31-2e9e-41a5-8103-0c23977c5a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_OfficeSpaceLeaseExpiringDecember312024Member_03549699-2fde-4b98-b161-632fb122ef69" xlink:href="sls-20210630.xsd#sls_OfficeSpaceLeaseExpiringDecember312024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_57371f31-2e9e-41a5-8103-0c23977c5a00" xlink:to="loc_sls_OfficeSpaceLeaseExpiringDecember312024Member_03549699-2fde-4b98-b161-632fb122ef69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9f381485-59b7-4ff7-a703-a4138c4a1b70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ef3a861d-e411-4964-b2e8-819e51fd3657" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9f381485-59b7-4ff7-a703-a4138c4a1b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d5455df8-e8d0-4891-abc9-9af437f3ac06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9f381485-59b7-4ff7-a703-a4138c4a1b70" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d5455df8-e8d0-4891-abc9-9af437f3ac06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_OperatingLeaseRemainingLeaseTerm_b5306808-83ed-45b5-add0-c6612cc5fc3f" xlink:href="sls-20210630.xsd#sls_OperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9f381485-59b7-4ff7-a703-a4138c4a1b70" xlink:to="loc_sls_OperatingLeaseRemainingLeaseTerm_b5306808-83ed-45b5-add0-c6612cc5fc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_c108a83c-fc56-402c-814b-1084c22cea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9f381485-59b7-4ff7-a703-a4138c4a1b70" xlink:to="loc_us-gaap_OperatingLeaseExpense_c108a83c-fc56-402c-814b-1084c22cea5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_0d6a5a98-b9f8-4e49-8bc1-a0f3ac5a36d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9f381485-59b7-4ff7-a703-a4138c4a1b70" xlink:to="loc_us-gaap_OperatingLeasePayments_0d6a5a98-b9f8-4e49-8bc1-a0f3ac5a36d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_510daa2c-77f8-49bd-883a-0f26b892fa99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_9f381485-59b7-4ff7-a703-a4138c4a1b70" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_510daa2c-77f8-49bd-883a-0f26b892fa99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details" xlink:type="simple" xlink:href="sls-20210630.xsd#CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18d66297-3ff9-4711-9a3f-87428c340c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_046e2d10-0ac5-4e3e-be62-edb1af427a84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18d66297-3ff9-4711-9a3f-87428c340c8e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_046e2d10-0ac5-4e3e-be62-edb1af427a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cc537631-5214-458c-93a4-76fc71df6bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18d66297-3ff9-4711-9a3f-87428c340c8e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_cc537631-5214-458c-93a4-76fc71df6bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a44be876-1d9e-42da-aef3-4e09350686f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18d66297-3ff9-4711-9a3f-87428c340c8e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a44be876-1d9e-42da-aef3-4e09350686f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_55e55774-8479-49a4-9313-9b89180c6a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18d66297-3ff9-4711-9a3f-87428c340c8e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_55e55774-8479-49a4-9313-9b89180c6a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f24948f1-d3f0-4d0d-be1c-8541b5954a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18d66297-3ff9-4711-9a3f-87428c340c8e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f24948f1-d3f0-4d0d-be1c-8541b5954a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7305a434-4226-4ca6-b6a8-199674dbee55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18d66297-3ff9-4711-9a3f-87428c340c8e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7305a434-4226-4ca6-b6a8-199674dbee55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f78fdf41-64bf-4a2a-96f6-227b42b0d3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18d66297-3ff9-4711-9a3f-87428c340c8e" xlink:to="loc_us-gaap_OperatingLeaseLiability_f78fdf41-64bf-4a2a-96f6-227b42b0d3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1" xlink:type="simple" xlink:href="sls-20210630.xsd#CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockholdersEquity" xlink:type="simple" xlink:href="sls-20210630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f0c92b59-d1a1-4949-9127-2f643cb82c98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_287278fd-3428-401a-a7cd-109162b09321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f0c92b59-d1a1-4949-9127-2f643cb82c98" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_287278fd-3428-401a-a7cd-109162b09321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="sls-20210630.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b7eb9ae3-81fd-4e96-9709-f6e831ac8c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_CommonStockAreReservedForFutureIssuanceTableTextBlock_6f3aa5ba-f424-4afb-9db8-ec9c353a3506" xlink:href="sls-20210630.xsd#sls_CommonStockAreReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b7eb9ae3-81fd-4e96-9709-f6e831ac8c1e" xlink:to="loc_sls_CommonStockAreReservedForFutureIssuanceTableTextBlock_6f3aa5ba-f424-4afb-9db8-ec9c353a3506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ae231714-89b9-4247-80c9-a7f0d3e298a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_08dd4208-0bb3-46f6-9986-3c64fa57e5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ae231714-89b9-4247-80c9-a7f0d3e298a0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_08dd4208-0bb3-46f6-9986-3c64fa57e5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_44424b16-6301-4cf0-b97f-ab9a3bb76d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ae231714-89b9-4247-80c9-a7f0d3e298a0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_44424b16-6301-4cf0-b97f-ab9a3bb76d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2ecf3dbe-f47d-49d2-915d-3000bb6e7ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ae231714-89b9-4247-80c9-a7f0d3e298a0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2ecf3dbe-f47d-49d2-915d-3000bb6e7ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_65c47717-49ff-4622-9b42-9cd015c5a16d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ae231714-89b9-4247-80c9-a7f0d3e298a0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_65c47717-49ff-4622-9b42-9cd015c5a16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_59c0f9b5-92dc-46ab-97e3-03b2c1321303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca225fb7-9cfe-4155-b94e-2d974c0c7808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_59c0f9b5-92dc-46ab-97e3-03b2c1321303" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca225fb7-9cfe-4155-b94e-2d974c0c7808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5c20db70-f2ed-4dc7-9afd-4594a76c33a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca225fb7-9cfe-4155-b94e-2d974c0c7808" xlink:to="loc_us-gaap_AwardTypeAxis_5c20db70-f2ed-4dc7-9afd-4594a76c33a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7b62f46-4181-4fc6-8470-73f538e137bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5c20db70-f2ed-4dc7-9afd-4594a76c33a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7b62f46-4181-4fc6-8470-73f538e137bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a1f84d11-cafd-4897-8524-f9afe82326dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a7b62f46-4181-4fc6-8470-73f538e137bc" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a1f84d11-cafd-4897-8524-f9afe82326dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_bf2293c6-9e45-40a6-b2f4-c1942ed90283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca225fb7-9cfe-4155-b94e-2d974c0c7808" xlink:to="loc_us-gaap_PlanNameAxis_bf2293c6-9e45-40a6-b2f4-c1942ed90283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d8939a25-ff4b-46c4-a62a-4d03813b4dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_bf2293c6-9e45-40a6-b2f4-c1942ed90283" xlink:to="loc_us-gaap_PlanNameDomain_d8939a25-ff4b-46c4-a62a-4d03813b4dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_A2019EquityIncentivePlanMember_c257091e-9da1-4a2b-903d-0d744d80d9d5" xlink:href="sls-20210630.xsd#sls_A2019EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d8939a25-ff4b-46c4-a62a-4d03813b4dc6" xlink:to="loc_sls_A2019EquityIncentivePlanMember_c257091e-9da1-4a2b-903d-0d744d80d9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_A2021EmployeeStockPurchasePlanMember_2de1ad68-1393-43a1-8c9d-0936f77c6399" xlink:href="sls-20210630.xsd#sls_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d8939a25-ff4b-46c4-a62a-4d03813b4dc6" xlink:to="loc_sls_A2021EmployeeStockPurchasePlanMember_2de1ad68-1393-43a1-8c9d-0936f77c6399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_A2017EmployeeStockPurchasePlanMember_cbf4287e-4ad4-4af7-a677-7d4025618937" xlink:href="sls-20210630.xsd#sls_A2017EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d8939a25-ff4b-46c4-a62a-4d03813b4dc6" xlink:to="loc_sls_A2017EmployeeStockPurchasePlanMember_cbf4287e-4ad4-4af7-a677-7d4025618937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1231436-2f59-46e5-84e6-ee55bb747789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ca225fb7-9cfe-4155-b94e-2d974c0c7808" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1231436-2f59-46e5-84e6-ee55bb747789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d73aa6e7-09d7-4c92-ae46-527e70e7ec7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1231436-2f59-46e5-84e6-ee55bb747789" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d73aa6e7-09d7-4c92-ae46-527e70e7ec7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_886c1dab-e369-4b0e-b4cb-952b214d5348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1231436-2f59-46e5-84e6-ee55bb747789" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_886c1dab-e369-4b0e-b4cb-952b214d5348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fd9438dc-35a8-4f9f-aeba-22c895a4b854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1231436-2f59-46e5-84e6-ee55bb747789" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fd9438dc-35a8-4f9f-aeba-22c895a4b854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4aa8c9f9-72bc-4cbf-8f32-ab0418bf1541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1231436-2f59-46e5-84e6-ee55bb747789" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4aa8c9f9-72bc-4cbf-8f32-ab0418bf1541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_15d513e8-84d5-49e7-9732-b9143cbd3297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e1231436-2f59-46e5-84e6-ee55bb747789" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_15d513e8-84d5-49e7-9732-b9143cbd3297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStock" xlink:type="simple" xlink:href="sls-20210630.xsd#WarrantstoAcquireSharesofCommonStock"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_c7565d03-cd35-4533-99ae-754fe98113c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_7ba921e0-6059-40dc-89a5-ddf57c5d5f55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_c7565d03-cd35-4533-99ae-754fe98113c5" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock_7ba921e0-6059-40dc-89a5-ddf57c5d5f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockTables" xlink:type="simple" xlink:href="sls-20210630.xsd#WarrantstoAcquireSharesofCommonStockTables"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_1526d720-4d7c-4806-8240-96336775ea98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ScheduleOfWarrantActivityTableTextBlock_5e188f7d-1b54-489b-a553-94b996842051" xlink:href="sls-20210630.xsd#sls_ScheduleOfWarrantActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_1526d720-4d7c-4806-8240-96336775ea98" xlink:to="loc_sls_ScheduleOfWarrantActivityTableTextBlock_5e188f7d-1b54-489b-a553-94b996842051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock_310c215d-46cd-497b-81e0-cd81430bef80" xlink:href="sls-20210630.xsd#sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_1526d720-4d7c-4806-8240-96336775ea98" xlink:to="loc_sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock_310c215d-46cd-497b-81e0-cd81430bef80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock_dbf512c6-48d4-48ed-942d-4ae41c7076cf" xlink:href="sls-20210630.xsd#sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_1526d720-4d7c-4806-8240-96336775ea98" xlink:to="loc_sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock_dbf512c6-48d4-48ed-942d-4ae41c7076cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_00db4cf0-2411-4d88-9c78-dd5ad09dc5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_11a97fe5-28c4-4367-a177-b9b37feeeb68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_00db4cf0-2411-4d88-9c78-dd5ad09dc5a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_11a97fe5-28c4-4367-a177-b9b37feeeb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b6f2dcdd-3a48-4195-a1dc-0a7c580d699a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_11a97fe5-28c4-4367-a177-b9b37feeeb68" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b6f2dcdd-3a48-4195-a1dc-0a7c580d699a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b6f2dcdd-3a48-4195-a1dc-0a7c580d699a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_July2020PIPEOfferingMember_2bd7a004-bd85-4b77-936a-2e39da441c61" xlink:href="sls-20210630.xsd#sls_July2020PIPEOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:to="loc_sls_July2020PIPEOfferingMember_2bd7a004-bd85-4b77-936a-2e39da441c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_January2020OfferingMember_22478612-f3f8-4a7c-a900-5a30c8bdd1d3" xlink:href="sls-20210630.xsd#sls_January2020OfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:to="loc_sls_January2020OfferingMember_22478612-f3f8-4a7c-a900-5a30c8bdd1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_July2019OfferingMember_db076802-ad6b-452d-ba04-0d9d40bd159f" xlink:href="sls-20210630.xsd#sls_July2019OfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:to="loc_sls_July2019OfferingMember_db076802-ad6b-452d-ba04-0d9d40bd159f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_WarrantExerciseAgreementMember_cdfeb5b3-5216-4d2c-8616-9e39c5279d8a" xlink:href="sls-20210630.xsd#sls_WarrantExerciseAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:to="loc_sls_WarrantExerciseAgreementMember_cdfeb5b3-5216-4d2c-8616-9e39c5279d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_July2018OfferingMember_9b860ff0-1d0a-468f-8047-8ee062405769" xlink:href="sls-20210630.xsd#sls_July2018OfferingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:to="loc_sls_July2018OfferingMember_9b860ff0-1d0a-468f-8047-8ee062405769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_OtherWarrantIssuesMember_d66e731f-903d-4960-b1f9-73ec6fd50f35" xlink:href="sls-20210630.xsd#sls_OtherWarrantIssuesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_067142be-2920-4606-a667-8ced89745819" xlink:to="loc_sls_OtherWarrantIssuesMember_d66e731f-903d-4960-b1f9-73ec6fd50f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_4b754f30-7f8a-421c-a1a8-a809389b6d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_11a97fe5-28c4-4367-a177-b9b37feeeb68" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_4b754f30-7f8a-421c-a1a8-a809389b6d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClassofWarrantorRightOutstandingRollForward_a975a5b8-9a3f-4173-996e-7d3b1090ffcb" xlink:href="sls-20210630.xsd#sls_ClassofWarrantorRightOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4b754f30-7f8a-421c-a1a8-a809389b6d93" xlink:to="loc_sls_ClassofWarrantorRightOutstandingRollForward_a975a5b8-9a3f-4173-996e-7d3b1090ffcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_71cc816a-ac4d-48bb-876b-a76ab0673bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sls_ClassofWarrantorRightOutstandingRollForward_a975a5b8-9a3f-4173-996e-7d3b1090ffcb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_71cc816a-ac4d-48bb-876b-a76ab0673bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued_dc802a11-d554-42da-ac60-2c6e82b4b193" xlink:href="sls-20210630.xsd#sls_ClassOfWarrantOrRightNumberOfWarrantsIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sls_ClassofWarrantorRightOutstandingRollForward_a975a5b8-9a3f-4173-996e-7d3b1090ffcb" xlink:to="loc_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued_dc802a11-d554-42da-ac60-2c6e82b4b193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised_3ed31956-1853-46c5-b725-179714e2a06e" xlink:href="sls-20210630.xsd#sls_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sls_ClassofWarrantorRightOutstandingRollForward_a975a5b8-9a3f-4173-996e-7d3b1090ffcb" xlink:to="loc_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised_3ed31956-1853-46c5-b725-179714e2a06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClassofWarrantorRightCanceledOrExpired_97f57f73-a478-4162-b6bc-8cb2ce60cf8f" xlink:href="sls-20210630.xsd#sls_ClassofWarrantorRightCanceledOrExpired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sls_ClassofWarrantorRightOutstandingRollForward_a975a5b8-9a3f-4173-996e-7d3b1090ffcb" xlink:to="loc_sls_ClassofWarrantorRightCanceledOrExpired_97f57f73-a478-4162-b6bc-8cb2ce60cf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_adf6af05-09d3-4783-8f28-44b3e3c9b41f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sls_ClassofWarrantorRightOutstandingRollForward_a975a5b8-9a3f-4173-996e-7d3b1090ffcb" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_adf6af05-09d3-4783-8f28-44b3e3c9b41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_a1b5d7cd-20d2-4e1f-916b-9e13cb33962a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_913f6486-b9e6-4121-9e4e-927d289c58da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_a1b5d7cd-20d2-4e1f-916b-9e13cb33962a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_913f6486-b9e6-4121-9e4e-927d289c58da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_11ee6eae-a5aa-497d-b5c1-b7c47bdd06d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_913f6486-b9e6-4121-9e4e-927d289c58da" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_11ee6eae-a5aa-497d-b5c1-b7c47bdd06d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_bc07299b-9e97-496c-bbc5-4228a0271287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_11ee6eae-a5aa-497d-b5c1-b7c47bdd06d4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_bc07299b-9e97-496c-bbc5-4228a0271287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_OtherLiabilityClassifiedMember_70c75ec9-e828-4a94-a72e-0c0f6271b160" xlink:href="sls-20210630.xsd#sls_OtherLiabilityClassifiedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_bc07299b-9e97-496c-bbc5-4228a0271287" xlink:to="loc_sls_OtherLiabilityClassifiedMember_70c75ec9-e828-4a94-a72e-0c0f6271b160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_5b040d4e-44d9-40c9-89c7-b6b73488404c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_913f6486-b9e6-4121-9e4e-927d289c58da" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_5b040d4e-44d9-40c9-89c7-b6b73488404c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6ab35b70-9895-428f-b524-74e33452638f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5b040d4e-44d9-40c9-89c7-b6b73488404c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6ab35b70-9895-428f-b524-74e33452638f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_WarrantStrikePrice_0a0483e4-941d-4f19-8661-520806ddb30c" xlink:href="sls-20210630.xsd#sls_WarrantStrikePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5b040d4e-44d9-40c9-89c7-b6b73488404c" xlink:to="loc_sls_WarrantStrikePrice_0a0483e4-941d-4f19-8661-520806ddb30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_c1071423-7d2a-4f19-aa10-60067d03c1cf" xlink:href="sls-20210630.xsd#sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5b040d4e-44d9-40c9-89c7-b6b73488404c" xlink:to="loc_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm_c1071423-7d2a-4f19-aa10-60067d03c1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_WarrantsFairValueAssumptionsExpectedVolatility_2fc374af-2b38-417a-bd29-0c970116998a" xlink:href="sls-20210630.xsd#sls_WarrantsFairValueAssumptionsExpectedVolatility"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5b040d4e-44d9-40c9-89c7-b6b73488404c" xlink:to="loc_sls_WarrantsFairValueAssumptionsExpectedVolatility_2fc374af-2b38-417a-bd29-0c970116998a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate_896650c2-f116-4abd-af75-49fe7fa167d0" xlink:href="sls-20210630.xsd#sls_WarrantsFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5b040d4e-44d9-40c9-89c7-b6b73488404c" xlink:to="loc_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate_896650c2-f116-4abd-af75-49fe7fa167d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#WarrantstoAcquireSharesofCommonStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_7911c6c7-c662-411c-9be9-9384484a888e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_d795b9d0-6bce-4424-8fb2-fcbed529b374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_7911c6c7-c662-411c-9be9-9384484a888e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_d795b9d0-6bce-4424-8fb2-fcbed529b374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_a5576b26-6ebd-4138-82d7-b670c63b910d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d795b9d0-6bce-4424-8fb2-fcbed529b374" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_a5576b26-6ebd-4138-82d7-b670c63b910d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_72f31366-b86a-4a3f-bdb6-0c636203c289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_a5576b26-6ebd-4138-82d7-b670c63b910d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_72f31366-b86a-4a3f-bdb6-0c636203c289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_7c14d0c2-5c27-4a43-80b3-5a01e417336f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_72f31366-b86a-4a3f-bdb6-0c636203c289" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_7c14d0c2-5c27-4a43-80b3-5a01e417336f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8a5d6b80-f0b2-40d2-aefa-15a7d0957a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_72f31366-b86a-4a3f-bdb6-0c636203c289" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_8a5d6b80-f0b2-40d2-aefa-15a7d0957a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_5889e047-6f76-407a-93c9-5627147054eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d795b9d0-6bce-4424-8fb2-fcbed529b374" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_5889e047-6f76-407a-93c9-5627147054eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_4af16d77-5581-4b55-a130-357e2ea49975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_5889e047-6f76-407a-93c9-5627147054eb" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_4af16d77-5581-4b55-a130-357e2ea49975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_db8d6a1f-6279-478f-9ac9-3e09230b25af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_0889193b-28c2-41d5-9344-6d58e6d7f595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_db8d6a1f-6279-478f-9ac9-3e09230b25af" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_0889193b-28c2-41d5-9344-6d58e6d7f595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a2029740-d525-41e7-97ea-7d742bb9498d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0889193b-28c2-41d5-9344-6d58e6d7f595" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a2029740-d525-41e7-97ea-7d742bb9498d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f523de7a-e604-4ea4-a787-67f53dd6ef7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a2029740-d525-41e7-97ea-7d742bb9498d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f523de7a-e604-4ea4-a787-67f53dd6ef7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_OtherLiabilityClassifiedMember_2832df28-2ba2-4c27-9ecb-acedbf25a6a2" xlink:href="sls-20210630.xsd#sls_OtherLiabilityClassifiedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f523de7a-e604-4ea4-a787-67f53dd6ef7d" xlink:to="loc_sls_OtherLiabilityClassifiedMember_2832df28-2ba2-4c27-9ecb-acedbf25a6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_bbc6100b-6bc5-4805-8ed8-4a52f0a71309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_0889193b-28c2-41d5-9344-6d58e6d7f595" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_bbc6100b-6bc5-4805-8ed8-4a52f0a71309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClassofWarrantorRightFairValueRollForward_de2d118e-bbf7-4001-9920-048cd2db693f" xlink:href="sls-20210630.xsd#sls_ClassofWarrantorRightFairValueRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_bbc6100b-6bc5-4805-8ed8-4a52f0a71309" xlink:to="loc_sls_ClassofWarrantorRightFairValueRollForward_de2d118e-bbf7-4001-9920-048cd2db693f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_FairValueOfWarrantsLiabilities_4898a948-da68-4e91-b9ab-b38cc1b8a3a4" xlink:href="sls-20210630.xsd#sls_FairValueOfWarrantsLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sls_ClassofWarrantorRightFairValueRollForward_de2d118e-bbf7-4001-9920-048cd2db693f" xlink:to="loc_sls_FairValueOfWarrantsLiabilities_4898a948-da68-4e91-b9ab-b38cc1b8a3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ChangeInFairValueOfWarrantLiabilities_3b5d1400-8210-4feb-93cc-2f367c8cdc7b" xlink:href="sls-20210630.xsd#sls_ChangeInFairValueOfWarrantLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sls_ClassofWarrantorRightFairValueRollForward_de2d118e-bbf7-4001-9920-048cd2db693f" xlink:to="loc_sls_ChangeInFairValueOfWarrantLiabilities_3b5d1400-8210-4feb-93cc-2f367c8cdc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_FairValueOfWarrantsLiabilities_49d578f1-d231-412b-a895-9c4cc678db92" xlink:href="sls-20210630.xsd#sls_FairValueOfWarrantsLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sls_ClassofWarrantorRightFairValueRollForward_de2d118e-bbf7-4001-9920-048cd2db693f" xlink:to="loc_sls_FairValueOfWarrantsLiabilities_49d578f1-d231-412b-a895-9c4cc678db92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesInc" xlink:type="simple" xlink:href="sls-20210630.xsd#LicenseRevenuewith3DMedicinesInc"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fb97ef02-cc81-4930-b1fa-a7397db34cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0d2104e6-70f3-4524-b069-a13913a547aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fb97ef02-cc81-4930-b1fa-a7397db34cb7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0d2104e6-70f3-4524-b069-a13913a547aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncTables" xlink:type="simple" xlink:href="sls-20210630.xsd#LicenseRevenuewith3DMedicinesIncTables"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4d430901-2851-492e-8d23-ef3a3857ef54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_8df151a3-6cbe-477a-b713-b05b805f6d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4d430901-2851-492e-8d23-ef3a3857ef54" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_8df151a3-6cbe-477a-b713-b05b805f6d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#LicenseRevenuewith3DMedicinesIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e14a179-3b3c-41a8-926e-4de0e48fa405" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ResearchAndDevelopmentArrangementCashPaymentReceived_a743969a-7456-4c45-89d0-2aedaaa25863" xlink:href="sls-20210630.xsd#sls_ResearchAndDevelopmentArrangementCashPaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e14a179-3b3c-41a8-926e-4de0e48fa405" xlink:to="loc_sls_ResearchAndDevelopmentArrangementCashPaymentReceived_a743969a-7456-4c45-89d0-2aedaaa25863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum_a0c79905-0335-445d-9cd4-3275cc3f3c1f" xlink:href="sls-20210630.xsd#sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e14a179-3b3c-41a8-926e-4de0e48fa405" xlink:to="loc_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum_a0c79905-0335-445d-9cd4-3275cc3f3c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm_ffb20076-c0f4-4803-9338-1c8360135859" xlink:href="sls-20210630.xsd#sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e14a179-3b3c-41a8-926e-4de0e48fa405" xlink:to="loc_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm_ffb20076-c0f4-4803-9338-1c8360135859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm_1542e191-855b-48a8-b7ac-88a124a4d52a" xlink:href="sls-20210630.xsd#sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e14a179-3b3c-41a8-926e-4de0e48fa405" xlink:to="loc_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm_1542e191-855b-48a8-b7ac-88a124a4d52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_f4f649fc-4a3a-4109-9fd1-cff535ce62ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e14a179-3b3c-41a8-926e-4de0e48fa405" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_f4f649fc-4a3a-4109-9fd1-cff535ce62ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved_f6a0a0d4-7514-42d5-8568-8cdfac6a848f" xlink:href="sls-20210630.xsd#sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e14a179-3b3c-41a8-926e-4de0e48fa405" xlink:to="loc_sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved_f6a0a0d4-7514-42d5-8568-8cdfac6a848f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments_1ec7f6f1-1f7d-431a-aaf4-8af402fcaa00" xlink:href="sls-20210630.xsd#sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e14a179-3b3c-41a8-926e-4de0e48fa405" xlink:to="loc_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments_1ec7f6f1-1f7d-431a-aaf4-8af402fcaa00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived_75e4b50d-ce2b-430f-a76a-214c5faab712" xlink:href="sls-20210630.xsd#sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e14a179-3b3c-41a8-926e-4de0e48fa405" xlink:to="loc_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived_75e4b50d-ce2b-430f-a76a-214c5faab712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized_b9f7d87f-0a5b-4968-8835-e060c40f8660" xlink:href="sls-20210630.xsd#sls_ContractWithCustomerLiabilityNewContractRevenueRecognized"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e14a179-3b3c-41a8-926e-4de0e48fa405" xlink:to="loc_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized_b9f7d87f-0a5b-4968-8835-e060c40f8660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_f117ef5e-a57b-412d-9e2a-255546cc43bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e14a179-3b3c-41a8-926e-4de0e48fa405" xlink:to="loc_us-gaap_CapitalizedContractCostGross_f117ef5e-a57b-412d-9e2a-255546cc43bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_d2eec0ed-4276-49f7-9a79-1aa23ffe4937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e14a179-3b3c-41a8-926e-4de0e48fa405" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_d2eec0ed-4276-49f7-9a79-1aa23ffe4937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d3a404d5-1b23-4d09-ad63-92ba9f5c5873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5e14a179-3b3c-41a8-926e-4de0e48fa405" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d3a404d5-1b23-4d09-ad63-92ba9f5c5873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncDeferredRevenueDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#LicenseRevenuewith3DMedicinesIncDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7db0eb53-bfff-411a-be96-56014f447dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward_0fee2ed6-2240-4364-bc4e-124f010af6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInDeferredRevenueRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7db0eb53-bfff-411a-be96-56014f447dfd" xlink:to="loc_us-gaap_MovementInDeferredRevenueRollForward_0fee2ed6-2240-4364-bc4e-124f010af6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d3d7f04f-74e2-4202-9f71-6c7ac930cfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_0fee2ed6-2240-4364-bc4e-124f010af6a9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d3d7f04f-74e2-4202-9f71-6c7ac930cfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d96db0e5-d06a-4531-92bc-8718484a629b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_0fee2ed6-2240-4364-bc4e-124f010af6a9" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d96db0e5-d06a-4531-92bc-8718484a629b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized_4bbaeb40-62ab-4a53-97b8-ad89c9083167" xlink:href="sls-20210630.xsd#sls_ContractWithCustomerLiabilityNewContractRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_0fee2ed6-2240-4364-bc4e-124f010af6a9" xlink:to="loc_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized_4bbaeb40-62ab-4a53-97b8-ad89c9083167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8cae6c53-4a99-44ff-ba1f-dd80ba9910ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_0fee2ed6-2240-4364-bc4e-124f010af6a9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8cae6c53-4a99-44ff-ba1f-dd80ba9910ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="sls-20210630.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02b0cd72-b028-4451-80a2-3405048db960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_38472f59-1e4a-4f7e-b944-026126abdb80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02b0cd72-b028-4451-80a2-3405048db960" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_38472f59-1e4a-4f7e-b944-026126abdb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="sls-20210630.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4425eca8-c9be-4b89-b9f0-79db8410ed19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a9f6fa97-6518-4482-812f-fa6792b8fa17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4425eca8-c9be-4b89-b9f0-79db8410ed19" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a9f6fa97-6518-4482-812f-fa6792b8fa17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d59d1f08-12a1-4fb7-99ef-168d00453e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4425eca8-c9be-4b89-b9f0-79db8410ed19" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d59d1f08-12a1-4fb7-99ef-168d00453e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_eeafb72e-ae88-4099-82e9-43ec1f7053b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4425eca8-c9be-4b89-b9f0-79db8410ed19" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_eeafb72e-ae88-4099-82e9-43ec1f7053b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e89184f1-57d7-4584-acfc-30e4d12f3bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4425eca8-c9be-4b89-b9f0-79db8410ed19" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_e89184f1-57d7-4584-acfc-30e4d12f3bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12f1603a-baed-4e80-8916-6d5d8cf684d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e704b84-c1dd-474d-8d63-ca63bdccfb16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_12f1603a-baed-4e80-8916-6d5d8cf684d4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e704b84-c1dd-474d-8d63-ca63bdccfb16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9b3a69a8-7304-4721-ac93-e44c245e1970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e704b84-c1dd-474d-8d63-ca63bdccfb16" xlink:to="loc_us-gaap_PlanNameAxis_9b3a69a8-7304-4721-ac93-e44c245e1970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8309b9f3-5507-4915-bbe6-87953597624b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9b3a69a8-7304-4721-ac93-e44c245e1970" xlink:to="loc_us-gaap_PlanNameDomain_8309b9f3-5507-4915-bbe6-87953597624b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_TwoThousandAndSeventeenEquityIncentivePlanMember_4033a1a0-ab94-41c7-a6ca-c491c691dbfb" xlink:href="sls-20210630.xsd#sls_TwoThousandAndSeventeenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8309b9f3-5507-4915-bbe6-87953597624b" xlink:to="loc_sls_TwoThousandAndSeventeenEquityIncentivePlanMember_4033a1a0-ab94-41c7-a6ca-c491c691dbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_TwoThousandAndNineteenEquityIncentivePlanMember_a789d893-32b8-431b-9cdb-efa1ce2b553f" xlink:href="sls-20210630.xsd#sls_TwoThousandAndNineteenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8309b9f3-5507-4915-bbe6-87953597624b" xlink:to="loc_sls_TwoThousandAndNineteenEquityIncentivePlanMember_a789d893-32b8-431b-9cdb-efa1ce2b553f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_A2021EmployeeStockPurchasePlanMember_5e4e7254-8550-4ca6-9263-9786edba5c8d" xlink:href="sls-20210630.xsd#sls_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8309b9f3-5507-4915-bbe6-87953597624b" xlink:to="loc_sls_A2021EmployeeStockPurchasePlanMember_5e4e7254-8550-4ca6-9263-9786edba5c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3790f4fa-1dc3-43bf-9d3b-1592e8fcb704" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e704b84-c1dd-474d-8d63-ca63bdccfb16" xlink:to="loc_srt_RangeAxis_3790f4fa-1dc3-43bf-9d3b-1592e8fcb704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8c7ddcfa-3e81-44ad-9afb-a7e0b86fd92b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3790f4fa-1dc3-43bf-9d3b-1592e8fcb704" xlink:to="loc_srt_RangeMember_8c7ddcfa-3e81-44ad-9afb-a7e0b86fd92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6694ef12-cce5-4747-bbf5-b876410115f5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8c7ddcfa-3e81-44ad-9afb-a7e0b86fd92b" xlink:to="loc_srt_MaximumMember_6694ef12-cce5-4747-bbf5-b876410115f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9fbf151a-0524-439a-9c06-806403e09472" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8c7ddcfa-3e81-44ad-9afb-a7e0b86fd92b" xlink:to="loc_srt_MinimumMember_9fbf151a-0524-439a-9c06-806403e09472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8798f5b8-d43c-49c2-bba0-3306cb59983d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e704b84-c1dd-474d-8d63-ca63bdccfb16" xlink:to="loc_us-gaap_AwardTypeAxis_8798f5b8-d43c-49c2-bba0-3306cb59983d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_38f996b0-11c3-4c67-86a4-8818795b6395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8798f5b8-d43c-49c2-bba0-3306cb59983d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_38f996b0-11c3-4c67-86a4-8818795b6395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_490cd849-4a2e-44b4-9fea-cd9c8a3ef435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_38f996b0-11c3-4c67-86a4-8818795b6395" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_490cd849-4a2e-44b4-9fea-cd9c8a3ef435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2806177c-5c4e-43f6-8bbf-81952bcffc08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_38f996b0-11c3-4c67-86a4-8818795b6395" xlink:to="loc_us-gaap_EmployeeStockMember_2806177c-5c4e-43f6-8bbf-81952bcffc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4e704b84-c1dd-474d-8d63-ca63bdccfb16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_164940bf-c6bd-4d75-8e9a-fe40d998249c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_164940bf-c6bd-4d75-8e9a-fe40d998249c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_51a49bcb-d9e5-4e2c-964a-48fcc297e733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_51a49bcb-d9e5-4e2c-964a-48fcc297e733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f00d4dd8-a8bc-4b50-bfdf-6e1589412625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f00d4dd8-a8bc-4b50-bfdf-6e1589412625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_efafce58-e170-4a7e-b834-3d5fd859a481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_efafce58-e170-4a7e-b834-3d5fd859a481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_ClosingPriceOfCommonStock_83461034-eaa3-4fa0-b501-083cfdd57807" xlink:href="sls-20210630.xsd#sls_ClosingPriceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_sls_ClosingPriceOfCommonStock_83461034-eaa3-4fa0-b501-083cfdd57807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_995d9250-6501-4186-88de-91d0854bdfa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_995d9250-6501-4186-88de-91d0854bdfa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_9338cb26-a144-47bf-adbb-b6366c25a873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_9338cb26-a144-47bf-adbb-b6366c25a873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_49b66512-22be-4d0d-93d4-5caa4e17c5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_49b66512-22be-4d0d-93d4-5caa4e17c5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_817a11b9-3700-4a66-805a-6a95485ab5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_817a11b9-3700-4a66-805a-6a95485ab5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_895c04db-d98a-42bd-94e6-574c631d8b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_895c04db-d98a-42bd-94e6-574c631d8b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_a9bfbc9e-b746-4359-8607-975248952ec7" xlink:href="sls-20210630.xsd#sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition_a9bfbc9e-b746-4359-8607-975248952ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3853e8b3-b592-455e-83cf-f3211fa12325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3853e8b3-b592-455e-83cf-f3211fa12325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_34a98fa9-aa6a-479b-9f64-aba2cfa1e6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_34a98fa9-aa6a-479b-9f64-aba2cfa1e6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8cbf2aaf-fdbc-4990-a79b-64befcb0e93b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_8cbf2aaf-fdbc-4990-a79b-64befcb0e93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0f859128-af2f-4683-8725-1afede607fce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afad69d2-7ee4-4321-989f-19a13db003f2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_0f859128-af2f-4683-8725-1afede607fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d731148-5ff9-4d0b-87b3-79bfaf892013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_261c0a17-a6fd-407d-b31a-e194e71d75a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d731148-5ff9-4d0b-87b3-79bfaf892013" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_261c0a17-a6fd-407d-b31a-e194e71d75a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f5d39fc9-6928-4014-beac-1c0f361f66c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_261c0a17-a6fd-407d-b31a-e194e71d75a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f5d39fc9-6928-4014-beac-1c0f361f66c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b715fbee-77b7-4f1c-834f-a16795147415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_261c0a17-a6fd-407d-b31a-e194e71d75a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b715fbee-77b7-4f1c-834f-a16795147415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ba55dbb5-8b8b-4d72-868c-b24d462cfb75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_261c0a17-a6fd-407d-b31a-e194e71d75a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ba55dbb5-8b8b-4d72-868c-b24d462cfb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a8c904c5-725f-48ae-b8da-ae087eaa6b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d731148-5ff9-4d0b-87b3-79bfaf892013" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a8c904c5-725f-48ae-b8da-ae087eaa6b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac8eb9a7-90c3-4461-900b-03fd8d1b6d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d731148-5ff9-4d0b-87b3-79bfaf892013" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac8eb9a7-90c3-4461-900b-03fd8d1b6d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4031c9ef-a08b-45e0-8c13-d2b359d2f200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac8eb9a7-90c3-4461-900b-03fd8d1b6d21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4031c9ef-a08b-45e0-8c13-d2b359d2f200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2558016a-7112-4550-b408-135f6b78cb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac8eb9a7-90c3-4461-900b-03fd8d1b6d21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2558016a-7112-4550-b408-135f6b78cb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_65cd3821-b9af-4908-aa62-d361a736b0af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac8eb9a7-90c3-4461-900b-03fd8d1b6d21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_65cd3821-b9af-4908-aa62-d361a736b0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3543b235-6ac9-403a-8aad-f610c455c0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d731148-5ff9-4d0b-87b3-79bfaf892013" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3543b235-6ac9-403a-8aad-f610c455c0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5d98f876-4394-4ea1-8775-befb1451307a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d731148-5ff9-4d0b-87b3-79bfaf892013" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5d98f876-4394-4ea1-8775-befb1451307a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_212fc2a8-fda5-4adc-9a81-65c9a819d299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d731148-5ff9-4d0b-87b3-79bfaf892013" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_212fc2a8-fda5-4adc-9a81-65c9a819d299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_3eb10f84-e999-4806-9c0d-b231012bda3f" xlink:href="sls-20210630.xsd#sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d731148-5ff9-4d0b-87b3-79bfaf892013" xlink:to="loc_sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_3eb10f84-e999-4806-9c0d-b231012bda3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b7056ae6-4815-46cf-ac64-15fb9dd8828d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_3eb10f84-e999-4806-9c0d-b231012bda3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b7056ae6-4815-46cf-ac64-15fb9dd8828d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_358f634f-dd5f-4952-855a-621ba1bbc16a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward_3eb10f84-e999-4806-9c0d-b231012bda3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_358f634f-dd5f-4952-855a-621ba1bbc16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_ecd8486d-1552-4269-9ffe-466b80d3160e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5d731148-5ff9-4d0b-87b3-79bfaf892013" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_ecd8486d-1552-4269-9ffe-466b80d3160e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#StockBasedCompensationAllocatedStockbasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4325761-b7b7-41ea-bbcd-7c5ee41e16d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7898dc85-3089-4f88-80de-5505d1453608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b4325761-b7b7-41ea-bbcd-7c5ee41e16d7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7898dc85-3089-4f88-80de-5505d1453608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f37fa56b-bc1e-44c6-bd02-67530d4ff161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7898dc85-3089-4f88-80de-5505d1453608" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f37fa56b-bc1e-44c6-bd02-67530d4ff161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4dbef4c3-687c-42b8-86f4-ba0879e608ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f37fa56b-bc1e-44c6-bd02-67530d4ff161" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4dbef4c3-687c-42b8-86f4-ba0879e608ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0c5aa457-125f-4c18-a230-7bd1726bd359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4dbef4c3-687c-42b8-86f4-ba0879e608ea" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0c5aa457-125f-4c18-a230-7bd1726bd359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ec1bc0bf-4d7e-42cd-bddc-b71684846c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4dbef4c3-687c-42b8-86f4-ba0879e608ea" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ec1bc0bf-4d7e-42cd-bddc-b71684846c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_32b25edc-be28-47ff-b171-86acb2a26084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7898dc85-3089-4f88-80de-5505d1453608" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_32b25edc-be28-47ff-b171-86acb2a26084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e9e981cf-8cbe-450c-991a-2702b27c5523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_32b25edc-be28-47ff-b171-86acb2a26084" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e9e981cf-8cbe-450c-991a-2702b27c5523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5648308b-88ef-482b-bb9e-7d56679507bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_80a83e97-bae2-44d9-9a7b-8eb0d19ee274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5648308b-88ef-482b-bb9e-7d56679507bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_80a83e97-bae2-44d9-9a7b-8eb0d19ee274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_09ef950c-c098-4f91-adb9-abea619d4bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5648308b-88ef-482b-bb9e-7d56679507bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_09ef950c-c098-4f91-adb9-abea619d4bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b6a80b58-87b4-40cf-b063-28445a1bac19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5648308b-88ef-482b-bb9e-7d56679507bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b6a80b58-87b4-40cf-b063-28445a1bac19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7fce8174-0e10-4fa2-b757-fcac70af0b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5648308b-88ef-482b-bb9e-7d56679507bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7fce8174-0e10-4fa2-b757-fcac70af0b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails" xlink:type="simple" xlink:href="sls-20210630.xsd#StockBasedCompensationSummaryofRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cbc59912-eb99-4ced-88f2-762c54fe486c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a405e2df-81c9-4a10-b8b0-725da865c8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cbc59912-eb99-4ced-88f2-762c54fe486c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a405e2df-81c9-4a10-b8b0-725da865c8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b60392ae-39d7-4b45-9d61-83d6cfcaf01d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a405e2df-81c9-4a10-b8b0-725da865c8ae" xlink:to="loc_us-gaap_AwardTypeAxis_b60392ae-39d7-4b45-9d61-83d6cfcaf01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26aee7ba-e87e-45df-a4ba-d5f5a6332ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b60392ae-39d7-4b45-9d61-83d6cfcaf01d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26aee7ba-e87e-45df-a4ba-d5f5a6332ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e03c23ca-ea4d-41d1-98bd-dbad70780e50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26aee7ba-e87e-45df-a4ba-d5f5a6332ef1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e03c23ca-ea4d-41d1-98bd-dbad70780e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d47f54-79d1-4a15-b150-17c16ac2f079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a405e2df-81c9-4a10-b8b0-725da865c8ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d47f54-79d1-4a15-b150-17c16ac2f079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2f43dd32-b830-4755-8e80-461c08cf024e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d47f54-79d1-4a15-b150-17c16ac2f079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2f43dd32-b830-4755-8e80-461c08cf024e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f137f2ff-4b5e-4af0-a904-6cb5e1c051eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2f43dd32-b830-4755-8e80-461c08cf024e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f137f2ff-4b5e-4af0-a904-6cb5e1c051eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5b0d96f2-63f8-4835-887b-30a395adc302" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2f43dd32-b830-4755-8e80-461c08cf024e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5b0d96f2-63f8-4835-887b-30a395adc302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_aebbba9e-66f5-49be-96f4-b9920d7e93e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2f43dd32-b830-4755-8e80-461c08cf024e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_aebbba9e-66f5-49be-96f4-b9920d7e93e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a551557d-f439-40dd-9784-832519945e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2f43dd32-b830-4755-8e80-461c08cf024e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a551557d-f439-40dd-9784-832519945e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_697b33a9-75d3-4d53-afbd-d0e6c9b21c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_97d47f54-79d1-4a15-b150-17c16ac2f079" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_697b33a9-75d3-4d53-afbd-d0e6c9b21c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1bdcd6c1-65a7-486d-ac08-53eff464e34a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_697b33a9-75d3-4d53-afbd-d0e6c9b21c25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1bdcd6c1-65a7-486d-ac08-53eff464e34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_89500d63-1b1e-4abc-a6a6-668c16c34927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_697b33a9-75d3-4d53-afbd-d0e6c9b21c25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_89500d63-1b1e-4abc-a6a6-668c16c34927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_98f0c6d8-bf8c-480c-a996-3ab002bbaa98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_697b33a9-75d3-4d53-afbd-d0e6c9b21c25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_98f0c6d8-bf8c-480c-a996-3ab002bbaa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_cb72d9e5-c662-4fa1-a962-64dd170c0b52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_697b33a9-75d3-4d53-afbd-d0e6c9b21c25" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_cb72d9e5-c662-4fa1-a962-64dd170c0b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sellaslife.com/role/SubsequentEvents" xlink:type="simple" xlink:href="sls-20210630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.sellaslife.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9e02de38-4f7e-4794-9ecd-9e08c22be314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_2f55e8c0-cd56-403a-b876-2b8b1dc458c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9e02de38-4f7e-4794-9ecd-9e08c22be314" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_2f55e8c0-cd56-403a-b876-2b8b1dc458c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>sls-20210630_g1.jpg
<TEXT>
begin 644 sls-20210630_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "L @D# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZP_X*Y_\
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MAMJECI=PH>*[UF:'2UD4]&5)V61E/4,JD$=Z]%_XAZOVFO\ H6_#O_@_MO\
MXJOHIXKAV@_9R=&+73W-#YV&%XBKKVL56DGU]_4\5_X>=?M#?]%H^(W_ (/)
M_P#XJG1_\%/OVB(GW#XS_$3\=:F8?D37M'_$/5^TU_T+?AW_ ,']M_\ %5'<
M_P#!O?\ M.00,R^%M F91D(GB"UW-[#+ ?F:G^T>'/YZ/_DA?]F\2?R5O_)S
MG?A9_P %ROVF/A;?QR?\+"?Q':QG+VFN:?;WD<OL7V+,/^ R"OT2_8/_ .#B
M;P5\>-:L?#/Q6TRU^'?B"\98H=5BF,FBW4AX =G^>VR3@;RZ<9,B\"OR _:+
M_8Y^*'[)>KQ6?Q$\%:UX7:X8I!/<1B2TN6')$=Q&6BD(ZD*Y(KS2HQW"N39G
M1YJ<(J^TH67STT?SN5@>+,YRRMRU)R=MXSN_EKJOE8_KJCD6:-65E96&58'(
M(]13J_)W_@W:_P""CNL>.)9/@/XPNKK4I--LGO?"U]+F1XH(\>99.W7:BG?&
M3]U0Z9P(U'ZQ5^#9WD];+,7+"5M;:I]T]G_6ST/WO(\XHYG@XXNCI?1KLUNO
MZW5F?@3_ ,%[_P!@K4/V:OVHK_XB:7:%O _Q,O'O4FC7Y;#4F&^X@?L#(V^9
M.F0S@?ZLFO@FOZKOVGOV;_#/[6OP.U_P#XLM?M&D:];F/S% \ZSE',<\1/22
M-P&!Z'&#D$@_S-_M;_LM^)OV-?CYKW@#Q5#MO]'ES!<HI6'4;9N8KF+/5'7G
MU4AE/S*0/V?@/B18["K!UG^]IK_P**T3]5L_D^I^+<>\,O 8KZY17[JH[_X9
M/5KT>Z^:Z'ZP?\$ /^"H/_"U?"UK\#O'6H[O$VAVY_X1>]N'^;4[.-<FT8GK
M+"HRO]Z($?\ +,EOU"K^27P;XQU3X>^+--U[0[ZYTO6-'N8[RRN[=]DMM-&P
M9'4]B" :_H^_X)7?\%$=+_X*#_L]0ZI*UM9^./#XCL_$NG1G CF(^6XC7KY,
MVTLO]U@Z9.W)^.X^X7^JU'F.%7[N3]Y+[,GU]'^#]4?9>'_%7UJDLMQ3_>17
MNM_:BNGJOQ7HSZ<HHHK\S/TX**** "BBB@ K^;?_ (+4?\I0/BU_V$+;_P!(
M;>OZ2*_FW_X+4?\ *4#XM?\ 80MO_2&WK]*\+_\ D95?\#_]*B?FGBC_ ,BV
ME_U\7_I,CF_^"57_ "D:^#?_ &,]K_Z%7]-E?S)_\$JO^4C7P;_[&>U_]"K^
MFRM/%'_?J/\ @_5F7A;_ +C6_P ?_MJ"BBBOS$_4 HHHH **** "BBB@#XM_
MX.!/^47_ (T_["&E_P#I=#7\\M?T-?\ !P)_RB_\:?\ 80TO_P!+H:_GEK]X
M\,_^13+_ !O_ -)B?@GB=_R-H_\ 7M?^E2/WD_X-J/\ E'QJW_8YWW_I-9U^
MA%?GO_P;4?\ */C5O^QSOO\ TFLZ_0BORCBS_D<8C_$S]9X3_P"1/A_\*"BB
MBOGCZ(**** "BBB@ K\&O^#E?_E(/I/_ &)EC_Z4WE?O+7X-?\'*_P#RD'TG
M_L3+'_TIO*^]\./^1Q_V[+]#X'Q(_P"1,_\ %']3X$\/_P#(>L?^OB/_ -"%
M?UP5_(_X?_Y#UC_U\1_^A"OZX*]_Q5WPW_;_ /[8?/\ A3MBO^W/_;PHHHK\
MC/UX**** "BBB@ HHHH ***\R_;+_:(M/V3_ -ESQO\ $*[\LGPWI<D]K'(?
MEN+IL1V\1_WYGC7_ (%6M&C.M4C2IJ\I-)>KT1E7K0HTY5:CM&*;;\EJS\//
M^"^_[4?_  T+^WKJNB6-QYVA?#6 >'K<*V4:Z4E[M\=F$I\H^UNM?*O[/'P6
MU+]HSXZ>$_ NCAO[0\5:I!IT;A=P@5W >4C^ZB;G/LIKE]<UN\\3:W>:EJ%Q
M)=WVH3O<W,\AR\TCL6=V/J6))^M?IE_P;._LM?\ ";?'?Q3\6-0M]UCX*M/[
M*TMV7AKZY4^8ZGUCMPRD>ERM?TCBJE/(\E?)_P NXV7G+9??)W9_-6$IU,]S
MM<__ "\G=^4=W]T59?(\A_X+N_L2:;^Q]^U)HMQX8T\:?X-\7:';M81(N(X)
M[2-+::,>IVK#*3W,YKXO\->([[P?XCT_5M-N)+/4M+N8[RUGC.&AEC8.CCW#
M '\*_H"_X+\?LP?\-!?L#ZMK=E;^=KGPVG'B&W*KEVME!2[3/91"QE/O M?S
MWUR\$YJ\?E4?:N\H>[*_6VWWIKYW.OCC*?[/S67LE:,_>C;I??[FG\K']57[
M)WQ]L?VH_P!FSP7\0-/\M8?%&E0WDL:'*V\^-L\/_;.59$^J5Z%7Y8_\&R/[
M4'_"2_"KQG\)-0N-UUX9N1KVDHS?,;2<A)T4?W8Y@C'WN:_4ZOPSB#+'E^85
M<+T3T]'JOP?WG[KP]FBS#+J6*ZM:_P"):/\ %?<%%%%>,>T%? /_  <>?&:]
M^&W[ MOH-A*T+^.O$%MIET5.";6-)+EQGWDAA!'<%A['[^K\P_\ @Z&_Y-G^
M&O\ V,\O_I+)7TG"%.-3.</&>W-?[DVOQ1\WQA5E3R;$2AORV^]I/\&?B?7[
M*?\ !OG_ ,$S_#?_  JVR^.WC32[?6-;U:XE'A>VNHQ)#ID$,C1FZV'@S/(C
MA21\BH&7E\C\:Z_ID_X),1K%_P $W?@Z%4*/^$=A/'J68G]:_6/$;,*V&RV,
M*+MSRLVNUFVOGU\M#\D\-\OHXG,Y3K*_)&Z3[W2O\NGGKT/HBBBBOP,_?PHH
MHH YWXK?";PW\<? &I>%O%VBV.O^']6B,-U97<>^.0=B.ZL#RK*0RD @@@&O
MRQ\'?\&Q4-Q^T/KTVO\ CEK?X6V][YFD6UBN_6+V!@&\N5W7RX2A)3> Y?9G
M:F1C]<**]G*^(,?ET)PPE3E4M^OS5]GTO_P#Q<TX?P&8SA/%T^9QVZ?)VW76
MW_!/.?V;?V2?AW^R+X,&A?#WPKIGAVS8+]HEA3?=7K#HTTS9DE;K]YCC.!@<
M5Z-117E5JU2K-U*LG*3W;=V_F>M1HTZ4%3I148K9)62^05\;?\%EO^";,/[>
M/P#.I>'[6)?B5X-BDN-%D&%;4HOO26+MZ/C*$\+(!R%=R?LFBNC+\?6P6(CB
MJ#M*+O\ \!^3V9S9AE]'&X>>%Q"O&2L_\UYK='\C%]8SZ7?36MU#+;W-N[12
MQ2H4DB=3AE93R""""#R#7K?[#?[9/B3]A?\ :&T?QUX=9IH[<_9]4TXN5BU:
MR8CS8'],X#*V#M=5;!Q@_?7_  <)?\$R_P#A$=:N/CUX(T_&EZI,J^+[.!.+
M6X8A4OP!_#(Q"R>DA5N?,8C\I:_I3+,PPN=9?[1*\9JTHOH^J?Z/M9G\T9GE
M^*R7,/9MVE!WC)=5T:_7SNC^KK]G_P"/'AK]IKX/:#XY\(WRZAH/B"V%Q;OP
M'B/1XI!D[9$8,C+V92*[*OY_/^")'_!3F3]BKXQ_\(;XLOF7X8^-+E5N7D;Y
M-#O#A4O!Z1GY4E_V0K?\L\'^@&*59XEDC971P&5E.0P/0@U^!\4</U,IQCI/
M6$M8ONNWJMG]_4_H#A?B&GFV#59:3CI)=GW]'NONZ#J***^;/I HHHH *^,_
MVD/^"%WP7_:F^.?B#X@^)K[QTNN>))4FNH[+4X8K962)(AL4P,P^5!U8\YK[
M,J.ZNXK&W:::2.&&,99W8*JCW)KMP.88K!S=3"S<)-6NNW8X<=EV%QD%3Q<%
M.*=[/OW/BWX%?\$%O@?^SS\8?#OCC0;OQT^M>%[Y+^S6[U2&2 R(<C>HA!(]
M@17VM7.R?%[PG"^U_%'AU6'4'4H0?_0J;_PN/PC_ -#5X;_\&</_ ,56N.QF
M-QDE/%2E-I63=WH9X'!X'!1<,+&,$W=I66ITE%<W_P +C\(_]#5X;_\ !G#_
M /%4?\+C\(_]#5X;_P#!G#_\57#[&I_*_N.[VU/^9?>=)17-_P#"X_"/_0U>
M&_\ P9P__%4?\+C\(_\ 0U>&_P#P9P__ !5'L:G\K^X/;4_YE]YTE%9>@>-M
M%\5R2)I>KZ7J3P@-(MK=),4!Z$[2<?C6I42BT[,N,DU=!1112&?%O_!P)_RB
M_P#&G_80TO\ ]+H:_GEK^AK_ (.!/^47_C3_ +"&E_\ I=#7\\M?O'AG_P B
MF7^-_P#I,3\$\3O^1M'_ *]K_P!*D?O)_P &U'_*/C5O^QSOO_2:SK]"*_/?
M_@VH_P"4?&K?]CG??^DUG7Z$5^4<6?\ (XQ'^)GZSPG_ ,B?#_X4%%%%?/'T
M04444 %%%% !7X-?\'*__*0?2?\ L3+'_P!*;ROWEK\&O^#E?_E(/I/_ &)E
MC_Z4WE?>^''_ "./^W9?H? ^)'_(F?\ BC^I\">'_P#D/6/_ %\1_P#H0K^N
M"OY'_#__ "'K'_KXC_\ 0A7]<%>_XJ[X;_M__P!L/G_"G;%?]N?^WA1117Y&
M?KP4444 %%%% !1110 5^3O_  <Y_M1_V7X4\#_!_3[C;-JDA\2:RBM@B&,M
M%:H?56D\]B#WA0U^L$TRV\+22,L<<8+,S'"J!U)-?S!_\%&?VG7_ &O_ -L[
MQUXXCF:72[W4&M-(!Z+80#R;? [;D0.1_>=J^^\.\K^M9E]8DO=I*_\ V\](
M_J_D?G_B-FOU7+/J\7[U5V_[=6LOT7S/$:_I=_X).?LM?\,C?L)^"?#=U;_9
M]=U*V_MS6@5VO]LN@)&1O]J./RX?^V(K\-/^"2G[+7_#6_[=_@GP]=6_VC0M
M)N/[>UH%=R&TM2'*,/[LDGE1'_KK7]+5?0>)^:?PLO@_[TORC^K^X^?\+\J_
MBYC-?W(_@Y/\E]Y3U_0;/Q3H-]I>H6\=WI^I6\EK<P2#*31.I5T(]"I(/UK^
M6?\ :^_9]O/V5OVF_&WP^O?,9O#&JRVT$D@PUQ;$[[>4_P"_"T;_ / J_JDK
M\:/^#G']F#^P/B-X)^+FGV^VV\00'P]J[JN%%S"&DMW8]V>(R+]+85XOAOFG
MU?,'A)/W:J_\F6J_"Z^X]KQ*ROZQE\<7%>]2?_DLM'^-G]Y\8?\ !*[]J#_A
MDC]NCP+XIN+C[/HMU>#1]9);"?8KG$3NWM&Q27ZQ"OZ9J_D3K^EK_@DI^U!_
MPUE^P;X'\0W-Q]HUS2[;^PM9);<_VNU C+O_ +4D?E2G_KK7M>*&5_PLP@O[
MLOSC^OX'B^%V::U<OF_[\?P4OT?WGTE1117Y"?L 5^8W_!T) [?LP?#B4*?+
M3Q2ZD^A-I*1_(_E7Z<U\H?\ !:;]E6\_:R_8'\3:;H]L]YX@\+2Q^)=+@1=S
MSR6ZN)(U'4LUO).% ZL5%>]POBH8?-J%:IHE+7ROI?\ $^?XJPM3$Y37HTE>
M3C=+O;6WX'\X5?TJ_P#!'7Q19^+/^":/PCN+.598[;1S928/W)89I(G4^A#(
M?TK^:JON;_@C_P#\%>Y_V ]3N_"/BZUO=9^&>N77VIQ;8:ZT2Y("M/$I(#QL
M N^/(/RAEYW*_P"U<=9+7S'+U'#*\X/FMW5FFEYZW^5C\4X$SNAEN8.6)=H3
MCRW[.Z:;\M+?.Y_0-17E7P4_;C^$/[1&C0WO@[XC>$]8690WV<:@D-Y%G^_;
MR%94/LRBO0_^$QTC_H*:;_X$I_C7\^U<-6I2Y*D7%]FFF?T+1Q-&K'GI24D^
MJ::-*BLW_A,=(_Z"FF_^!*?XTY/%NE2N%74]/9FZ 7"$G]:SY)=C3GCW-"B@
M-N&1R#T-%24%%%% !1110!G^+/"FF^._"^HZ+K%C;ZEI.K6TEG>VEPF^*YAD
M4JZ,.ZE201[U_-'_ ,%.?V/+/]AO]L#Q%X%TO5;?5=&58]1TTK,)+BTMI\LD
M%P!]V5!QSRR['P X _>[_@I#^W=HO[ '[-^H>++WR+SQ!?;K+P]I;MSJ%X5X
MW <^5&/G<\<# .YE!_FL^)/Q&UKXO>/M8\4>(]0N-5UW7KN2]OKN8Y>:5SDG
MT [ #       K]=\,<%BXNIBKVI/2W\TEU7IM?K>W33\@\4,=@Y*GA4KUEK?
M^6+Z/UWMTM?KKB5_0I_P0&_:,UO]H3_@G[I\6OR375YX%U6;PQ%=RDEKJWBB
M@EAR>Y2.=8OI$I/)S7X&_"/X4:_\=/B9HG@_POI\VJ>(/$-VEG96T8Y=V[D]
M%51EF8\*JDG !-?TV?L)?LDZ7^Q%^R_X9^'NFR)=3:9"9M2O57'V^]D.Z>7U
MVECM4'D(J#M7I^)N*PZP4,/+6HY77=)7N_1[>?R/,\,,+B7C:F)CI34;/LV[
M67JM_+YGKU%%%?AY^Y!1110 5_/=_P %\/V@O%'Q+_X*#>,/"U]JU\WAGP;]
MDL=+TSSF^S0$VL,LDFS.TR/)(Y+$;MH5<X45_0C7\V__  6H_P"4H'Q:_P"P
MA;?^D-O7Z-X94X2S.<I*[4';R]Z*/S?Q.JSCE<(Q=DYI/S]V3_,^6Z*[S]E_
MX&S?M+_M">$/ ,&HQZ1-XLU*+3DO9(3,ML7.-Y0$%L>F17Z1?\0LVO\ _19-
M'_\ "<D_^2*_7,SXAR_+YJGC*G*VKK1O3Y)GY#E?#N8YC!U,'3YDG9ZI:_-H
M_*&BOU>_XA9M?_Z+)H__ (3DG_R11_Q"S:__ -%DT?\ \)R3_P"2*\W_ %XR
M/_G^O_ 9?_(GI_ZBYY_SX?\ X%'_ .2/RAHK]7O^(6;7_P#HLFC_ /A.2?\
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MOB/_ -"%?UP5[_BKOAO^W_\ VP^?\*=L5_VY_P"WA1117Y&?KP4444 %%%%
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M=AX8\8:?'XAL+.(8CL#)))'- @[*)8F95'"K(JCI7]%=?B1_P=!?\G5?#O\
M[%0_^EDU??>'&*J0S;V47[LHNZ]%=?=_F?G_ (D86G4RGVLE[T)*S]79_?\
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M@:*^?O\ AZO^SC_T63P+_P"# 4?\/5_V<?\ HLG@7_P8"OS?^R<=_P ^9_\
M@+_R/TG^U\#_ ,_H?^!1_P SZ!HKY^_X>K_LX_\ 19/ O_@P%'_#U?\ 9Q_Z
M+)X%_P#!@*/[)QW_ #YG_P" O_(/[7P/_/Z'_@4?\SZ!HKY^_P"'J_[./_19
M/ O_ (,!1_P]7_9Q_P"BR>!?_!@*/[)QW_/F?_@+_P @_M? _P#/Z'_@4?\
M,^@:***\\] ^+?\ @X$_Y1?^-/\ L(:7_P"ET-?SRU_0U_P<"?\ *+_QI_V$
M-+_]+H:_GEK]X\,_^13+_&__ $F)^">)W_(VC_U[7_I4C]Y/^#:C_E'QJW_8
MYWW_ *36=?H17Y2?\$#_ -M[X1_L[?L3:EH/CCX@^&?"^LR^*KR\2SO[H12M
M"UO:JKX_NDHPS_LFOMK_ (>K_LX_]%D\"_\ @P%?FO%&6XR>;8B<*4FG)V:B
MVOR/TSA?,\'3RG#PG5BFHJZ<DG^9] T5\_?\/5_V<?\ HLG@7_P8"C_AZO\
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M:I[*S^9Q\$\&X/'8%XO'Q;YG:.K6BT;T:W=U\C\8/^(7#QM_T5?PM_X*I_\
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M?#%E7J(_$5K(WY*Y/Z4O[-QG_/J7_@+_ ,A_VG@_^?L?_ E_F>W5\M_MX_\
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M.UU=>JFO'J_J7_:L_8I^&O[:O@Z+1?B)X9M=:CM"S65VK-!>Z>S=3%,A#KG
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MTMQI_BKXE:3;R,6%JE]:31Q>RE[<MC_>+'WK/_XA@_@Y_P!#Y\3/^_\ 8_\
MR/7[)'Q$R9J_-+_P%GXQ+PYSI.W+'_P)'X>T5^X7_$,'\'/^A\^)G_?^Q_\
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M8J2OPC,,;/%XJIBJF\VW]_3Y;'[UEV!A@\+3PM/:"2^[K\]PHHHKC.P****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[]LSQ]\$/V(K[XW?$KQ-XD\;77B#6DT/PIH<^IO9V\H0L9[AVC7<?]7,HR"
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M#*2I!/IU<E:C4HU'2JIJ2=FGNF=="O3K4U5I-2C)736S045\[^$/V\W\5?\
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=T]_)GK8O!TL33]E65U=/MK%IK;S2"BBBN4ZC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>sls-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sls="http://www.sellaslife.com/20210630"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sls-20210630.xsd" xlink:type="simple"/>
    <context id="if7416b7a9cde449e9f869c897319832a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9a892d5d25b8461b97fc446b4c189943_I20210812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="i8d028055c2e64d5e9dab5f9331370054_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib3da468c26204b08b77feb6a7b00001f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibf4612fe88f64808b8d0d2c12012d345_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib69a37222fd941b78bea430bbe0462bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib67017fc406240feb6270ad2079440bd_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i07c36ae937694c63b10658b767e16510_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9d02464dad0041958b0fab78708a2174_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if863226dc0724e56bf43f3b1ff67fffc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7d744a0c3d154b118fd1398efd967c38_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i55be4a1b9d7945e1a7df3335dc287d83_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id0549b9745c54a4a82c51e4b803e22ca_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i274e8814ad244aaa9f27ee58126839b1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2d8817680df2485bab16391f20f795f3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9bb7f8716a0d4caaa768d3669f37d68e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="icbab7f5989004cf9a988181f7b725951_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i31ce168dc5e644718859ca9b623e68b2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i61c430eb60c04fd480ba1b6c3c09ab45_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3800086248c45cebf643a6fcf7192a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iefbe1927948046feaeb6e3e3ce6c19d5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b8fae89d58849ac8cd70c40f8a2da16_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3bbe90aea6ce4ba897f9a44f95d343af_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i70c599afdc614f3482861b5c48fd1e0a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibcdc516de7334f91b176b211161b8e6e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icfda986c11714d6bb1d5b24be92e2a2f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia79f32850e854189b3295d67b790dcdf_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i660f1425ddfa4dda85f51c113de04b3e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9b35a3bd1e0a4431b15acba6941f5f47_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0fcb89f394a14d90a5ea1862dbd7af35_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i71259de5a94b42459fed552bab9b67b8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibedd4733b3614b92b8f20aa69691c575_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2be78beb508f4988ae137bb70fb5e7c4_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icce1dd99c16b4ec291627c253ff14547_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8e81f95995f142afb3eaed854f43ad80_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea42d6c53bbb4f8783846d9ea9891e59_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id69a6adea6624cb7b4b433f41d4dc840_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1ce9074c50144420a1bfafad23e559d3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i939616e9c3844b8b81fb48909a77e68e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2e24296575c34c609ccf83d3d2c409eb_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7e84c865aaab4f7d93617acbb36a98b3_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie077fe8f1fa546518ab2e7996f804236_D20210416-20210416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-16</startDate>
            <endDate>2021-04-16</endDate>
        </period>
    </context>
    <context id="ib40089611a434490a15e807711e0febb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7d5ca04db51e482796a8bcd426e5cf11_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia6d6d49da9294db98abbd7d306232e0e_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sls:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="id8555ccfc9b945a59123f108d50b1d06_D20210702-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i95e27891b14a478b8f8be763dda2f1fd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if65aed140a5941fa9eab141c9d95f9be_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iabe6e36564484068baac5e49c21a346e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2ab00b1183924bdb9188ae231bdbefd9_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i916c92e4c67d42dc92aa2fd9eccecc12_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i572c1e1b6c34427d95e51bbb5e40be56_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id299f8f9d64c460fbab097e59032b733_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i20b6583c6c4a4427a2154f30c7a4d759_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib2cfc63428564e92ac87c7615fb89ca7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i63ad3d82d21047e2a9bb504f8640be57_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i94e62635663940f0a1122ae9dd5b94de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14237fe221f44d34a5583869de1d051e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i23b95e026b9d4e318900dfe9940adf09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa99ebdccce94e8caa2de707cacf92af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ae6ab8b28e8405fb45e31fe8cff6e47_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42a0e682866c4ad485eb808d137a33a4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i69f52ca633da4c9fa61aac1b2d469ba6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i707b6253a0f14414a1bc6beca9cc2c6f_I20111231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:AptheraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-12-31</instant>
        </period>
    </context>
    <context id="ibb2e72136f1d4a248d844448ac121df9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:AptheraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2bdb237db5d747d296f136aa84ea8854_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:AptheraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i09934cd16082484c8827742d0199f8e8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:AptheraInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sls:MeasurementInputWeightedAverageCostOfCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i25cd3b9620c54b4e9fce77a21dc1f63f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:AptheraInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sls:MeasurementInputCostOfDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id0a9aad2208d4af3861b03029b413458_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:AptheraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1a03f8fd056b46cbb0fb3aa49612a705_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sls:AptheraInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia44788b499c14745a5543c4a56408ada_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sls:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i06156e81794f42c1a865af738d386a08_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sls:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9b25700382c9420ca66cff20eaedf21a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sls:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i375c691af6b54e09a2f25fecd7b8dc1a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sls:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0c3f2fed3a4c4b6cb082afcd2c660434_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sls:OfficeSpaceLeaseExpiringDecember312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i880559595c4c4de0b7dc3629958abd33_D20200713-20200716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2020-07-13</startDate>
            <endDate>2020-07-16</endDate>
        </period>
    </context>
    <context id="i111b00fe2e9a484ab732132f92c59d7e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i09f2e17d90504212b4f4df2b5b769f5f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:A2019EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6b1a536e4ed7497d9180567e5c395379_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i53f109f3f922470f8caedb485b977400_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:A2017EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9b57b69674ea45d89f949a22963281ef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2020PIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i382d0ff9116248889bfe35c9548bb1ad_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2020PIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1696facd34e04e7fabcf3bf12a67fc37_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2020PIPEOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i055485f92470418a8842a2c2ea3403fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:January2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae1ab75d176f43859c532c0d5a6b9757_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:January2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1abab26a331b4d2bbc52b859b5ddb6d1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:January2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i27b4f5e1ef5b476eb4b27190b75d9193_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1602f66b4bcd4b2fa1f1a8b24f7dd4e1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i412c4e10b3ae49dd8a8769d97061c813_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2b0b95c6b8aa4fb6baa41a60c4f64951_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:WarrantExerciseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i947de4d2c94b4605b378f1b0d070bc03_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:WarrantExerciseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icde798f1922a4c969d6f8e4f31c629b2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:WarrantExerciseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i19c88fd5d77f4b98a7abbb7fbdd57812_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2018OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c3ab494f63a4840a5e8d7c78a0058e7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2018OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4d5dabb9e85f4ddf985e3b83dbcc8a7f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:July2018OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i251355b170d24283aef38a929d6b4ddb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherWarrantIssuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b0f1fdbd95d469f9e4960e2aff67576_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherWarrantIssuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia7d574a5c54b4ecf988952bb6423ecf0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherWarrantIssuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if448fa0842d047f7b8837ba649615db8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherLiabilityClassifiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2bb40a5e73b94b1b8f47f0ddc5d2a834_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherLiabilityClassifiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i144421cce0de42f196e8d03018a26b22_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherLiabilityClassifiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5503f2dea367480f98b7b0fa4b8c7314_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sls:OtherLiabilityClassifiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id11e0beb0d474e3e908dfebf56c545ca_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i407d77e6977a4e69b6cad45ca4a965ca_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i688ab895304a4f60b76983dc097aef85_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iad04bd0225e946c686ea366ea6d4337c_I20171229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="i2cdec16105b14f11a00088c335a3fc87_I20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-10</instant>
        </period>
    </context>
    <context id="id18a6212741d45d5b62f720726640f94_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3326b9a650f54279992091454bb1af76_D20190910-20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-10</startDate>
            <endDate>2019-09-10</endDate>
        </period>
    </context>
    <context id="i7c1fcbbb7fa2469ea57dccaece19d2c0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:TwoThousandAndNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic7eacc21cecb4153bd972290a5d92a75_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i524a7778f45b41d493eb970513cfe899_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i455f2bcd2a26422b8ef4b6956db962dd_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib57038e75a2e456f9153d4562f7875c9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib53ff491bb4d406dbfc18398cc46aed4_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6957c26fb4be459faf509b1dc44c22e1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i34c6000daa9d4a529f676d7a949697c9_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if259b3f68de54eb69651fd71f0d90e8a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i69480503f88f4c8b8e46355038c252d7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1eabe9b7328c4b42883ac930dcae2966_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic3b2daec188244b58b5c6404473e5b28_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd04b0465a9c4a3b89d3acede77717db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i018e48b1dacd47c68c32d3cc244c3f52_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9994aed68348440999b4cb1d1a4ac219_I20210422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-22</instant>
        </period>
    </context>
    <context id="ie5c340905f4d47a1a0096f2680c0f9f4_D20210422-20210422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sls:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-22</startDate>
            <endDate>2021-04-22</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="complaint">
        <measure>sls:complaint</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80L2ZyYWc6NTk2YTc2YzY5MmNmNDFiNDkyYmM2N2Q0N2E2Njk4NjkvdGFibGU6ODk2ZjI4ZTQ4OTAxNGZlMjk5MDI3YmQwNzM4ZDI5NDIvdGFibGVyYW5nZTo4OTZmMjhlNDg5MDE0ZmUyOTkwMjdiZDA3MzhkMjk0Ml80LTEtMS0xLTA_91da2317-41c3-4ec9-b7a4-274c73b64da4">0001390478</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80L2ZyYWc6NTk2YTc2YzY5MmNmNDFiNDkyYmM2N2Q0N2E2Njk4NjkvdGFibGU6ODk2ZjI4ZTQ4OTAxNGZlMjk5MDI3YmQwNzM4ZDI5NDIvdGFibGVyYW5nZTo4OTZmMjhlNDg5MDE0ZmUyOTkwMjdiZDA3MzhkMjk0Ml81LTEtMS0xLTA_58670ac3-bf61-42b0-9a09-ed4fe0744195">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80L2ZyYWc6NTk2YTc2YzY5MmNmNDFiNDkyYmM2N2Q0N2E2Njk4NjkvdGFibGU6ODk2ZjI4ZTQ4OTAxNGZlMjk5MDI3YmQwNzM4ZDI5NDIvdGFibGVyYW5nZTo4OTZmMjhlNDg5MDE0ZmUyOTkwMjdiZDA3MzhkMjk0Ml85LTEtMS0xLTA_c150b96a-ccaa-4b53-85d7-df95cb3aaa9b">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80L2ZyYWc6NTk2YTc2YzY5MmNmNDFiNDkyYmM2N2Q0N2E2Njk4NjkvdGFibGU6ODk2ZjI4ZTQ4OTAxNGZlMjk5MDI3YmQwNzM4ZDI5NDIvdGFibGVyYW5nZTo4OTZmMjhlNDg5MDE0ZmUyOTkwMjdiZDA3MzhkMjk0Ml8xMC0xLTEtMS0w_1217e832-7017-4963-8cb4-e1fb33128003">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80L2ZyYWc6NTk2YTc2YzY5MmNmNDFiNDkyYmM2N2Q0N2E2Njk4NjkvdGFibGU6ODk2ZjI4ZTQ4OTAxNGZlMjk5MDI3YmQwNzM4ZDI5NDIvdGFibGVyYW5nZTo4OTZmMjhlNDg5MDE0ZmUyOTkwMjdiZDA3MzhkMjk0Ml8xMS0xLTEtMS0w_558bc328-6d49-4772-b392-cdf516602924">false</dei:AmendmentFlag>
    <sls:BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones
      contextRef="id0a9aad2208d4af3861b03029b413458_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjU0Nw_9e3118b3-4753-413f-9bca-561259d241ac">P5Y</sls:BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones>
    <dei:DocumentType
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDg0_03b88e82-ae69-4de1-b085-a4ee1d3fd600">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6ZGY1OWQ4ZTYxN2YzNDYzYTlmMTY2YWRlYjJhZmJlMTIvdGFibGVyYW5nZTpkZjU5ZDhlNjE3ZjM0NjNhOWYxNjZhZGViMmFmYmUxMl8wLTAtMS0xLTA_d7b66ed5-8c47-4723-a9f3-db91f6f76972">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18xOTE_d6f0b814-3440-4400-8cd0-6263cec49a05">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6OTk3MDgwMWY0ZTExNDllNGEzZWUxODJiMjYxMWMwODIvdGFibGVyYW5nZTo5OTcwODAxZjRlMTE0OWU0YTNlZTE4MmIyNjExYzA4Ml8wLTAtMS0xLTA_fbe1feb5-522a-4735-b7b8-4f03bf7e0c4d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDg4_94f13906-ec19-4017-8d6f-a7fb762fa449">001-33958</dei:EntityFileNumber>
    <dei:EntityFileNumber
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDg4_f6c7a421-d3b6-48f5-8edc-aa1bc3d84b9d">001-33958</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDg1_24908d17-6057-44ca-9dbd-f5b26f75a4b2">SELLAS Life Sciences Group, Inc.</dei:EntityRegistrantName>
    <dei:EntityRegistrantName
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDg1_e625ffae-dca7-44c0-88af-7df26ca26d61">SELLAS Life Sciences Group, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6ZGY3NWJhOTZkYTgxNDlhYzhjZjhhZTVjMjhkOTdiNmQvdGFibGVyYW5nZTpkZjc1YmE5NmRhODE0OWFjOGNmOGFlNWMyOGQ5N2I2ZF8wLTAtMS0xLTA_82bab763-b37b-4e12-b3e7-210806c5b212">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6ZGY3NWJhOTZkYTgxNDlhYzhjZjhhZTVjMjhkOTdiNmQvdGFibGVyYW5nZTpkZjc1YmE5NmRhODE0OWFjOGNmOGFlNWMyOGQ5N2I2ZF8wLTItMS0xLTA_3f72ef83-4994-4b25-8bcb-6192c35050f1">20-8099512</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDg2_5a7894e7-4f08-4145-85de-46c5d0357a8a">7 Times Square, Suite 2503,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDc5_e4cc44b8-bc98-4ca7-81b7-ed10d5cae9fe">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDgw_92e7d1fe-c0a9-473b-9883-85ab5f41a46b">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18zNjg_f6f9e3fe-f8df-40c6-bf53-748a7ef229c8">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18zNzI_81b8e956-365e-44e7-9eb9-2dc3c7afd6a5">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDgx_d4d8b7aa-c9f8-45de-a36e-b1062746f7a1">200-5278</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6NjQzYWU4MDI1YmNmNDIxZDk4ODgwNWVmMmFlZjQyMzkvdGFibGVyYW5nZTo2NDNhZTgwMjViY2Y0MjFkOTg4ODA1ZWYyYWVmNDIzOV8xLTAtMS0xLTA_4024339b-50e5-45bf-b617-9271a43c2f34">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6NjQzYWU4MDI1YmNmNDIxZDk4ODgwNWVmMmFlZjQyMzkvdGFibGVyYW5nZTo2NDNhZTgwMjViY2Y0MjFkOTg4ODA1ZWYyYWVmNDIzOV8xLTEtMS0xLTA_34b089bd-c4a5-4ecd-8e46-2c4f1061790b">SLS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6NjQzYWU4MDI1YmNmNDIxZDk4ODgwNWVmMmFlZjQyMzkvdGFibGVyYW5nZTo2NDNhZTgwMjViY2Y0MjFkOTg4ODA1ZWYyYWVmNDIzOV8xLTItMS0xLTA_6389dd70-098a-45c1-92eb-0c8dec27d12e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDg5_84da9cf4-5e89-45e9-af1c-19e794c2f8e6">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDgy_5c9a983b-1e2a-4765-85bd-8f9bec4ce296">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6ZjQ2ZTE4N2ZjYTliNGZlZThhZTQ4Y2NkZTc4NGMzY2EvdGFibGVyYW5nZTpmNDZlMTg3ZmNhOWI0ZmVlOGFlNDhjY2RlNzg0YzNjYV8yLTAtMS0xLTA_a896f792-4ceb-4667-affd-b663e90cca58">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6ZjQ2ZTE4N2ZjYTliNGZlZThhZTQ4Y2NkZTc4NGMzY2EvdGFibGVyYW5nZTpmNDZlMTg3ZmNhOWI0ZmVlOGFlNDhjY2RlNzg0YzNjYV8yLTYtMS0xLTA_cce61055-926a-44b4-a8f1-e0800a6c60fd">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGFibGU6ZjQ2ZTE4N2ZjYTliNGZlZThhZTQ4Y2NkZTc4NGMzY2EvdGFibGVyYW5nZTpmNDZlMTg3ZmNhOWI0ZmVlOGFlNDhjY2RlNzg0YzNjYV80LTItMS0xLTA_084b6d57-66ec-4a94-8cee-e32bd2533d0b">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDkw_41fdaeb9-6c9c-4684-ad06-9e3f0bd427ef">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i9a892d5d25b8461b97fc446b4c189943_I20210812"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xL2ZyYWc6NTlhNjhlOGE4MzIwNGY0ZWE5M2FhYTIwYjQ5YjhhYTMvdGV4dHJlZ2lvbjo1OWE2OGU4YTgzMjA0ZjRlYTkzYWFhMjBiNDliOGFhM18yMDUy_1345a8f2-e654-41a0-8229-66f15cc1552c"
      unitRef="shares">15873941</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNC0xLTEtMS0w_d5290e25-286e-4688-9892-ea11eeff9a9a"
      unitRef="usd">29917000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNC0zLTEtMS0w_dc4be7fc-51b7-4234-9ee0-7572efde1a97"
      unitRef="usd">35302000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNS0xLTEtMS0w_80516b8f-3a29-475d-b2ae-f17bd4bae76e"
      unitRef="usd">100000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNS0zLTEtMS0w_6ec93752-abc5-4170-866d-0965bf160d9d"
      unitRef="usd">100000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <sls:StockSubscriptionReceivableCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNi0xLTEtMS0w_4fc7ae6e-ccd6-4a62-b14f-65f20c4281b7"
      unitRef="usd">2240000</sls:StockSubscriptionReceivableCurrent>
    <sls:StockSubscriptionReceivableCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNi0zLTEtMS0w_dd59714c-0a0d-4a2b-a52c-c99a73c4feef"
      unitRef="usd">0</sls:StockSubscriptionReceivableCurrent>
    <us-gaap:CapitalizedContractCostNetCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfOS0xLTEtMS0w_30292dd4-0dcc-4e13-a0db-fd6fdbb2089c"
      unitRef="usd">0</us-gaap:CapitalizedContractCostNetCurrent>
    <us-gaap:CapitalizedContractCostNetCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfOS0zLTEtMS0w_891b9e71-6c57-4b61-8a2c-a7439ce0750f"
      unitRef="usd">1128000</us-gaap:CapitalizedContractCostNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTAtMS0xLTEtMA_bc85a0bd-296b-4d29-9706-c26f2137ce1d"
      unitRef="usd">2318000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTAtMy0xLTEtMA_2f5d943a-5143-40c8-9693-5d2c9bd6ff6d"
      unitRef="usd">395000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTItMS0xLTEtMA_d3523582-e8db-4a8c-a53e-bd38c4387711"
      unitRef="usd">34575000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTItMy0xLTEtMA_cbf68d6b-2142-4281-b722-1866d8bda2f1"
      unitRef="usd">36925000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTQtMS0xLTEtMA_f27b2d72-261d-4c73-834d-5b4050eb3189"
      unitRef="usd">812000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTQtMy0xLTEtMA_656c9c92-2d0d-404f-b50e-00c900569be3"
      unitRef="usd">896000</us-gaap:OperatingLeaseRightOfUseAsset>
    <sls:InProcessResearchDevelopment
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTUtMS0xLTEtMA_2847e417-9ae6-4a1c-b9e3-d1751111c551"
      unitRef="usd">5700000</sls:InProcessResearchDevelopment>
    <sls:InProcessResearchDevelopment
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTUtMy0xLTEtMA_62e5c3c6-a721-451f-b408-2d81c618301a"
      unitRef="usd">5700000</sls:InProcessResearchDevelopment>
    <us-gaap:Goodwill
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTktMS0xLTEtMA_168e669b-43da-4f87-bddc-377fe5f52af1"
      unitRef="usd">1914000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMTktMy0xLTEtMA_38d0169a-97f8-46a6-b479-5ab28bda48d2"
      unitRef="usd">1914000</us-gaap:Goodwill>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjAtMS0xLTEtMA_67919464-c3fe-4f3d-a75f-4ad990916dd1"
      unitRef="usd">623000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjAtMy0xLTEtMA_f1871431-87f1-424a-a5f2-1fcdb2a2672a"
      unitRef="usd">614000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjEtMS0xLTEtMA_8e2ae47d-7657-4bca-ac6a-bf7ca6557d3b"
      unitRef="usd">43624000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjEtMy0xLTEtMA_242e13e2-2fc9-4f00-98f0-590d65b4bd68"
      unitRef="usd">46049000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjYtMS0xLTEtMA_4056e609-5884-4256-b0f0-da76214a1319"
      unitRef="usd">2276000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjYtMy0xLTEtMA_196f7a1c-3367-4258-aef9-f4b669fb75da"
      unitRef="usd">4657000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjctMS0xLTEtMA_a649b580-8de4-4388-8b61-9d31574aab48"
      unitRef="usd">1781000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjctMy0xLTEtMA_b295c00e-e67f-42b5-b53b-d9d9d3552097"
      unitRef="usd">1913000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjktMS0xLTEtMA_31d8d639-769a-4a65-8e82-62c5b2beef0b"
      unitRef="usd">182000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMjktMy0xLTEtMA_d4fd9c61-9921-4a59-8d60-5a05992643d0"
      unitRef="usd">166000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzAtMS0xLTEtMA_57083ebc-005f-41f2-bd47-54c4ccbbcb6c"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzAtMy0xLTEtMA_3f2cfde7-58c9-4ca7-823e-a338a68b8d42"
      unitRef="usd">5600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzItMS0xLTEtMA_bab4da5e-ae4d-4aee-bea2-aa164a78b957"
      unitRef="usd">4239000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzItMy0xLTEtMA_7ec8617f-a046-4651-8ba4-41f7ea04db63"
      unitRef="usd">12336000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzQtMS0xLTEtMA_a246bbd9-3e5f-4c7a-b911-af3293b7da2b"
      unitRef="usd">721000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzQtMy0xLTEtMA_6dd294cf-2c80-47f0-bbd5-0b27ec7d72dc"
      unitRef="usd">825000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzUtMS0xLTEtMA_94171886-e3bf-4569-b8a1-37fc4428bc4d"
      unitRef="usd">239000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzUtMy0xLTEtMA_ec67845d-a8c0-4e54-9a7d-3b39332833fe"
      unitRef="usd">239000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <sls:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzYtMS0xLTEtMA_46a31d4c-d062-4e65-bd63-d75fd205f1b0"
      unitRef="usd">114000</sls:FairValueOfWarrantsPotentiallySettleableInCash>
    <sls:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzYtMy0xLTEtMA_28589249-b31b-4e63-a402-71cded683e47"
      unitRef="usd">55000</sls:FairValueOfWarrantsPotentiallySettleableInCash>
    <sls:ContingentPurchasePriceConsiderationNetOfCurrentPortion
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzctMS0xLTEtMA_3c87d984-4e72-4030-ad22-791ee0fd2130"
      unitRef="usd">4896000</sls:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
    <sls:ContingentPurchasePriceConsiderationNetOfCurrentPortion
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzctMy0xLTEtMA_205777a1-7da4-4465-a5f5-c868cb9e4bb0"
      unitRef="usd">4633000</sls:ContingentPurchasePriceConsiderationNetOfCurrentPortion>
    <us-gaap:Liabilities
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzktMS0xLTEtMA_00105100-ef77-4547-b024-16f105ba56dc"
      unitRef="usd">10209000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfMzktMy0xLTEtMA_3180ef47-3a59-4c4f-98fc-95455193055e"
      unitRef="usd">18088000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDAtMS0xLTEtMA_3de36037-e4c1-42e2-95d5-87c179226c49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDAtMy0xLTEtMA_f7bff818-e301-4dc3-a1b3-aba9f77c9732"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzIx_7713f8ea-0db8-4694-bf83-f85ab0692937"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzIx_a28ae16a-c385-4253-8f7e-ca389543c047"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzM1_0df6a240-c2fb-401c-bf3c-abca38a69c11"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzM1_cf1fb8d9-81f0-4454-a336-ac2512e9619d"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibf4612fe88f64808b8d0d2c12012d345_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzk1_537c4839-1094-4a81-bdcd-da5c5b7b1a6d"
      unitRef="shares">17500</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib69a37222fd941b78bea430bbe0462bd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzk1_eef7adae-cd47-4a18-b78e-75a41ef05b5a"
      unitRef="shares">17500</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzExNw_0ec95f00-52e2-43d6-9965-89949729b967"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzExNw_185a53fe-cd35-4f0b-8502-5ab776fc6efc"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzExNw_48f517c9-1bb1-44a6-8afa-e867c173d925"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMC0xLTEtMC90ZXh0cmVnaW9uOmFhODVkYjM5MWMyOTQ2NzBhMTI4NjQyY2MwZGUwNzkyXzExNw_a71242eb-5337-459c-8f5b-6e563f4459a4"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMS0xLTEtMA_9f765783-9e7a-402c-b7b9-ac85d3ccc3de"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDItMy0xLTEtMA_707e9eae-83a6-42aa-a8c6-d247c49a518c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzE4_1a6a5c34-c362-40b7-a3ba-ed2244b08956"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzE4_ec0264e3-df5c-4a5e-ac42-e01deb03280d"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzMy_01496779-732c-41c5-937c-df77aa9063b7"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzMy_2765e9ae-2ab5-4137-80c2-7299cfda9502"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzU0_7884d571-c2c7-43a2-9ab9-eaa186106a8b"
      unitRef="shares">15873941</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzU0_b1aa6002-c6be-47ca-9051-4a77eabab04d"
      unitRef="shares">15873941</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzYx_12743c1e-6912-479b-980a-54daf712afeb"
      unitRef="shares">14254554</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMC0xLTEtMC90ZXh0cmVnaW9uOjg3YWRkNWJkZWM0OTQ4YjlhYzBlODI5MTUxN2RkYWM3XzYx_28f0976f-5efa-4563-b012-d17a2ffff284"
      unitRef="shares">14254554</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMS0xLTEtMA_77c28031-9bd2-4a8b-b234-93e1da194961"
      unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDMtMy0xLTEtMA_b98c6884-029a-4e8e-8b5f-513c68600a45"
      unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDQtMS0xLTEtMA_3ef30dc8-5d8d-443d-ae2d-caa1ff8f9146"
      unitRef="usd">158333000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDQtMy0xLTEtMA_d40f1a62-a4a9-4b6c-9728-b00954bd48ec"
      unitRef="usd">145864000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDUtMS0xLTEtMA_4fe1e780-7ce4-44bd-8ae0-1c38fa74cfdb"
      unitRef="usd">-124920000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDUtMy0xLTEtMA_dd787028-e241-4fe9-b70c-b9e1b5eeb6c3"
      unitRef="usd">-117904000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDctMS0xLTEtMA_7dcd25ad-0b95-4da2-9a4e-2f87fd87c7ef"
      unitRef="usd">33415000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDctMy0xLTEtMA_7302b952-29b4-4107-8e37-b55be755b71b"
      unitRef="usd">27961000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDgtMS0xLTEtMA_32abc0b1-d424-4f8c-8923-7b048b81eeb8"
      unitRef="usd">43624000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8xOS9mcmFnOjI3MWE2NTdkMjFhZjRjYjBiMzNkZTE4YWIxMWNiMGMyL3RhYmxlOjZmY2Y0NjYxNzcyNTRkMGU4N2I3OWRiNzNkYzlhMTQ3L3RhYmxlcmFuZ2U6NmZjZjQ2NjE3NzI1NGQwZTg3Yjc5ZGI3M2RjOWExNDdfNDgtMy0xLTEtMA_ba84b93a-46e8-4e0c-b473-37750df78c97"
      unitRef="usd">46049000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMi0xLTEtMS0w_8fd1a7b1-7c90-4a02-9115-b9239b12ac1e"
      unitRef="usd">1900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMi0zLTEtMS0w_7a678204-7fc3-49f7-b61c-0f40467eded5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMi01LTEtMS0w_46d2279c-8bea-4615-aedb-281fd159c58e"
      unitRef="usd">7600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMi03LTEtMS0w_8f0e6cd8-598a-43c8-9cb6-671c03131f65"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNC0xLTEtMS0w_c739b611-e380-43cf-8ea3-1b9d2ecb6c27"
      unitRef="usd">100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNC0zLTEtMS0w_79e184c5-16d2-43fb-b530-48632d5f11e3"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNC01LTEtMS0w_d5c69b27-9b5a-44a5-9e8b-10dc4217f2ce"
      unitRef="usd">200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNC03LTEtMS0w_3d288565-ff54-44e1-b1cf-d71035ec3bad"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNS0xLTEtMS0w_1d3cc98d-b6df-43f4-ad21-8c80c5a48095"
      unitRef="usd">3456000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNS0zLTEtMS0w_e2fcc02b-6dda-49aa-a2b7-e5021256e157"
      unitRef="usd">2280000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNS01LTEtMS0w_2c12e275-0db4-44d8-a4f8-b77b9d90e247"
      unitRef="usd">7740000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNS03LTEtMS0w_2bf0844a-2e01-4e8f-94ed-45cd6f406160"
      unitRef="usd">4144000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNi0xLTEtMS0w_5a1e6bd2-1bb3-44e1-bd18-1d07df028807"
      unitRef="usd">2797000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNi0zLTEtMS0w_b85df19e-730d-4b07-b28c-830c79bdc5f8"
      unitRef="usd">1987000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNi01LTEtMS0w_b479ddf7-61b5-4239-88c6-1759394104d8"
      unitRef="usd">6358000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfNi03LTEtMS0w_172bc47a-5fd2-4361-8505-1f79434d0145"
      unitRef="usd">4187000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOC0xLTEtMS0w_cef8ee54-83a2-44c7-bdba-d995f903e159"
      unitRef="usd">6353000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOC0zLTEtMS0w_fd85a601-84a4-447a-a5d8-065cad4d3903"
      unitRef="usd">4267000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOC01LTEtMS0w_e1c822c7-97b6-4400-9803-01820b8d641e"
      unitRef="usd">14298000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOC03LTEtMS0w_877ce647-38b9-466f-b721-60efd07892d3"
      unitRef="usd">8331000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOS0xLTEtMS0w_6d45b1fd-d073-41cc-abb6-e09ca1fafb22"
      unitRef="usd">-4453000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOS0zLTEtMS0w_944203eb-f4c3-44f6-8390-0ef67167514e"
      unitRef="usd">-4267000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOS01LTEtMS0w_656fb4e3-2f62-4283-815a-38ecf023079e"
      unitRef="usd">-6698000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfOS03LTEtMS0w_90d4a29d-5576-454f-8fbe-c9559bd4b19b"
      unitRef="usd">-8331000</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTItMS0xLTEtMA_de2e2de9-437a-4e85-b6d1-7b28ad5b7161"
      unitRef="usd">28000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTItMy0xLTEtMA_f6518495-a5fd-407f-bcd4-e1961d78537c"
      unitRef="usd">16000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTItNS0xLTEtMA_b7b6b720-6d36-42ba-a96b-f43e307eeaf6"
      unitRef="usd">59000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTItNy0xLTEtMA_02b4089f-557b-401a-a214-bde285388e0c"
      unitRef="usd">-19000</us-gaap:FairValueAdjustmentOfWarrants>
    <sls:ChangeInFairValueOfContingentPurchasePriceConsideration
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTQtMS0xLTEtMA_7e410067-6c4a-451e-9ebd-72e76c8df042"
      unitRef="usd">-134000</sls:ChangeInFairValueOfContingentPurchasePriceConsideration>
    <sls:ChangeInFairValueOfContingentPurchasePriceConsideration
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTQtMy0xLTEtMA_9a480e99-46bb-4c5b-ab1c-e406da51b878"
      unitRef="usd">-143000</sls:ChangeInFairValueOfContingentPurchasePriceConsideration>
    <sls:ChangeInFairValueOfContingentPurchasePriceConsideration
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTQtNS0xLTEtMA_f3b24d4c-e85e-41a2-995a-8369de34ce87"
      unitRef="usd">-263000</sls:ChangeInFairValueOfContingentPurchasePriceConsideration>
    <sls:ChangeInFairValueOfContingentPurchasePriceConsideration
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTQtNy0xLTEtMA_80dbf39d-bd78-40b7-9be9-9c5c7f7f1e5b"
      unitRef="usd">-281000</sls:ChangeInFairValueOfContingentPurchasePriceConsideration>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTctMS0xLTEtMA_31dcc68f-6cc8-44a9-b3a5-9b54963a88f9"
      unitRef="usd">2000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTctMy0xLTEtMA_f52c3ddb-18ef-4041-87f5-60af76d96dfe"
      unitRef="usd">1000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTctNS0xLTEtMA_31eb687d-b665-4697-967a-ea1831b451d9"
      unitRef="usd">4000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTctNy0xLTEtMA_3bfe2918-4902-43c5-99ea-5912d60a0f46"
      unitRef="usd">25000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTgtMS0xLTEtMA_aa3172d7-a6f2-4070-9b81-049c7f9cc109"
      unitRef="usd">-160000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTgtMy0xLTEtMA_76b3cd41-eab6-4ae9-8d1b-62bd4dadbadc"
      unitRef="usd">-158000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTgtNS0xLTEtMA_9f350e07-2ed4-4633-8fcc-164910a93813"
      unitRef="usd">-318000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMTgtNy0xLTEtMA_0f9a9372-cb76-4bee-bc25-51410d16565a"
      unitRef="usd">-237000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjQtMS0xLTEtMA_d96add2b-6127-4158-a6e6-52d941b8ee6e"
      unitRef="usd">-4613000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjQtMy0xLTEtMA_15f72bb2-0417-4487-be72-37c815f6bb86"
      unitRef="usd">-4425000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjQtNS0xLTEtMA_10a1a9c0-6d62-49c1-a5d5-333304246015"
      unitRef="usd">-7016000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjQtNy0xLTEtMA_b6eb1825-5fc3-4150-8c71-cd170e2405ca"
      unitRef="usd">-8568000</us-gaap:NetIncomeLoss>
    <sls:DividendArisingFromWarrantModifications
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjctMS0xLTEtMA_f59d9ca9-ad53-490f-8ed0-4368049c445c"
      unitRef="usd">0</sls:DividendArisingFromWarrantModifications>
    <sls:DividendArisingFromWarrantModifications
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjctMy0xLTEtMA_9aff95ae-26dd-4eb1-8168-e5d1d1645c4e"
      unitRef="usd">0</sls:DividendArisingFromWarrantModifications>
    <sls:DividendArisingFromWarrantModifications
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjctNS0xLTEtMA_6badab47-fb1a-4e8c-bd5c-cf0f0a0578ff"
      unitRef="usd">0</sls:DividendArisingFromWarrantModifications>
    <sls:DividendArisingFromWarrantModifications
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjctNy0xLTEtMA_3f5d13fa-761f-4043-a04d-9971ee457b58"
      unitRef="usd">78000</sls:DividendArisingFromWarrantModifications>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtMS0xLTEtMA_61675c91-4635-41fd-8bf5-3a5602e8a2b3"
      unitRef="usd">-4613000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtMS0xLTEtMA_9a343ad0-2855-40c4-aa65-e2c5b6d0040e"
      unitRef="usd">-4613000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtMy0xLTEtMA_909a9721-ff79-4aff-9587-e10d45cec7fb"
      unitRef="usd">-4425000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtMy0xLTEtMA_d97beb5c-7f27-436a-8b09-23d96f0e68d7"
      unitRef="usd">-4425000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtNS0xLTEtMA_1165aee4-fd64-4cfb-8b3e-efaed380a2c2"
      unitRef="usd">-7016000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtNS0xLTEtMA_a11cf32c-e11e-426f-b247-008a8df063d4"
      unitRef="usd">-7016000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtNy0xLTEtMA_1b73711d-b494-4091-9731-fbca93cd7a6b"
      unitRef="usd">-8646000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMjgtNy0xLTEtMA_6a0c1af1-98f3-4c53-a5cb-1d58387c77e9"
      unitRef="usd">-8646000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtMS0xLTEtMA_2dad3bf3-af0a-454c-9cc3-2229c72c8b2d"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtMS0xLTEtMA_91fb524b-8ba0-46f3-8c4b-03b36424e24e"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtMy0xLTEtMA_c02aa38d-6ee9-43a5-9b71-c6c8f784ac62"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtMy0xLTEtMA_e0c406d4-91b3-4279-8a94-e49c74d3575f"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtNS0xLTEtMA_0a79d185-d9a8-4780-88ca-ef5f534f83d6"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtNS0xLTEtMA_605278f4-d0e9-4b0b-8db6-3d313166b044"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtNy0xLTEtMA_225ac51f-9751-48dd-bcc5-c8eb3475906b"
      unitRef="usdPerShare">-1.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzMtNy0xLTEtMA_71921689-1b16-436e-a6eb-698ad44846ce"
      unitRef="usdPerShare">-1.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtMS0xLTEtMA_6b3a800e-9122-4e2a-8b32-068ab9d6c9ad"
      unitRef="shares">15270288</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtMS0xLTEtMA_815c84c7-1696-4722-80aa-90ba93e59ce4"
      unitRef="shares">15270288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtMy0xLTEtMA_15e5507b-dd8f-48ec-9bdd-e4fc369d7dc1"
      unitRef="shares">6717900</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtMy0xLTEtMA_acd7f150-957e-4ae0-aff4-a2f3b4413097"
      unitRef="shares">6717900</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtNS0xLTEtMA_0ae09cb1-1b72-443f-baf1-739e2899240b"
      unitRef="shares">15074887</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtNS0xLTEtMA_33d5d6a5-4815-44b3-b68c-6f5c70b10da7"
      unitRef="shares">15074887</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtNy0xLTEtMA_1384f45e-59bb-4bfb-8aae-d8419c6f9136"
      unitRef="shares">6546440</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yMi9mcmFnOjJmNmRmMGU1ZTZiYTQ5MzZhMDY4MmI1NWI1YjYwM2JkL3RhYmxlOmIxMTJmY2E5MTViNjQ2MGU4YmMwYmUxYjc4ZjJiNDA2L3RhYmxlcmFuZ2U6YjExMmZjYTkxNWI2NDYwZThiYzBiZTFiNzhmMmI0MDZfMzQtNy0xLTEtMA_ad56cf1f-1081-4942-8a79-633f99c5b32f"
      unitRef="shares">6546440</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i9d02464dad0041958b0fab78708a2174_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMy01LTEtMS0w_99186aff-0d18-456a-b2e7-5dc1075c1b38"
      unitRef="shares">15084754</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9d02464dad0041958b0fab78708a2174_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMy03LTEtMS0w_8e50b56f-df81-420f-969d-639844d7c02c"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if863226dc0724e56bf43f3b1ff67fffc_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMy05LTEtMS0w_80f0fcea-2c88-4fd6-a12d-487d7236992f"
      unitRef="usd">149047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7d744a0c3d154b118fd1398efd967c38_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMy0xMS0xLTEtMA_ba0b18dd-8004-4242-85f7-2cc27ffd2e11"
      unitRef="usd">-120307000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i55be4a1b9d7945e1a7df3335dc287d83_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMy0xNS0xLTEtMA_1bc16f05-5e9b-45d3-b8ef-63539ae80f10"
      unitRef="usd">28742000</us-gaap:StockholdersEquity>
    <sls:StockIssuedDuringPeriodSharesCommonStockandWarrants
      contextRef="id0549b9745c54a4a82c51e4b803e22ca_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfNC01LTEtMS0w_c610a9bd-6244-4341-9156-bb2b44fde557"
      unitRef="shares">786927</sls:StockIssuedDuringPeriodSharesCommonStockandWarrants>
    <sls:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="i274e8814ad244aaa9f27ee58126839b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfNC05LTEtMS0w_1ffc23fe-3a54-45ba-9065-2cafca5bb43d"
      unitRef="usd">9005000</sls:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <sls:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfNC0xNS0xLTEtMA_a3bf93dc-c84f-4e1a-a11a-8fc4ceaf3ea3"
      unitRef="usd">9005000</sls:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id0549b9745c54a4a82c51e4b803e22ca_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfNS01LTEtMS0w_09d372e4-378a-43b0-bbe8-3615d977e96b"
      unitRef="shares">2260</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i274e8814ad244aaa9f27ee58126839b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfNS05LTEtMS0w_1ab6c0e2-261b-4bd2-9c43-03978262f9b3"
      unitRef="usd">17000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfNS0xNS0xLTEtMA_3dbe94fb-c105-4f2b-bef0-b34e5bd5879c"
      unitRef="usd">17000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i274e8814ad244aaa9f27ee58126839b1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfOS05LTEtMS0w_81369b18-b0b9-43fb-bdd4-154e9315fcac"
      unitRef="usd">264000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfOS0xNS0xLTEtMA_ca64707e-04a5-44ab-952c-763e919d278d"
      unitRef="usd">264000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i2d8817680df2485bab16391f20f795f3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTAtMTEtMS0xLTA_815ae175-a6ba-42f8-aecb-3e5fd8eadd61"
      unitRef="usd">-4613000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTAtMTUtMS0xLTA_3d5c2f3f-f076-4a94-858e-a1629caee847"
      unitRef="usd">-4613000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i9bb7f8716a0d4caaa768d3669f37d68e_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTEtNS0xLTEtMA_adc3005f-b8b1-4407-9dbb-1234e21361b4"
      unitRef="shares">15873941</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9bb7f8716a0d4caaa768d3669f37d68e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTEtNy0xLTEtMA_16c704f4-2180-4e84-bba5-ecd8b43ac731"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icbab7f5989004cf9a988181f7b725951_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTEtOS0xLTEtMA_25cc0d4e-d6d8-4aca-8854-f8fdfe01cb2c"
      unitRef="usd">158333000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i31ce168dc5e644718859ca9b623e68b2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTEtMTEtMS0xLTA_ce7acb5c-ba6b-4fe3-ad81-2b979ba2a74f"
      unitRef="usd">-124920000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTEtMTUtMS0xLTA_1989710e-9f44-44a6-98d8-eec99ef8fbda"
      unitRef="usd">33415000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i61c430eb60c04fd480ba1b6c3c09ab45_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTYtNS0xLTEtMA_5e23585b-ff5d-45d5-853b-1e1bed9a2024"
      unitRef="shares">14254554</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i61c430eb60c04fd480ba1b6c3c09ab45_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTYtNy0xLTEtMA_b812d65f-eec9-4b0b-baa6-57ee731b610c"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id3800086248c45cebf643a6fcf7192a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTYtOS0xLTEtMA_b942449a-7c43-48c0-9b87-597c1292628a"
      unitRef="usd">145864000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iefbe1927948046feaeb6e3e3ce6c19d5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTYtMTEtMS0xLTA_35472348-f4b2-4138-90f5-c847aebcf7f2"
      unitRef="usd">-117904000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTYtMTUtMS0xLTA_0d41acc7-f00c-4222-92dc-2ae002469e5a"
      unitRef="usd">27961000</us-gaap:StockholdersEquity>
    <sls:StockIssuedDuringPeriodSharesCommonStockandWarrants
      contextRef="i0b8fae89d58849ac8cd70c40f8a2da16_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTctNS0xLTEtMA_ac1dfd6a-5c63-4bc8-8872-c0d7ba4fd91e"
      unitRef="shares">786927</sls:StockIssuedDuringPeriodSharesCommonStockandWarrants>
    <sls:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="i3bbe90aea6ce4ba897f9a44f95d343af_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTctOS0xLTEtMA_15b9cc10-0c3e-4e4d-ba1b-dcbf8a6db3c5"
      unitRef="usd">9005000</sls:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <sls:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMTctMTUtMS0xLTA_487bed4f-4072-4ff7-bc92-7e40cff9d095"
      unitRef="usd">9005000</sls:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0b8fae89d58849ac8cd70c40f8a2da16_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzItNS0xLTEtMA_62b9c314-cb4b-4a06-b23a-20abfce963c7"
      unitRef="shares">832460</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0b8fae89d58849ac8cd70c40f8a2da16_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzItNy0xLTEtMA_27840fe6-73f7-4788-818d-8c779ba4a779"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i3bbe90aea6ce4ba897f9a44f95d343af_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzItOS0xLTEtMA_6c98647a-6f9d-428c-a356-f3e747fd5267"
      unitRef="usd">3016000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzItMTUtMS0xLTA_92263eb8-b041-43da-a900-2f1cff379333"
      unitRef="usd">3017000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3bbe90aea6ce4ba897f9a44f95d343af_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzYtOS0xLTEtMA_34898026-8e8c-4a6f-a617-6138cb0e9dab"
      unitRef="usd">448000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzYtMTUtMS0xLTA_fcff96e2-d4cc-44da-b87a-d3022c393124"
      unitRef="usd">448000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i70c599afdc614f3482861b5c48fd1e0a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzgtMTEtMS0xLTA_c487c86c-0c92-408b-b4a8-dadc1746ea57"
      unitRef="usd">-7016000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzgtMTUtMS0xLTA_c4a56b8c-cf02-4ae8-a7ee-2cd5038b8ed7"
      unitRef="usd">-7016000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i9bb7f8716a0d4caaa768d3669f37d68e_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzktNS0xLTEtMA_81930e1d-4af9-4010-b9d8-57ac4ad92333"
      unitRef="shares">15873941</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9bb7f8716a0d4caaa768d3669f37d68e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzktNy0xLTEtMA_b59c2ada-f104-4b15-9cb0-22edf892b877"
      unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icbab7f5989004cf9a988181f7b725951_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzktOS0xLTEtMA_90e00d49-3c3a-4c41-afd2-3c7702db30be"
      unitRef="usd">158333000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i31ce168dc5e644718859ca9b623e68b2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzktMTEtMS0xLTA_b5356c83-5266-4efd-8853-0f0583772a5d"
      unitRef="usd">-124920000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRkZDA1NDUxM2M5NjQzNDU5MWU1YWM1OGY2YmU1ZjlmL3RhYmxlcmFuZ2U6ZGRkMDU0NTEzYzk2NDM0NTkxZTVhYzU4ZjZiZTVmOWZfMzktMTUtMS0xLTA_4d28616f-ae8a-47fa-a508-609f3df8d5df"
      unitRef="usd">33415000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ibcdc516de7334f91b176b211161b8e6e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNC01LTEtMS0w_4948232a-8d97-4517-bb04-d062ee704271"
      unitRef="shares">6717900</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibcdc516de7334f91b176b211161b8e6e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNC03LTEtMS0w_a5a7f297-e6bc-449a-92ca-bda8f4602b5c"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icfda986c11714d6bb1d5b24be92e2a2f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNC05LTEtMS0w_c769903b-a5eb-47a4-a8a3-9a733d27b66d"
      unitRef="usd">113351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia79f32850e854189b3295d67b790dcdf_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNC0xMS0xLTEtMA_6dc4d405-18b6-409a-af20-bc1b49e867cd"
      unitRef="usd">-105290000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i660f1425ddfa4dda85f51c113de04b3e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNC0xNS0xLTEtMA_691e09e8-c0aa-4f1a-a3af-dc0ef6bfedd3"
      unitRef="usd">8062000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9b35a3bd1e0a4431b15acba6941f5f47_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjAtOS0xLTEtMA_ad28d0fe-6eaf-45f5-af3f-76504ac528be"
      unitRef="usd">146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjAtMTUtMS0xLTA_cf797d95-b9a0-47c6-8308-a99bab84198b"
      unitRef="usd">146000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i0fcb89f394a14d90a5ea1862dbd7af35_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjItMTEtMS0xLTA_11b1b410-18af-43be-b7cc-5be6e10cbca4"
      unitRef="usd">-4425000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjItMTUtMS0xLTA_6a039072-77cb-4658-9e14-94d04e7f4575"
      unitRef="usd">-4425000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i71259de5a94b42459fed552bab9b67b8_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjMtNS0xLTEtMA_9d25d86a-fcbc-4457-8f64-1a5e0944a18b"
      unitRef="shares">6717900</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i71259de5a94b42459fed552bab9b67b8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjMtNy0xLTEtMA_b909929a-3c68-49c2-b37d-bd72bb41c1c9"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibedd4733b3614b92b8f20aa69691c575_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjMtOS0xLTEtMA_350ccf36-3176-49b1-8aa2-34380ac0c16d"
      unitRef="usd">113497000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2be78beb508f4988ae137bb70fb5e7c4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjMtMTEtMS0xLTA_fd8ae7e3-9f0e-4c52-9a0b-5cd362a9b628"
      unitRef="usd">-109715000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icce1dd99c16b4ec291627c253ff14547_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjMtMTUtMS0xLTA_41ff6e0d-02db-4339-acad-4078bfccaa3d"
      unitRef="usd">3783000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i8e81f95995f142afb3eaed854f43ad80_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjgtNS0xLTEtMA_88d619c4-7348-4cf9-9a62-300f31947496"
      unitRef="shares">5080100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8e81f95995f142afb3eaed854f43ad80_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjgtNy0xLTEtMA_9c5c37cd-6e11-4693-93c2-ef5edc5c33c4"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iea42d6c53bbb4f8783846d9ea9891e59_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjgtOS0xLTEtMA_9fbd6681-6b60-4186-9e3c-d63da2d3b73e"
      unitRef="usd">107239000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id69a6adea6624cb7b4b433f41d4dc840_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjgtMTEtMS0xLTA_dda65829-2f2b-41c9-8583-fc0ce1ac625a"
      unitRef="usd">-101147000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1ce9074c50144420a1bfafad23e559d3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjgtMTUtMS0xLTA_5d77f897-c70f-42ad-b8d3-197741bc70ff"
      unitRef="usd">6093000</us-gaap:StockholdersEquity>
    <sls:StockIssuedDuringPeriodSharesCommonStockandWarrants
      contextRef="i939616e9c3844b8b81fb48909a77e68e_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjktNS0xLTEtMA_62e3250b-6793-4d04-9201-d8e5f9b2700b"
      unitRef="shares">1189000</sls:StockIssuedDuringPeriodSharesCommonStockandWarrants>
    <sls:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="i2e24296575c34c609ccf83d3d2c409eb_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjktOS0xLTEtMA_1c50f4a5-48c9-4a37-a22a-f50ef4ae2e19"
      unitRef="usd">5963000</sls:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <sls:StockIssuedDuringPeriodValueCommonStockandWarrants
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfMjktMTUtMS0xLTA_8a45d524-70a7-4445-9ddd-7f6daf529f99"
      unitRef="usd">5963000</sls:StockIssuedDuringPeriodValueCommonStockandWarrants>
    <sls:StockIssuedDuringPeriodSharesPrefundedWarrant
      contextRef="i939616e9c3844b8b81fb48909a77e68e_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDMtNS0xLTEtMA_c4b209aa-20b8-4267-ba62-387d88a59beb"
      unitRef="shares">448800</sls:StockIssuedDuringPeriodSharesPrefundedWarrant>
    <sls:StockIssuedDuringPeriodValuePreFundedWarrant
      contextRef="i2e24296575c34c609ccf83d3d2c409eb_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDMtOS0xLTEtMA_12aa4fc3-b00c-4ec2-917d-37ffc1439f9d"
      unitRef="usd">4000</sls:StockIssuedDuringPeriodValuePreFundedWarrant>
    <sls:StockIssuedDuringPeriodValuePreFundedWarrant
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDMtMTUtMS0xLTA_97ad59ad-baf5-451e-aef8-c7ee5339fc24"
      unitRef="usd">4000</sls:StockIssuedDuringPeriodValuePreFundedWarrant>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2e24296575c34c609ccf83d3d2c409eb_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDUtOS0xLTEtMA_355832b3-0de0-4913-93e5-f77cda6bb20d"
      unitRef="usd">291000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDUtMTUtMS0xLTA_01a3f1ef-1ef2-4561-9a70-c09d70a21b72"
      unitRef="usd">291000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i7e84c865aaab4f7d93617acbb36a98b3_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDgtMTEtMS0xLTA_bb8c8058-9679-4c80-bebb-8b04f977ebf1"
      unitRef="usd">-8568000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDgtMTUtMS0xLTA_cbc91a82-bd56-43e2-9257-babf4ec35cab"
      unitRef="usd">-8568000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i71259de5a94b42459fed552bab9b67b8_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDktNS0xLTEtMA_eb8e2933-9276-4714-b29f-f5dec8e2bdb5"
      unitRef="shares">6717900</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i71259de5a94b42459fed552bab9b67b8_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDktNy0xLTEtMA_f5bbec70-48f0-404d-b88f-cfc5e1ba6ca9"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibedd4733b3614b92b8f20aa69691c575_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDktOS0xLTEtMA_396283f1-4931-4fdf-9c4c-42716a9b3beb"
      unitRef="usd">113497000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2be78beb508f4988ae137bb70fb5e7c4_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDktMTEtMS0xLTA_82e9a3af-a70d-4ce6-9543-ca09c786f989"
      unitRef="usd">-109715000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icce1dd99c16b4ec291627c253ff14547_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yNS9mcmFnOjRhYmQ2NWUzNjM2YzRlYzRiY2I5ZDZjYzk2MDQ1YjU5L3RhYmxlOmRhODQzNWMwMTI5MjQ0MGViMzY0NWFiYWFiNzczMDFkL3RhYmxlcmFuZ2U6ZGE4NDM1YzAxMjkyNDQwZWIzNjQ1YWJhYWI3NzMwMWRfNDktMTUtMS0xLTA_0892e8c1-8723-4f59-9c1d-07440d9219f4"
      unitRef="usd">3783000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMy0xLTEtMS0w_6914ba79-96ae-48af-bff8-fd29fb941397"
      unitRef="usd">-7016000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMy0zLTEtMS0w_764c4107-bb20-4c48-aa47-9a755c5a029c"
      unitRef="usd">-8568000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMTUtMS0xLTEtMA_f21731ed-6c92-4ee1-b730-fc0b3ca59fa7"
      unitRef="usd">448000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMTUtMy0xLTEtMA_fbfe9920-c0f7-413a-b959-b02c2af0207a"
      unitRef="usd">291000</us-gaap:ShareBasedCompensation>
    <sls:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMTctMS0xLTEtMA_1f00e25e-727f-442b-a12f-ebd451efb6ec"
      unitRef="usd">0</sls:ChangeInOperatingLeaseRightOfUseAssets>
    <sls:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMTctMy0xLTEtMA_871dea1c-b3e5-4ebd-aa85-ddf8f4735453"
      unitRef="usd">24000</sls:ChangeInOperatingLeaseRightOfUseAssets>
    <sls:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjEtMS0xLTEtMA_63207f70-20b9-411b-8e61-5e362327c1df"
      unitRef="usd">-59000</sls:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
    <sls:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjEtMy0xLTEtMA_d349f1ee-92fc-43ae-9230-662127c73470"
      unitRef="usd">19000</sls:ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings>
    <sls:ChangeInFairValueOfContingentPurchaseConsideration
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjMtMS0xLTEtMA_27d7df3c-909b-447a-9033-931f66ad6fad"
      unitRef="usd">-263000</sls:ChangeInFairValueOfContingentPurchaseConsideration>
    <sls:ChangeInFairValueOfContingentPurchaseConsideration
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjMtMy0xLTEtMA_b2353062-bf95-4b89-8e9d-221802a92497"
      unitRef="usd">-281000</sls:ChangeInFairValueOfContingentPurchaseConsideration>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjgtMS0xLTEtMA_ba14c70c-7ea7-480d-a882-6ad8e1c47176"
      unitRef="usd">-1128000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjgtMy0xLTEtMA_400f500e-c3a4-4053-8403-425088edec30"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjktMS0xLTEtMA_1f69178a-6076-4eab-a993-dc93c73210cc"
      unitRef="usd">1932000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMjktMy0xLTEtMA_00a2d9de-c309-4fda-9253-6779946c6dfc"
      unitRef="usd">1383000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMzItMS0xLTEtMA_a3ed8811-2662-456c-9f13-9f0ceac74b0a"
      unitRef="usd">-2381000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMzItMy0xLTEtMA_ca4e80e6-3329-458e-ad62-9a5c6142948f"
      unitRef="usd">-1476000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMzMtMS0xLTEtMA_f465601a-b041-4cfc-8112-7d01e0c4a3f2"
      unitRef="usd">-136000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMzMtMy0xLTEtMA_090d39b4-3f07-4b44-ba92-1a0f707eb47e"
      unitRef="usd">638000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <sls:IncreaseDecreaseInContractWithCustomerLiabilityNet
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMzQtMS0xLTEtMA_6ecefe3e-5b7d-4f84-91c5-500cbfd8e298"
      unitRef="usd">-5600000</sls:IncreaseDecreaseInContractWithCustomerLiabilityNet>
    <sls:IncreaseDecreaseInContractWithCustomerLiabilityNet
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfMzQtMy0xLTEtMA_b3d7345d-ad06-4bd4-af57-abed9320efd0"
      unitRef="usd">0</sls:IncreaseDecreaseInContractWithCustomerLiabilityNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNDEtMS0xLTEtMA_ab5ccae1-da74-4bce-805f-f1cc924156b6"
      unitRef="usd">-15167000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNDEtMy0xLTEtMA_6ee1ded3-a3e6-4f52-ba55-728679074cfe"
      unitRef="usd">-10212000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNTYtMS0xLTEtMA_18838a3c-d9ea-46b6-ab95-c275bd0fbd08"
      unitRef="usd">6765000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNTYtMy0xLTEtMA_50a15c9e-f3f8-48cb-830a-a50b63d47fca"
      unitRef="usd">5963000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <sls:ProceedsFromStockSubscriptionReceivable
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNTgtMS0xLTEtMA_f2e351a0-fa84-4f2d-a391-dab951f70cff"
      unitRef="usd">0</sls:ProceedsFromStockSubscriptionReceivable>
    <sls:ProceedsFromStockSubscriptionReceivable
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNTgtMy0xLTEtMA_7267a79d-27ba-4bb9-a5c0-1d6d25f1a50c"
      unitRef="usd">308000</sls:ProceedsFromStockSubscriptionReceivable>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNTktMS0xLTEtMA_df5084ff-be71-42c7-9a12-237d84e559c9"
      unitRef="usd">3017000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNTktMy0xLTEtMA_fb98d43f-7adf-403c-99ce-6e30f6469af8"
      unitRef="usd">4000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNjctMS0xLTEtMA_3d428414-5278-45f5-b1a5-2582fbba3435"
      unitRef="usd">9782000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNjctMy0xLTEtMA_d720ecd9-3525-4d21-af02-8ff98e8b63c4"
      unitRef="usd">6275000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNjgtMS0xLTEtMA_e0edf785-0cf5-4e1f-9aae-bce18851e198"
      unitRef="usd">-5385000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNjgtMy0xLTEtMA_3f515a72-6481-442c-8bab-ec23b9a398c0"
      unitRef="usd">-3937000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNjktMS0xLTEtMA_2955dbb6-2283-42d1-bfb5-2b27c3eff0d3"
      unitRef="usd">35402000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1ce9074c50144420a1bfafad23e559d3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNjktMy0xLTEtMA_5e810e4a-654e-4159-b49a-26f0f8d9ec34"
      unitRef="usd">7377000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNzAtMS0xLTEtMA_41b2a588-d3de-47d4-9354-350125ee5620"
      unitRef="usd">30017000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icce1dd99c16b4ec291627c253ff14547_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNzAtMy0xLTEtMA_e7799d7b-d5b7-4678-96ec-cc59b20b2f81"
      unitRef="usd">3440000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNzMtMS0xLTEtMA_b292f862-a1c6-4a8e-8a95-782a1414b043"
      unitRef="usd">4000</us-gaap:ProceedsFromInterestReceived>
    <us-gaap:ProceedsFromInterestReceived
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNzMtMy0xLTEtMA_3803ab7b-c1c3-4006-87f4-8445c6106fb6"
      unitRef="usd">25000</us-gaap:ProceedsFromInterestReceived>
    <sls:StockSubscriptionReceivable
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNzctMS0xLTEtMA_8ae5da80-9023-4fc4-83c2-f99a389a6b5a"
      unitRef="usd">2240000</sls:StockSubscriptionReceivable>
    <sls:StockSubscriptionReceivable
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfNzctMy0xLTEtMA_00a0c1ff-be53-4885-89d8-a82f2b3e7e66"
      unitRef="usd">0</sls:StockSubscriptionReceivable>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfODMtMS0xLTEtMA_8050ec6e-915a-41ce-98ce-2229c0f762ba"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfODMtMy0xLTEtMA_676b1f97-9073-40e0-a20f-21946c9364d7"
      unitRef="usd">976000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <sls:NoncashOfferingExpense
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfODUtMS0xLTEtMA_0fe7e716-9d96-4fc1-96b6-9082678d987a"
      unitRef="usd">0</sls:NoncashOfferingExpense>
    <sls:NoncashOfferingExpense
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8yOC9mcmFnOjBiYTlmN2JmNWIyOTRmNjI5YzhmNGI0YjJjOWY5MjdhL3RhYmxlOjM2MDcxZWNjMGNlZDQ5ZDk4ZjUzOWFhM2RmNDk3MGI4L3RhYmxlcmFuZ2U6MzYwNzFlY2MwY2VkNDlkOThmNTM5YWEzZGY0OTcwYjhfODUtMy0xLTEtMA_d342fbe7-1af1-4b57-9945-feb8559ed50f"
      unitRef="usd">25000</sls:NoncashOfferingExpense>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNC9mcmFnOjZkMTU3MTM2NGE2MTQ5ODU5ZTY0YWM1YWRhZDI0MjI2L3RleHRyZWdpb246NmQxNTcxMzY0YTYxNDk4NTllNjRhYzVhZGFkMjQyMjZfMzIyNg_5332fef3-da6c-4b05-b412-0e284128714f">Description of Business&lt;div&gt;&lt;span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SELLAS Life Sciences Group, Inc. (the "Company" or "SELLAS") is a late-stage clinical biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS&#x2019; lead product candidate, galinpepimut-S ("GPS"), is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center ("MSK") and targets the Wilms Tumor 1 ("WT1") protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. SELLAS&#x2019; second product candidate, nelipepimut-S ("NPS"), is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 ("HER2") expressing cancers with potential for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer ("TNBC") patients, following standard of care.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As used in this Quarterly Report on Form 10-Q, the words the "Company," and "SELLAS" refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following the completion of the business combination with Galena Biopharma, Inc., a Delaware corporation ("Galena"), and SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company ("Private SELLAS"), in December 2017. This business combination is referred to as the Merger. Upon completion of the Merger, the Company's name changed from "Galena Biopharma, Inc." to "SELLAS Life Sciences Group, Inc." and the Company's financial statements became those of Private SELLAS.&lt;/span&gt;&lt;/div&gt;On March 11, 2020, the World Health Organization declared the outbreak of a new coronavirus to be a &#x201c;pandemic&#x201d;. The COVID-19 pandemic continues to present substantial public health and economic challenges around the world which have impacted, and will continue to impact, millions of individuals and business worldwide. Efforts to contain the spread of the coronavirus since March 2020 have led to travel bans and restrictions, quarantines, shelter-in-place orders and shutdowns. The Company is continuously monitoring the impact of the pandemic on its clinical development programs. The full extent to which the COVID-19 pandemic directly or indirectly impacts the Company's business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and cannot be predicted with confidence, including the actions taken to contain or treat COVID-19, the ultimate overall duration of the pandemic, the emergence of new variants of COVID-19, the emergence of new geographic hotspots where the coronavirus is spreading more rapidly, and continued or new travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, as well as the effectiveness of actions taken globally to contain and treat the coronavirus, including the availability of safe and effective vaccines and the uptake thereof and whether existing vaccines are effective with respect to new variants. In particular, the continued spread of the coronavirus globally could adversely impact the Company's clinical trial operations and could have an adverse impact on our business and the financial results.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:LiquidationBasisOfAccountingTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMzY5NA_78654806-6cc2-47aa-a8be-798058457110">Liquidity&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception, the Company has incurred recurring losses and negative cash flows from operations and, as of June&#160;30, 2021, has an accumulated deficit of $124.9 million. During the six months ended June&#160;30, 2021, the Company used $15.2 million of cash in operations which included a net loss of $7.0 million, a $1.9&#160;million increase in prepaid expenses and other assets primarily for insurance and prepaid clinical trial costs, a $5.6&#160;million decrease in deferred revenue due to the recognition of licensing revenues and a $2.5&#160;million decrease in accounts payable and accrued expenses and other current liabilities, partially offset by a $1.1&#160;million decrease of contract acquisition costs related to the out-licensing of intellectual property rights and transfer of technical know-how and various net non-cash charges of $0.7&#160;million. The Company expects to continue to generate operating losses and negative cash flows for the next few years and will need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful development, approval, and commercialization of the Company's product candidates and the achievement of a level of revenues adequate to support its cost structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 16, 2021, the Company entered into a Controlled Equity Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald &amp;amp; Co. (the "Agent"). From time to time during the term of the Sales Agreement, the Company may offer and sell shares of common stock having an aggregate offering price up to a total of $50.0&#160;million in gross proceeds. The Agent will collect a fee equal to 3% of the gross sales price of all shares of common stock sold. Shares of common stock sold under the Sales Agreement will be offered and sold pursuant to the Company's registration statement on Form S-3, which was filed with the SEC on April 16, 2021 and was declared effective on April 29, 2021. During the three months ended June&#160;30, 2021, the Company sold 786,927 shares of common stock pursuant to the Sales Agreement at an average price of $12.04 per share for aggregate net proceeds of approximately $9.0&#160;million, of which approximately $2.2&#160;million in net proceeds were received in July 2021 and classified as a stock subscription receivable as of June 30, 2021. Other than the Sales Agreement, the Company currently does not have any commitments to obtain additional funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received $1.0&#160;million and $2.0&#160;million during the three and six months ended June&#160;30, 2021, respectively, for the achievement of certain development milestones pursuant to the Company's Exclusive License Agreement (the "3DMed License Agreement) with 3D Medicines, Inc. ("3DMed"). An additional $192.5&#160;million in potential future certain development, regulatory, and sales milestones remains under the 3DMed License Agreement, which milestones are variable in nature and not under the Company's control. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the Company had cash and cash equivalents of approximately $29.9&#160;million, restricted cash and cash equivalents of $0.1&#160;million, and $2.2&#160;million of stock subscription receivable which cash was received in July 2021. In accordance with Accounting Standards Codification ("ASC") 205-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements - Going Concern&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company expects its cash and cash equivalents, together with access to the Sales Agreement to sell common stock, will be sufficient to fund current planned operations for at least the next 12 months from the date of issuance of these financial statements, though it may pursue additional capital resources through public or private equity or debt financings or by entering into additional license agreements or collaborations with other companies. Management's expectations with respect to its ability to fund current planned operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management's estimates, the Company may need to seek additional strategic or financing opportunities sooner than would otherwise be expected. There is no guarantee that any of these strategic or financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders. If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research and development programs or be unable to expand its operations or otherwise prepare for the potential regulatory approval and commercialization of its product candidates, assuming positive data.&lt;/span&gt;&lt;/div&gt;</us-gaap:LiquidationBasisOfAccountingTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTY0_f0f3c510-a855-4af7-94cb-c15f63055660"
      unitRef="usd">-124900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMjQ0_81942550-0e75-4a8e-8e82-4ec51e93c7e0"
      unitRef="usd">-15200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetIncomeLoss
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTA5OTUxMTYzNjg0NA_8efb7f02-d14b-40e4-a97e-71b071c99a4c"
      unitRef="usd">-7000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfNDM4_b989745c-2f7f-4906-89ef-a2727e719755"
      unitRef="usd">1900000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMzI5ODUzNDg4ODQ0Mw_77f38fb0-dc6d-44a4-89a3-95fb69fb1383"
      unitRef="usd">-5600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfNTUw_9cc6e35a-12e1-4071-b74a-0bb94b1d1e4c"
      unitRef="usd">-2500000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTA5OTUxMTYzNjMxNg_04d82ec0-5c9a-4ac4-8971-0224e5f135a2"
      unitRef="usd">1100000</us-gaap:CapitalizedContractCostAmortization>
    <sls:NonCashCharges
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTA5OTUxMTYzNjY5Mw_94dd864e-0f90-4ea3-97ef-2524e6b5bd7d"
      unitRef="usd">700000</sls:NonCashCharges>
    <sls:SaleOfStockAuthorizedAmount
      contextRef="ie077fe8f1fa546518ab2e7996f804236_D20210416-20210416"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTM5NQ_20b8f93f-a846-4a64-a34c-49541c43e67d"
      unitRef="usd">50000000.0</sls:SaleOfStockAuthorizedAmount>
    <sls:SaleOfStockAgentFeePercentageOfGrossProceeds
      contextRef="ie077fe8f1fa546518ab2e7996f804236_D20210416-20210416"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTQ1NQ_f733042c-cd17-4b45-aa27-c6560878a937"
      unitRef="number">0.03</sls:SaleOfStockAgentFeePercentageOfGrossProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib40089611a434490a15e807711e0febb_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMzI5ODUzNDg4NzQzNg_a5db9cc9-c5db-48ab-b7ca-c4ba001de89b"
      unitRef="shares">786927</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i7d5ca04db51e482796a8bcd426e5cf11_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMzI5ODUzNDg4NzQ0NQ_d49323b0-2aa3-47f4-9668-131a16c44a07"
      unitRef="usdPerShare">12.04</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ib40089611a434490a15e807711e0febb_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMzI5ODUzNDg4NzQ1Mw_4b7b3826-a1a6-4250-aa69-c93686b081df"
      unitRef="usd">9000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ia6d6d49da9294db98abbd7d306232e0e_D20210701-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMzI5ODUzNDg5MTAwNg_a483966e-95d9-4cd5-808d-6658097f3f21"
      unitRef="usd">2200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sls:ProceedsFromResearchAndDevelopmentArrangementMilestonePayments
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTA5OTUxMTYzNDE3OQ_26054262-ac45-4232-a391-03735dd997f8"
      unitRef="usd">1000000.0</sls:ProceedsFromResearchAndDevelopmentArrangementMilestonePayments>
    <sls:ProceedsFromResearchAndDevelopmentArrangementMilestonePayments
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTA5OTUxMTYzNDE5Mw_19b8c857-f04c-4927-bf2e-feb28bac2cb4"
      unitRef="usd">2000000.0</sls:ProceedsFromResearchAndDevelopmentArrangementMilestonePayments>
    <sls:ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfMTA5OTUxMTYzNDIxMQ_ba378ef0-2daf-456e-85f4-910b8e31877d"
      unitRef="usd">192500000</sls:ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfNDk0NzgwMjMyOTU0OQ_232a370b-0a63-477f-8fd9-6a9b43c9caf0"
      unitRef="usd">29900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfNDk0NzgwMjMyOTU2NA_7a1b14f1-84b6-42a1-984c-ca156d47a20d"
      unitRef="usd">100000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <sls:StockSubscriptionReceivableCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV8zNy9mcmFnOmI4ZGVjNDVlOTE4MzQ5M2JiZjdjMzMxZTMwOGZiM2VhL3RleHRyZWdpb246YjhkZWM0NWU5MTgzNDkzYmJmN2MzMzFlMzA4ZmIzZWFfNjA0NzMxMzk2MDczMg_2b78f71e-26d7-4e48-a796-8fcdeb196b43"
      unitRef="usd">2200000</sls:StockSubscriptionReceivableCurrent>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfNTc1OQ_c2a612ac-f5da-4601-b85c-53911f665fc1">Basis of Presentation and Significant Accounting Policies&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's complete summary of significant accounting policies can be found in "Item 8. Financial Statements and Supplementary Data - Note 3. Basis of Presentation and Significant Accounting Policies" in the audited annual consolidated financial statements included in the 2020 Annual Report. The significant accounting policies summarized and included in the 2020 Annual Report have not materially changed, except as set forth below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates of the Financial Accounting Standards Board ("FASB").  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and its wholly owned subsidiaries, Private SELLAS, SLSG Limited, LLC, Sellas Life Sciences Limited, and Apthera, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unaudited Interim Results &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements and accompanying notes should be read in conjunction with the Company's annual consolidated financial statements and the notes thereto included in the 2020 Annual Report. The accompanying consolidated financial statements as of&#160;June&#160;30, 2021&#160;and for the three and six months ended June 30, 2021 and 2020, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December&#160;31, 2020 have been derived from the audited financial statements as of that date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on the Company's loss from operations, net loss, and net loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Subscription Receivable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with FASB ASC 505-10-45-2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables for Issuance of Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recorded a stock subscription receivable as of June&#160;30, 2021 related to the sale, prior to June&#160;30, 2021 and before the financial statements are issued or available to be issued, of 157,130 shares of common stock pursuant to the Sales Agreement for net proceeds of $2.2&#160;million which cash was collected on July 2, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Time-Vested Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2021, the Board of Directors granted restricted stock units ("RSUs") to employees that vest based on continuous service. Time-vested RSUs awarded to employees vest one-fourth per year annually over four years, provided the employee remains employed with the Company. The fair values of the RSUs are measured on the date of grant and are based on the Company's closing stock price on such date. Compensation expense for RSUs with only service conditions is recognized straight-line over the applicable service period. The Company accounts for forfeitures of RSUs when they occur. Previously recognized compensation expense for forfeited RSUs are reversed in the period the RSUs are forfeited.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Standards Adopted and Recent Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Standards Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which, among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard was adopted by the Company on January 1, 2021. This new standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent accounting standards not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which, among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument.  As a result, after adopting the ASU&#x2019;s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (ii) a convertible debt instrument was issued at a substantial premium. The standard becomes effective for the Company in the first quarter of 2022 and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfNTc2NQ_21e20f3a-a983-4716-8e8f-393d1d318fa2">Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates of the Financial Accounting Standards Board ("FASB").</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfNTc1MA_d02a942f-32ce-4fdd-9129-c684a139af57">&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and its wholly owned subsidiaries, Private SELLAS, SLSG Limited, LLC, Sellas Life Sciences Limited, and Apthera, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfMjc0ODc3OTA4NzE3Mg_72195f79-319d-4601-b059-78b4d4aa580b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on the Company's loss from operations, net loss, and net loss per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfMzI5ODUzNDkwMDc2MQ_328a2d19-71c1-4894-87c3-06c83d46ca71"
      unitRef="shares">157130</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="id8555ccfc9b945a59123f108d50b1d06_D20210702-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfMzI5ODUzNDkwMDc3MA_76a383b0-0168-4998-bfa6-ef96863ab1d6"
      unitRef="usd">2200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfNTc2Mg_53d14a5b-e824-4949-afa2-6d3968cddeb7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Time-Vested Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2021, the Board of Directors granted restricted stock units ("RSUs") to employees that vest based on continuous service. Time-vested RSUs awarded to employees vest one-fourth per year annually over four years, provided the employee remains employed with the Company. The fair values of the RSUs are measured on the date of grant and are based on the Company's closing stock price on such date. Compensation expense for RSUs with only service conditions is recognized straight-line over the applicable service period. The Company accounts for forfeitures of RSUs when they occur. Previously recognized compensation expense for forfeited RSUs are reversed in the period the RSUs are forfeited.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfMjQ2MQ_715b7cde-45e2-488c-86f1-1f55b1804af6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfNTc1MQ_adc91650-c9f5-46d9-ad72-ebe38d4e52e0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfNTc2Mw_d000c513-93fa-46ab-999a-aa15dbd4ac2f">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i95e27891b14a478b8f8be763dda2f1fd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfMi0xLTEtMS0w_97fc7374-94e8-4b03-9ced-4737955a741d"
      unitRef="shares">559000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if65aed140a5941fa9eab141c9d95f9be_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfMi0zLTEtMS0w_18ad59c3-d420-4efa-bd7d-2a73ce6eeb5d"
      unitRef="shares">1120000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iabe6e36564484068baac5e49c21a346e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfMy0xLTEtMS0w_b182eb14-b3cb-4857-8785-6721b18515a2"
      unitRef="shares">520000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2ab00b1183924bdb9188ae231bdbefd9_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfMy0zLTEtMS0w_71945545-14d6-42c6-8335-1d39733b31de"
      unitRef="shares">208000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i916c92e4c67d42dc92aa2fd9eccecc12_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfNC0xLTEtMS0w_5000c735-73b8-4c7a-9d18-5dd7138621a8"
      unitRef="shares">210000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i572c1e1b6c34427d95e51bbb5e40be56_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfNC0zLTEtMS0w_93e25ea7-0d71-48e4-8e79-a13a317cdf64"
      unitRef="shares">170000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfNS0xLTEtMS0w_070d8718-ce48-4471-b7a4-9d75feef2dca"
      unitRef="shares">1289000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RhYmxlOmJlZGVkMTI4N2UxZjQ0NzRhOGU4MjMwOGMyYjA1OGUzL3RhYmxlcmFuZ2U6YmVkZWQxMjg3ZTFmNDQ3NGE4ZTgyMzA4YzJiMDU4ZTNfNS0zLTEtMS0w_b19b6db7-9333-4022-a067-ba9976f63093"
      unitRef="shares">1498000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80MC9mcmFnOjI3NzNmNjljM2U4MjRlYzc4ODJiYzJkZWY5MGMwYjA2L3RleHRyZWdpb246Mjc3M2Y2OWMzZTgyNGVjNzg4MmJjMmRlZjkwYzBiMDZfMjc0ODc3OTA4NzE2OQ_727d430b-a49b-4e67-a1da-7ec712993f10">&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Standards Adopted and Recent Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Standards Adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which, among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard was adopted by the Company on January 1, 2021. This new standard did not have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent accounting standards not yet adopted&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which, among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument.  As a result, after adopting the ASU&#x2019;s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (ii) a convertible debt instrument was issued at a substantial premium. The standard becomes effective for the Company in the first quarter of 2022 and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjU2NQ_3fce455a-bbfe-427f-95ac-50c91e73e28d">Fair Value Measurements&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quoted&#160;Prices&#160;In&lt;br/&gt;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unobservable&#160;&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quoted&#160;Prices&#160;In&#160;&#160;&lt;br/&gt;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unobservable&#160;&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:49.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not transfer any financial instruments into or out of Level 3 classification during the six months ended June&#160;30, 2021 or during the year ended December 31, 2020.  See Note 8, Warrants to Acquire Shares of Common Stock, for a reconciliation of the changes in the fair value of the warrant liability for the six months ended June&#160;30, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the change in the fair value of the contingent consideration liability for the six months ended June&#160;30, 2021 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;br/&gt;Measurements&lt;br/&gt;Using&#160;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the estimated fair value of the contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena's acquisition of Apthera, Inc. in 2011 and the future contingent payments of up to $32.0 million based on the achievement of certain development and commercial milestones relating to the Company&#x2019;s NPS product candidate, of which $2.0 million has been paid to date. The remaining contingent consideration of up to $30.0 million is payable at the election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration, unless it has first obtained approval from its stockholders in accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. &lt;/span&gt;&lt;/div&gt;The significant unobservable assumptions include the probability of achieving each milestone, the date the Company expects to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. Changes in fair value reflect new information about the probability and anticipated timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time. As of June&#160;30, 2021, estimated future contingent milestone payments related to the Company's business range from zero, if no milestone events are achieved, to a maximum of $30.0 million if all development and commercial milestones are reached. As of June&#160;30, 2021, resulting probability-weighted cash flows were discounted using a weighted average cost of capital of 11.8% for development milestones and cost of debt of 5.4% for the commercial milestones. The Company estimates the timing of achievement of these development milestones to range from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjU0Nw_9e3118b3-4753-413f-9bca-561259d241ac"&gt;five&lt;/span&gt; to eight years as of June&#160;30, 2021.</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjU3NA_0356fd4a-69fd-4d78-8289-21e3dde13e7b">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quoted&#160;Prices&#160;In&lt;br/&gt;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unobservable&#160;&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Quoted&#160;Prices&#160;In&#160;&#160;&lt;br/&gt;Active Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;&lt;br/&gt;Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unobservable&#160;&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities measured and recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id299f8f9d64c460fbab097e59032b733_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMi0xLTEtMS0w_71a595c5-16bf-4518-8e6d-1cfeed5fcc34"
      unitRef="usd">29455000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i20b6583c6c4a4427a2154f30c7a4d759_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMi0zLTEtMS0w_ebe4cc8b-934a-465c-9058-315f9ba1fc75"
      unitRef="usd">29455000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib2cfc63428564e92ac87c7615fb89ca7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMi01LTEtMS0w_a7899169-0ddb-494e-9ff7-c7683b8f89a5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i63ad3d82d21047e2a9bb504f8640be57_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMi03LTEtMS0w_b39af5c0-cc6a-42b7-b324-4bd581af9555"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <sls:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="id299f8f9d64c460fbab097e59032b733_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMy0xLTEtMS0w_442ca541-d060-4b5a-8e74-f216ef8d6f2c"
      unitRef="usd">100000</sls:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <sls:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="i20b6583c6c4a4427a2154f30c7a4d759_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMy0zLTEtMS0w_02e5f224-4124-41f5-ba6c-749e719b67f7"
      unitRef="usd">100000</sls:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <sls:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="ib2cfc63428564e92ac87c7615fb89ca7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMy01LTEtMS0w_8d92dc21-9b9e-4b07-bc07-434f7df2be1c"
      unitRef="usd">0</sls:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <sls:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="i63ad3d82d21047e2a9bb504f8640be57_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfMy03LTEtMS0w_ed894c25-fba4-487c-ab77-d8fdf1d7a2e7"
      unitRef="usd">0</sls:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id299f8f9d64c460fbab097e59032b733_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNC0xLTEtMS0w_c0aabafd-c69e-4ac5-afcf-829158bd69e6"
      unitRef="usd">29555000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i20b6583c6c4a4427a2154f30c7a4d759_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNC0zLTEtMS0w_bd1c111f-7f42-4176-8573-af1a4780de8e"
      unitRef="usd">29555000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib2cfc63428564e92ac87c7615fb89ca7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNC01LTEtMS0w_a79358a1-d38d-4def-94af-d14a6cd7059e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i63ad3d82d21047e2a9bb504f8640be57_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNC03LTEtMS0w_4b843023-70eb-4010-8f89-448670de4489"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <sls:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="id299f8f9d64c460fbab097e59032b733_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNi0xLTEtMS0w_d05e7a54-24bd-40da-86d7-f319776e30a6"
      unitRef="usd">114000</sls:FairValueOfWarrantsPotentiallySettleableInCash>
    <sls:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="i20b6583c6c4a4427a2154f30c7a4d759_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNi0zLTEtMS0w_ae2dbb5f-df3f-4dba-a205-38a545b91981"
      unitRef="usd">0</sls:FairValueOfWarrantsPotentiallySettleableInCash>
    <sls:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="ib2cfc63428564e92ac87c7615fb89ca7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNi01LTEtMS0w_6b40098e-573e-400d-a284-25b88b1c18a1"
      unitRef="usd">0</sls:FairValueOfWarrantsPotentiallySettleableInCash>
    <sls:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="i63ad3d82d21047e2a9bb504f8640be57_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNi03LTEtMS0w_9bf51a2a-3105-45ab-9e2e-bad900a1bc6d"
      unitRef="usd">114000</sls:FairValueOfWarrantsPotentiallySettleableInCash>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id299f8f9d64c460fbab097e59032b733_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNy0xLTEtMS0w_587d4eeb-2c35-46be-ab8f-14c96496dcda"
      unitRef="usd">4896000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i20b6583c6c4a4427a2154f30c7a4d759_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNy0zLTEtMS0w_a8407dc2-a643-4f2b-b7a5-97a9ce9628ba"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib2cfc63428564e92ac87c7615fb89ca7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNy01LTEtMS0w_494b99eb-cc1b-4695-b6e3-395b36fcdcb7"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i63ad3d82d21047e2a9bb504f8640be57_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfNy03LTEtMS0w_fe009ec5-4f48-43a3-9c56-a66c167e358f"
      unitRef="usd">4896000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id299f8f9d64c460fbab097e59032b733_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfOC0xLTEtMS0w_13e6f538-69df-43c3-a015-248d43ddc816"
      unitRef="usd">5010000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i20b6583c6c4a4427a2154f30c7a4d759_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfOC0zLTEtMS0w_91d9593a-0d51-4680-8f5d-fa7a1222a847"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib2cfc63428564e92ac87c7615fb89ca7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfOC01LTEtMS0w_8708f7e2-89d2-4bed-af27-fe3bbfc83768"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i63ad3d82d21047e2a9bb504f8640be57_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjk1MmNjMGUxYzA4ZDRkMDI4YmZlNjY4MzBkMTg5ZWJkL3RhYmxlcmFuZ2U6OTUyY2MwZTFjMDhkNGQwMjhiZmU2NjgzMGQxODllYmRfOC03LTEtMS0w_05e38a90-4774-4416-b3c6-8a7711598434"
      unitRef="usd">5010000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i94e62635663940f0a1122ae9dd5b94de_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMi0xLTEtMS0w_0af49403-c08b-46d2-94a9-5048b30cbdc9"
      unitRef="usd">34959000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i14237fe221f44d34a5583869de1d051e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMi0zLTEtMS0w_9f0a8ddb-b904-4257-a020-482f26f90889"
      unitRef="usd">34959000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i23b95e026b9d4e318900dfe9940adf09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMi01LTEtMS0w_036350e1-1de2-4241-9ec4-e15e2f8f93f0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifa99ebdccce94e8caa2de707cacf92af_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMi03LTEtMS0w_efa661e7-d2bf-484f-831c-21a795346fca"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <sls:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="i94e62635663940f0a1122ae9dd5b94de_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMy0xLTEtMS0w_5a087169-c1b9-412a-bce6-47a7ab1bb62c"
      unitRef="usd">100000</sls:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <sls:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="i14237fe221f44d34a5583869de1d051e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMy0zLTEtMS0w_cd3a13b1-191c-4206-b5eb-d9d47f47d548"
      unitRef="usd">100000</sls:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <sls:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="i23b95e026b9d4e318900dfe9940adf09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMy01LTEtMS0w_8657931d-24f7-4155-8c16-03d59e83b1a6"
      unitRef="usd">0</sls:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <sls:RestrictedCashAndCashEquivalentsFairValueDisclosure
      contextRef="ifa99ebdccce94e8caa2de707cacf92af_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfMy03LTEtMS0w_c6f11b02-9887-4093-b9d8-037254d49869"
      unitRef="usd">0</sls:RestrictedCashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i94e62635663940f0a1122ae9dd5b94de_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNC0xLTEtMS0w_49046f1b-c9d7-4477-a114-0c24250ac0e3"
      unitRef="usd">35059000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i14237fe221f44d34a5583869de1d051e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNC0zLTEtMS0w_50335553-136e-4a5d-ab44-ee737adad062"
      unitRef="usd">35059000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i23b95e026b9d4e318900dfe9940adf09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNC01LTEtMS0w_0fd5d69b-0a3c-4442-b1fb-e5af8222207f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifa99ebdccce94e8caa2de707cacf92af_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNC03LTEtMS0w_a6a3a285-4857-4f4b-9784-76f531f9e325"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <sls:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="i94e62635663940f0a1122ae9dd5b94de_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNi0xLTEtMS0w_a73dfa62-13bb-4390-80f7-f9665f1aa476"
      unitRef="usd">55000</sls:FairValueOfWarrantsPotentiallySettleableInCash>
    <sls:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="i14237fe221f44d34a5583869de1d051e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNi0zLTEtMS0w_4b412776-39ad-45dc-b098-e81415a2f8b3"
      unitRef="usd">0</sls:FairValueOfWarrantsPotentiallySettleableInCash>
    <sls:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="i23b95e026b9d4e318900dfe9940adf09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNi01LTEtMS0w_582d234a-97c8-4c5b-a08e-2ca9179a1ceb"
      unitRef="usd">0</sls:FairValueOfWarrantsPotentiallySettleableInCash>
    <sls:FairValueOfWarrantsPotentiallySettleableInCash
      contextRef="ifa99ebdccce94e8caa2de707cacf92af_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNi03LTEtMS0w_5c069086-c304-461b-853d-6ab9129522ba"
      unitRef="usd">55000</sls:FairValueOfWarrantsPotentiallySettleableInCash>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i94e62635663940f0a1122ae9dd5b94de_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNy0xLTEtMS0w_05c484e2-85ff-4189-81df-05c956024678"
      unitRef="usd">4633000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i14237fe221f44d34a5583869de1d051e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNy0zLTEtMS0w_676f287a-614d-4d6a-a499-edb1afaa02b5"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i23b95e026b9d4e318900dfe9940adf09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNy01LTEtMS0w_5ad11e73-f227-469c-ac6e-cb41900684ee"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ifa99ebdccce94e8caa2de707cacf92af_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfNy03LTEtMS0w_2aaa8652-99d1-4786-9621-58fbb956fbfb"
      unitRef="usd">4633000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i94e62635663940f0a1122ae9dd5b94de_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfOC0xLTEtMS0w_69dc8531-2277-42b4-807d-bb1c9f770122"
      unitRef="usd">4688000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i14237fe221f44d34a5583869de1d051e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfOC0zLTEtMS0w_73db9f60-dcc5-447c-b02a-4320efb912f8"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i23b95e026b9d4e318900dfe9940adf09_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfOC01LTEtMS0w_d93b1c35-0c2f-4f93-a550-931701180cb6"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ifa99ebdccce94e8caa2de707cacf92af_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOjkzZjRhMTdkOTgzODQ2ZTlhNzE0M2NiODk2MzgxMmRiL3RhYmxlcmFuZ2U6OTNmNGExN2Q5ODM4NDZlOWE3MTQzY2I4OTYzODEyZGJfOC03LTEtMS0w_710dd59b-fcea-4485-a2b9-a043a08fde85"
      unitRef="usd">4688000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjU4OA_8fb54975-c26e-4a11-a12f-b9dd6664f4a3">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the change in the fair value of the contingent consideration liability for the six months ended June&#160;30, 2021 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;br/&gt;Measurements&lt;br/&gt;Using&#160;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in the estimated fair value of the contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i8ae6ab8b28e8405fb45e31fe8cff6e47_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOmJkMGYwNjk0NjNlMjQ5NjQ5YjJiN2M3NDRiNTc2MWM2L3RhYmxlcmFuZ2U6YmQwZjA2OTQ2M2UyNDk2NDliMmI3Yzc0NGI1NzYxYzZfMS0xLTEtMS0w_e24ec615-2751-460d-a088-41406c48bd8a"
      unitRef="usd">4633000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="i42a0e682866c4ad485eb808d137a33a4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOmJkMGYwNjk0NjNlMjQ5NjQ5YjJiN2M3NDRiNTc2MWM2L3RhYmxlcmFuZ2U6YmQwZjA2OTQ2M2UyNDk2NDliMmI3Yzc0NGI1NzYxYzZfMi0xLTEtMS0w_92715dc6-8f41-430a-b012-2a54f950f971"
      unitRef="usd">263000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i69f52ca633da4c9fa61aac1b2d469ba6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RhYmxlOmJkMGYwNjk0NjNlMjQ5NjQ5YjJiN2M3NDRiNTc2MWM2L3RhYmxlcmFuZ2U6YmQwZjA2OTQ2M2UyNDk2NDliMmI3Yzc0NGI1NzYxYzZfMy0xLTEtMS0w_42711eee-cce1-44d9-af21-bb4945f9ad9a"
      unitRef="usd">4896000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i707b6253a0f14414a1bc6beca9cc2c6f_I20111231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfOTcy_49693db4-c947-40b9-86cc-ee5f33e21d0c"
      unitRef="usd">32000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ibb2e72136f1d4a248d844448ac121df9_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMTEwNw_6fc5c1a2-3e89-43a7-82c3-598f87ccc7cd"
      unitRef="usd">2000000.0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2bdb237db5d747d296f136aa84ea8854_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMTE4MQ_2618d687-8b80-448e-bb87-98247a84cb2e"
      unitRef="usd">30000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow
      contextRef="i2bdb237db5d747d296f136aa84ea8854_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjEzOQ_8f0b76f5-c9aa-4a89-bda9-62a2d29c8e79"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="i2bdb237db5d747d296f136aa84ea8854_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjE5Ng_2e4a4412-9ee4-4529-a9f1-b8aa4cf550fd"
      unitRef="usd">30000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i09934cd16082484c8827742d0199f8e8_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjM2OQ_92b6b7d3-434f-403a-98a5-282e9b0158e8"
      unitRef="number">0.118</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i25cd3b9620c54b4e9fce77a21dc1f63f_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjQxOQ_4826bd97-a30f-44c9-b3ad-817148375f08"
      unitRef="number">0.054</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <sls:BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones
      contextRef="i1a03f8fd056b46cbb0fb3aa49612a705_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjU1Mw_75a8de2e-52de-45db-ab41-a8cb258a6b5d">P8Y</sls:BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RleHRyZWdpb246NTAyY2NjYjJiMmZhNDc3MWE1YTNhODA2YmIyY2Q4ZTJfMjEx_3bb356c0-3c18-40ca-85b0-eaa86ccf7931">Balance Sheet Accounts&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RleHRyZWdpb246NTAyY2NjYjJiMmZhNDc3MWE1YTNhODA2YmIyY2Q4ZTJfMjIx_71cb7e51-31fa-432a-b9af-560ea3c1465b">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfMS0xLTEtMS0w_62d99996-99e4-42b9-8a81-fff984e7adf8"
      unitRef="usd">1247000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfMS0zLTEtMS0w_fa931aaa-078f-42b0-8cdb-ac84cca0ca21"
      unitRef="usd">221000</us-gaap:PrepaidInsurance>
    <sls:PrepaidResearchAndDevelopment
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfMi0xLTEtMS0w_188e8dbf-fdbb-42e5-b724-4d2dd0114bfe"
      unitRef="usd">996000</sls:PrepaidResearchAndDevelopment>
    <sls:PrepaidResearchAndDevelopment
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfMi0zLTEtMS0w_6bca4430-dc09-408c-9031-bbb2974496ea"
      unitRef="usd">95000</sls:PrepaidResearchAndDevelopment>
    <sls:PrepaidProfessionalServices
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfMy0xLTEtMS0w_c96023b6-9a89-48f0-8f41-8742937f6b00"
      unitRef="usd">72000</sls:PrepaidProfessionalServices>
    <sls:PrepaidProfessionalServices
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfMy0zLTEtMS0w_f4a7b2a7-b6af-4c70-b8e9-cc530fefdb09"
      unitRef="usd">49000</sls:PrepaidProfessionalServices>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfNC0xLTEtMS0w_f4946eaa-1ca1-47f5-94b6-0daa59464572"
      unitRef="usd">3000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfNC0zLTEtMS0w_5315b071-73a0-4cbd-84cb-091c27a72a62"
      unitRef="usd">30000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfNS0xLTEtMS0w_38b920f9-6252-4ee4-8665-c3ba6cc53133"
      unitRef="usd">2318000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjc4YjBiMDBmNmE3NzRjMTU5MDNhOWViYzliZjRkNTA3L3RhYmxlcmFuZ2U6NzhiMGIwMGY2YTc3NGMxNTkwM2E5ZWJjOWJmNGQ1MDdfNS0zLTEtMS0w_850899b5-c8bd-42f9-be98-e309053d0a51"
      unitRef="usd">395000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RleHRyZWdpb246NTAyY2NjYjJiMmZhNDc3MWE1YTNhODA2YmIyY2Q4ZTJfMjA5_26546c15-fb6b-49c0-ba86-ab97ab5b72cd">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <sls:ContractResearchPayable
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMS0xLTEtMS0w_fd9ad198-2210-47c2-95d9-6b56734599a2"
      unitRef="usd">806000</sls:ContractResearchPayable>
    <sls:ContractResearchPayable
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMS0zLTEtMS0w_39278edd-fea7-43f8-80c3-431a564ac9d1"
      unitRef="usd">631000</sls:ContractResearchPayable>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMi0xLTEtMS0w_8d1346f7-2aa7-47b8-8f72-ec975b48207c"
      unitRef="usd">576000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMi0zLTEtMS0w_b4cc87b3-ed15-49b2-ac19-19ba688e6780"
      unitRef="usd">812000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMy0xLTEtMS0w_e2785f3b-ce9b-48ef-a8b2-217d5d4e7cc4"
      unitRef="usd">149000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMy0zLTEtMS0w_82369057-8638-4bb5-b6c1-29b7c8c46ca4"
      unitRef="usd">276000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMTMtMS0xLTEtMA_904d76f6-630b-4e21-92b8-d4b9d04660da"
      unitRef="usd">250000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMTMtMy0xLTEtMA_6d5a67bb-e537-4002-9710-a07228dea771"
      unitRef="usd">194000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMTUtMS0xLTEtMA_11eec0b7-5e11-467a-b3c8-dda7eb543a82"
      unitRef="usd">1781000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80Ni9mcmFnOjUwMmNjY2IyYjJmYTQ3NzFhNWEzYTgwNmJiMmNkOGUyL3RhYmxlOjA5Njc1MzAwOTQzZTQ5Nzg5NmU5N2Y1ODEyMzMwM2JlL3RhYmxlcmFuZ2U6MDk2NzUzMDA5NDNlNDk3ODk2ZTk3ZjU4MTIzMzAzYmVfMTUtMy0xLTEtMA_6c9cb4f1-5a70-4436-ac62-3719ca43b578"
      unitRef="usd">1913000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfNTk5Ng_e8e9f5aa-965d-4e80-a371-9c8ca508d8c6">Commitments and Contingencies&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lease&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a non-cancelable operating lease for certain executive, administrative, and general business office space for its headquarters in New York, New York, which began on June 5, 2020 and has a term through December 31, 2024. The discount rate of the Company's operating lease under ASC 842: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is the Company's estimated incremental borrowing rate of 13%. As of June&#160;30, 2021, the lease has a remaining term of 3.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense related to the Company's operating lease was approximately $0.1 million for each of the three months ended June&#160;30, 2021 and 2020 and $0.1&#160;million and $0.2&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; f&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or the six months ended June&#160;30, 2021 and 2020, respectively. The Company made cash payments related to its operating lease of approximately $0.1&#160;million for each of the three months ended June&#160;30, 2021 and 2020 and $0.2&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for each of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the six months ended June&#160;30, 2021 and 2020. Future minimum lease payments under the Company's non-cancelable operating lease are as follows as of June&#160;30, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum lease payments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current and non-current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company&#x2019;s consolidated results of operations, financial position or cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s predecessor company, Galena, was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal. The remaining legal proceedings to which the Company is now subject are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 13, 2017, certain putative shareholder securities class action complaints were filed in federal court alleging, among other things, that Galena and certain of Galena's former officers and directors failed to disclose that Galena&#x2019;s promotional practices for Abstral&#xae; (fentanyl sublingual tablets) were allegedly improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena&#x2019;s statements about its business misleading. The actions were consolidated, lead plaintiffs were named by the U.S. District Court for the District of New Jersey and a consolidated complaint was filed. The Company filed a motion to dismiss the consolidated complaint. On August 21, 2018, the Company's motion to dismiss the consolidated complaint was granted without prejudice to file an amended complaint. On September 20, 2018, the plaintiffs filed an amended complaint. On October 22, 2018, the Company filed a motion to dismiss the amended complaint. On November 13, 2019, the U.S. District Court for the District of New Jersey granted the Company's motion to dismiss without prejudice to file an amended complaint. On December 20, 2019, the lead plaintiffs filed a second Amended Consolidated Class Action Complaint. On January 29, 2020, the Company filed a motion to dismiss the amended complaint. On January 5, 2021, the U.S. District Court for the District of New Jersey granted the Company's motion to dismiss without prejudice to file an amended complaint. On February 18, 2021, the lead plaintiffs filed a third Amended Consolidated Class Action Complaint. The Company has reached a settlement in principle with the plaintiffs in this action which is subject to final documentation and court approval and which will be fully covered by the Company's directors and officers insurance policy applicable to this case.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#x2019;s former directors and Galena, as a nominal defendant. In July 2017, a derivative complaint was filed in California state court against the Company&#x2019;s former directors and Galena, as a nominal defendant. In January 2018, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#x2019;s former directors, officers and employees, and the Company as a nominal defendant. These complaints purport to assert derivative claims for breach of fiduciary duty on the Company&#x2019;s behalf against the Company&#x2019;s former directors and, in certain of the complaints, the Company&#x2019;s current directors, and the Company&#x2019;s former officers and former employees, based on substantially similar facts as alleged in the putative shareholder securities class action complaints mentioned above. The derivative lawsuit filed in California state court is currently stayed pending resolution of a motion to dismiss in the referenced securities class action. On July 13, 2020 and July 16, 2020, respectively, the Company filed motions to dismiss the two complaints filed in the U.S. District Court for the District of New Jersey. The Company has reached a settlement in principle with the plaintiffs in these three cases which is subject to final documentation and court approval and which will be fully covered by the Company's directors and officers insurance policy applicable to these cases.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia44788b499c14745a5543c4a56408ada_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfNzIz_12bb03e8-6e97-4eee-a9f2-b004b4c5dd54"
      unitRef="number">0.13</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <sls:OperatingLeaseRemainingLeaseTerm
      contextRef="i06156e81794f42c1a865af738d386a08_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfNzcx_779b224f-3b43-401e-b4f8-40a2cff6a569">P3Y6M</sls:OperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseExpense
      contextRef="i9b25700382c9420ca66cff20eaedf21a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfODQ4_eccf3f29-7b89-4d00-ab4f-a284c94b767b"
      unitRef="usd">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i375c691af6b54e09a2f25fecd7b8dc1a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfODQ4_fcf85631-0550-4c1d-9dee-38835dbca1fa"
      unitRef="usd">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i06156e81794f42c1a865af738d386a08_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfMzI5ODUzNDg4OTkwNg_84537e26-01aa-465c-8ba5-728fe7158301"
      unitRef="usd">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i0c3f2fed3a4c4b6cb082afcd2c660434_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfMTA5OTUxMTYzNDUyMQ_89a35c1f-3661-412a-ae38-5443444d7147"
      unitRef="usd">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="i375c691af6b54e09a2f25fecd7b8dc1a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfOTc2_96f2a6bf-2162-414f-ad6e-42f90369f8a0"
      unitRef="usd">100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i9b25700382c9420ca66cff20eaedf21a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfOTc2_c20b6d4c-5dd3-4f3f-8464-dd61a595e6d9"
      unitRef="usd">100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i06156e81794f42c1a865af738d386a08_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfMzI5ODUzNDg4OTk3Mw_4e75e646-bc5c-4389-a8fd-ce4440f07906"
      unitRef="usd">200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i0c3f2fed3a4c4b6cb082afcd2c660434_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfMzI5ODUzNDg4OTk3Mw_b3b0d62e-8fd8-427f-a803-60b3ddae9ada"
      unitRef="usd">200000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfNjAwMQ_823b3ba8-3102-407b-838c-d3aec9f72367">Future minimum lease payments under the Company's non-cancelable operating lease are as follows as of June&#160;30, 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Future minimum lease payments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 (remaining)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current and non-current operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RhYmxlOmNmZDUzY2EyYmFkMzQzMGM4YmZmNjU4YWIyMmE5YmI5L3RhYmxlcmFuZ2U6Y2ZkNTNjYTJiYWQzNDMwYzhiZmY2NThhYjIyYTliYjlfMS0yLTEtMS0w_8f08b19e-e8ce-4886-b042-40b0379fcfc1"
      unitRef="usd">152000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RhYmxlOmNmZDUzY2EyYmFkMzQzMGM4YmZmNjU4YWIyMmE5YmI5L3RhYmxlcmFuZ2U6Y2ZkNTNjYTJiYWQzNDMwYzhiZmY2NThhYjIyYTliYjlfMi0yLTEtMS0w_59f99fce-eb1f-40a3-af17-975e533b2968"
      unitRef="usd">311000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RhYmxlOmNmZDUzY2EyYmFkMzQzMGM4YmZmNjU4YWIyMmE5YmI5L3RhYmxlcmFuZ2U6Y2ZkNTNjYTJiYWQzNDMwYzhiZmY2NThhYjIyYTliYjlfMy0yLTEtMS0w_a1266a3a-185f-4fca-a80d-c6fab90d0a6a"
      unitRef="usd">321000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RhYmxlOmNmZDUzY2EyYmFkMzQzMGM4YmZmNjU4YWIyMmE5YmI5L3RhYmxlcmFuZ2U6Y2ZkNTNjYTJiYWQzNDMwYzhiZmY2NThhYjIyYTliYjlfNC0yLTEtMS0w_abe8c841-7451-4232-a025-6dbf9e94feb8"
      unitRef="usd">330000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RhYmxlOmNmZDUzY2EyYmFkMzQzMGM4YmZmNjU4YWIyMmE5YmI5L3RhYmxlcmFuZ2U6Y2ZkNTNjYTJiYWQzNDMwYzhiZmY2NThhYjIyYTliYjlfNS0yLTEtMS0w_55c05738-6c5c-4b7c-9a00-4fc3c4b4bef7"
      unitRef="usd">1114000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RhYmxlOmNmZDUzY2EyYmFkMzQzMGM4YmZmNjU4YWIyMmE5YmI5L3RhYmxlcmFuZ2U6Y2ZkNTNjYTJiYWQzNDMwYzhiZmY2NThhYjIyYTliYjlfNi0yLTEtMS0w_2b25647b-ce8a-4edb-a993-c14fd4227b61"
      unitRef="usd">211000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RhYmxlOmNmZDUzY2EyYmFkMzQzMGM4YmZmNjU4YWIyMmE5YmI5L3RhYmxlcmFuZ2U6Y2ZkNTNjYTJiYWQzNDMwYzhiZmY2NThhYjIyYTliYjlfNy0yLTEtMS0w_681d2651-15c3-472c-b867-40a6ba315b4f"
      unitRef="usd">903000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="i880559595c4c4de0b7dc3629958abd33_D20200713-20200716"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80OS9mcmFnOjk1YWIxMGQwM2Y5MDQ5ZTVhMTkxYzcxNjVjM2I5NTY0L3RleHRyZWdpb246OTVhYjEwZDAzZjkwNDllNWExOTFjNzE2NWMzYjk1NjRfNTc2MA_7f7a6fed-a7a2-4615-a5b9-577ace19024f"
      unitRef="complaint">2</us-gaap:LossContingencyClaimsDismissedNumber>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RleHRyZWdpb246Y2EyYTlhY2Y2YWIwNDYwZWEyMTVkMGI1MGUwZThjMzVfMzg1_243c5237-31f5-4c16-837d-5e9f7c761c63">Stockholders&#x2019; Equity&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has authorized up to 5,000,000&#160;shares of preferred stock, $0.0001&#160;par value per share, for issuance. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has authorized up to 350,000,000&#160;shares of common stock, $0.0001&#160;par value per share, for issuance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the Company has shares of common stock reserved for future issuance as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the Company&#x2019;s 2019 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the 2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the 2017 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RleHRyZWdpb246Y2EyYTlhY2Y2YWIwNDYwZWEyMTVkMGI1MGUwZThjMzVfODE_0f387138-d0dd-4b19-8d8a-dedcad62c8cc"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RleHRyZWdpb246Y2EyYTlhY2Y2YWIwNDYwZWEyMTVkMGI1MGUwZThjMzVfMTEx_70efc906-4941-489b-9a29-77c8da908962"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RleHRyZWdpb246Y2EyYTlhY2Y2YWIwNDYwZWEyMTVkMGI1MGUwZThjMzVfMzI5ODUzNDg4Mzc5Ng_37d58a8c-ab83-4b6c-8e6b-360c78b44294"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RleHRyZWdpb246Y2EyYTlhY2Y2YWIwNDYwZWEyMTVkMGI1MGUwZThjMzVfMjI2_8c67aaff-5d65-4797-95da-c18e4b49afbc"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <sls:CommonStockAreReservedForFutureIssuanceTableTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RleHRyZWdpb246Y2EyYTlhY2Y2YWIwNDYwZWEyMTVkMGI1MGUwZThjMzVfMzc2_be9bb6b8-5fbc-4d57-9c14-ed40a4927db2">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the Company has shares of common stock reserved for future issuance as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the Company&#x2019;s 2019 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the 2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares reserved for future issuance under the 2017 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sls:CommonStockAreReservedForFutureIssuanceTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RhYmxlOmQ5ZGEwNTk4NmZkYzQyNDA4NzA4ZGQwZWQ2NTg2Mzk1L3RhYmxlcmFuZ2U6ZDlkYTA1OTg2ZmRjNDI0MDg3MDhkZDBlZDY1ODYzOTVfMC0xLTEtMS0w_0638aa43-a62a-43c1-aebc-dd339c4a18bf"
      unitRef="shares">559000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RhYmxlOmQ5ZGEwNTk4NmZkYzQyNDA4NzA4ZGQwZWQ2NTg2Mzk1L3RhYmxlcmFuZ2U6ZDlkYTA1OTg2ZmRjNDI0MDg3MDhkZDBlZDY1ODYzOTVfMi0xLTEtMS0w_6deb8795-c87b-48d7-b335-41e04123f24b"
      unitRef="shares">520000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i111b00fe2e9a484ab732132f92c59d7e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RhYmxlOmQ5ZGEwNTk4NmZkYzQyNDA4NzA4ZGQwZWQ2NTg2Mzk1L3RhYmxlcmFuZ2U6ZDlkYTA1OTg2ZmRjNDI0MDg3MDhkZDBlZDY1ODYzOTVfMy0xLTEtMS0w_b7789d16-2764-4e42-9e54-3644a0d51697"
      unitRef="shares">210000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i09f2e17d90504212b4f4df2b5b769f5f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RhYmxlOmQ5ZGEwNTk4NmZkYzQyNDA4NzA4ZGQwZWQ2NTg2Mzk1L3RhYmxlcmFuZ2U6ZDlkYTA1OTg2ZmRjNDI0MDg3MDhkZDBlZDY1ODYzOTVfNC0xLTEtMS0w_45242d98-966b-47c4-a4a2-f41a10fc1a9c"
      unitRef="shares">463000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i6b1a536e4ed7497d9180567e5c395379_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RhYmxlOmQ5ZGEwNTk4NmZkYzQyNDA4NzA4ZGQwZWQ2NTg2Mzk1L3RhYmxlcmFuZ2U6ZDlkYTA1OTg2ZmRjNDI0MDg3MDhkZDBlZDY1ODYzOTVfNS0xLTEtMS0xMDI4_e344a617-605c-4ae9-9e81-eee23bbbebfa"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i53f109f3f922470f8caedb485b977400_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RhYmxlOmQ5ZGEwNTk4NmZkYzQyNDA4NzA4ZGQwZWQ2NTg2Mzk1L3RhYmxlcmFuZ2U6ZDlkYTA1OTg2ZmRjNDI0MDg3MDhkZDBlZDY1ODYzOTVfNS0xLTEtMS0w_fa7564b8-0255-4965-baee-0a31a4d8ff9e"
      unitRef="shares">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81Mi9mcmFnOmNhMmE5YWNmNmFiMDQ2MGVhMjE1ZDBiNTBlMGU4YzM1L3RhYmxlOmQ5ZGEwNTk4NmZkYzQyNDA4NzA4ZGQwZWQ2NTg2Mzk1L3RhYmxlcmFuZ2U6ZDlkYTA1OTg2ZmRjNDI0MDg3MDhkZDBlZDY1ODYzOTVfNy0xLTEtMS0w_32869fac-7afd-4602-804b-9ead6ae96884"
      unitRef="shares">2063000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RleHRyZWdpb246NjQ3N2ZjYWQwM2NlNGNiN2ExYmJhZmQ5NjY3ZTZiYWVfMjY5Mw_b8535618-c0f4-4833-8283-992d233c7618">Warrants to Acquire Shares of Common Stock&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants Outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the activity of the Company's warrants to acquire shares of common stock for the six months ended June&#160;30, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2020 PIPE Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;August 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2020 Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2019 Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2019 Exercise Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2018 Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 2021 - November 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants to acquire shares of common stock consist of warrants that may be settled in cash, which are liability-classified warrants, and equity-classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants Classified as Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liability-classified warrants consist of warrants to acquire common stock issued in connection with certain previous equity financings. These warrants may be settled in cash and were determined not to be indexed to the Company&#x2019;s common stock. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of operations as change in fair value of warrant liability. The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Strike price (per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Volatility %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free rate %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other warrants (liability-classified)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Strike price (per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Volatility %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free rate %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other warrants (liability-classified)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in fair value of the warrant liability for the six months ended June 30, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant liability, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant liability, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other warrants (liability-classified)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock>
    <sls:ScheduleOfWarrantActivityTableTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RleHRyZWdpb246NjQ3N2ZjYWQwM2NlNGNiN2ExYmJhZmQ5NjY3ZTZiYWVfMjcwMw_4071b8b0-46cb-4e32-952a-42eaff901470">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the activity of the Company's warrants to acquire shares of common stock for the six months ended June&#160;30, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.357%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Canceled/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2020 PIPE Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;August 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2020 Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2019 Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2019 Exercise Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2018 Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 2021 - November 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sls:ScheduleOfWarrantActivityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i9b57b69674ea45d89f949a22963281ef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMS0xLTEtMS0w_4c057fc2-fbe0-4aa1-843f-a5c7a7bac98b"
      unitRef="shares">445000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sls:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="i382d0ff9116248889bfe35c9548bb1ad_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMS0zLTEtMS0w_09ec37ac-0b7c-4d58-b921-2ca83090c62d"
      unitRef="shares">0</sls:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <sls:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="i382d0ff9116248889bfe35c9548bb1ad_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMS01LTEtMS0w_e16bb4d6-9ab0-4c07-8756-1c5f44e7ef52"
      unitRef="shares">420000</sls:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <sls:ClassofWarrantorRightCanceledOrExpired
      contextRef="i382d0ff9116248889bfe35c9548bb1ad_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMS03LTEtMS0w_16adfdaf-981a-41c2-a501-924a39eb4b78"
      unitRef="shares">0</sls:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1696facd34e04e7fabcf3bf12a67fc37_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMS05LTEtMS0w_f9665c58-b401-4d22-8152-f6005f42f084"
      unitRef="shares">25000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i055485f92470418a8842a2c2ea3403fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMi0xLTEtMS0w_269f580c-3a34-4b78-be74-b7717ea4932d"
      unitRef="shares">719000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sls:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="iae1ab75d176f43859c532c0d5a6b9757_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMi0zLTEtMS0w_231ff82d-0b59-42c5-82ac-6f642331c828"
      unitRef="shares">0</sls:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <sls:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="iae1ab75d176f43859c532c0d5a6b9757_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMi01LTEtMS0w_70ab27d2-2170-4961-8d03-fb8ff3a0cf53"
      unitRef="shares">410000</sls:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <sls:ClassofWarrantorRightCanceledOrExpired
      contextRef="iae1ab75d176f43859c532c0d5a6b9757_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMi03LTEtMS0w_34fa09bf-5abe-4bb7-afc9-8c3c8f5528dc"
      unitRef="shares">0</sls:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1abab26a331b4d2bbc52b859b5ddb6d1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMi05LTEtMS0w_0db177f4-04db-4da6-82b1-91ab119b91b8"
      unitRef="shares">309000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i27b4f5e1ef5b476eb4b27190b75d9193_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNC0xLTEtMS0w_5174844c-710b-4eac-884b-43f472062042"
      unitRef="shares">2000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sls:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="i1602f66b4bcd4b2fa1f1a8b24f7dd4e1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNC0zLTEtMS0w_c494605c-b7f3-4a4d-b553-59c3df797f8a"
      unitRef="shares">0</sls:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <sls:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="i1602f66b4bcd4b2fa1f1a8b24f7dd4e1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNC01LTEtMS0w_9aa7ce38-3316-4c91-a87d-b16f40207ae9"
      unitRef="shares">1000</sls:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <sls:ClassofWarrantorRightCanceledOrExpired
      contextRef="i1602f66b4bcd4b2fa1f1a8b24f7dd4e1_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNC03LTEtMS0w_2391e353-905b-4914-ac18-24947f71b6fb"
      unitRef="shares">0</sls:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i412c4e10b3ae49dd8a8769d97061c813_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNC05LTEtMS0w_5280e458-029d-4877-9c55-4340532e20b3"
      unitRef="shares">1000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2b0b95c6b8aa4fb6baa41a60c4f64951_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNi0xLTEtMS0w_7a5af1aa-57be-44a5-9940-32b501501e2f"
      unitRef="shares">63000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sls:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="i947de4d2c94b4605b378f1b0d070bc03_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNi0zLTEtMS0w_a7241be0-9615-43cc-aa6a-2c1889a17273"
      unitRef="shares">0</sls:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <sls:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="i947de4d2c94b4605b378f1b0d070bc03_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNi01LTEtMS0w_1c2041b6-f913-4eb6-8138-a165aeed2733"
      unitRef="shares">0</sls:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <sls:ClassofWarrantorRightCanceledOrExpired
      contextRef="i947de4d2c94b4605b378f1b0d070bc03_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNi03LTEtMS0w_2246faa6-2583-497c-b9d3-6dc15786301f"
      unitRef="shares">0</sls:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="icde798f1922a4c969d6f8e4f31c629b2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNi05LTEtMS0w_2eaf2583-3c33-4637-af2c-414f2446fb2e"
      unitRef="shares">63000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i19c88fd5d77f4b98a7abbb7fbdd57812_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNy0xLTEtMS0w_64242737-5308-4140-8ca3-f92fa21116fa"
      unitRef="shares">141000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sls:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="i1c3ab494f63a4840a5e8d7c78a0058e7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNy0zLTEtMS0w_6176aaf3-ebd4-4865-8457-9a4918ee93ab"
      unitRef="shares">0</sls:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <sls:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="i1c3ab494f63a4840a5e8d7c78a0058e7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNy01LTEtMS0w_b26912ca-441c-4371-bb6d-74e3ba4da8eb"
      unitRef="shares">1000</sls:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <sls:ClassofWarrantorRightCanceledOrExpired
      contextRef="i1c3ab494f63a4840a5e8d7c78a0058e7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNy03LTEtMS0w_e2156866-3406-4c11-bb39-41ffb52299e3"
      unitRef="shares">0</sls:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i4d5dabb9e85f4ddf985e3b83dbcc8a7f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfNy05LTEtMS0w_80dfcadb-6f9a-4a20-ad34-348b8fb364b3"
      unitRef="shares">140000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i251355b170d24283aef38a929d6b4ddb_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTItMS0xLTEtMA_232c5ad0-1207-454f-9f09-77f2a17f6807"
      unitRef="shares">22000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sls:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="i9b0f1fdbd95d469f9e4960e2aff67576_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTItMy0xLTEtMA_6fd810f6-52a5-4ee1-b125-a29f267a2640"
      unitRef="shares">0</sls:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <sls:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="i9b0f1fdbd95d469f9e4960e2aff67576_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTItNS0xLTEtMA_4dc4e65c-d726-4afa-824c-46a9c2a67591"
      unitRef="shares">0</sls:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <sls:ClassofWarrantorRightCanceledOrExpired
      contextRef="i9b0f1fdbd95d469f9e4960e2aff67576_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTItNy0xLTEtMA_f6b60f39-a24b-4a9d-85f9-47a5dadf4189"
      unitRef="shares">1000</sls:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia7d574a5c54b4ecf988952bb6423ecf0_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTItOS0xLTEtMA_3c5998b4-fad3-4d3c-8b9d-32ed7df38df6"
      unitRef="shares">21000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTktMS0xLTEtMA_f5bd43e6-f9e9-4b53-9459-2c3567f6271b"
      unitRef="shares">1392000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sls:ClassOfWarrantOrRightNumberOfWarrantsIssued
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTktMy0xLTEtMA_5e5ba82f-0c6f-42f7-9b46-ab72aa47dfd5"
      unitRef="shares">0</sls:ClassOfWarrantOrRightNumberOfWarrantsIssued>
    <sls:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTktNS0xLTEtMA_c8a735b4-2985-4217-b702-b4f5324a141e"
      unitRef="shares">832000</sls:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <sls:ClassofWarrantorRightCanceledOrExpired
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTktNy0xLTEtMA_84857660-41a7-43f8-b986-c0c207d0f858"
      unitRef="shares">1000</sls:ClassofWarrantorRightCanceledOrExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmYwNjE1YTY1YTMyODRiYmViZmI5MzliMjE1MjZkYjIwL3RhYmxlcmFuZ2U6ZjA2MTVhNjVhMzI4NGJiZWJmYjkzOWIyMTUyNmRiMjBfMTktOS0xLTEtMA_d1b6fb37-a42b-405c-b7a5-bed97f2e985d"
      unitRef="shares">559000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sls:ScheduleOfWarrantValuationAssumptionsTableTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RleHRyZWdpb246NjQ3N2ZjYWQwM2NlNGNiN2ExYmJhZmQ5NjY3ZTZiYWVfMjcwNA_b08e4f62-5c11-4ed7-a7ae-e0314c4aacde">The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;As of June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Strike price (per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Volatility %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free rate %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other warrants (liability-classified)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;151.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Strike price (per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Volatility %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free rate %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other warrants (liability-classified)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</sls:ScheduleOfWarrantValuationAssumptionsTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if448fa0842d047f7b8837ba649615db8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMy0xLTEtMS0w_fcb037b0-5410-41ed-8ab6-2983c64853e5"
      unitRef="shares">13000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sls:WarrantStrikePrice
      contextRef="if448fa0842d047f7b8837ba649615db8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMy0zLTEtMS0w_7a760801-401d-46af-a9b2-f06b978112fb"
      unitRef="usdPerShare">7.50</sls:WarrantStrikePrice>
    <sls:FairValueOfWarrantLiabilityAssumptionsExpectedTerm
      contextRef="i2bb40a5e73b94b1b8f47f0ddc5d2a834_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMy01LTEtMS0w_936c9c4a-c889-41e3-bbb6-7b2d19ee7ee5">P2Y3M3D</sls:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
    <sls:WarrantsFairValueAssumptionsExpectedVolatility
      contextRef="if448fa0842d047f7b8837ba649615db8_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMy03LTEtMS0w_545fd78d-c763-4531-824e-bcbceb0f30bb"
      unitRef="number">1.5145</sls:WarrantsFairValueAssumptionsExpectedVolatility>
    <sls:WarrantsFairValueAssumptionsRiskFreeInterestRate
      contextRef="if448fa0842d047f7b8837ba649615db8_I20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMy05LTEtMS0w_42ef9667-3433-47da-940e-7842ba9dcfd3"
      unitRef="number">0.0030</sls:WarrantsFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i144421cce0de42f196e8d03018a26b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMTItMS0xLTEtMA_7927849b-235e-43fa-b745-63dc4da31c1a"
      unitRef="shares">13000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sls:WarrantStrikePrice
      contextRef="i144421cce0de42f196e8d03018a26b22_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMTItMy0xLTEtMA_728309cb-0d3b-4bf6-85ca-1c2987b1ef9e"
      unitRef="usdPerShare">7.50</sls:WarrantStrikePrice>
    <sls:FairValueOfWarrantLiabilityAssumptionsExpectedTerm
      contextRef="i5503f2dea367480f98b7b0fa4b8c7314_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMTItNS0xLTEtMA_1d1b6c05-07ec-4a2b-88f3-671c494f0da5">P2Y9M</sls:FairValueOfWarrantLiabilityAssumptionsExpectedTerm>
    <sls:WarrantsFairValueAssumptionsExpectedVolatility
      contextRef="i144421cce0de42f196e8d03018a26b22_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMTItNy0xLTEtMA_0df17c58-54e8-491e-8089-22a7ff9cfb93"
      unitRef="number">1.5038</sls:WarrantsFairValueAssumptionsExpectedVolatility>
    <sls:WarrantsFairValueAssumptionsRiskFreeInterestRate
      contextRef="i144421cce0de42f196e8d03018a26b22_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOmFjYTE3YzExNGE3ZDRiNWFhZjQ5MDYwNTIzMjE0ZGQ4L3RhYmxlcmFuZ2U6YWNhMTdjMTE0YTdkNGI1YWFmNDkwNjA1MjMyMTRkZDhfMTItOS0xLTEtMA_4a2060c4-a1d1-43fd-bc97-9bed0f0730a9"
      unitRef="number">0.0016</sls:WarrantsFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="id11e0beb0d474e3e908dfebf56c545ca_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RleHRyZWdpb246NjQ3N2ZjYWQwM2NlNGNiN2ExYmJhZmQ5NjY3ZTZiYWVfMjQxOQ_46d4ff7c-bfd3-4bed-9659-4b5b07092ee5"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i407d77e6977a4e69b6cad45ca4a965ca_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RleHRyZWdpb246NjQ3N2ZjYWQwM2NlNGNiN2ExYmJhZmQ5NjY3ZTZiYWVfMjUxOQ_aa7ba07a-46ba-4168-9571-d659d0ead8c6"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <sls:ChangesInFairValueOfWarrantLiabilityTableTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RleHRyZWdpb246NjQ3N2ZjYWQwM2NlNGNiN2ExYmJhZmQ5NjY3ZTZiYWVfMjY5OA_85771d3f-2313-4e59-b9a1-dfde77e1177b">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in fair value of the warrant liability for the six months ended June 30, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant liability, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrant liability, June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other warrants (liability-classified)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sls:ChangesInFairValueOfWarrantLiabilityTableTextBlock>
    <sls:FairValueOfWarrantsLiabilities
      contextRef="i144421cce0de42f196e8d03018a26b22_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOjNlNmNmZjc5NWY1MDRkODA4OTczYzQzODdlYWRkMTllL3RhYmxlcmFuZ2U6M2U2Y2ZmNzk1ZjUwNGQ4MDg5NzNjNDM4N2VhZGQxOWVfMS0xLTEtMS0w_7b23d66f-3168-4ad7-bff4-8bf17c7afef1"
      unitRef="usd">55000</sls:FairValueOfWarrantsLiabilities>
    <sls:ChangeInFairValueOfWarrantLiabilities
      contextRef="i2bb40a5e73b94b1b8f47f0ddc5d2a834_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOjNlNmNmZjc5NWY1MDRkODA4OTczYzQzODdlYWRkMTllL3RhYmxlcmFuZ2U6M2U2Y2ZmNzk1ZjUwNGQ4MDg5NzNjNDM4N2VhZGQxOWVfMS05LTEtMS0w_6a696ddc-5b31-424a-9da4-d1c73b28b623"
      unitRef="usd">59000</sls:ChangeInFairValueOfWarrantLiabilities>
    <sls:FairValueOfWarrantsLiabilities
      contextRef="if448fa0842d047f7b8837ba649615db8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOjNlNmNmZjc5NWY1MDRkODA4OTczYzQzODdlYWRkMTllL3RhYmxlcmFuZ2U6M2U2Y2ZmNzk1ZjUwNGQ4MDg5NzNjNDM4N2VhZGQxOWVfMS0xMS0xLTEtMA_080189b1-3b45-4f0b-b581-e31f6fe6ae6d"
      unitRef="usd">114000</sls:FairValueOfWarrantsLiabilities>
    <sls:FairValueOfWarrantsLiabilities
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOjNlNmNmZjc5NWY1MDRkODA4OTczYzQzODdlYWRkMTllL3RhYmxlcmFuZ2U6M2U2Y2ZmNzk1ZjUwNGQ4MDg5NzNjNDM4N2VhZGQxOWVfOC0xLTEtMS0w_89450ce2-fc69-4e67-ab0e-13b370116669"
      unitRef="usd">55000</sls:FairValueOfWarrantsLiabilities>
    <sls:ChangeInFairValueOfWarrantLiabilities
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOjNlNmNmZjc5NWY1MDRkODA4OTczYzQzODdlYWRkMTllL3RhYmxlcmFuZ2U6M2U2Y2ZmNzk1ZjUwNGQ4MDg5NzNjNDM4N2VhZGQxOWVfOC05LTEtMS0w_433c1634-11d7-432f-b5a7-cb615b567177"
      unitRef="usd">59000</sls:ChangeInFairValueOfWarrantLiabilities>
    <sls:FairValueOfWarrantsLiabilities
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV81OC9mcmFnOjY0NzdmY2FkMDNjZTRjYjdhMWJiYWZkOTY2N2U2YmFlL3RhYmxlOjNlNmNmZjc5NWY1MDRkODA4OTczYzQzODdlYWRkMTllL3RhYmxlcmFuZ2U6M2U2Y2ZmNzk1ZjUwNGQ4MDg5NzNjNDM4N2VhZGQxOWVfOC0xMS0xLTEtMA_003fe86a-c4d0-465f-953c-0f1d70521a77"
      unitRef="usd">114000</sls:FairValueOfWarrantsLiabilities>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfOTI0Nw_2cc413d8-5028-43f8-95eb-b08184ace4d4">License Revenue with 3D Medicines, Inc.&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exclusive License Agreement with 3D Medicines, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company, together with its wholly-owned subsidiary, SLSG Limited, LLC, entered into an Exclusive License Agreement (the &#x201c;3DMed License Agreement&#x201d;) with 3D Medicines Inc. ("3DMed"), pursuant to which the Company granted 3DMed a sublicensable, royalty-bearing license, under certain intellectual property owned or controlled by the Company, to develop, manufacture and have manufactured, and commercialize GPS and heptavalent GPS (referred to as GPS Plus) product candidates ("GPS Licensed Products") for all therapeutic and other diagnostic uses in mainland China, Hong Kong, Macau and Taiwan ("3DMed Territory"). The license is exclusive, except with respect to certain know-how that has been non-exclusively licensed to the Company and is sublicensed to 3DMed on a non-exclusive basis. The Company has retained development, manufacturing and commercialization rights with respect to the GPS Licensed Products in the rest of the world.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In partial consideration for the rights granted by the Company, 3DMed agreed to pay the Company (i) a one-time upfront cash payment of $7.5&#160;million, and (ii) milestone payments totaling up to $194.5&#160;million in the aggregate upon the achievement of certain technology transfer, development and regulatory milestones, as well as sales milestones based on certain net sales thresholds of GPS Licensed Products in the 3DMed Territory in a given calendar year. The Company is responsible for providing the licensed technology and data (the "3DMed License") as well as transferring certain technological and manufacturing know-how (the "transfer of know-how").&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3DMed also agreed to pay tiered royalties based upon a percentage of annual net sales of GPS Licensed Products in the 3DMed Territory ranging from the high single digits to the low double digits. The royalties are payable on a GPS Licensed Product-by-GPS Licensed Product and region-by-region basis commencing on the first commercial sale of a GPS Licensed Product in a region and continuing until the latest of (i) the date that is 15 years from the receipt of marketing authorization for such GPS Licensed Product in such region and (ii) the date that is 10 years from the expiration of the last valid claim of a licensed patent covering or claiming such GPS Licensed Product in such region. The royalty rate is subject to reduction under certain circumstances, including when generic competition for a GPS Licensed Product exists in a particular region.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3DMed is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the GPS Licensed Products in the 3DMed Territory. 3DMed is required to use commercially reasonable best efforts to develop and obtain regulatory approval for, and upon receipt of regulatory approval, commercialize the GPS Licensed Products in the 3DMed Territory. A joint steering committee has been established between 3DMed and the Company to coordinate and review the development, manufacturing and commercialization plans with respect to the GPS Licensed Products in the 3DMed Territory. The Company and 3DMed also agreed to negotiate in good faith the terms and conditions of a clinical supply agreement, a commercial supply agreement, and related quality agreements pursuant to which the Company will manufacture or have manufactured and supply 3DMed with all quantities of the GPS Licensed Products necessary for 3DMed to develop and commercialize the GPS Licensed Products in the 3DMed Territory until 3DMed has received all approvals required for 3DMed or its designated contract manufacturing organization to manufacture the GPS Licensed Products in the 3DMed Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 3DMed License Agreement will expire on a GPS Licensed Product-by-GPS Licensed Product and region-by-region basis on the date of the expiration of all of 3DMed&#x2019;s payment obligations to the Company. Upon expiration of the 3DMed License Agreement, the license granted to 3DMed will become fully paid-up, perpetual and irrevocable. Either party may terminate the 3DMed License Agreement for the other party&#x2019;s material breach following a cure period or upon certain insolvency events. The Company may terminate the 3DMed License Agreement if 3DMed or its affiliates or sublicensees challenge the validity or enforceability of the licensed patents. At any time following the two-year anniversary of the effective date, 3DMed has the right to terminate the 3DMed License Agreement for convenience, subject to certain requirements. 3DMed may terminate the 3DMed License Agreement upon prior notice to the Company if the grant of the license to 3DMed is prohibited or delayed for a period of time due to a change of U.S. export laws and regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 3DMed License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the 3DMed License Agreement and concluded that 3DMed was a customer and the 3DMed License Agreement should be evaluated under ASC 606. In determining the appropriate amount of revenue to be recognized under ASC 606 as the Company fulfills its obligations under the 3DMed License Agreement, the Company performs the following steps: (i) identifies the promised goods or services in the contract; (ii) determines whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measures the transaction price, including any constraints on variable consideration; (iv) allocates the transaction price to the performance obligations; and (v) recognizes revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company identified the 3DMed License and the transfer of know-how to be the material promises under the 3DMed License Agreement. The Company determined that the 3DMed License and the transfer of know-how are not distinct from each other. As such, for the purposes of ASC 606, the Company determined that these two material promises, described above, should be combined into a single performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the initial transaction price of the single performance obligation to be $9.5&#160;million, which includes the $7.5&#160;million upfront fee as well as $2.0&#160;million in development milestones that are assessed to be probable of being achieved at the inception of the 3DMed License Agreement and therefore were not constrained. The Company achieved $1.0&#160;million of these milestones in the first quarter of 2021 and achieved the remaining $1.0&#160;million milestone in the second quarter of 2021. The Company determined that $192.5&#160;million in future certain development, regulatory, and sales milestones to be variable consideration subject to constraint at inception. At the end of each subsequent reporting period, the Company will reevaluate the probability of achievement of the future development, regulatory, and sales milestones subject to constraint and, if necessary, will adjust its estimate of the overall transaction price. Any such adjustments will be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the sales-based royalties, the Company will recognize revenue when the related sales occur. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 3DMed benefited from the combined single performance obligation relating to the 3DMed License and the transfer of know-how as the technology transfer occurred, the Company recognized the transaction price over the technology transfer period, which was finalized in the second quarter of 2021. The revenue recognized was based on an output method to measure progress, using a straight-line convention, which the Company believes reasonably approximates its efforts in satisfying the combined performance obligation. The Company recognized $1.9&#160;million and $7.6&#160;million of license revenue during the three and six months ended June&#160;30, 2021, respectively. As of June 30, 2021, the initial transaction price of the single performance obligation of $9.5&#160;million has been fully recognized as licensing revenue. There was no license revenue recognized during the three and six months ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the activity in the Company's deferred revenue, related to the total cash payments received of $9.5&#160;million to date under the 3DMed License, during the six months ended June&#160;30, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue Recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of Contract Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred contract acquisition costs (commissions) recorded as a contract asset amounting to approximately $1.4&#160;million at inception of the 3DMed License Agreement which were capitalized under ASC 340-40 as incremental costs of obtaining the 3DMed License Agreement. These costs are amortized through general and administrative expense over the technology transfer period, commensurate with when the license revenue is recognized. The Company recognized $0.3&#160;million and $1.1&#160;million in expense associated with these costs during the three and six months ended June&#160;30, 2021, respectively. There was no contract acquisitions expense during the three and six months ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of License Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred $0.1&#160;million and $0.2&#160;million of sublicensing fees payable under its license from MSK in connection with the 3DMed License during the three and six months ended June&#160;30, 2021, respectively. There was no cost of license revenue during the three and six months ended June 30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <sls:ResearchAndDevelopmentArrangementCashPaymentReceived
      contextRef="i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfMTE4NQ_008b7a86-4945-48f9-96cc-d4103e0ed56e"
      unitRef="usd">7500000</sls:ResearchAndDevelopmentArrangementCashPaymentReceived>
    <sls:ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum
      contextRef="i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfMTIzMg_1f884f5a-1f1b-412f-ba8d-bd3a0e2d8521"
      unitRef="usd">194500000</sls:ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum>
    <sls:ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm
      contextRef="i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfMjExNw_474390f2-17d8-4e4e-b229-ecb266ffba3b">P15Y</sls:ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm>
    <sls:ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm
      contextRef="i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfMjIzNQ_f71e8e5e-75ad-4502-943b-8d378ef76d19">P10Y</sls:ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNjI3NQ_87fe7754-5701-455c-9eac-eda42b243553"
      unitRef="usd">9500000</us-gaap:RevenueRemainingPerformanceObligation>
    <sls:ResearchAndDevelopmentArrangementCashPaymentReceived
      contextRef="i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNjI5OA_276db935-c99c-4f14-b50d-aa9eedac2199"
      unitRef="usd">7500000</sls:ResearchAndDevelopmentArrangementCashPaymentReceived>
    <sls:ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved
      contextRef="i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNjMyNA_a437dc70-c5d5-40d4-b4d2-3ac9f5a9a536"
      unitRef="usd">2000000.0</sls:ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved>
    <sls:ProceedsFromResearchAndDevelopmentArrangementMilestonePayments
      contextRef="i688ab895304a4f60b76983dc097aef85_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNjUwOQ_894c9c74-c465-4ff4-845b-4c304e5a33d8"
      unitRef="usd">1000000.0</sls:ProceedsFromResearchAndDevelopmentArrangementMilestonePayments>
    <sls:ProceedsFromResearchAndDevelopmentArrangementMilestonePayments
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNjU5OA_c21c00dc-ab47-4d93-91cd-3c6ed6aa189a"
      unitRef="usd">1000000.0</sls:ProceedsFromResearchAndDevelopmentArrangementMilestonePayments>
    <sls:ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNjY2MA_7d0e54d1-d3fa-4281-9d41-d98d2816fef9"
      unitRef="usd">192500000</sls:ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived>
    <sls:ContractWithCustomerLiabilityNewContractRevenueRecognized
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfMTY0OTI2NzQ1MTA5MQ_3bc1276a-48e5-44ac-bba9-b93c6b4f4fdb"
      unitRef="usd">1900000</sls:ContractWithCustomerLiabilityNewContractRevenueRecognized>
    <sls:ContractWithCustomerLiabilityNewContractRevenueRecognized
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNzk3MA_004aaf22-1dee-43ae-b29c-5d59d4f1decb"
      unitRef="usd">7600000</sls:ContractWithCustomerLiabilityNewContractRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfNjA0NzMxMzk2MjcwNQ_6f387353-e9ef-41ca-acfe-ddd3eef8c86d"
      unitRef="usd">9500000</us-gaap:RevenueRemainingPerformanceObligation>
    <sls:ContractWithCustomerLiabilityNewContractRevenueRecognized
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfODAzNg_670c011b-7a71-4cf3-bab1-2729e42a0d89"
      unitRef="usd">0</sls:ContractWithCustomerLiabilityNewContractRevenueRecognized>
    <sls:ContractWithCustomerLiabilityNewContractRevenueRecognized
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfODAzNg_98be0ddc-5615-4bee-b1c1-739f2c85e2b2"
      unitRef="usd">0</sls:ContractWithCustomerLiabilityNewContractRevenueRecognized>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfOTI0OA_390f04f5-3c37-4884-921a-c449889061ef">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the activity in the Company's deferred revenue, related to the total cash payments received of $9.5&#160;million to date under the 3DMed License, during the six months ended June&#160;30, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue Recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <sls:ResearchAndDevelopmentArrangementCashPaymentReceived
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfODI1MA_95253805-d71b-41ae-bf5a-b3f30be62212"
      unitRef="usd">9500000</sls:ResearchAndDevelopmentArrangementCashPaymentReceived>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RhYmxlOmMwOGFkYzM4ZWRlNTRjZDBiMDg3N2U5MGY0ZGMwNWRjL3RhYmxlcmFuZ2U6YzA4YWRjMzhlZGU1NGNkMGIwODc3ZTkwZjRkYzA1ZGNfMS0xLTEtMS0w_93e51278-ae45-4ae3-be3b-01fec892c065"
      unitRef="usd">5600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RhYmxlOmMwOGFkYzM4ZWRlNTRjZDBiMDg3N2U5MGY0ZGMwNWRjL3RhYmxlcmFuZ2U6YzA4YWRjMzhlZGU1NGNkMGIwODc3ZTkwZjRkYzA1ZGNfMS0zLTEtMS0w_f0cfb491-4a5a-4587-87bd-4e9d7d0ab35a"
      unitRef="usd">2000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <sls:ContractWithCustomerLiabilityNewContractRevenueRecognized
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RhYmxlOmMwOGFkYzM4ZWRlNTRjZDBiMDg3N2U5MGY0ZGMwNWRjL3RhYmxlcmFuZ2U6YzA4YWRjMzhlZGU1NGNkMGIwODc3ZTkwZjRkYzA1ZGNfMS01LTEtMS0w_77583ab8-b375-466f-9de3-743f155b15ff"
      unitRef="usd">7600000</sls:ContractWithCustomerLiabilityNewContractRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RhYmxlOmMwOGFkYzM4ZWRlNTRjZDBiMDg3N2U5MGY0ZGMwNWRjL3RhYmxlcmFuZ2U6YzA4YWRjMzhlZGU1NGNkMGIwODc3ZTkwZjRkYzA1ZGNfMS03LTEtMS0w_edace3be-b722-4168-aa2c-19cab41d01d9"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:CapitalizedContractCostGross
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfODQ4Nw_67d70434-0979-4daa-9241-32ce4af70fc1"
      unitRef="usd">1400000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfMTA5OTUxMTYzNzEzMg_f69a5508-aacb-4b6f-a936-35ac32c0cf74"
      unitRef="usd">300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfODgyNA_879e9d62-cb98-4bcc-b24f-52e0ca38fcb5"
      unitRef="usd">1100000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfODkxMA_d0980b61-f14b-445a-83bc-41c01a4ce697"
      unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfODkxMA_e7806925-dfcd-477f-bccf-0b7da059a89a"
      unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfMTY0OTI2NzQ1MTIwNA_78459b02-706b-49e0-9579-7c1adc219fb7"
      unitRef="usd">100000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfOTAzNg_0fb8335d-2615-4784-a922-93b8b572c7df"
      unitRef="usd">200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfOTE3Ng_4b7df5a4-1f8b-4486-b630-b1667235e24d"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82MS9mcmFnOjEwNGEwNTZjMjBiNjQ0MzJiZjdmZDc3NGVjMzU4ZGI2L3RleHRyZWdpb246MTA0YTA1NmMyMGI2NDQzMmJmN2ZkNzc0ZWMzNThkYjZfOTE3Ng_63c90eb5-b4bf-4cfe-9538-1c2ae4983378"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDE1MA_cb17b692-c0ac-4688-8d8f-b30464760f7f">Stock-Based Compensation&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Equity Incentive Plan &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29, 2017, the 2017 Equity Incentive Plan was approved by the stockholders of the Company, which provided for the issuance of up to a maximum of 24,204 shares of common stock underlying stock options granted prior to September 10, 2019. The 2017 Equity Incentive Plan was terminated upon the approval of the 2019 Incentive Plan subject to outstanding stock options granted under the 2017 Equity Incentive Plan that remain exercisable through maturity for the Company's employees and directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Equity Incentive Plan &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 10, 2019, the 2019 Equity Incentive Plan was approved by the stockholders of the Company, which currently allows for issuance of up to approximately (i) 1,191,000 shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate plus (ii) 2,684 shares of common stock under the 2017 Equity Incentive Plan that were forfeited back to the Company subsequent to September 10, 2019 and are available for future issuance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares reserved for issuance under the 2019 Equity Incentive Plan will automatically increase on January 1&#160;of each year, for a period of not more than four years, commencing on January 1, 2020 and ending on (and including) January&#160;1, 2023, by an amount equal to the lesser of (i) 5% of the total number of shares of common stock outstanding at the end of the prior fiscal year; and (ii) an amount determined by the board of directors or authorized committee. As of June&#160;30, 2021, approximately 463,000 shares of common stock were reserved for future grants under the 2019 Equity Incentive Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Options to Purchase Shares of Common Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity of the Company for the six months ended June 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;br/&gt;Number of&lt;br/&gt;Shares &lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (In Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.48&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic values of outstanding and exercisable stock options at June&#160;30, 2021 were calculated based on the closing price of the Company&#x2019;s common stock as reported on the Nasdaq Capital Market on June&#160;30, 2021 of $11.10 per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company&#x2019;s common stock and the exercise price of the underlying stock options.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three and six months ended June&#160;30, 2021 and 2020, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option-pricing model to determine the fair value of all its stock options granted. The assumptions used during the three and six months ended June&#160;30, 2021 and 2020, respectively, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected lives (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of options granted during the three months ended June&#160;30, 2021 and 2020 was $6.89 and $1.35, respectively. The weighted-average grant date fair value of options granted during the six months ended June 30, 2021 and 2020 was $6.97 and $1.53, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company&#x2019;s options of ten years with the average vesting term of four years for an average of approximately six years. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, there was $2.4 million of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company&#x2019;s operating expenses over a weighted-average period of 2.98 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Time-vested RSUs and RSUs with Performance Conditions &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity of the Company for the six months ended June 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, there was $0.6 million of unrecognized compensation cost related to outstanding RSUs that is expected to be recognized as a component of the Company's operating expenses over a weighted-average period of 2.94 years. No RSUs vested during the three and six months ended June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 22, 2021, the Board of Directors adopted the 2021 Employee Stock Purchase Plan ("2021 ESPP") which was approved by the Company's stockholders on June 8, 2021. The 2021 ESPP allows employees to contribute up to 20% of their cash earnings, subject to a maximum of $25,000 per year under Internal Revenue Service rules, to be used to purchase shares of the Company&#x2019;s common stock on semi-annual purchase dates. The 2021 ESPP allows eligible employees to purchase shares of common stock at a price per share equal to 85% of the lower of the fair market value of the common stock at the beginning or end of each six-month offering period during the term of the 2021 ESPP. The first offering period will begin in September 2021. There are currently 300,000 shares of common stock reserved for issuance under the 2021 ESPP.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="iad04bd0225e946c686ea366ea6d4337c_I20171229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMjIx_f55c2fa6-4d3d-4960-8136-94e6f3372ad3"
      unitRef="shares">24204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i2cdec16105b14f11a00088c335a3fc87_I20190910"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNzYz_e1df2341-7dcb-462f-8fde-84eef3f54c30"
      unitRef="shares">1191000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id18a6212741d45d5b62f720726640f94_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfOTky_b1e29ecd-e783-48de-a2f0-a7a365daf8ad"
      unitRef="shares">2684</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i3326b9a650f54279992091454bb1af76_D20190910-20190910"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMTMzNA_927df775-fc1d-4812-9a07-5cab84b2cbd0">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i3326b9a650f54279992091454bb1af76_D20190910-20190910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMTQ1NQ_767ae8e7-c646-4472-9c8a-1d93cb455e2c"
      unitRef="number">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7c1fcbbb7fa2469ea57dccaece19d2c0_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMTY1OA_c8b7b6a3-4304-478a-a6bb-be546b1b09a6"
      unitRef="shares">463000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDE0Nw_3d93d932-fc35-46bc-bb7d-f0befc983383">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity of the Company for the six months ended June 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;br/&gt;Number of&lt;br/&gt;Shares &lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (In Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.48&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfMS0xLTEtMS0w_41e3b61b-c267-4fcc-b05f-dabf573b79af"
      unitRef="shares">208000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfMS0zLTEtMS0w_da627da1-573a-49df-a502-e464e538dade"
      unitRef="usdPerShare">13.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic7eacc21cecb4153bd972290a5d92a75_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfMS01LTEtMS0w_d6db4d4a-c5cf-4608-bd4f-b42e20ddf439">P9Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib3da468c26204b08b77feb6a7b00001f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfMS03LTEtMS0w_f6d98d9b-1609-4068-8522-613a4ac1dfcf"
      unitRef="usd">733000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfMi0xLTEtMS0w_c8587579-a1c5-47a0-b5e8-a5805f20d9fa"
      unitRef="shares">312000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfMi0zLTEtMS0w_c2a4354b-9e32-41c6-adeb-71bbba1f73cd"
      unitRef="usdPerShare">7.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNS0xLTEtMS0w_00782922-25de-438f-917f-333cc33f7ce8"
      unitRef="shares">520000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNS0zLTEtMS0w_fd31b450-36cb-4abe-98c5-41965fdc7d0c"
      unitRef="usdPerShare">10.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNS01LTEtMS0w_70e18881-28c7-4fec-b0d5-7fd203b68a92">P9Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNS03LTEtMS0w_aeeee0e4-3b96-41d8-9cf3-c271b6232955"
      unitRef="usd">2688000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNi0xLTEtMS0w_83724371-d792-493b-b59d-599f9b2b39b5"
      unitRef="shares">90000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNi0zLTEtMS0w_7996eea8-e33e-43b3-83c9-c39653a2a286"
      unitRef="usdPerShare">23.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNi01LTEtMS0w_57fc09a9-2f05-4975-a413-21a7379d47c1">P8Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmI0MTJmNDY4NmIyYTQ3Nzk5NzRiYmNkZGVkODEyNzk3L3RhYmxlcmFuZ2U6YjQxMmY0Njg2YjJhNDc3OTk3NGJiY2RkZWQ4MTI3OTdfNi03LTEtMS0w_2d9cead3-fb76-4c96-b1f1-050c09114b26"
      unitRef="usd">695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <sls:ClosingPriceOfCommonStock
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMjA4OQ_b00f3a9e-11eb-4f8e-aeac-9bb311e22a23"
      unitRef="usdPerShare">11.10</sls:ClosingPriceOfCommonStock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDE0OQ_ecddf231-d4c2-426c-aed8-2fe43134123d">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three and six months ended June&#160;30, 2021 and 2020, respectively (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i524a7778f45b41d493eb970513cfe899_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMi0xLTEtMS0w_82519406-05bf-4488-96e4-098e3b7c93ee"
      unitRef="usd">35000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i455f2bcd2a26422b8ef4b6956db962dd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMi0zLTEtMS0w_a5c7dd7e-0b4a-472b-9eef-8d75b7e4de35"
      unitRef="usd">4000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib57038e75a2e456f9153d4562f7875c9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMi01LTEtMS0w_e433c318-9df6-4b31-b80d-46a87b304a19"
      unitRef="usd">48000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib53ff491bb4d406dbfc18398cc46aed4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMi03LTEtMS0w_ddeca4f2-b661-430f-baaf-a14d6be5a49b"
      unitRef="usd">5000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6957c26fb4be459faf509b1dc44c22e1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMy0xLTEtMS0w_79d2cbfa-db5f-4775-8f6e-a74527a261bc"
      unitRef="usd">229000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i34c6000daa9d4a529f676d7a949697c9_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMy0zLTEtMS0w_35be9862-2720-4192-a08b-b0d50eb4f77d"
      unitRef="usd">142000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if259b3f68de54eb69651fd71f0d90e8a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMy01LTEtMS0w_ce5bf1bd-e7af-41d0-87cf-4c752d51e1e6"
      unitRef="usd">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i69480503f88f4c8b8e46355038c252d7_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfMy03LTEtMS0w_01d0a9c8-fc57-4cf2-b012-336d65b0c4f2"
      unitRef="usd">286000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfNC0xLTEtMS0w_42cca71d-a0d2-4b99-86db-b9c1433b30b9"
      unitRef="usd">264000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfNC0zLTEtMS0w_9c748253-92f3-4746-b73a-7ceb504c887e"
      unitRef="usd">146000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfNC01LTEtMS0w_488a9116-32b4-4d5b-b177-7c432647d47b"
      unitRef="usd">448000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjI4NDYzNjljMjVhYzRiYjY4MDRmZWRiM2M1YTI4ODI2L3RhYmxlcmFuZ2U6Mjg0NjM2OWMyNWFjNGJiNjgwNGZlZGIzYzVhMjg4MjZfNC03LTEtMS0w_48352a68-543f-46f2-803b-e67b9b3eb3cc"
      unitRef="usd">291000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDE1NA_e1c3d781-1cd3-428c-868e-6783d4401192">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option-pricing model to determine the fair value of all its stock options granted. The assumptions used during the three and six months ended June&#160;30, 2021 and 2020, respectively, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected lives (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMi0xLTEtMS0w_2e676166-ad16-47a1-9edd-c2f9ca01b49b"
      unitRef="number">0.0112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMi0zLTEtMS0w_9bfbd6f8-0b7f-4672-b061-aff5fb196088"
      unitRef="number">0.0053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMi01LTEtMS0w_05034f18-fd02-4021-9e09-c6968463b855"
      unitRef="number">0.0104</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMi03LTEtMS0w_8ab817cc-6df8-47cb-ba58-c8413b4ad834"
      unitRef="number">0.0062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMy0xLTEtMS0w_434cbf27-1961-4111-85bd-953a97e16d64"
      unitRef="number">1.2147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMy0zLTEtMS0w_8004b511-b1c8-4f04-b3ab-ca50bf9fb837"
      unitRef="number">1.0808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMy01LTEtMS0w_b7e26c56-94a7-454c-b01e-bae25e3b75c3"
      unitRef="number">1.2123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfMy03LTEtMS0w_b271e054-8917-4126-af11-5cdbc513dae0"
      unitRef="number">1.0624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNC0xLTEtMS0w_28f3ab72-311e-4614-b677-01cf4ea49716">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNC0zLTEtMS0w_0bf44671-e2ff-4994-83f7-bb49041ff3df">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNC01LTEtMS0w_453d41bf-22ed-4b53-a05b-57a8c84dc10c">P6Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNC03LTEtMS0w_ae27991c-5813-4ff6-88c7-c14f00f3f2cd">P6Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNS0xLTEtMS0w_802d69a8-9ddb-4ee8-9d70-859a2465ba1a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNS0zLTEtMS0w_5f5a54d6-623d-4945-802b-47e6abd885bd"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNS01LTEtMS0w_73a263b2-ae06-42ce-9546-12c96e352383"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOmMwNTY4YTIxNmEzZDQ2ZGE4MzBjY2E5ZmRlOTA3ZjMxL3RhYmxlcmFuZ2U6YzA1NjhhMjE2YTNkNDZkYTgzMGNjYTlmZGU5MDdmMzFfNS03LTEtMS0w_81715e5b-7d56-41e9-9cdb-d3999bf5d9a6"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzI5ODUzNDg5MDcxMQ_0d29b7d5-e21f-4eba-b93b-5b99fc39b10a"
      unitRef="usdPerShare">6.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib67017fc406240feb6270ad2079440bd_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzI5ODUzNDg5MDcwNg_ee806dce-fddd-4059-9cf8-6940900076bc"
      unitRef="usdPerShare">1.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzI5ODUzNDg5MDcxOQ_43f382be-4d3c-4ffc-87f3-33179fb72f46"
      unitRef="usdPerShare">6.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i07c36ae937694c63b10658b767e16510_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzI5ODUzNDg5MDcyNw_a79efa40-dd86-4d40-a642-769e56de269b"
      unitRef="usdPerShare">1.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzE4Mw_75814b5b-1f0c-4077-ba86-7c0ba4fe9057">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i1eabe9b7328c4b42883ac930dcae2966_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzIxOQ_1b235e73-16e0-490b-836d-bb1d992e42a1">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ic3b2daec188244b58b5c6404473e5b28_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzI1NA_33c39ff9-e5c7-43cb-bd2e-0aef5c5d4586">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzM5MQ_eecaf4ac-dec1-4961-9eee-e0ad0e873af0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i8d028055c2e64d5e9dab5f9331370054_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzY2NA_a260fe5e-06de-4b4d-8f09-1adf98386efb"
      unitRef="usd">2400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <sls:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDk0NzgwMjMzMjE0MA_2b12ec91-f67b-4162-8c24-bb345b4e3544">P2Y11M23D</sls:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDEzNw_44bbd153-3b99-4fed-9a2e-9eccc32c80e4">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity of the Company for the six months ended June 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares&lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idd04b0465a9c4a3b89d3acede77717db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfMS0xLTEtMS0w_e3c603af-ca7f-408c-b1ae-572d6e143d47"
      unitRef="shares">170000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="idd04b0465a9c4a3b89d3acede77717db_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfMS0zLTEtMS0w_08085594-f515-441c-8c4d-de26d2ff8df2"
      unitRef="usdPerShare">1.89</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfMi0xLTEtMS0w_4053df9a-e320-4232-a7e7-694310f88329"
      unitRef="shares">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfMi0zLTEtMS0w_b14a628f-62e6-4310-8f09-118f95b00c9f"
      unitRef="usdPerShare">8.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfMy0xLTEtMS0w_ea7e022b-42b2-43bb-a1c4-68df9958e315"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfMy0zLTEtMS0w_d07618be-76ca-4c13-94f4-907c7a05bb1b"
      unitRef="usdPerShare">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i111b00fe2e9a484ab732132f92c59d7e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfNC0xLTEtMS0w_3328c4a2-d7d0-4fe0-b71d-824fd03922a6"
      unitRef="shares">210000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i111b00fe2e9a484ab732132f92c59d7e_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RhYmxlOjY0MjVhMzRhMDMzZDQ1ZTA4ODI5NjU1ODk4Mjg1OTlmL3RhYmxlcmFuZ2U6NjQyNWEzNGEwMzNkNDVlMDg4Mjk2NTU4OTgyODU5OWZfNC0zLTEtMS0w_dc93bd5f-2b12-4a8a-80c6-717afb592fdd"
      unitRef="usdPerShare">3.06</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i111b00fe2e9a484ab732132f92c59d7e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMzI5ODUzNDg5MDczMg_ea01e095-5bc5-4625-a467-2f21722a08bb"
      unitRef="usd">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <sls:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition
      contextRef="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNjA0NzMxMzk2MTUxNQ_51c11c95-4e2b-4848-9c29-6b9d2d14c8d5">P2Y11M8D</sls:EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMjc0ODc3OTA3Njg4Mw_2bdad1c3-a5ae-4f42-926a-d1c9a81beacf"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i018e48b1dacd47c68c32d3cc244c3f52_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfMjc0ODc3OTA3Njg4Mw_7f42dddc-9faf-4be6-ab10-233e12a9ee83"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i9994aed68348440999b4cb1d1a4ac219_I20210422"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDk0NzgwMjMzMjE0Mg_69763ba4-ed58-4c04-a53a-cb6e464277e4"
      unitRef="number">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ie5c340905f4d47a1a0096f2680c0f9f4_D20210422-20210422"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDk0NzgwMjMzMjE0Nw_cf3eed79-8a14-4f3f-84d5-1d91b40a4670"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9994aed68348440999b4cb1d1a4ac219_I20210422"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82NC9mcmFnOmExNDNlODIzZmZhMTQxYjc5M2I5NWIwZGZhZDBjMWFiL3RleHRyZWdpb246YTE0M2U4MjNmZmExNDFiNzkzYjk1YjBkZmFkMGMxYWJfNDk0NzgwMjMzMjE1Mg_00e41ded-1f0e-497b-be2a-d11267ed3255"
      unitRef="shares">300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="if7416b7a9cde449e9f869c897319832a_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV82Ny9mcmFnOjQyZGE5ZWJmNDA5MDQ5OTY5MjdiZWIxNDAwZjIyNmRiL3RleHRyZWdpb246NDJkYTllYmY0MDkwNDk5NjkyN2JlYjE0MDBmMjI2ZGJfMzE0_ddefd509-3947-4c8e-ada8-7400d2ee7d8d">Subsequent EventsThe Company evaluated all events or transactions that occurred after June&#160;30, 2021 up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the consolidated financial statements, the Company did not have any material subsequent events.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046710949816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SELLAS Life Sciences Group, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8099512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7 Times Square, Suite 2503,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">200-5278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,873,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001390478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046728611000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 29,917<span></span>
</td>
<td class="nump">$ 35,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockSubscriptionReceivableCurrent', window );">Stock subscription receivable</a></td>
<td class="nump">2,240<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetCurrent', window );">Contract asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,318<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">34,575<span></span>
</td>
<td class="nump">36,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_InProcessResearchDevelopment', window );">In-process research and development</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,914<span></span>
</td>
<td class="nump">1,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">623<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">43,624<span></span>
</td>
<td class="nump">46,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,276<span></span>
</td>
<td class="nump">4,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,781<span></span>
</td>
<td class="nump">1,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">182<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,239<span></span>
</td>
<td class="nump">12,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current</a></td>
<td class="nump">721<span></span>
</td>
<td class="nump">825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrant liability</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion', window );">Contingent consideration</a></td>
<td class="nump">4,896<span></span>
</td>
<td class="nump">4,633<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">10,209<span></span>
</td>
<td class="nump">18,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001&#160;par value; 5,000,000&#160;shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at June 30, 2021 and December 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001&#160;par value; 350,000,000&#160;shares authorized, 15,873,941 and 14,254,554&#160;shares issued and outstanding at June 30, 2021 and December&#160;31, 2020, respectively.</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">158,333<span></span>
</td>
<td class="nump">145,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(124,920)<span></span>
</td>
<td class="num">(117,904)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">33,415<span></span>
</td>
<td class="nump">27,961<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 43,624<span></span>
</td>
<td class="nump">$ 46,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent purchase price consideration, net of current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_InProcessResearchDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_InProcessResearchDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockSubscriptionReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Subscription Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockSubscriptionReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046622920712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">15,873,941<span></span>
</td>
<td class="nump">14,254,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">15,873,941<span></span>
</td>
<td class="nump">14,254,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046623544360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Licensing revenue</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of licensing revenue</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,456,000<span></span>
</td>
<td class="nump">2,280,000<span></span>
</td>
<td class="nump">7,740,000<span></span>
</td>
<td class="nump">4,144,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,797,000<span></span>
</td>
<td class="nump">1,987,000<span></span>
</td>
<td class="nump">6,358,000<span></span>
</td>
<td class="nump">4,187,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,353,000<span></span>
</td>
<td class="nump">4,267,000<span></span>
</td>
<td class="nump">14,298,000<span></span>
</td>
<td class="nump">8,331,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(4,453,000)<span></span>
</td>
<td class="num">(4,267,000)<span></span>
</td>
<td class="num">(6,698,000)<span></span>
</td>
<td class="num">(8,331,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(28,000)<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
<td class="num">(59,000)<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ChangeInFairValueOfContingentPurchasePriceConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(134,000)<span></span>
</td>
<td class="num">(143,000)<span></span>
</td>
<td class="num">(263,000)<span></span>
</td>
<td class="num">(281,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total non-operating expense, net</a></td>
<td class="num">(160,000)<span></span>
</td>
<td class="num">(158,000)<span></span>
</td>
<td class="num">(318,000)<span></span>
</td>
<td class="num">(237,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,613,000)<span></span>
</td>
<td class="num">(4,425,000)<span></span>
</td>
<td class="num">(7,016,000)<span></span>
</td>
<td class="num">(8,568,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_DividendArisingFromWarrantModifications', window );">Deemed dividend arising from warrant modifications</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(78,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders, basic</a></td>
<td class="num">(4,613,000)<span></span>
</td>
<td class="num">(4,425,000)<span></span>
</td>
<td class="num">(7,016,000)<span></span>
</td>
<td class="num">(8,646,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders, diluted</a></td>
<td class="num">$ (4,613,000)<span></span>
</td>
<td class="num">$ (4,425,000)<span></span>
</td>
<td class="num">$ (7,016,000)<span></span>
</td>
<td class="num">$ (8,646,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share attributable to common stockholders, basic (in dollars per share)</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="num">$ (1.32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share attributable to common stockholders, diluted (in dollars per share)</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="num">$ (1.32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">15,270,288<span></span>
</td>
<td class="nump">6,717,900<span></span>
</td>
<td class="nump">15,074,887<span></span>
</td>
<td class="nump">6,546,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">15,270,288<span></span>
</td>
<td class="nump">6,717,900<span></span>
</td>
<td class="nump">15,074,887<span></span>
</td>
<td class="nump">6,546,440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ChangeInFairValueOfContingentPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the fair value of contingent purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ChangeInFairValueOfContingentPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_DividendArisingFromWarrantModifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividend Arising From Warrant Modifications</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_DividendArisingFromWarrantModifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046623652920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,080,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 6,093<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 107,239<span></span>
</td>
<td class="num">$ (101,147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants', window );">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValueCommonStockandWarrants', window );">Issuance of common stock and common stock warrants, net of issuance costs</a></td>
<td class="nump">5,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodSharesPrefundedWarrant', window );">Issuance of common stock upon exercise of pre-funded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValuePreFundedWarrant', window );">Issuance of common stock upon exercise of pre-funded warrants</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,568)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,717,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">3,783<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">113,497<span></span>
</td>
<td class="num">(109,715)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,717,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">8,062<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">113,351<span></span>
</td>
<td class="num">(105,290)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,425)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,717,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">3,783<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">113,497<span></span>
</td>
<td class="num">(109,715)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,254,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">27,961<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">145,864<span></span>
</td>
<td class="num">(117,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants', window );">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValueCommonStockandWarrants', window );">Issuance of common stock and common stock warrants, net of issuance costs</a></td>
<td class="nump">9,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">832,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">3,017<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,016)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,016)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,873,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">33,415<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">158,333<span></span>
</td>
<td class="num">(124,920)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,084,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">28,742<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">149,047<span></span>
</td>
<td class="num">(120,307)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants', window );">Issuance of common stock and common stock warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockIssuedDuringPeriodValueCommonStockandWarrants', window );">Issuance of common stock and common stock warrants, net of issuance costs</a></td>
<td class="nump">9,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,613)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,873,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 33,415<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 158,333<span></span>
</td>
<td class="num">$ (124,920)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodSharesCommonStockandWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Common Stock and Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodSharesCommonStockandWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodSharesPrefundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Pre-funded Warrant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodSharesPrefundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodValueCommonStockandWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Common Stock and Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodValueCommonStockandWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockIssuedDuringPeriodValuePreFundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value, Pre-Funded Warrant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockIssuedDuringPeriodValuePreFundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046623418296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,016)<span></span>
</td>
<td class="num">$ (8,568)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ChangeInOperatingLeaseRightOfUseAssets', window );">Change in operating lease right of use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings', window );">Change in fair value of common stock warrants</a></td>
<td class="nump">59<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ChangeInFairValueOfContingentPurchaseConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Contract asset</a></td>
<td class="nump">1,128<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(1,932)<span></span>
</td>
<td class="num">(1,383)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,381)<span></span>
</td>
<td class="num">(1,476)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(136)<span></span>
</td>
<td class="nump">638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_IncreaseDecreaseInContractWithCustomerLiabilityNet', window );">Deferred revenue</a></td>
<td class="num">(5,600)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(15,167)<span></span>
</td>
<td class="num">(10,212)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">6,765<span></span>
</td>
<td class="nump">5,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ProceedsFromStockSubscriptionReceivable', window );">Collection of stock subscription receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from exercise of warrants</a></td>
<td class="nump">3,017<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">9,782<span></span>
</td>
<td class="nump">6,275<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents</a></td>
<td class="num">(5,385)<span></span>
</td>
<td class="num">(3,937)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period</a></td>
<td class="nump">35,402<span></span>
</td>
<td class="nump">7,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period</a></td>
<td class="nump">30,017<span></span>
</td>
<td class="nump">3,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Cash received during the period for interest</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockSubscriptionReceivable', window );">Stock subscription receivable</a></td>
<td class="nump">2,240<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating right of use asset and current and non-current lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_NoncashOfferingExpense', window );">Offering expenses in accounts payable and accrued expenses and other current liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of common stock warrants issued in connection with various equity financings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ChangeInFairValueOfContingentPurchaseConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of contingent purchase consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ChangeInFairValueOfContingentPurchaseConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Operating Lease Right of Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_IncreaseDecreaseInContractWithCustomerLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Contract with Customer, Liability, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_IncreaseDecreaseInContractWithCustomerLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_NoncashOfferingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Offering Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_NoncashOfferingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ProceedsFromStockSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Stock Subscription Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ProceedsFromStockSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Subscription Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046618755176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div><span style="color:#006ebf;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SELLAS Life Sciences Group, Inc. (the "Company" or "SELLAS") is a late-stage clinical biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS&#8217; lead product candidate, galinpepimut-S ("GPS"), is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center ("MSK") and targets the Wilms Tumor 1 ("WT1") protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. SELLAS&#8217; second product candidate, nelipepimut-S ("NPS"), is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 ("HER2") expressing cancers with potential for the treatment of patients with early stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer ("TNBC") patients, following standard of care.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Quarterly Report on Form 10-Q, the words the "Company," and "SELLAS" refer to SELLAS Life Sciences Group, Inc. and its consolidated subsidiaries following the completion of the business combination with Galena Biopharma, Inc., a Delaware corporation ("Galena"), and SELLAS Life Sciences Group, Ltd., a privately held Bermuda exempted company ("Private SELLAS"), in December 2017. This business combination is referred to as the Merger. Upon completion of the Merger, the Company's name changed from "Galena Biopharma, Inc." to "SELLAS Life Sciences Group, Inc." and the Company's financial statements became those of Private SELLAS.</span></div>On March 11, 2020, the World Health Organization declared the outbreak of a new coronavirus to be a &#8220;pandemic&#8221;. The COVID-19 pandemic continues to present substantial public health and economic challenges around the world which have impacted, and will continue to impact, millions of individuals and business worldwide. Efforts to contain the spread of the coronavirus since March 2020 have led to travel bans and restrictions, quarantines, shelter-in-place orders and shutdowns. The Company is continuously monitoring the impact of the pandemic on its clinical development programs. The full extent to which the COVID-19 pandemic directly or indirectly impacts the Company's business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and cannot be predicted with confidence, including the actions taken to contain or treat COVID-19, the ultimate overall duration of the pandemic, the emergence of new variants of COVID-19, the emergence of new geographic hotspots where the coronavirus is spreading more rapidly, and continued or new travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, as well as the effectiveness of actions taken globally to contain and treat the coronavirus, including the availability of safe and effective vaccines and the uptake thereof and whether existing vaccines are effective with respect to new variants. In particular, the continued spread of the coronavirus globally could adversely impact the Company's clinical trial operations and could have an adverse impact on our business and the financial results.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046620722504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidationBasisOfAccountingTextBlock', window );">Liquidity</a></td>
<td class="text">Liquidity<div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has incurred recurring losses and negative cash flows from operations and, as of June&#160;30, 2021, has an accumulated deficit of $124.9 million. During the six months ended June&#160;30, 2021, the Company used $15.2 million of cash in operations which included a net loss of $7.0 million, a $1.9&#160;million increase in prepaid expenses and other assets primarily for insurance and prepaid clinical trial costs, a $5.6&#160;million decrease in deferred revenue due to the recognition of licensing revenues and a $2.5&#160;million decrease in accounts payable and accrued expenses and other current liabilities, partially offset by a $1.1&#160;million decrease of contract acquisition costs related to the out-licensing of intellectual property rights and transfer of technical know-how and various net non-cash charges of $0.7&#160;million. The Company expects to continue to generate operating losses and negative cash flows for the next few years and will need additional funding to support its planned operating activities through profitability. The transition to profitability is dependent upon the successful development, approval, and commercialization of the Company's product candidates and the achievement of a level of revenues adequate to support its cost structure.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2021, the Company entered into a Controlled Equity Offering</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the "Sales Agreement") with Cantor Fitzgerald &amp; Co. (the "Agent"). From time to time during the term of the Sales Agreement, the Company may offer and sell shares of common stock having an aggregate offering price up to a total of $50.0&#160;million in gross proceeds. The Agent will collect a fee equal to 3% of the gross sales price of all shares of common stock sold. Shares of common stock sold under the Sales Agreement will be offered and sold pursuant to the Company's registration statement on Form S-3, which was filed with the SEC on April 16, 2021 and was declared effective on April 29, 2021. During the three months ended June&#160;30, 2021, the Company sold 786,927 shares of common stock pursuant to the Sales Agreement at an average price of $12.04 per share for aggregate net proceeds of approximately $9.0&#160;million, of which approximately $2.2&#160;million in net proceeds were received in July 2021 and classified as a stock subscription receivable as of June 30, 2021. Other than the Sales Agreement, the Company currently does not have any commitments to obtain additional funds.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received $1.0&#160;million and $2.0&#160;million during the three and six months ended June&#160;30, 2021, respectively, for the achievement of certain development milestones pursuant to the Company's Exclusive License Agreement (the "3DMed License Agreement) with 3D Medicines, Inc. ("3DMed"). An additional $192.5&#160;million in potential future certain development, regulatory, and sales milestones remains under the 3DMed License Agreement, which milestones are variable in nature and not under the Company's control. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company had cash and cash equivalents of approximately $29.9&#160;million, restricted cash and cash equivalents of $0.1&#160;million, and $2.2&#160;million of stock subscription receivable which cash was received in July 2021. In accordance with Accounting Standards Codification ("ASC") 205-40, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements - Going Concern</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the consolidated financial statements are issued. The Company expects its cash and cash equivalents, together with access to the Sales Agreement to sell common stock, will be sufficient to fund current planned operations for at least the next 12 months from the date of issuance of these financial statements, though it may pursue additional capital resources through public or private equity or debt financings or by entering into additional license agreements or collaborations with other companies. Management's expectations with respect to its ability to fund current planned operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management's estimates, the Company may need to seek additional strategic or financing opportunities sooner than would otherwise be expected. There is no guarantee that any of these strategic or financing opportunities will be executed or executed on favorable terms, and some could be dilutive to existing stockholders. If the Company is unable to obtain additional funding on a timely basis, it may be forced to significantly curtail, delay, or discontinue one or more of its planned research and development programs or be unable to expand its operations or otherwise prepare for the potential regulatory approval and commercialization of its product candidates, assuming positive data.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidationBasisOfAccountingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the liquidation basis of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=35686142<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiquidationBasisOfAccountingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046618750872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Significant Accounting Policies<div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's complete summary of significant accounting policies can be found in "Item 8. Financial Statements and Supplementary Data - Note 3. Basis of Presentation and Significant Accounting Policies" in the audited annual consolidated financial statements included in the 2020 Annual Report. The significant accounting policies summarized and included in the 2020 Annual Report have not materially changed, except as set forth below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates of the Financial Accounting Standards Board ("FASB").  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and its wholly owned subsidiaries, Private SELLAS, SLSG Limited, LLC, Sellas Life Sciences Limited, and Apthera, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unaudited Interim Results </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements and accompanying notes should be read in conjunction with the Company's annual consolidated financial statements and the notes thereto included in the 2020 Annual Report. The accompanying consolidated financial statements as of&#160;June&#160;30, 2021&#160;and for the three and six months ended June 30, 2021 and 2020, are unaudited, but include all adjustments, consisting of normal recurring entries, that management believes to be necessary for a fair presentation of the periods presented. Interim results are not necessarily indicative of results for a full year. Balance sheet amounts as of December&#160;31, 2020 have been derived from the audited financial statements as of that date.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassification</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on the Company's loss from operations, net loss, and net loss per share.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Subscription Receivable</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with FASB ASC 505-10-45-2, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables for Issuance of Equity</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recorded a stock subscription receivable as of June&#160;30, 2021 related to the sale, prior to June&#160;30, 2021 and before the financial statements are issued or available to be issued, of 157,130 shares of common stock pursuant to the Sales Agreement for net proceeds of $2.2&#160;million which cash was collected on July 2, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Time-Vested Restricted Stock Units</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, the Board of Directors granted restricted stock units ("RSUs") to employees that vest based on continuous service. Time-vested RSUs awarded to employees vest one-fourth per year annually over four years, provided the employee remains employed with the Company. The fair values of the RSUs are measured on the date of grant and are based on the Company's closing stock price on such date. Compensation expense for RSUs with only service conditions is recognized straight-line over the applicable service period. The Company accounts for forfeitures of RSUs when they occur. Previously recognized compensation expense for forfeited RSUs are reversed in the period the RSUs are forfeited.</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Standards Adopted and Recent Accounting Standards Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Standards Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which, among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard was adopted by the Company on January 1, 2021. This new standard did not have a material impact on the Company&#8217;s financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting standards not yet adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which, among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument.  As a result, after adopting the ASU&#8217;s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (ii) a convertible debt instrument was issued at a substantial premium. The standard becomes effective for the Company in the first quarter of 2022 and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046622877112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted&#160;Prices&#160;In<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant&#160;Other<br/>Observable&#160;<br/>Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable&#160;<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured and recorded at fair value</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,555&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,555&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured and recorded at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted&#160;Prices&#160;In&#160;&#160;<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant&#160;Other<br/>Observable&#160;<br/>Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable&#160;<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured and recorded at fair value</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,059&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,059&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured and recorded at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,688&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,688&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:49.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not transfer any financial instruments into or out of Level 3 classification during the six months ended June&#160;30, 2021 or during the year ended December 31, 2020.  See Note 8, Warrants to Acquire Shares of Common Stock, for a reconciliation of the changes in the fair value of the warrant liability for the six months ended June&#160;30, 2021. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in the fair value of the contingent consideration liability for the six months ended June&#160;30, 2021 is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value<br/>Measurements<br/>Using&#160;Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,633&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the estimated fair value of the contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,896&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The contingent consideration relates to Galena's acquisition of Apthera, Inc. in 2011 and the future contingent payments of up to $32.0 million based on the achievement of certain development and commercial milestones relating to the Company&#8217;s NPS product candidate, of which $2.0 million has been paid to date. The remaining contingent consideration of up to $30.0 million is payable at the election of the Company in either cash or shares of common stock, provided that the Company may not issue any shares in satisfaction of any contingent consideration, unless it has first obtained approval from its stockholders in accordance with Rule 5635(a) of the Nasdaq Marketplace Rules. </span></div>The significant unobservable assumptions include the probability of achieving each milestone, the date the Company expects to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. Changes in fair value reflect new information about the probability and anticipated timing of meeting the conditions of the milestone payments. In the absence of new information, changes in fair value will only reflect the interest component of contingent consideration related to the passage of time. As of June&#160;30, 2021, estimated future contingent milestone payments related to the Company's business range from zero, if no milestone events are achieved, to a maximum of $30.0 million if all development and commercial milestones are reached. As of June&#160;30, 2021, resulting probability-weighted cash flows were discounted using a weighted average cost of capital of 11.8% for development milestones and cost of debt of 5.4% for the commercial milestones. The Company estimates the timing of achievement of these development milestones to range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ1NjM1ZGRiZTA2YzQyNzM4ZDEwZGJiOWNhZTExNjY1L3NlYzo0NTYzNWRkYmUwNmM0MjczOGQxMGRiYjljYWUxMTY2NV80My9mcmFnOmIzOTQyNzhmNzZhMDRmZDZiZTg4MGM3NmI5NTFjOGE0L3RleHRyZWdpb246YjM5NDI3OGY3NmEwNGZkNmJlODgwYzc2Yjk1MWM4YTRfMjU0Nw_9e3118b3-4753-413f-9bca-561259d241ac">five</span> to eight years as of June&#160;30, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046620239160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Accounts</a></td>
<td class="text">Balance Sheet Accounts<div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046620232776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lease</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a non-cancelable operating lease for certain executive, administrative, and general business office space for its headquarters in New York, New York, which began on June 5, 2020 and has a term through December 31, 2024. The discount rate of the Company's operating lease under ASC 842: </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the Company's estimated incremental borrowing rate of 13%. As of June&#160;30, 2021, the lease has a remaining term of 3.5 years.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense related to the Company's operating lease was approximately $0.1 million for each of the three months ended June&#160;30, 2021 and 2020 and $0.1&#160;million and $0.2&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> f</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the six months ended June&#160;30, 2021 and 2020, respectively. The Company made cash payments related to its operating lease of approximately $0.1&#160;million for each of the three months ended June&#160;30, 2021 and 2020 and $0.2&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for each of</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the six months ended June&#160;30, 2021 and 2020. Future minimum lease payments under the Company's non-cancelable operating lease are as follows as of June&#160;30, 2021 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum lease payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current and non-current operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. The Company records a liability in its consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when the Company has assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, the Company records the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. The Company discloses a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect the Company&#8217;s consolidated results of operations, financial position or cash flows. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s predecessor company, Galena, was involved in multiple legal proceedings and administrative actions, including stockholder class actions, both state and federal. The remaining legal proceedings to which the Company is now subject are as follows: </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2017, certain putative shareholder securities class action complaints were filed in federal court alleging, among other things, that Galena and certain of Galena's former officers and directors failed to disclose that Galena&#8217;s promotional practices for Abstral&#174; (fentanyl sublingual tablets) were allegedly improper and that Galena may be subject to civil and criminal liability, and that these alleged failures rendered Galena&#8217;s statements about its business misleading. The actions were consolidated, lead plaintiffs were named by the U.S. District Court for the District of New Jersey and a consolidated complaint was filed. The Company filed a motion to dismiss the consolidated complaint. On August 21, 2018, the Company's motion to dismiss the consolidated complaint was granted without prejudice to file an amended complaint. On September 20, 2018, the plaintiffs filed an amended complaint. On October 22, 2018, the Company filed a motion to dismiss the amended complaint. On November 13, 2019, the U.S. District Court for the District of New Jersey granted the Company's motion to dismiss without prejudice to file an amended complaint. On December 20, 2019, the lead plaintiffs filed a second Amended Consolidated Class Action Complaint. On January 29, 2020, the Company filed a motion to dismiss the amended complaint. On January 5, 2021, the U.S. District Court for the District of New Jersey granted the Company's motion to dismiss without prejudice to file an amended complaint. On February 18, 2021, the lead plaintiffs filed a third Amended Consolidated Class Action Complaint. The Company has reached a settlement in principle with the plaintiffs in this action which is subject to final documentation and court approval and which will be fully covered by the Company's directors and officers insurance policy applicable to this case.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors and Galena, as a nominal defendant. In July 2017, a derivative complaint was filed in California state court against the Company&#8217;s former directors and Galena, as a nominal defendant. In January 2018, a derivative complaint was filed in the U.S. District Court for the District of New Jersey against the Company&#8217;s former directors, officers and employees, and the Company as a nominal defendant. These complaints purport to assert derivative claims for breach of fiduciary duty on the Company&#8217;s behalf against the Company&#8217;s former directors and, in certain of the complaints, the Company&#8217;s current directors, and the Company&#8217;s former officers and former employees, based on substantially similar facts as alleged in the putative shareholder securities class action complaints mentioned above. The derivative lawsuit filed in California state court is currently stayed pending resolution of a motion to dismiss in the referenced securities class action. On July 13, 2020 and July 16, 2020, respectively, the Company filed motions to dismiss the two complaints filed in the U.S. District Court for the District of New Jersey. The Company has reached a settlement in principle with the plaintiffs in these three cases which is subject to final documentation and court approval and which will be fully covered by the Company's directors and officers insurance policy applicable to these cases.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046618801080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized up to 5,000,000&#160;shares of preferred stock, $0.0001&#160;par value per share, for issuance. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized up to 350,000,000&#160;shares of common stock, $0.0001&#160;par value per share, for issuance. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company has shares of common stock reserved for future issuance as follows (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Company&#8217;s 2019 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the 2021 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the 2017 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,063&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046623526056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock', window );">Warrants to Acquire Shares of Common Stock</a></td>
<td class="text">Warrants to Acquire Shares of Common Stock<div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants Outstanding</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity of the Company's warrants to acquire shares of common stock for the six months ended June&#160;30, 2021 (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled/Expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2020 PIPE Offering</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(420)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2020 Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2019 Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2019 Exercise Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2018 Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 2021 - November 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(832)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to acquire shares of common stock consist of warrants that may be settled in cash, which are liability-classified warrants, and equity-classified warrants.</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants Classified as Liabilities </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability-classified warrants consist of warrants to acquire common stock issued in connection with certain previous equity financings. These warrants may be settled in cash and were determined not to be indexed to the Company&#8217;s common stock. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the consolidated statement of operations as change in fair value of warrant liability. The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: </span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:27.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of June 30, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Strike price (per share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Volatility %</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free rate %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other warrants (liability-classified)</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.50&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151.45&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding (in thousands)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Strike price (per share)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Volatility %</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free rate %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other warrants (liability-classified)</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.50&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150.38&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in fair value of the warrant liability for the six months ended June 30, 2021 were as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability, June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other warrants (liability-classified)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for freestanding contract indexed to and potentially settled in entity's own stock. Includes, but is not limited to, strike price and number of shares to which contract is indexed, settlement date, and settlement alternatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229355<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046708803624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Revenue with 3D Medicines, Inc.<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">License Revenue with 3D Medicines, Inc.</a></td>
<td class="text">License Revenue with 3D Medicines, Inc.<div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exclusive License Agreement with 3D Medicines, Inc.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company, together with its wholly-owned subsidiary, SLSG Limited, LLC, entered into an Exclusive License Agreement (the &#8220;3DMed License Agreement&#8221;) with 3D Medicines Inc. ("3DMed"), pursuant to which the Company granted 3DMed a sublicensable, royalty-bearing license, under certain intellectual property owned or controlled by the Company, to develop, manufacture and have manufactured, and commercialize GPS and heptavalent GPS (referred to as GPS Plus) product candidates ("GPS Licensed Products") for all therapeutic and other diagnostic uses in mainland China, Hong Kong, Macau and Taiwan ("3DMed Territory"). The license is exclusive, except with respect to certain know-how that has been non-exclusively licensed to the Company and is sublicensed to 3DMed on a non-exclusive basis. The Company has retained development, manufacturing and commercialization rights with respect to the GPS Licensed Products in the rest of the world.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In partial consideration for the rights granted by the Company, 3DMed agreed to pay the Company (i) a one-time upfront cash payment of $7.5&#160;million, and (ii) milestone payments totaling up to $194.5&#160;million in the aggregate upon the achievement of certain technology transfer, development and regulatory milestones, as well as sales milestones based on certain net sales thresholds of GPS Licensed Products in the 3DMed Territory in a given calendar year. The Company is responsible for providing the licensed technology and data (the "3DMed License") as well as transferring certain technological and manufacturing know-how (the "transfer of know-how").</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3DMed also agreed to pay tiered royalties based upon a percentage of annual net sales of GPS Licensed Products in the 3DMed Territory ranging from the high single digits to the low double digits. The royalties are payable on a GPS Licensed Product-by-GPS Licensed Product and region-by-region basis commencing on the first commercial sale of a GPS Licensed Product in a region and continuing until the latest of (i) the date that is 15 years from the receipt of marketing authorization for such GPS Licensed Product in such region and (ii) the date that is 10 years from the expiration of the last valid claim of a licensed patent covering or claiming such GPS Licensed Product in such region. The royalty rate is subject to reduction under certain circumstances, including when generic competition for a GPS Licensed Product exists in a particular region.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3DMed is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the GPS Licensed Products in the 3DMed Territory. 3DMed is required to use commercially reasonable best efforts to develop and obtain regulatory approval for, and upon receipt of regulatory approval, commercialize the GPS Licensed Products in the 3DMed Territory. A joint steering committee has been established between 3DMed and the Company to coordinate and review the development, manufacturing and commercialization plans with respect to the GPS Licensed Products in the 3DMed Territory. The Company and 3DMed also agreed to negotiate in good faith the terms and conditions of a clinical supply agreement, a commercial supply agreement, and related quality agreements pursuant to which the Company will manufacture or have manufactured and supply 3DMed with all quantities of the GPS Licensed Products necessary for 3DMed to develop and commercialize the GPS Licensed Products in the 3DMed Territory until 3DMed has received all approvals required for 3DMed or its designated contract manufacturing organization to manufacture the GPS Licensed Products in the 3DMed Territory.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 3DMed License Agreement will expire on a GPS Licensed Product-by-GPS Licensed Product and region-by-region basis on the date of the expiration of all of 3DMed&#8217;s payment obligations to the Company. Upon expiration of the 3DMed License Agreement, the license granted to 3DMed will become fully paid-up, perpetual and irrevocable. Either party may terminate the 3DMed License Agreement for the other party&#8217;s material breach following a cure period or upon certain insolvency events. The Company may terminate the 3DMed License Agreement if 3DMed or its affiliates or sublicensees challenge the validity or enforceability of the licensed patents. At any time following the two-year anniversary of the effective date, 3DMed has the right to terminate the 3DMed License Agreement for convenience, subject to certain requirements. 3DMed may terminate the 3DMed License Agreement upon prior notice to the Company if the grant of the license to 3DMed is prohibited or delayed for a period of time due to a change of U.S. export laws and regulations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 3DMed License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the 3DMed License Agreement and concluded that 3DMed was a customer and the 3DMed License Agreement should be evaluated under ASC 606. In determining the appropriate amount of revenue to be recognized under ASC 606 as the Company fulfills its obligations under the 3DMed License Agreement, the Company performs the following steps: (i) identifies the promised goods or services in the contract; (ii) determines whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measures the transaction price, including any constraints on variable consideration; (iv) allocates the transaction price to the performance obligations; and (v) recognizes revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified the 3DMed License and the transfer of know-how to be the material promises under the 3DMed License Agreement. The Company determined that the 3DMed License and the transfer of know-how are not distinct from each other. As such, for the purposes of ASC 606, the Company determined that these two material promises, described above, should be combined into a single performance obligation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price of the single performance obligation to be $9.5&#160;million, which includes the $7.5&#160;million upfront fee as well as $2.0&#160;million in development milestones that are assessed to be probable of being achieved at the inception of the 3DMed License Agreement and therefore were not constrained. The Company achieved $1.0&#160;million of these milestones in the first quarter of 2021 and achieved the remaining $1.0&#160;million milestone in the second quarter of 2021. The Company determined that $192.5&#160;million in future certain development, regulatory, and sales milestones to be variable consideration subject to constraint at inception. At the end of each subsequent reporting period, the Company will reevaluate the probability of achievement of the future development, regulatory, and sales milestones subject to constraint and, if necessary, will adjust its estimate of the overall transaction price. Any such adjustments will be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the sales-based royalties, the Company will recognize revenue when the related sales occur. To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 3DMed benefited from the combined single performance obligation relating to the 3DMed License and the transfer of know-how as the technology transfer occurred, the Company recognized the transaction price over the technology transfer period, which was finalized in the second quarter of 2021. The revenue recognized was based on an output method to measure progress, using a straight-line convention, which the Company believes reasonably approximates its efforts in satisfying the combined performance obligation. The Company recognized $1.9&#160;million and $7.6&#160;million of license revenue during the three and six months ended June&#160;30, 2021, respectively. As of June 30, 2021, the initial transaction price of the single performance obligation of $9.5&#160;million has been fully recognized as licensing revenue. There was no license revenue recognized during the three and six months ended June 30, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the activity in the Company's deferred revenue, related to the total cash payments received of $9.5&#160;million to date under the 3DMed License, during the six months ended June&#160;30, 2021 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,600)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Contract Acquisition</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred contract acquisition costs (commissions) recorded as a contract asset amounting to approximately $1.4&#160;million at inception of the 3DMed License Agreement which were capitalized under ASC 340-40 as incremental costs of obtaining the 3DMed License Agreement. These costs are amortized through general and administrative expense over the technology transfer period, commensurate with when the license revenue is recognized. The Company recognized $0.3&#160;million and $1.1&#160;million in expense associated with these costs during the three and six months ended June&#160;30, 2021, respectively. There was no contract acquisitions expense during the three and six months ended June 30, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of License Revenue</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $0.1&#160;million and $0.2&#160;million of sublicensing fees payable under its license from MSK in connection with the 3DMed License during the three and six months ended June&#160;30, 2021, respectively. There was no cost of license revenue during the three and six months ended June 30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046708803624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Equity Incentive Plan </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the 2017 Equity Incentive Plan was approved by the stockholders of the Company, which provided for the issuance of up to a maximum of 24,204 shares of common stock underlying stock options granted prior to September 10, 2019. The 2017 Equity Incentive Plan was terminated upon the approval of the 2019 Incentive Plan subject to outstanding stock options granted under the 2017 Equity Incentive Plan that remain exercisable through maturity for the Company's employees and directors. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Equity Incentive Plan </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2019, the 2019 Equity Incentive Plan was approved by the stockholders of the Company, which currently allows for issuance of up to approximately (i) 1,191,000 shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate plus (ii) 2,684 shares of common stock under the 2017 Equity Incentive Plan that were forfeited back to the Company subsequent to September 10, 2019 and are available for future issuance. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares reserved for issuance under the 2019 Equity Incentive Plan will automatically increase on January 1&#160;of each year, for a period of not more than four years, commencing on January 1, 2020 and ending on (and including) January&#160;1, 2023, by an amount equal to the lesser of (i) 5% of the total number of shares of common stock outstanding at the end of the prior fiscal year; and (ii) an amount determined by the board of directors or authorized committee. As of June&#160;30, 2021, approximately 463,000 shares of common stock were reserved for future grants under the 2019 Equity Incentive Plan. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options to Purchase Shares of Common Stock </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity of the Company for the six months ended June 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Number of<br/>Shares <br/>(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (In Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.08</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.48</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values of outstanding and exercisable stock options at June&#160;30, 2021 were calculated based on the closing price of the Company&#8217;s common stock as reported on the Nasdaq Capital Market on June&#160;30, 2021 of $11.10 per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company&#8217;s common stock and the exercise price of the underlying stock options.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three and six months ended June&#160;30, 2021 and 2020, respectively (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to determine the fair value of all its stock options granted. The assumptions used during the three and six months ended June&#160;30, 2021 and 2020, respectively, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.53&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.04&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected lives (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the three months ended June&#160;30, 2021 and 2020 was $6.89 and $1.35, respectively. The weighted-average grant date fair value of options granted during the six months ended June 30, 2021 and 2020 was $6.97 and $1.53, respectively. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method, which averages the contractual term of the Company&#8217;s options of ten years with the average vesting term of four years for an average of approximately six years. The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company accounts for forfeitures as they occur.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, there was $2.4 million of unrecognized compensation cost related to outstanding stock options that is expected to be recognized as a component of the Company&#8217;s operating expenses over a weighted-average period of 2.98 years.</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Time-vested RSUs and RSUs with Performance Conditions </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity of the Company for the six months ended June 30, 2021:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares<br/>(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.89&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, there was $0.6 million of unrecognized compensation cost related to outstanding RSUs that is expected to be recognized as a component of the Company's operating expenses over a weighted-average period of 2.94 years. No RSUs vested during the three and six months ended June&#160;30, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2021, the Board of Directors adopted the 2021 Employee Stock Purchase Plan ("2021 ESPP") which was approved by the Company's stockholders on June 8, 2021. The 2021 ESPP allows employees to contribute up to 20% of their cash earnings, subject to a maximum of $25,000 per year under Internal Revenue Service rules, to be used to purchase shares of the Company&#8217;s common stock on semi-annual purchase dates. The 2021 ESPP allows eligible employees to purchase shares of common stock at a price per share equal to 85% of the lower of the fair market value of the common stock at the beginning or end of each six-month offering period during the term of the 2021 ESPP. The first offering period will begin in September 2021. There are currently 300,000 shares of common stock reserved for issuance under the 2021 ESPP.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046620115736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsThe Company evaluated all events or transactions that occurred after June&#160;30, 2021 up through the date these financial statements were issued. Other than as disclosed elsewhere in the notes to the consolidated financial statements, the Company did not have any material subsequent events.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046623965512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates of the Financial Accounting Standards Board ("FASB").<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated upon consolidation. Unless the context otherwise indicates, reference in these notes to the "Company" refer to SELLAS Life Sciences Group, Inc., and its wholly owned subsidiaries, Private SELLAS, SLSG Limited, LLC, Sellas Life Sciences Limited, and Apthera, Inc. The functional currency of the Company's non-U.S. operations is the U.S. dollar.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassification</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on the Company's loss from operations, net loss, and net loss per share.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Time-Vested Restricted Stock Units</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Time-Vested Restricted Stock Units</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, the Board of Directors granted restricted stock units ("RSUs") to employees that vest based on continuous service. Time-vested RSUs awarded to employees vest one-fourth per year annually over four years, provided the employee remains employed with the Company. The fair values of the RSUs are measured on the date of grant and are based on the Company's closing stock price on such date. Compensation expense for RSUs with only service conditions is recognized straight-line over the applicable service period. The Company accounts for forfeitures of RSUs when they occur. Previously recognized compensation expense for forfeited RSUs are reversed in the period the RSUs are forfeited.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards Adopted and Recent Accounting Standards Not Yet Adopted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Standards Adopted and Recent Accounting Standards Not Yet Adopted</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Standards Adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which, among other things, eliminates certain exceptions in the current rules regarding the approach for intraperiod tax allocations and the methodology for calculating income taxes in an interim period, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard was adopted by the Company on January 1, 2021. This new standard did not have a material impact on the Company&#8217;s financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent accounting standards not yet adopted</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which, among other things, simplifies the accounting models for the allocation of proceeds attributable to the issuance of a convertible debt instrument.  As a result, after adopting the ASU&#8217;s guidance, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, and for convertible preferred stock wholly as preferred stock (i.e., as a single unit of account), unless (i) a convertible instrument contains features that require bifurcation as a derivative under ASC 815 or (ii) a convertible debt instrument was issued at a substantial premium. The standard becomes effective for the Company in the first quarter of 2022 and early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046620030200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Outstanding Excluded from Computation of Diluted Weighted Average Shares Outstanding</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,498&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046618493784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present information about the Company's assets and liabilities measured at fair value on a recurring basis in the consolidated balance sheets (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted&#160;Prices&#160;In<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant&#160;Other<br/>Observable&#160;<br/>Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable&#160;<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,455&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured and recorded at fair value</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,555&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,555&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured and recorded at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Quoted&#160;Prices&#160;In&#160;&#160;<br/>Active Markets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Significant&#160;Other<br/>Observable&#160;<br/>Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unobservable&#160;<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured and recorded at fair value</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,059&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,059&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities measured and recorded at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,688&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,688&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Level 3 Liabilities</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the change in the fair value of the contingent consideration liability for the six months ended June&#160;30, 2021 is as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value<br/>Measurements<br/>Using&#160;Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,633&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in the estimated fair value of the contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,896&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046618655384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,913&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046620742616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Lease Payments</a></td>
<td class="text">Future minimum lease payments under the Company's non-cancelable operating lease are as follows as of June&#160;30, 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:78.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Future minimum lease payments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current and non-current operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046623845432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_CommonStockAreReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the Company has shares of common stock reserved for future issuance as follows (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.836%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the Company&#8217;s 2019 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the 2021 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares reserved for future issuance under the 2017 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock reserved for future issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,063&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_CommonStockAreReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock are reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_CommonStockAreReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046618526952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ScheduleOfWarrantActivityTableTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity of the Company's warrants to acquire shares of common stock for the six months ended June&#160;30, 2021 (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled/Expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding, June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2020 PIPE Offering</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(420)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2020 Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2025</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2019 Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2019 Exercise Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2018 Offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 2021 - November 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(832)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model</a></td>
<td class="text">The fair value of the warrants is estimated using a Black-Scholes pricing model with the following inputs: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:27.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.539%"/><td style="width:0.1%"/></tr><tr><td colspan="30" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of June 30, 2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding (in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Strike price (per share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Volatility %</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free rate %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other warrants (liability-classified)</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.50&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151.45&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of December 31, 2020</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding (in thousands)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Strike price (per share)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Volatility %</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free rate %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other warrants (liability-classified)</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.50&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150.38&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock', window );">Schedule of Changes in Fair Value of Warrant Liability</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in fair value of the warrant liability for the six months ended June 30, 2021 were as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant Issuance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability, June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other warrants (liability-classified)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ScheduleOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ScheduleOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Warrant Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046618785000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Revenue with 3D Medicines, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Deferred Revenue, Related to Upfront Cash Payment Received</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the activity in the Company's deferred revenue, related to the total cash payments received of $9.5&#160;million to date under the 3DMed License, during the six months ended June&#160;30, 2021 (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,600)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046708891592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity of the Company for the six months ended June 30, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Number of<br/>Shares <br/>(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (In Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.08</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.48</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Stock-based Compensation Expense</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of stock-based compensation expense in the consolidated statements of operations for the three and six months ended June&#160;30, 2021 and 2020, respectively (in thousands):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions for Option Grants Issued</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to determine the fair value of all its stock options granted. The assumptions used during the three and six months ended June&#160;30, 2021 and 2020, respectively, were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.53&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.04&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.62&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected lives (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSU Activity</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity of the Company for the six months ended June 30, 2021:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares<br/>(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.89&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046622205256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Apr. 16, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,920,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,920,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,904,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,425,000<span></span>
</td>
<td class="nump">7,016,000<span></span>
</td>
<td class="nump">$ 8,568,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,167,000<span></span>
</td>
<td class="nump">10,212,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Increase in prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,932,000<span></span>
</td>
<td class="nump">1,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Decrease in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_NonCashCharges', window );">Non-cash charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived', window );">Potential milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,302,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_StockSubscriptionReceivableCurrent', window );">Stock subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds of common stock</a></td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sls_SalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SaleOfStockAuthorizedAmount', window );">Sale of shares, common stock gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SaleOfStockAgentFeePercentageOfGrossProceeds', window );">Percentage gross proceeds from the sale of share (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">786,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sls_SalesAgreementMember', window );">Sales Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_NonCashCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_NonCashCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Research And Development Arrangement, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Potential Milestone Payments To Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SaleOfStockAgentFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Agent Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SaleOfStockAgentFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SaleOfStockAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SaleOfStockAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_StockSubscriptionReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Subscription Receivable, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_StockSubscriptionReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sls_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sls_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046618505880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Stock Subscription Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds of common stock</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046620139432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Time - Vested Restricted Stock Units (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock unit award vested period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046711525704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">1,289<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046623327624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrant liability</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">29,455<span></span>
</td>
<td class="nump">34,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">29,555<span></span>
</td>
<td class="nump">35,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrant liability</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">4,896<span></span>
</td>
<td class="nump">4,633<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">5,010<span></span>
</td>
<td class="nump">4,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted&#160;Prices&#160;In Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">29,455<span></span>
</td>
<td class="nump">34,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">29,555<span></span>
</td>
<td class="nump">35,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;Other Observable&#160; Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Unobservable&#160; Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure', window );">Restricted cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsPotentiallySettleableInCash', window );">Warrant liability</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">4,896<span></span>
</td>
<td class="nump">4,633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">$ 5,010<span></span>
</td>
<td class="nump">$ 4,688<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_FairValueOfWarrantsPotentiallySettleableInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants potentially settleable in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_FairValueOfWarrantsPotentiallySettleableInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_RestrictedCashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_RestrictedCashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046620218728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details) - Unobservable&#160; Inputs (Level 3)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration, December 31, 2020</a></td>
<td class="nump">$ 4,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Change in the estimated fair value of the contingent consideration</a></td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent consideration, June 30, 2021</a></td>
<td class="nump">$ 4,896<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046623478856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - Apthera, Inc.<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2011 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration payable, maximum amount</a></td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="nump">$ 32,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration paid</a></td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow', window );">Contingent consideration payable, minimum amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sls_AptheraInc.Member', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones', window );">Business combination, contingent consideration, timing of development milestones</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sls_AptheraInc.Member', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones', window );">Business combination, contingent consideration, timing of development milestones</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sls_AptheraInc.Member', window );">Weighted average cost of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, measurement input (as a percent)</a></td>
<td class="nump">0.118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sls_AptheraInc.Member', window );">Cost of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, measurement input (as a percent)</a></td>
<td class="nump">0.054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Timing Of Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sls_AptheraInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sls_AptheraInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sls_MeasurementInputWeightedAverageCostOfCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sls_MeasurementInputWeightedAverageCostOfCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sls_MeasurementInputCostOfDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sls_MeasurementInputCostOfDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046624143208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">$ 1,247<span></span>
</td>
<td class="nump">$ 221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PrepaidResearchAndDevelopment', window );">Clinical trial costs</a></td>
<td class="nump">996<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_PrepaidProfessionalServices', window );">Professional fees</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 2,318<span></span>
</td>
<td class="nump">$ 395<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_PrepaidProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Professional Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_PrepaidProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_PrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Research And Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_PrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046623267912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ContractResearchPayable', window );">Clinical trial costs</a></td>
<td class="nump">$ 806<span></span>
</td>
<td class="nump">$ 631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,781<span></span>
</td>
<td class="nump">$ 1,913<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ContractResearchPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract Research Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ContractResearchPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046711438680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 16, 2020 </div>
<div>complaint</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of claims which the Company filed motions to dismiss | complaint</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=sls_OfficeSpaceLeaseExpiringDecember312024Member', window );">Office Space Lease Expiring December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_OperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments related to operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_OperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_OperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=sls_OfficeSpaceLeaseExpiringDecember312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=sls_OfficeSpaceLeaseExpiringDecember312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046624146872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of Lease Liabilities - 842 (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (remaining)</a></td>
<td class="nump">$ 152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Current and non-current operating lease liability</a></td>
<td class="nump">$ 903<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046620339528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046711154024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding (in shares)</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common stock reserved for future issuance (in shares)</a></td>
<td class="nump">2,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sls_A2019EquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sls_A2021EmployeeStockPurchasePlanMember', window );">2021 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sls_A2017EmployeeStockPurchasePlanMember', window );">2017 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding (in shares)</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sls_A2019EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sls_A2019EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sls_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sls_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sls_A2017EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sls_A2017EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046623770392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock - Warrants Outstanding (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(832)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sls_July2020PIPEOfferingMember', window );">July 2020 PIPE Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sls_January2020OfferingMember', window );">January 2020 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sls_July2019OfferingMember', window );">June 2019 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sls_WarrantExerciseAgreementMember', window );">March 2019 Exercise Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sls_July2018OfferingMember', window );">July 2018 Offering</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sls_OtherWarrantIssuesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightOutstandingRollForward', window );"><strong>Class of Warrant or Right, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightCanceledOrExpired', window );">Canceled/Expired (in shares)</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ClassOfWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ClassOfWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ClassOfWarrantOrRightNumberOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ClassOfWarrantOrRightNumberOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ClassofWarrantorRightCanceledOrExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Canceled Or Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ClassofWarrantorRightCanceledOrExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ClassofWarrantorRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ClassofWarrantorRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_July2020PIPEOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_July2020PIPEOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_January2020OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_January2020OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_July2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_July2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_WarrantExerciseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_WarrantExerciseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_July2018OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_July2018OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_OtherWarrantIssuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_OtherWarrantIssuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046623953784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sls_OtherLiabilityClassifiedMember', window );">Other warrants (liability-classified)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_WarrantStrikePrice', window );">Strike price (in dollars per share)</a></td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm', window );">Expected term (years)</a></td>
<td class="text">2 years 3 months 3 days<span></span>
</td>
<td class="text">2 years 9 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_WarrantsFairValueAssumptionsExpectedVolatility', window );">Volatility %</a></td>
<td class="nump">151.45%<span></span>
</td>
<td class="nump">150.38%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate %</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.16%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Warrant Liability Assumptions Expected Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_WarrantStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Strike Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_WarrantStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_WarrantsFairValueAssumptionsExpectedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Expected Volatility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_WarrantsFairValueAssumptionsExpectedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_WarrantsFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Fair Value Assumptions Risk Free Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_WarrantsFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_OtherLiabilityClassifiedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_OtherLiabilityClassifiedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046624098424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input coupon rate</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input coupon rate</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046623990440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsLiabilities', window );">Warrant liability, beginning balance</a></td>
<td class="nump">$ 55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsLiabilities', window );">Warrant liability, ending balance</a></td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sls_OtherLiabilityClassifiedMember', window );">Other warrants (liability-classified)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClassofWarrantorRightFairValueRollForward', window );"><strong>Class of Warrant or Right, Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsLiabilities', window );">Warrant liability, beginning balance</a></td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ChangeInFairValueOfWarrantLiabilities', window );">Change in fair value of warrants</a></td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_FairValueOfWarrantsLiabilities', window );">Warrant liability, ending balance</a></td>
<td class="nump">$ 114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ChangeInFairValueOfWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ChangeInFairValueOfWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ClassofWarrantorRightFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Fair Value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ClassofWarrantorRightFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_FairValueOfWarrantsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_FairValueOfWarrantsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sls_OtherLiabilityClassifiedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sls_OtherLiabilityClassifiedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046620427944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Revenue with 3D Medicines, Inc. - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ResearchAndDevelopmentArrangementCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum', window );">Future milestone payments received</a></td>
<td class="nump">$ 194,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm', window );">Royalties payable, maximum term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm', window );">Royalties payable, minimum term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligation, amount</a></td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved', window );">Milestones probable of being achieved</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived', window );">Potential milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized', window );">Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Contract acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, New Contract Revenue, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ContractWithCustomerLiabilityNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Research And Development Arrangement, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ResearchAndDevelopmentArrangementCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Cash Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ResearchAndDevelopmentArrangementCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Milestones Probable Of Being Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Potential Milestone Payments To Be Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Potential Milestone Payments To Be Received, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Royalties Payable, Maximum Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Arrangement, Royalties Payable, Minimum Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046711796376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Revenue with 3D Medicines, Inc. - Deferred Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInDeferredRevenueRollForward', window );"><strong>Movement in Deferred Revenue [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized', window );">Revenue Recognized</a></td>
<td class="num">$ (1,900,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(7,600,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ContractWithCustomerLiabilityNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, New Contract Revenue, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ContractWithCustomerLiabilityNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInDeferredRevenueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInDeferredRevenueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046616258056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 22, 2021</div></th>
<th class="th"><div>Sep. 10, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_ClosingPriceOfCommonStock', window );">Closing price of the Company's common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.89<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="nump">$ 6.97<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Averages contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition', window );">Operating expenses weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition', window );">Operating expenses weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sls_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sls_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Equity Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sls_TwoThousandAndNineteenEquityIncentivePlanMember', window );">2019 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,191,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Increase in number of shares available for future issuance under stock based awards (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sls_A2021EmployeeStockPurchasePlanMember', window );">2021 ESPP | Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Cash earnings contributed per year</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_ClosingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_ClosingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sls_TwoThousandAndSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sls_TwoThousandAndSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sls_TwoThousandAndNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sls_TwoThousandAndNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sls_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sls_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046622920648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 13.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="nump">7.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in dollars per share)</a></td>
<td class="nump">10.14<span></span>
</td>
<td class="nump">$ 13.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">$ 23.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term, outstanding (in years)</a></td>
<td class="text">9 years 3 months<span></span>
</td>
<td class="text">9 years 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, options exercisable (in years)</a></td>
<td class="text">8 years 5 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, beginning balance</a></td>
<td class="nump">$ 733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, ending balance</a></td>
<td class="nump">2,688<span></span>
</td>
<td class="nump">$ 733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, options exercisable</a></td>
<td class="nump">$ 695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sls_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046708934056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Allocated Stock-based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 448<span></span>
</td>
<td class="nump">$ 291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046623493816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions for Option Grants Issued (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.12%<span></span>
</td>
<td class="nump">0.53%<span></span>
</td>
<td class="nump">1.04%<span></span>
</td>
<td class="nump">0.62%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">121.47%<span></span>
</td>
<td class="nump">108.08%<span></span>
</td>
<td class="nump">121.23%<span></span>
</td>
<td class="nump">106.24%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected lives (years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
<td class="text">6 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140046623753272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSU Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 6.89<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="nump">$ 6.97<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares (In Thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>63
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M&.CO[[C&6O=B+JNW_YR8_P-02P,$%     @ )H(,4WO_*.?B @  ; H  !@
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MK"'DZWP+GI75?[1OL,X +;:EY'D3K)X@3XOZEWYKA#@(4'G@ -($D-, KR?
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M9R@$(6&% &2/0@#2JA#I[!MQK![FB0E4KJG0"VJ]::=FB\VUD,X>$7R>^*I
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MGU0S,HE>_*/1VYL$E9X(=>T1L*0G_E'/<DU[!*PBL[U#6)AEFNY+JF(S58?
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MN:[V!,4\@Q8HB6XB-O+*(<<GM(Q&DQ9U71L\]>W$1376R(EUL27YACYG(Z6
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MYDNVDJY4B0_SZ?E S=]'?",\,AP$[R@&;5(B2F6(::ICW!OJ".R@^(QZ"J+
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M4M$X( 1\SC<N>D0OJ#?0(HY2G&)8U3E]6)\Y"H^RD8"":"I:Y!OD.S896JM
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M1FYPV?=_BOLGALZG!(XC$/S B#Q].1W/I_$:Z9WB^P5-QSSZ_J,J-C SB89
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M;+NDMI9]H?25@XM@,S':F4*EPD-M*0JA$TFA"!T]"3*F=O#CGA[2N72)555
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MKZ4PS/$\E98%L)X9' +K#W:P>?">_ -02P,$%     @ )H(,4]=@('WC @
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M/%HEY6K<1VO)+UJ[5.)=;3>I=.Y"+!-$5MN"<Y;"-*Y_IW* 1QRYBSA )?2
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MM #/2VM#=T$*^F^ME_\#4$L#!!0    ( ":"#%,94\W/[P(  &('   9
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M<VAE970Q-2YX;6RM6MMRVS@2_164UK5K5\FR+#O)Y%KE.'-/JE+QS.[#UCY
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M[E18L^U3FFN"3[*Z4S";5PHD43#J@!>)H*PJ2JZ]QA^K9C"W)*89!-""%8)
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MF6IW>R6,I7W!"EG7B(*<ETHL&OC!J[RH%+$3[WDO79#LGW\Z/1N](@5">E'
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M(Q)'\7C 7M*%G#A[R3^'?,UTQJ6-6I,_+U-M%-Z2OP9\3#H?$^=C<L+'I=:
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MP6B\ WVOM';[@Q<8EOKB-U!+ P04    "  F@@Q3J@NL),$"  !S!@  &0
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MDDEX,*8DJHU_C PDJI*VGMC6VKYWLWK,G]WKQ_*&Z0VGX@5F!(VZ%\, =/T
MU0>K2C_T:V5)P7Z;TYN-VCG0?::4;0XN0?LO,/T#4$L#!!0    ( ":"#%/-
M$2JEV@0  *@,   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;*U7;4_C
M1A#^*Z.4JT#B'+\D3D(A4H"[*Y5.AW@[554_;.Q)8K'VNKMK0OKK.[-V3.#
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M(/U70-8#LE!HIRR4=4LL*7*M=J!]MF/S0? FH%TU3/I37%GM5IG#V>*&&&9
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ML^:'#:T/X/^E,;1W_ '34[GZ!U!+ P04    "  F@@Q37X15%_L"  !>"@
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M&4V8+&\PUY="Z.>#,D&[T[;X!U!+ P04    "  F@@Q3M0#+"5P#  !)"@
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MT@TW"[G["%4\?<N72J[=/]F5MH,KCZ0;;611@=&#@HGR29^K/!P D*<9$%:
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MZPGVQ+*%_:$O&^J<*CR\FG!8HE30&6"65=FDRHF1:U>%'Z7!FNZ&.?9U4-8
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M@HN68SQB(?.U,4'AWYJ-61@:2^#']]QH:S>G 98_/UF_38.'8&94L;$(O_)
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MY^I:]2G/YZQ\(UEF!HD%DVHL,<M8S:; -4"]7S(F=QMMH)QV!W\!4$L#!!0
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MH:P$DT\3J2=F*T'#EV^^#'4$%C25]<>ASN WL,IK!] UN%\]@+E*:2+>P$6
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M)8D? <RO((HP!-Y&',$4@ 8,B:)J']S;C\+-/A6VOX*-?P-02P,$%     @
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MB2M;RKFBY>DS@],G$I__!5!+ P04    "  F@@Q3.(-O)L0!   -'@  &@
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ )H(,4YE<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "  F@@Q3,"NN+4D%  !S%0  &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ )H(,4_7RL"DL!@
MJ!@  !@              ("!C T  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( ":"#%-[_RCGX@(  &P*   8              " @>X3
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  F@@Q3:?CU
M2\@%  ";&0  &               @($&%P  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ )H(,4Y KM5!$!@  :R$  !@
M ("!!!T  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( ":"
M#%,Q1H@PZ 4  #47   8              " @7XC  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    "  F@@Q3,DC1+"$%  !["P  &
M        @(&<*0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ )H(,4R:VTF!V"0  F1<  !@              ("!\RX  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ":"#%,Q,08"K L  %(>   8
M              " @9\X  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    "  F@@Q3;S[D78T%  #\#@  &0              @(&!1   >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ":"#%/78"!]XP(
M -0&   9              " @45*  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ )H(,4V^\?8;6"0  =QT  !D              ("!
M7TT  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  F@@Q3
M&5/-S^\"  !B!P  &0              @(%L5P  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( ":"#%. 8,B_Y@4  *\/   9
M      " @9):  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ )H(,4U7C_D<T#@  WRH  !D              ("!KV   'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  F@@Q37D2/FDH*  "5'0
M&0              @($:;P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( ":"#%,.6.;S< (  '4%   9              " @9MY  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ )H(,4U8_)J^9
M"0  =!D  !D              ("!0GP  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    "  F@@Q3QN45+=H"   J!@  &0
M@($2A@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( ":"
M#%.>R\]"U ,   (+   9              " @2.)  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ )H(,4V0^4U07 P  J0<  !D
M         ("!+HT  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    "  F@@Q3#^FGGJL"  #@!0  &0              @(%\D   >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ":"#%.J"ZPDP0(  ',&
M   9              " @5Z3  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ )H(,4_1W';U[!   #PP  !D              ("!5I8
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  F@@Q38!T@
M"N8"   1!@  &0              @($(FP  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( ":"#%/-$2JEV@0  *@,   9
M  " @26>  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
M)H(,4V)83L"<!0  <!@  !D              ("!-J,  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    "  F@@Q3Y C=HVX"  #)!0  &0
M            @($)J0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( ":"#%/C\N"]80(  #8%   9              " @:ZK  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ )H(,4U^$51?[ @
M7@H  !D              ("!1JX  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    "  F@@Q3$\P@!O($  !\&0  &0              @(%X
ML0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ":"#%/.
M>E":N0(  $X&   9              " @:&V  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ )H(,4PBNF+F+ P  \ T  !D
M     ("!D;D  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ":"#%-3?>G#9@(  +P&   9              "
M@:W)  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ )H(,
M4P/-VJ(V P  )0P  !D              ("!2LP  'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    "  F@@Q3C<P2_]<$  !U&P  &0
M        @(&WSP  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( ":"#%.U ,L)7 ,  $D*   9              " @<74  !X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ )H(,4W<3<;=3 @  [@4
M !D              ("!6-@  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    "  F@@Q30CG0C,<"  !-"   &0              @('BV@
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ":"#%.)MW$4
M# 0  '0/   9              " @>#=  !X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ )H(,4R.$2)>] @  -0@  !D
M ("!(^(  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  F
M@@Q3YK7>RN8%  "4'   &0              @($7Y0  >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ":"#%-_('W2(00  +0/   9
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M;',O+G)E;'-02P$"% ,4    "  F@@Q3!<3\^!T$  "F(0  #P
M    @ '__0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ )H(,4SB#;R;$
M 0  #1X  !H              ( !20(! 'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ )H(,4X"$^)W  0   !X  !,
M ( !100! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #H .@#-#P  -@8!
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>128</ContextCount>
  <ElementCount>309</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Balance Sheet Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/BalanceSheetAccounts</Role>
      <ShortName>Balance Sheet Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Warrants to Acquire Shares of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStock</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2133109 - Disclosure - License Revenue with 3D Medicines, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesInc</Role>
      <ShortName>License Revenue with 3D Medicines, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2144111 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2205201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sellaslife.com/role/FairValueMeasurements</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Balance Sheet Accounts (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/BalanceSheetAccountsTables</Role>
      <ShortName>Balance Sheet Accounts (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sellaslife.com/role/BalanceSheetAccounts</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sellaslife.com/role/CommitmentsandContingencies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sellaslife.com/role/StockholdersEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Warrants to Acquire Shares of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockTables</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStock</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2334307 - Disclosure - License Revenue with 3D Medicines, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncTables</Role>
      <ShortName>License Revenue with 3D Medicines, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesInc</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2338308 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sellaslife.com/role/StockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/LiquidityDetails</Role>
      <ShortName>Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sellaslife.com/role/Liquidity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Basis of Presentation and Significant Accounting Policies - Stock Subscription Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Stock Subscription Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Time - Vested Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Time - Vested Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Basis of Presentation and Significant Accounting Policies - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities - 842 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details</Role>
      <ShortName>Commitments and Contingencies - Maturities of Lease Liabilities - 842 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2429414 - Disclosure - Warrants to Acquire Shares of Common Stock - Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock - Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2430415 - Disclosure - Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Warrants to Acquire Shares of Common Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails</Role>
      <ShortName>Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2435418 - Disclosure - License Revenue with 3D Medicines, Inc. - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails</Role>
      <ShortName>License Revenue with 3D Medicines, Inc. - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - License Revenue with 3D Medicines, Inc. - Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncDeferredRevenueDetails</Role>
      <ShortName>License Revenue with 3D Medicines, Inc. - Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Stock-Based Compensation - Allocated Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation - Allocated Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Stock-Based Compensation - Assumptions for Option Grants Issued (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions for Option Grants Issued (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sls-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="sls-20210630.htm">sls-20210630.htm</File>
    <File>sls-20160630ex101.htm</File>
    <File>sls-20210630.xsd</File>
    <File>sls-20210630_cal.xml</File>
    <File>sls-20210630_def.xml</File>
    <File>sls-20210630_lab.xml</File>
    <File>sls-20210630_pre.xml</File>
    <File>sls-20210630ex311.htm</File>
    <File>sls-20210630ex312.htm</File>
    <File>sls-20210630ex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>sls-20210630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>69
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sls-20210630.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "contextCount": 128,
   "dts": {
    "calculationLink": {
     "local": [
      "sls-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sls-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sls-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sls-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sls-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "sls-20210630.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 366,
   "entityCount": 1,
   "hidden": {
    "http://www.sellaslife.com/20210630": 1,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 6
   },
   "keyCustom": 49,
   "keyStandard": 260,
   "memberCustom": 17,
   "memberStandard": 19,
   "nsprefix": "sls",
   "nsuri": "http://www.sellaslife.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.sellaslife.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Fair Value Measurements",
     "role": "http://www.sellaslife.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Balance Sheet Accounts",
     "role": "http://www.sellaslife.com/role/BalanceSheetAccounts",
     "shortName": "Balance Sheet Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Commitments and Contingencies",
     "role": "http://www.sellaslife.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Stockholders' Equity",
     "role": "http://www.sellaslife.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Warrants to Acquire Shares of Common Stock",
     "role": "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStock",
     "shortName": "Warrants to Acquire Shares of Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2133109 - Disclosure - License Revenue with 3D Medicines, Inc.",
     "role": "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesInc",
     "shortName": "License Revenue with 3D Medicines, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - Stock-Based Compensation",
     "role": "http://www.sellaslife.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144111 - Disclosure - Subsequent Events",
     "role": "http://www.sellaslife.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2205201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "role": "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)",
     "role": "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.sellaslife.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Balance Sheet Accounts (Tables)",
     "role": "http://www.sellaslife.com/role/BalanceSheetAccountsTables",
     "shortName": "Balance Sheet Accounts (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.sellaslife.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sls:CommonStockAreReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.sellaslife.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sls:CommonStockAreReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sls:ScheduleOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Warrants to Acquire Shares of Common Stock (Tables)",
     "role": "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockTables",
     "shortName": "Warrants to Acquire Shares of Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sls:ScheduleOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2334307 - Disclosure - License Revenue with 3D Medicines, Inc. (Tables)",
     "role": "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncTables",
     "shortName": "License Revenue with 3D Medicines, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338308 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.sellaslife.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Liquidity (Details)",
     "role": "http://www.sellaslife.com/role/LiquidityDetails",
     "shortName": "Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Basis of Presentation and Significant Accounting Policies - Stock Subscription Receivable (Details)",
     "role": "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Stock Subscription Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Time - Vested Restricted Stock Units (Details)",
     "role": "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Time - Vested Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Basis of Presentation and Significant Accounting Policies - Antidilutive Securities (Details)",
     "role": "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sls:FairValueOfWarrantsPotentiallySettleableInCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details)",
     "role": "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "id299f8f9d64c460fbab097e59032b733_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8ae6ab8b28e8405fb45e31fe8cff6e47_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details)",
     "role": "http://www.sellaslife.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails",
     "shortName": "Fair Value Measurements - Reconciliation of Level 3 Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8ae6ab8b28e8405fb45e31fe8cff6e47_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i2bdb237db5d747d296f136aa84ea8854_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i2bdb237db5d747d296f136aa84ea8854_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sls:ContractResearchPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details)",
     "role": "http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sls:ContractResearchPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i880559595c4c4de0b7dc3629958abd33_D20200713-20200716",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyClaimsDismissedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "complaint",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i880559595c4c4de0b7dc3629958abd33_D20200713-20200716",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyClaimsDismissedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "complaint",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities - 842 (Details)",
     "role": "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details",
     "shortName": "Commitments and Contingencies - Maturities of Lease Liabilities - 842 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.sellaslife.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sls:CommonStockAreReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details)",
     "role": "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails",
     "shortName": "Stockholders' Equity - Common Stock are Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sls:CommonStockAreReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i09f2e17d90504212b4f4df2b5b769f5f_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sls:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "ib3da468c26204b08b77feb6a7b00001f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429414 - Disclosure - Warrants to Acquire Shares of Common Stock - Warrants Outstanding (Details)",
     "role": "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails",
     "shortName": "Warrants to Acquire Shares of Common Stock - Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sls:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "sls:ClassOfWarrantOrRightNumberOfWarrantsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sls:CommonStockAreReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430415 - Disclosure - Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details)",
     "role": "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails",
     "shortName": "Warrants to Acquire Shares of Common Stock - Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if448fa0842d047f7b8837ba649615db8_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "id11e0beb0d474e3e908dfebf56c545ca_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Warrants to Acquire Shares of Common Stock - Narrative (Details)",
     "role": "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails",
     "shortName": "Warrants to Acquire Shares of Common Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "id11e0beb0d474e3e908dfebf56c545ca_I20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sls:ChangesInFairValueOfWarrantLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "ib3da468c26204b08b77feb6a7b00001f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sls:FairValueOfWarrantsLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)",
     "role": "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails",
     "shortName": "Warrants to Acquire Shares of Common Stock - Changes in Fair Value of Warrant Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sls:ChangesInFairValueOfWarrantLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "ib3da468c26204b08b77feb6a7b00001f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sls:FairValueOfWarrantsLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sls:ResearchAndDevelopmentArrangementCashPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435418 - Disclosure - License Revenue with 3D Medicines, Inc. - Narrative (Details)",
     "role": "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails",
     "shortName": "License Revenue with 3D Medicines, Inc. - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i18baec49fe024c018d43c4b74cc545c7_D20201201-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sls:ResearchAndDevelopmentArrangementCashPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "ib3da468c26204b08b77feb6a7b00001f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - License Revenue with 3D Medicines, Inc. - Deferred Revenue (Details)",
     "role": "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncDeferredRevenueDetails",
     "shortName": "License Revenue with 3D Medicines, Inc. - Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sls:CommonStockAreReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8d028055c2e64d5e9dab5f9331370054_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "ib3da468c26204b08b77feb6a7b00001f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Stock-Based Compensation - Allocated Stock-based Compensation (Details)",
     "role": "http://www.sellaslife.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails",
     "shortName": "Stock-Based Compensation - Allocated Stock-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Stock-Based Compensation - Assumptions for Option Grants Issued (Details)",
     "role": "http://www.sellaslife.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails",
     "shortName": "Stock-Based Compensation - Assumptions for Option Grants Issued (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8e81f95995f142afb3eaed854f43ad80_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i8e81f95995f142afb3eaed854f43ad80_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i2de00b626d6346b6a6859bbffb4d9bc0_D20210401-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Details)",
     "role": "http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "i6e495fbe39b94625bc5d109ee275d484_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.sellaslife.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiquidationBasisOfAccountingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Liquidity",
     "role": "http://www.sellaslife.com/role/Liquidity",
     "shortName": "Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiquidationBasisOfAccountingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "role": "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20210630.htm",
      "contextRef": "if7416b7a9cde449e9f869c897319832a_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 37,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sellaslife.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sls_A2017EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Employee Stock Purchase Plan",
        "label": "2017 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2017 ESPP"
       }
      }
     },
     "localname": "A2017EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_A2019EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Equity Incentive Plan",
        "label": "2019 Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "A2019EquityIncentivePlanMember",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_A2021EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Employee Stock Purchase Plan",
        "label": "2021 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 ESPP"
       }
      }
     },
     "localname": "A2021EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_AptheraInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apthera, Inc. [Member]",
        "label": "Apthera, Inc. [Member]",
        "terseLabel": "Apthera, Inc."
       }
      }
     },
     "localname": "AptheraInc.Member",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Timing Of Milestones",
        "label": "Business Combination, Contingent Consideration Arrangements, Timing Of Milestones",
        "terseLabel": "Business combination, contingent consideration, timing of development milestones"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsTimingOfMilestones",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sls_ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of common stock warrants issued in connection with various equity financings.",
        "label": "Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings",
        "negatedTerseLabel": "Change in fair value of common stock warrants"
       }
      }
     },
     "localname": "ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_ChangeInFairValueOfContingentPurchaseConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of contingent purchase consideration.",
        "label": "Change In Fair Value Of Contingent Purchase Consideration",
        "negatedTerseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "ChangeInFairValueOfContingentPurchaseConsideration",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_ChangeInFairValueOfContingentPurchasePriceConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in the fair value of contingent purchase price consideration.",
        "label": "Change In Fair Value Of Contingent Purchase Price Consideration",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "ChangeInFairValueOfContingentPurchasePriceConsideration",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_ChangeInFairValueOfWarrantLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Fair Value Of Warrant Liabilities",
        "label": "Change In Fair Value Of Warrant Liabilities",
        "terseLabel": "Change in fair value of warrants"
       }
      }
     },
     "localname": "ChangeInFairValueOfWarrantLiabilities",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_ChangeInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Operating Lease Right of Use Assets",
        "label": "Change In Operating Lease Right Of Use Assets",
        "terseLabel": "Change in operating lease right of use assets"
       }
      }
     },
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_ChangesInFairValueOfWarrantLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes In Fair Value Of Warrant Liability",
        "label": "Changes In Fair Value Of Warrant Liability [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of Warrant Liability"
       }
      }
     },
     "localname": "ChangesInFairValueOfWarrantLiabilityTableTextBlock",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sls_ClassOfWarrantOrRightNumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Warrants Exercised",
        "label": "Class Of Warrant Or Right, Number Of Warrants Exercised",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sls_ClassOfWarrantOrRightNumberOfWarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Number Of Warrants Issued",
        "label": "Class Of Warrant Or Right, Number Of Warrants Issued",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsIssued",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sls_ClassofWarrantorRightCanceledOrExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Canceled Or Expired",
        "label": "Class of Warrant or Right, Canceled Or Expired",
        "negatedTerseLabel": "Canceled/Expired (in shares)"
       }
      }
     },
     "localname": "ClassofWarrantorRightCanceledOrExpired",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sls_ClassofWarrantorRightFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Fair Value [Roll Forward]",
        "label": "Class of Warrant or Right, Fair Value [Roll Forward]",
        "terseLabel": "Class of Warrant or Right, Fair Value [Roll Forward]"
       }
      }
     },
     "localname": "ClassofWarrantorRightFairValueRollForward",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sls_ClassofWarrantorRightOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Outstanding [Roll Forward]",
        "label": "Class of Warrant or Right, Outstanding [Roll Forward]",
        "terseLabel": "Class of Warrant or Right, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ClassofWarrantorRightOutstandingRollForward",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sls_ClosingPriceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing price of common stock.",
        "label": "Closing Price Of Common Stock",
        "terseLabel": "Closing price of the Company's common stock (in dollars per share)"
       }
      }
     },
     "localname": "ClosingPriceOfCommonStock",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sls_CommonStockAreReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock are reserved for future issuance.",
        "label": "Common Stock Are Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockAreReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sls_ContingentPurchasePriceConsiderationNetOfCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent purchase price consideration, net of current portion.",
        "label": "Contingent Purchase Price Consideration Net Of Current Portion",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "ContingentPurchasePriceConsiderationNetOfCurrentPortion",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_ContractResearchPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Research Payable",
        "label": "Contract Research Payable",
        "terseLabel": "Clinical trial costs"
       }
      }
     },
     "localname": "ContractResearchPayable",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_ContractWithCustomerLiabilityNewContractRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, New Contract Revenue, Recognized",
        "label": "Contract With Customer, Liability, New Contract Revenue, Recognized",
        "negatedTerseLabel": "Revenue Recognized",
        "terseLabel": "Licensing revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNewContractRevenueRecognized",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncDeferredRevenueDetails",
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_DividendArisingFromWarrantModifications": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend Arising From Warrant Modifications",
        "label": "Dividend Arising From Warrant Modifications",
        "negatedLabel": "Deemed dividend arising from warrant modifications"
       }
      }
     },
     "localname": "DividendArisingFromWarrantModifications",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition",
        "label": "Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition",
        "terseLabel": "Operating expenses weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sls_FairValueOfWarrantLiabilityAssumptionsExpectedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value of Warrant Liability Assumptions Expected Term",
        "label": "Fair Value Of Warrant Liability Assumptions Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "FairValueOfWarrantLiabilityAssumptionsExpectedTerm",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sls_FairValueOfWarrantsLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrant liabilities as of the balance sheet date.",
        "label": "Fair Value Of Warrants Liabilities",
        "periodEndLabel": "Warrant liability, ending balance",
        "periodStartLabel": "Warrant liability, beginning balance"
       }
      }
     },
     "localname": "FairValueOfWarrantsLiabilities",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_FairValueOfWarrantsPotentiallySettleableInCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrants potentially settleable in cash.",
        "label": "Fair Value Of Warrants Potentially Settleable In Cash",
        "terseLabel": "Warrant liability",
        "verboseLabel": "Warrant liability"
       }
      }
     },
     "localname": "FairValueOfWarrantsPotentiallySettleableInCash",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_InProcessResearchDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In-process research and development.",
        "label": "In Process Research Development",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchDevelopment",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_IncreaseDecreaseInContractWithCustomerLiabilityNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Contract with Customer, Liability, Net",
        "label": "Increase (Decrease) in Contract with Customer, Liability, Net",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiabilityNet",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_January2020OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January 2020 Offering [Member]",
        "label": "January 2020 Offering [Member]",
        "terseLabel": "January 2020 Offering"
       }
      }
     },
     "localname": "January2020OfferingMember",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_July2018OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July 2018 Offering [Member]",
        "label": "July 2018 Offering [Member]",
        "verboseLabel": "July 2018 Offering"
       }
      }
     },
     "localname": "July2018OfferingMember",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_July2019OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July 2019 Offering [Member]",
        "label": "July 2019 Offering [Member]",
        "terseLabel": "June 2019 Offering"
       }
      }
     },
     "localname": "July2019OfferingMember",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_July2020PIPEOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July 2020 PIPE Offering [Member]",
        "label": "July 2020 PIPE Offering [Member]",
        "terseLabel": "July 2020 PIPE Offering"
       }
      }
     },
     "localname": "July2020PIPEOfferingMember",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_MeasurementInputCostOfDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Cost Of Debt [Member]",
        "label": "Measurement Input, Cost Of Debt [Member]",
        "terseLabel": "Cost of debt"
       }
      }
     },
     "localname": "MeasurementInputCostOfDebtMember",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_MeasurementInputWeightedAverageCostOfCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Weighted Average Cost Of Capital [Member]",
        "label": "Measurement Input, Weighted Average Cost Of Capital [Member]",
        "terseLabel": "Weighted average cost of capital"
       }
      }
     },
     "localname": "MeasurementInputWeightedAverageCostOfCapitalMember",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_NonCashCharges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Charges",
        "label": "Non-Cash Charges",
        "terseLabel": "Non-cash charges"
       }
      }
     },
     "localname": "NonCashCharges",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_NoncashOfferingExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Offering Expense",
        "label": "Noncash Offering Expense",
        "terseLabel": "Offering expenses in accounts payable and accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "NoncashOfferingExpense",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_OfficeSpaceLeaseExpiringDecember312024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Space Lease Expiring December 31, 2024",
        "label": "Office Space Lease Expiring December 31, 2024 [Member]",
        "terseLabel": "Office Space Lease Expiring December 31, 2024"
       }
      }
     },
     "localname": "OfficeSpaceLeaseExpiringDecember312024Member",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_OperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Remaining Lease Term",
        "label": "Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining term"
       }
      }
     },
     "localname": "OperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sls_OtherLiabilityClassifiedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Liability Classified [Member]",
        "label": "Other Liability Classified [Member]",
        "terseLabel": "Other warrants (liability-classified)"
       }
      }
     },
     "localname": "OtherLiabilityClassifiedMember",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails",
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_OtherWarrantIssuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Warrant Issues [Member]",
        "label": "Other Warrant Issues [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherWarrantIssuesMember",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_PrepaidProfessionalServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Professional Services",
        "label": "Prepaid Professional Services",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "PrepaidProfessionalServices",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_PrepaidResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Research And Development",
        "label": "Prepaid Research And Development",
        "terseLabel": "Clinical trial costs"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopment",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_ProceedsFromResearchAndDevelopmentArrangementMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Research And Development Arrangement, Milestone Payments",
        "label": "Proceeds From Research And Development Arrangement, Milestone Payments",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "localname": "ProceedsFromResearchAndDevelopmentArrangementMilestonePayments",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails",
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_ProceedsFromStockSubscriptionReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Stock Subscription Receivable",
        "label": "Proceeds From Stock Subscription Receivable",
        "terseLabel": "Collection of stock subscription receivable"
       }
      }
     },
     "localname": "ProceedsFromStockSubscriptionReceivable",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_ResearchAndDevelopmentArrangementCashPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Cash Payment Received",
        "label": "Research And Development Arrangement, Cash Payment Received",
        "terseLabel": "Upfront cash payment received"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementCashPaymentReceived",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Milestones Probable Of Being Achieved",
        "label": "Research And Development Arrangement, Milestones Probable Of Being Achieved",
        "terseLabel": "Milestones probable of being achieved"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementMilestonesProbableOfBeingAchieved",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Potential Milestone Payments To Be Received",
        "label": "Research And Development Arrangement, Potential Milestone Payments To Be Received",
        "terseLabel": "Potential milestone payments to be received"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceived",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails",
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Potential Milestone Payments To Be Received, Maximum",
        "label": "Research And Development Arrangement, Potential Milestone Payments To Be Received, Maximum",
        "terseLabel": "Future milestone payments received"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementPotentialMilestonePaymentsToBeReceivedMaximum",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Royalties Payable, Maximum Term",
        "label": "Research And Development Arrangement, Royalties Payable, Maximum Term",
        "terseLabel": "Royalties payable, maximum term"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementRoyaltiesPayableMaximumTerm",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sls_ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Arrangement, Royalties Payable, Minimum Term",
        "label": "Research And Development Arrangement, Royalties Payable, Minimum Term",
        "terseLabel": "Royalties payable, minimum term"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementRoyaltiesPayableMinimumTerm",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sls_RestrictedCashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Cash Equivalents, Fair Value Disclosure",
        "label": "Restricted Cash And Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Restricted cash equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_SaleOfStockAgentFeePercentageOfGrossProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Agent Fee, Percentage Of Gross Proceeds",
        "label": "Sale Of Stock, Agent Fee, Percentage Of Gross Proceeds",
        "terseLabel": "Percentage gross proceeds from the sale of share (as a percent)"
       }
      }
     },
     "localname": "SaleOfStockAgentFeePercentageOfGrossProceeds",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sls_SaleOfStockAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Authorized Amount",
        "label": "Sale Of Stock, Authorized Amount",
        "terseLabel": "Sale of shares, common stock gross proceeds"
       }
      }
     },
     "localname": "SaleOfStockAuthorizedAmount",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreement Member",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_ScheduleOfWarrantActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Warrant Activity",
        "label": "Schedule Of Warrant Activity [Table Text Block]",
        "terseLabel": "Schedule of Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfWarrantActivityTableTextBlock",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sls_ScheduleOfWarrantValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Warrant Valuation Assumptions",
        "label": "Schedule Of Warrant Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfWarrantValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sls_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Aggregate Intrinsic Value [Roll Forward]"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingAggregateIntrinsicValueRollForward",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sls_StockIssuedDuringPeriodSharesCommonStockandWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Common Stock and Warrants",
        "label": "Stock Issued During Period, Shares, Common Stock and Warrants",
        "terseLabel": "Issuance of common stock and common stock warrants, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCommonStockandWarrants",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "sls_StockIssuedDuringPeriodSharesPrefundedWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Pre-funded Warrant",
        "label": "Stock Issued During Period, Shares, Pre-funded Warrant",
        "terseLabel": "Issuance of common stock upon exercise of pre-funded warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPrefundedWarrant",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "sls_StockIssuedDuringPeriodValueCommonStockandWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Common Stock and Warrants",
        "label": "Stock Issued During Period, Value, Common Stock and Warrants",
        "terseLabel": "Issuance of common stock and common stock warrants, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCommonStockandWarrants",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_StockIssuedDuringPeriodValuePreFundedWarrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value, Pre-Funded Warrant",
        "label": "Stock Issued During Period Value, Pre-Funded Warrant",
        "terseLabel": "Issuance of common stock upon exercise of pre-funded warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePreFundedWarrant",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_StockSubscriptionReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Subscription Receivable",
        "label": "Stock Subscription Receivable",
        "terseLabel": "Stock subscription receivable"
       }
      }
     },
     "localname": "StockSubscriptionReceivable",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_StockSubscriptionReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Subscription Receivable, Current",
        "label": "Stock Subscription Receivable, Current",
        "terseLabel": "Stock subscription receivable"
       }
      }
     },
     "localname": "StockSubscriptionReceivableCurrent",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sls_TwoThousandAndNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Nineteen Equity Incentive Plan [Member]",
        "label": "Two Thousand And Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndNineteenEquityIncentivePlanMember",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_TwoThousandAndSeventeenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Seventeen Equity Incentive Plan [Member]",
        "label": "Two Thousand And Seventeen Equity Incentive Plan [Member]",
        "terseLabel": "2017 Equity Plan"
       }
      }
     },
     "localname": "TwoThousandAndSeventeenEquityIncentivePlanMember",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_WarrantExerciseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Exercise Agreement",
        "label": "Warrant Exercise Agreement [Member]",
        "verboseLabel": "March 2019 Exercise Agreement"
       }
      }
     },
     "localname": "WarrantExerciseAgreementMember",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sls_WarrantStrikePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Strike Price",
        "label": "Warrant Strike Price",
        "terseLabel": "Strike price (in dollars per share)"
       }
      }
     },
     "localname": "WarrantStrikePrice",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sls_WarrantsFairValueAssumptionsExpectedVolatility": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Fair Value Assumptions Expected Volatility",
        "label": "Warrants Fair Value Assumptions Expected Volatility",
        "terseLabel": "Volatility %"
       }
      }
     },
     "localname": "WarrantsFairValueAssumptionsExpectedVolatility",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sls_WarrantsFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Fair Value Assumptions Risk Free Interest Rate",
        "label": "Warrants Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free rate %"
       }
      }
     },
     "localname": "WarrantsFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://www.sellaslife.com/20210630",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r160",
      "r170",
      "r221",
      "r223",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r375",
      "r376",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r160",
      "r170",
      "r221",
      "r223",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r375",
      "r376",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r160",
      "r170",
      "r211",
      "r221",
      "r223",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r375",
      "r376",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r160",
      "r170",
      "r211",
      "r221",
      "r223",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r375",
      "r376",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31",
      "r342"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r33"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r259",
      "r260",
      "r261",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r224",
      "r226",
      "r265",
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r226",
      "r252",
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Allocated share based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r65",
      "r111",
      "r114",
      "r120",
      "r128",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r282",
      "r285",
      "r312",
      "r340",
      "r342",
      "r363",
      "r369"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r12",
      "r14",
      "r39",
      "r65",
      "r128",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r282",
      "r285",
      "r312",
      "r340",
      "r342"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured and recorded at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r227",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r220",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r220",
      "r222",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent consideration payable, maximum amount"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low",
        "terseLabel": "Contingent consideration payable, minimum amount"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r277",
      "r278",
      "r279"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails",
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Business combination, contingent consideration, measurement input (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortization of contract asset"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails",
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostGross": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Gross",
        "terseLabel": "Contract acquisition costs"
       }
      }
     },
     "localname": "CapitalizedContractCostGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetCurrent": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.",
        "label": "Capitalized Contract Cost, Net, Current",
        "terseLabel": "Contract asset"
       }
      }
     },
     "localname": "CapitalizedContractCostNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r9",
      "r29",
      "r59"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r54",
      "r59",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period",
        "periodStartLabel": "Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r54",
      "r321"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r63",
      "r65",
      "r88",
      "r89",
      "r94",
      "r97",
      "r99",
      "r105",
      "r106",
      "r107",
      "r128",
      "r149",
      "r153",
      "r154",
      "r155",
      "r158",
      "r159",
      "r168",
      "r169",
      "r173",
      "r177",
      "r312",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r192",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails",
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails",
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails",
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails",
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)",
        "terseLabel": "Warrants outstanding (in shares)",
        "verboseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails",
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r192",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockChangesinFairValueofWarrantLiabilityDetails",
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockFairValueofWarrantsisEstimatedUsingBlackScholesOptionPricingModelDetails",
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails",
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r35",
      "r146",
      "r365",
      "r372"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r147",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares of common stock reserved for issuance (in shares)",
        "totalLabel": "Total common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r67",
      "r68",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sellaslife.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sellaslife.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r342"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001\u00a0par value; 350,000,000\u00a0shares authorized, 15,873,941 and 14,254,554\u00a0shares issued and outstanding at June 30, 2021 and December\u00a031, 2020, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Deferred Revenue, Related to Upfront Cash Payment Received"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r194",
      "r195",
      "r207"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Decrease in deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r49",
      "r358"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of licensing revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BalanceSheetAccountsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.",
        "label": "Deposits Assets, Noncurrent",
        "terseLabel": "Deposits and other assets"
       }
      }
     },
     "localname": "DepositsAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r47",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r85",
      "r88",
      "r97",
      "r98",
      "r99",
      "r102",
      "r103",
      "r298",
      "r299",
      "r367",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share attributable to common stockholders, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Per share information:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r47",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r88",
      "r97",
      "r98",
      "r99",
      "r102",
      "r103",
      "r298",
      "r299",
      "r367",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share attributable to common stockholders, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and related benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r43",
      "r44",
      "r45",
      "r67",
      "r68",
      "r69",
      "r72",
      "r81",
      "r83",
      "r104",
      "r132",
      "r184",
      "r191",
      "r259",
      "r260",
      "r261",
      "r273",
      "r274",
      "r297",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r379",
      "r380",
      "r381",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r57",
      "r164"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails",
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r301",
      "r302",
      "r303",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails",
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r302",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails",
      "http://www.sellaslife.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r301",
      "r302",
      "r305",
      "r306",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r161",
      "r212",
      "r213",
      "r218",
      "r219",
      "r302",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0Prices\u00a0In Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r212",
      "r213",
      "r218",
      "r219",
      "r302",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant\u00a0Other Observable\u00a0 Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r302",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Unobservable\u00a0 Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails",
      "http://www.sellaslife.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r307",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r307",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Level 3 Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "verboseLabel": "Change in the estimated fair value of the contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r307"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Contingent consideration, June 30, 2021",
        "periodStartLabel": "Contingent consideration, December 31, 2020"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails",
      "http://www.sellaslife.com/role/FairValueMeasurementsReconciliationofLevel3LiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r309",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r139",
      "r140",
      "r342",
      "r362"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r141",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "negatedTerseLabel": "Decrease in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedTerseLabel": "Contract asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r56",
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets",
        "terseLabel": "Increase in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021 (remaining)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r32",
      "r65",
      "r115",
      "r128",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r283",
      "r285",
      "r286",
      "r312",
      "r340",
      "r341"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r65",
      "r128",
      "r312",
      "r342",
      "r364",
      "r371"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r65",
      "r128",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r283",
      "r285",
      "r286",
      "r312",
      "r340",
      "r341",
      "r342"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r301"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities measured and recorded at fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsContingentPurchasePriceConsiderationMeasuredatEstimatedFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiquidationBasisOfAccountingTextBlock": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the liquidation basis of accounting.",
        "label": "Liquidation Basis of Accounting [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidationBasisOfAccountingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/Liquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Number of claims which the Company filed motions to dismiss"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Measurement Input, Expected Dividend Rate"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input, Risk Free Interest Rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInDeferredRevenueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Movement in Deferred Revenue [Roll Forward]",
        "terseLabel": "Movement in Deferred Revenue [Roll Forward]"
       }
      }
     },
     "localname": "MovementInDeferredRevenueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r54",
      "r55",
      "r58"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedTerseLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r6",
      "r41",
      "r42",
      "r45",
      "r46",
      "r58",
      "r65",
      "r71",
      "r76",
      "r77",
      "r78",
      "r79",
      "r82",
      "r83",
      "r95",
      "r111",
      "r113",
      "r116",
      "r119",
      "r121",
      "r128",
      "r149",
      "r150",
      "r151",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r299",
      "r312",
      "r366",
      "r373"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTerseLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r76",
      "r77",
      "r78",
      "r79",
      "r85",
      "r86",
      "r96",
      "r99",
      "r111",
      "r113",
      "r116",
      "r119",
      "r121"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders, basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r87",
      "r90",
      "r91",
      "r92",
      "r93",
      "r96",
      "r99"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net loss attributable to common stockholders, diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r78",
      "r84",
      "r102",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r148",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r271",
      "r272",
      "r273",
      "r274",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r339",
      "r359",
      "r360",
      "r361",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Standards Adopted and Recent Accounting Standards Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Non-operating income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r111",
      "r113",
      "r116",
      "r119",
      "r121"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Current and non-current operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesMaturitiesofLeaseLiabilities842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, non-current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r332",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash payments related to operating lease"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r329"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r336",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, discount rate (as a percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityDescriptionTextBlock": {
     "auth_ref": [
      "r288",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for freestanding contract indexed to and potentially settled in entity's own stock. Includes, but is not limited to, strike price and number of shares to which contract is indexed, settlement date, and settlement alternatives.",
        "label": "Contract Indexed to Issuer's Equity [Text Block]",
        "terseLabel": "Warrants to Acquire Shares of Common Stock"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityDescriptionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r8",
      "r66",
      "r108",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r33"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BalanceSheetAccountsAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "totalLabel": "Total non-operating expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r10",
      "r13",
      "r136"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "terseLabel": "Contingent consideration paid"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r227",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sellaslife.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sellaslife.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r20",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r20",
      "r342"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001\u00a0par value; 5,000,000\u00a0shares authorized; Series A convertible preferred stock, 17,500 shares designated; no shares issued and outstanding at June 30, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r12",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails",
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r11",
      "r13",
      "r135",
      "r136"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BalanceSheetAccountsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromInterestReceived": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest received on loans and other debt instruments during the current period.",
        "label": "Proceeds from Interest Received",
        "terseLabel": "Cash received during the period for interest"
       }
      }
     },
     "localname": "ProceedsFromInterestReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Net proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r268",
      "r357",
      "r392"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r9",
      "r18",
      "r59",
      "r60"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash and cash equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r191",
      "r262",
      "r342",
      "r370",
      "r383",
      "r388"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r67",
      "r68",
      "r69",
      "r72",
      "r81",
      "r83",
      "r132",
      "r259",
      "r260",
      "r261",
      "r273",
      "r274",
      "r297",
      "r379",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r109",
      "r110",
      "r112",
      "r117",
      "r118",
      "r122",
      "r123",
      "r124",
      "r205",
      "r206",
      "r358"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Licensing revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r203",
      "r204",
      "r209",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "License Revenue with 3D Medicines, Inc."
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Performance obligation, amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/LicenseRevenuewith3DMedicinesIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r335",
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating right of use asset and current and non-current lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds of common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails",
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares of stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails",
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Stock price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BalanceSheetAccountsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails",
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Outstanding Excluded from Computation of Diluted Weighted Average Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r226",
      "r251",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r226",
      "r251",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Allocated Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r227",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r233",
      "r240",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions for Option Grants Issued"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r36",
      "r63",
      "r105",
      "r106",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r173",
      "r177",
      "r182",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationAllocatedStockbasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Restricted stock unit award vested period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "RSUs outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)",
        "terseLabel": "RSUs Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Expected dividend yield (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Cash earnings contributed per year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares of common stock authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r254"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average exercise price, granted (in dollars per share)",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, ending balance",
        "periodStartLabel": "Aggregate intrinsic value, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r235",
      "r254"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)",
        "verboseLabel": "Stock options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Shares (In Thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted average exercise price, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "verboseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Increase in number of shares available for future issuance under stock based awards (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r225",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesTimeVestedRestrictedStockUnitsDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails",
      "http://www.sellaslife.com/role/StockholdersEquityCommonStockareReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r227",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Time-Vested Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Option term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r246",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected lives (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationAssumptionsforOptionGrantsIssuedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, options exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Average vesting term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationSummaryofRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Averages contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r61",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r63",
      "r65",
      "r88",
      "r89",
      "r94",
      "r97",
      "r99",
      "r105",
      "r106",
      "r107",
      "r128",
      "r149",
      "r153",
      "r154",
      "r155",
      "r158",
      "r159",
      "r168",
      "r169",
      "r173",
      "r177",
      "r184",
      "r312",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r38",
      "r43",
      "r44",
      "r45",
      "r67",
      "r68",
      "r69",
      "r72",
      "r81",
      "r83",
      "r104",
      "r132",
      "r184",
      "r191",
      "r259",
      "r260",
      "r261",
      "r273",
      "r274",
      "r297",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r379",
      "r380",
      "r381",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r104",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r184",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r184",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r24",
      "r25",
      "r65",
      "r125",
      "r128",
      "r312",
      "r342"
     ],
     "calculation": {
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r169",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r191",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r328",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails",
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r328",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails",
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r328",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesStockSubscriptionReceivableDetails",
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r343",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/LiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Accounts"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BalanceSheetAccounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/BasisofPresentationandSignificantAccountingPoliciesAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]",
        "terseLabel": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants and rights outstanding, measurement input coupon rate"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/WarrantstoAcquireSharesofCommonStockNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r87",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r85",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sellaslife.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/subtopic&trid=2229355"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r393": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r394": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r395": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r396": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r397": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r398": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r399": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3337-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=35686142"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0001390478-21-000030-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001390478-21-000030-xbrl.zip
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M F^AL(!6R<:T^YT=CF/2 I,O'&3WESD1K:_PR@/9#E.NYK&B61_8],$YKYI
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M\LXSO:]VS8^C>7OC&4XI?SOTZ :*(I6N&Q>/6S!0(9)F+&-P$]X!5;41&,@
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M*$T9 Z*<$_G=*MQ\Y;:'J+Z<@KE&/\4SV65Q B+EP7,S+9_U0B.<)'G(6J5
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M$3Q3L;1VXP7S"N8UX8GGP+RD.)%.6>-#Y-Q$D[0T7AO%B-&,VHFI1XJIMQ+
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M^!,+5&LA!4I)Y Z$D2!'P$ .BF FHF?.AB9JV*7V5V^N,_XJ#J+M^^.Z/"6
M'][IG>8BO]5OK]Y(7WR.6\$Q70"'=BZH\GP<$RQH- \:'<YXZB0P[XT.R,F0
MLKW/$3AJ!&FOL1>6:VS$QB9K<2$;U)SYR?97;[RO7F3XH63XPF>/-'F/J4,R
M!/ %C+7(4J=0% "Z5,A(A )?H$7UPMY D>$FRO##9N<4&5Z:#%_X\]03&JD2
M"(?<F(\'C2Q/&CFEG D&1\I5SL-1O,CP6LKPDCWZ(L,/)<,7GCUU"6O.+:(1
MJ,2C3LCP&! 7/L@$!A:(Z<8F;Q&^MH-.FNO7_QZ[L6\[M5MOPTF[VQX,^W4;
MGG++_KB>_6'LP%[?3P@$F+1UB3P%ENX 2[/57,*2*/-45>(<FP0< ]&(!*Q"
MPE1K7+L'RJ@&A1O+9<%*NOA%F.]#F"]\?:=%2,1$I!@&R\)AA1S-35P9]LJX
MX$72=6FF+L*\EL+\D+Y^$>;[$.8+I]]Q94)("DGB!.*4&:2UEX@H89CA8%\%
M$&;98D(785Y'87Y(I[\(\WT(\X7W3Q1UGBN+1*HSYR1!6F"!2 (SB_& 29Z8
M#MY_HS3SR@TE6Y65CS \[3'"*N.A)+TK13KK/3)MM0,N.:LKYW--(']0,'\.
MS#^X5.<0DXY1<'"_+& ^]^"-!6=1,$8D@UDDPHP-N&5-IV]*]?23FINVVB&9
M(NZ+B?M%\"4%+:P$FFAN\R4M&'M6!(W :/<V\,! Y+.)1^7")EX1]W42]X<,
MVA1Q7TS<+\(SD7A-*>ATHYP$<<<8&8T9PD13['20O&Z#!_)N%H[/%'E?)WE_
MR+A.D??%Y'VF,XA2/DJN$-/.("YE0DY1@B2.*6"E#0V@WG6+L2<V&[6)@8>+
MOB"=WN!NX89E=')J$D#]]+#QA@$\*OPV!U2=TVRWZWLG\240KJ#5/&@U6[DA
M Q>.I(  FACBQ'MD'=@I$1MO2;+)Y3%:O,6OB3W\HVD-C![A3NE)BOT2X@Y%
M[!]!["]B$$ GBEET*/'<J98GB30S&(&-(A612A >;XI!%+%_HF*_A/A#$?M'
M$/N+6(04$DRSR!!-DB).-4.:" NN2O0)4P8 'O--@[PF%%'$_HF*_1+"$$7L
M'T'L+T(2!@=NJ0E(""41%SPAG5Q$W@APUP)WQ+B;0A*-$_LU[E*ZW^NBBR2(
M=LWYU4^39(A_M*IN'):VI4_E,TI.55-RJE:S5&W[V';?QSPZ.=EVO_ID.Z-Z
M[/:9[?=M=UAUVM:U.^WAER=3N?; D<W+!LT+(,)?F09;X<-H,,REL@?IS9@6
MQ;29JP_[T6XV:\8QS*V_0Z01J&409\KF>EF1N] 0I!S5-@BGB"0;FW0)#LV*
M.BUK*Z-+"$,6&;U'&?UR+J,)_$3-C4!6I( X5@DY'SB*Q$@2E!9,^8U-<K4Y
M5)'1%9?1I;>!+3*Z3!G=O]"C3CD@%,5(!B81I\XB:V2^(6"1816C37)C4Y@B
MHZL@HX\4WRNR>H^R>J%/,74<:Y-R0,^!/B6Y5QOAR($Q#,I4ZXBS/KTJJZ5$
M;.U6/I&.NC>%,S*4P6, M.1?!^U0AT][W2?3:?>Q\K7&4#_H#'X9DV:W>P[W
M!VG[G"I_C/K^V [B'_VVC]NS%"H*8"X%\.=LT$-%#M27"DG/+>*"1&2B"TC1
MJ*37(6%.00&PJRW";F^ME0Y_C93A929?%1E^<!F^,.),[HL=3<X1=V#$>>&0
M=<2C")0-5A"G56["PQ=)O"PRW$@97F8F59'AAY;AF:!)8H[RP$%HM8B($TN1
M,<(BS:0)D7$?=>Z*)XL,KYT,+S]L4F3X 67X0@]K'%QB)B 7E$9@0N5Q6-$@
MXX572242A<L7B(OD1CU<I]WF!2A6964YV*9$J%8SX687E$,_#H:3Q+TGDU;S
MF%DUTS,?9PE/BI?WX[#HP[GTH9^-+3$2O)<Z(>F]SD,A#7(L3X9T@AO)K-;)
M@#YLT-U"N0QL4DNA(J'W(Z$SZ32">A:"0T3'!!8K)TBK))#$-BD9C PIMQ0I
M$KJ.$KKTC)HBH4N2T/U9'0K(J54>B"@%XM* 3RF51=$2S8CC@@30H0L/<"D2
MVD0)74)DJ$CH_4CHA0YE+D5J"!BX!N=&RQX,7!,M$H;0 (H4)R[!RA4-$M$G
MU0RX>ZD6;E(#5Y? E:; CY[U<5ZE.SR._6]*=0L\W1&>WL\ZX=8RHFA0R,I$
M<\8\!O];$X2Y\2H9[PDV.6/^ZAS'N8/23:G3+]T"FY884L3\?L3\P@I1TC$?
MP'^/-C<'!:,1Z4 <DM0%'FQP-N1$WFLFMQ0Q?Z)BOOS<D2+F]R+F,^$ DYC
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MIUQB(C8V50LOHU-<$?GU$/E':4]?1'XAD;_0\DY&1W2.D:<\B(8(C+17!/E
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MQ469P*N/[W:VR/X.?![=$_L?_OP*OXN]-Z_)VS=[Y.#WMQ3V0-Y]Z)Q\6R8
MS_-Q;^<U[/7YU_S9^SM[\/O'S^^._CI^^_4U?_?A'3SO7R<';]ZEO2^8U"4"
MA_CL;V.(EC8EA /1B MID:-1(1$\P4IXXI@>EZMIWE*"+[<HH$QI;82$K]&0
MU@4A[>J\S;OA61ZS^0UFS9C]8Z-_HRE3,E<$M-@Y:.DHL!,RH9!R91/%"1EI
M I+,:,Z#\ICZC<VKK?D*5A6L6F>L2EHR2F7P6%$>A72)L\0<24FJE)*_&:MN
M;WH5&%L0QL0%C.&$DX\64:_!]DI!(DMH0%RKH"B3QN0"3<)-"U_3]+J 60&S
ME0.S[[;._@;-0 @XM]BS0 1WA.@4""CXF(*1RC-],YK-/^"\P-JBL/9YIBVD
ML]B1W#9;@\T,]EFN/!=) <YY"HHHT$@( !O%+8:O EOCAI8O"=/N,36@X.2:
MX>0<,"F$B]P29X(R7$1B54B,,1$\!3M"LV+T-0$=9SI$$>>)3%@@$8U#7 2&
M'&@U\%X%,S:"54@P>*^ZI?BJN+!+FLH\!B'35!3:'0Q&]75&+U6S(YCK_O*7
M_G!F^WW;'0Y:53<.\_+V]*V^-QC>YB)P=6\_;CNF9A70]MH;CH %-\XH+KS@
MEEM-O2"1.XU9I-3;'[0RO]U5QZ S&,-N9KH8=D9].,P_X.EZDV9:XR2D>@FP
MWYL)PY6+D#EP>7][YB+$2X*M<0%)RL%F99P@0X1$SE''P3>/0JB-3:5ER]"%
MG?'F39U:5]'^O_^E*:&_%OHTE#YS&+I4\:@UX3: A%IK3:(J1J$)E9H91WZ
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MX5YACU2T"G&- [):4P1.A8[$<T64W-@D+4(73GHLOD4#97L)OL7WTGB*-#^
M-%]X&< .26 <D6>6(XX%0YICAC@56.L(= /R-3"?9YF&>Z-MC3_Z\=2V0Q4_
MYWS@.#;8>\/CV%\DTW#-;XF6G&HXI]DQ(=E.3+'?C^'YF');W7"0R592FNZ
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MDHCP6#.@"B+<$R)\F0EI1 *GRY!E$=R@)"AR5@BDJ);*8,5] J."X!:X02N
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M=4_C:?MD-$2'U4\;O_\!S] :/\1-NZC@L>HK&9^C-&$\GG8OGO3ZV5P_[/2
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M-\Z^,B,,E:1 &FNP!PG/89LO 'X4+61A<HE=6'NK;C('UZ.HE-OE_05&%ZX
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M.$>,([(Z.7S3&2_WQ)V9S*J2OFH5,O8BQ6J_I!"_;;'J9>-HGL(P5FNL5]@
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MKL7\&@FNS6@KN/8.LUQSQ7#0RFL !6R54SPH4W8CR<=(D"]"@ENG'=4@\0M
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M_5<6%5G>$F_V6QTPV)O^+/O<Z^CNPXI+8S;1[%S,_GW<GY:V'7ED^EY_0SK
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MJW<6/#18J&&:X$%%K_X=IF9X39O"=W5;IN9;4A;A^>&[;A_$:^ "9EWRWM#
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M _B@M=,^V$]0G X ,6=7N$._?>JID2V&LV<+9E3^:BU]M!;)C21YI%/<8TZ
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MA=^7E;Y9I#Z;<"R#2WY<>\.PX(S&!O1L ,84 S/J!O)9$ZR:H@=N>C053H_
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M;EPFQ0J>AFIF>.D9=B+'F:0ILMY8Q(7P""#&(ZR%53B5*K(H+77VZ3+/H)R
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M-(!P=W[?!XJ2U6[-S-RVZ[C>BC HW=&WJ1F4=G'KX-_=]O9GWN[NGGT^^,#
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M*F.Y,%EN&+7,&# V#/,IO65UK49J5DYJ!,B)M=8@Z95'7+L,*4TPHHPY0A4
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MNF!OC)AL"]@!U,P ,.PO(EYL!R_7IG.0GP ^7Z3?Q-2SZ87'GSZ:RDO$B4&
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M:H"BLEJ99OH-%1DY<H4-=G1VF\SH=KP9QCH(G8G]3> :3A:QX#N B>V/$(_
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M"K&W9E\NJ^AR6S377(OF#&/;ZZY'ZVK@EJ(9U#B+IL+(^/)!8KA?[Y<B&'[
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MVM/0%7Y=S:,J-M@N"_2Q$\6-Y6A66]$(TG? J9*8=2X+$L<8O5U.,J). MR
M6;X>3N1[]RY@:L-JM#B:ZF6#M4=_<Z;^8I$%;7]QU!S;;_IHG6*LOSQM*^9R
M(=DQ:)3U7L7G! 4!I+BF/)U"Y]XL2DD->F5#:3PZ)W/A)HW2/<JJ"%FBI)7%
M+9WE@*J9LZEM!'@X<AI)TM8G-.6P*,1.%VLZ /U36::0U9'I%V[*OB%JH,(\
M# QSJ)RC;-RU@0>&+#W'1:3!?#&(?G=\6"X5#NG2, VRWHK*VZ!X<TEP-WM4
M^!(.E!;(92$FUS#R2#C7&\V7J DS4W$V50F[(SE3EWU]IAH= Z<O4MT'"@MJ
M*R8+J20+JX%75/TREXP7"RYE&?JJ&YY6Z+(<FN=(='%/LA %YVMAB:W6B[ZX
MOLQ?S#%<&CTO+D?1HZ45N:.R^$ZM\.B2(.&NX32PE&ZD=!)(09+)(:C4.HVN
M<BE$:*2J<)P76$##4,Q#JINA3O1TMZ%/,,H'8]&-!6SCE@55Y-%EA X*PC@)
MZV+S#YTD%U;7!.AR'9\ZZ*T7RYN<?)2M%OTDQBQ.1<OYL5 +)"ME)7J$*N\L
M3H$KD_GW::HEVQG9@FJQ5!VH;$>#W7^T\G\7H(2?>\&R@MKE[A8;9EO_RBJ9
M1PEKX^5 /<M\ZWV=(JN?S"Z>+-/4,L,:S88 68EJD4=9OI/LP:#=*7/;'9!O
MF'E-K9K$=^&D^%9S8153$KAL.B#&2/*RZT)!_:Q*HS)5664>ZZ#M.%'J)7J&
MJ,EY(MQO(<$N3G(Y+(^,A6]B9ZA(KU&GS$=T:B@[2/9SX ,>.=EL9NPF248.
ME>F2 L-:0NQW@-6[*E%RA@V*4NHF0+)OO ;@56:9NKDO0MG$J"4%+3D-1K:4
MCPG2:J=F,7LP T%FR!8,0]NA6E&ZG)39S_1W!A2)'?M[EC^@<@Y+HDM>H/IZ
M+K::0"'ZV8Y=^R_#EQ6=^-ZKLQ/9U95M@[S U93YV;+#/*M2>;8\N6%EI(LG
MV-FJ.XILTU$OZ6.X'PQ[GI7%!L69'G92:E*M, ?@>Q+HOO=-J+X%^0A)+@$/
M"BT]UR%8RBH('="^BW?@,F5^9D?Y0+!<ZVA5LZ96J,N-5KQ$TGV<M=JV?<GG
M>6R-ZH2X(<FB'?(,JF_?RHD^AT%-5GMB;UVIU%YC46"(62B?1;*G_((G"_.3
M"74R3YZ,4E6T$B(VAPFM(]N+L(]Q*A0%W]H1%NL#U\C"=O/NW[,S,6:ZX,Z!
M4FFQ*XI=?>)$[@5DTGGQ$\U1C\0(G90X?PB(,E -JVDMS+?A=@SP%Q2@L!5J
MC;AOQ'B"?@ :L,>9.C*^8.\B96R<R?2GY;+D,K)KMNN]SMZXZK)\EMK[' <!
MIA]?DEXD&8T.JA_&LN6(HP"5ZVUN\J0 I?+$8CE-BW*9\,G<JZ".3].L 250
M*,ZG47V1*0)%'<R#,$_O4C3/XACG1*A%N6^7*AKFQ+Z6[*"6-Q;!G"<]]>8S
M=HIJJ2@3'H:4-)L/ 8THY^;L9;M6L:/8^Z[Z.(([!;_&'K1R!PU3=HJZ%#;W
M_\+>$7)(D)!YPW*DSS+D91'AG](L57ZP%QO_3D%7"=13\I?P+7B]4\-JU/[]
MP*8-+R]$W5T=HL;M>NZ_7GGM3K?5<=VA:'2==K/7ZKM6PQT.!XXM+*O;[?QO
MK_MJ]UHVM >]QVG94-JD(6.%:^HN3F8U,,4G9HJS%4PAF_,"T>^IAJ?F2MF$
M0<X@B],I*LZ_1:RBT24]DK+9>P2N)=EA+$/HB*)D80K;=>/7;^^[Q$W"V=N.
MNC!<X#2Y3\6]V):PAE,B<(366_67=R#O9[X]?^L%=&YZZ%WQBA@7 #N5%(%<
MA-;CKR4Q#P;U7J.'])Q$\']7+2Q)O4ZD_B9QE[_K6/5NO[/RZT;=6OG=7:^U
MVG6K/7C0:^_^KM-J59OMK+>A-T0,3!#8$P^(^5^O6J\6;F;?-@R+V%J]+_OI
M8.FGS=EW_/$RQ2^2*%/G4\J*!LL*9/4EB8BLGC'SXBDW ,@]/_U1>.<_E0(#
M!4P#[^ -,I(,!-V[?<$%BM8U@+[.45\.Q!J/0Z:[?O(3\C@*9[^'F7!:\)AZ
M'=?D]O .<C2Z"]F8@K*D2\/9DY_V8];M)EIH[E.4Z"O/N"ZQ-XPUH?!,:/_I
MT0ZN'YC:X^W(B2UST&@L%,1M^>R ;F-#&-PE5^_CLT4I5-'NH=(NIB5:S7<5
M]5;4NX?4N\.2=V-39T3_VP=3)[]T4I>(;]?Q">X[\3H.P8M]QY8L9Y9@S7JS
MLYNDM:*UY$KR:FX&@5()OE,"[:'B;(?4[<$BYX=LI0I!!\X]6U+XNRZA5Q5A
M/$A$EX!@YXFL9;8[W0W)[ Y4/Y8,6-<@.33T-'$Z:H6>746/95J]9^2>%V)&
MK\X0?S&6=-/L#7J5J;:KZ+',0;]"S\ZBIV_MOR6]BX+Y.DSRS'DM@/8CUO,/
MA:]WB>BZ9JO3>IAML"LW$5LTZPX&K6VSV=U4U%=HW7FT-LU&_X&6_,[=O>Q1
MFDD8J^+XY4%O#[!*#H8<C]IFN]-ZO6O7@,]@:!X22D%S5"@]))1:_>[.(?2
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M$Z2L>3ZK"V7O+ K=U %[$Z1MO,%$);[H+R''ZPD8P.-)R8],>N\)=I6%74R
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M-),16(WG?8!*@E>,442%$OUL3^*4#Z*3A-(MT#_I-.J-Q?;/!KC=<9RQ(-O
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M!D*[&7JA-C$S$YRTI'X N6M%*2LIV4:#GQ@>7W&CO6%AU"S-9TJ8HI"606&
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MY%R!=Y9#_CG%QI9_+^=)<+\_:LW.SZ+G9.-DC^/\TGU%=SIZ7.8KP?.8A4?
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M.:WQURFP=!KQ^D"^EGSJM;I1:QA["'-.R<#GT/;HY J&V'?X^9[O_O"QD(N
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M0SWV9.\3%*VS4FEGX'P7;W#JZH):?6*_7YR<++^3C.=P<O[_BWZKRH?YK+H
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MD82.B/97/U]T2]RSO-Q5=&DD5O+M?>#=GUGIV*NZ8Z_D_;XJIX7"U?U<%U4
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MEK$+R)8NT^\4E+!59_J[]NK^#MV]A#_I0G)=VDV%$/_'%4*23X9!-H19GM"
M0X_!\QB) 307: @NI.Z.U&NO?H JW%ER&U=AQ]=$GD_.SX?S)C/OQ^DR?Q^;
M6>Y[7Q;9YNF=7!G9F9VUBR/9@_2.1YN#E5(J)T3*.D4--H8,=K#-B_8+<;R%
MWT]BG%PT;W@WG8SQV[BHI3B=/C\K*'T]OOJ)(5*!JGESF1YW65@FK2+*A=)3
M%A'H#17$2U:ZM'D63)W;#7N3OF]XZ/1S4X$R_O0&C5]8\T[+.*GRYO=^#N_0
MR$:R!DE)I5*V!&RBI>]A4^?G2,FG").%C[1.:=RVE/;O0_:+P_6 4U5-=AQG
MN$[K>RCB7?WT$:;G@Z $U98V;>GQ(%!!$9^0RJ@UPP-!Y2ARBSC#?>]Y*ACI
M7.85 M77Z7OYQV?T 0!M>VJ]%9'DTLI(4K3LD/M \-<R<A[!JSH3!6\EYZG@
MI3N=5$AZ72=J>2]H-J!)>^6=)<'AGB9!.F)#Q#V-EJU,>:%3G7&FM]/SM*&R
MDU9JC.>>E.K;E>GY]?G(#\]G>!B>#V<S2&\O&J]#,9H\^AG$F$(C.AG$6N$)
MS5P'ZWCV[4*@6R.G#75/#4>=:ZS#&OU]);2(' ,BWVJ6",@RY,DUF1[ 8Y<Y
M4"RGXC$?E;/1:]WS8='7GV:/I;ZYV:[+@BL#B2_\J)B"35354E,N%A@B% I/
M0G DR,1)Z0[!J2TCA"OMBALH.E3.J$=,K.^%7>BF@JE^&UW+9&D;RJJ6'6VF
M[3!E1]WHL 4P]E! OQ!11AB6!2,<'!#)O"HUEX+0R(4S!HU"6B?8UC<T[BD[
MZAL9V\B]X[*CTYR'$3Y\]A%6GN2PY--?0&R,4<%097*9!*!"X3;I'.$Y(9VA
M. ],,Z(%SX%Q#EFW*3C:YIW]&]E=Z6G2@Y#[:LCU83Z)OYU-1OB*V<M_7@SG
M7TL.83)N?N^G^*S2M!-2GDQ?7<POIO!Z-KOP>!;OGG[9^Y6=Y&2Z97PM46.#
MBE%FT,8'])2"5<8Y2?$#P(W.<K#WV_<[*3Z<X3M^0KRFT@\<]\[U"[$_??WV
MD65<X:1T./]F\0/C@DFA$<S*E4(J7#$2- %0*@0CC;%U3-7]:=_WG$7_>#8[
MS;^6C-IX?CI]7\+^IQ?SV=R/$R[^03+">PV&4%?F247'B0>IB>(&# 4#T=2Y
M<7L?9?WON3TC;?UH[E15%2ZC["R>T\]-S_@KK"S#--;JR)(/!(0NS?PIH"$3
M W&*!\YD4J)=+4M_ZW(3*T\.K(<%0P6'9&>&%D?BZ_%L/KU8./WE$ME']/N7
MK+Z=C+_ ;'X9G,S)26%31//=6R*SR[B,@R><1^N4EW@"UQE'T!N+WU?#48"G
M0FYM9T87Y)_FYJ^SDR]H&);PUZO)]._EM!M([VUTV1'#0\2S+61BL\ #+E#)
M;,A,51I*5XNC[VO@$-"HD"*\XNPL[^$L"%VY/:_6W9X!4TDQ46*XLK3&=FBQ
M.8,$!X>RC2$)[NHD<+8F]<F!M*XR*Z02/\0S2!<C6"Z/NR0WVR2ZY;P2S[G*
M <F/N82-5)GW)8'PY(R,-!I+*QG;7;'05XKQT!OI051^+/G&!?FK&[8J<IJ"
MH23S4G.6HBGEAZ7ZS$EO="Q3=JJ ]AH9A\HL'@@)DZXT<@@W;:,@OK$Q3N]&
M?OS6GZ]N<+;AJ6I2L@97ATEG[@&6;>W)OC3]4%#L3= \2XW+VS)T#:/&,P=9
M-2(K88$)$^KT67XXZ+TGXWKDX-U&P15 BS;R?#J,<TB-_?P+*F3V_L,ORX2A
M9QDM9,9(;&1DG2%6<4DRR@PL%URG.NB[DZPC='"J:WY22VTUIG0L^6P67,B<
M.X&\.9#H:E&O24"N261.XA)TE-LZ+3.O4O&T;;V=]5$AUKBV!MI04]5(.P;S
M:G?];%#T'L*M<,2L496L$\YS17*6 ;WH*(G7W.-93(5E(N"97.<NX1'8(K4T
MO8U,NVY*R2ESJXQ'N6(X_ *%NE6CC-+"W#$@+GD\Y#P/Q%&1"$U&RF1I<FFM
MW=CM'2KO?$O_!L$^\I]4$5['ES5/B@I>GG\>3;X"-#;&NXMI/"NW?+[1QQ,P
MG[0E3#A!))K.95 RTN>$SL9$+=;OT&Q2[KWO>L@J[E:0%=:ON8^^&++DUJ#A
MX<N$4%]N5VACB$F2<J49RJ95G]D6[WK(BNY6D!NMKXXK,)>U2;/Y9-EQ=Y$]
MF>0K>9759ZY4>.Q>?[GG"SNIONR2Z;7:R\13Y,8%EE&K@@HGC6(0P%*%MI;0
M@SW?7:%V\%N.0P:C9!;HA6:+F.=EMB/SEGB+>Y%U0:=*\Y/OIFN?':YY\F3U
MY,F-$KSWD]'HU61:?*V!=T9Y%2QQ7F1TLXP@SFG ]2D"HX[F'$.+C6Z+5_:_
MWW6(@*O[7RTQ5PA0W%N4:5B,EFE/2D-P(FT(Q!H=B#?:!ZJ-".LP>'3ULU55
MNFV1[#;ZZ-@^NI6V577+:I<NA060!BE:RLOHNZ04GNX\%8(U);PT2"I3'MGZ
MYKEY]VCWRL>%AYKR[C"6U9K,EW_ - YG2*F ))A3FC"K1#$J%0D&;4QFG&$2
MN*?Z/JMI^[<^47#L)O4NFZUNDL;S4GPT@G0Z;:YI(87.9&6R*??4C45!:$Z"
M#A&]O\ C:!JS;=/RJ-W;'BD>NI5RA7*O>X\WG[+VF:IR!P1Q:JP@-G.D5 8!
M(KH@63X"<Z,CSI>ME!DJ/8,BW**'+85&3YBA)QQ<$/A[@*#K5*YMIJFO4K0*
M!GC' C^6NK%;V5D$SW5&-SLE(KPL2]HIY"9%0KV)RM*DG:LS*V<C28?*,7:E
M\C9(VEKT%=))MQ*VRGBU(*UJ.O$.X@Z36^Q(C6W L8<.>H8)>HQ,<EQ>W/$R
M@Z%,UM6X.&R$9)V1RK(Z5X=[A\<]^<C^T;&-Z#OVY/_K8O05]4+?O7[W\C1G
M*&T25OF7D(RG5)*0K")X !OBA/:$@W#)2\FB9BW,\,UO.)(HWRY*F'0NP8Y3
ME?_EQQ=^VA"V3A1'6UHS3K(H'>,0NL0[2HGR@D8;4F*I33QFXPL>B58[D5^5
MQ<K<&D4I4*,MY<0G7<;R\%3&>DI24N&2AL24:^,OW_[T1Z+._277<:QLR=XJ
M+G/R:0J-F[#*B:8,005!%&>:R%0ZRVI6RF*$BXH;EZQOH=.[W_(X=-NA)#N.
M=RU19]=0YX+5-&=*6*+HRVJ;B:42&06@FDNJ3*NV3K<__7'HM /)=1BS:GI*
ME>OJ2QZ;2/MLM8=H#4:PO*A"DDY3$EBYPRL@ZIP4S:)-,=>FYS\.?78BO9L:
M50>K_;@<GW89:)T-9R]G\^&YGT/Z959&I(U\_.U#/,-'SA8]#MY-A[& >9)@
M5+=2I#/R>JLKJ2/0]2H4X Y0E"ZQ+*453D=A=+2>\I!YS*VJ4#JCM&K-B@I4
MTB2!2)D<D30Z8ETT)<9OA+164EGGEDJ=FI76:0/M@U#E+I.SZ)Y+CD=$*-<\
MC 0AT,+38CUY].BJ%"H@9.OBA&W4T+'KNR3JPWPZ_ W*NH,!1:/>"I#$28:G
M3&;(JM8,34)JJ4XIH.O6WIJ^\N1'H=0.A-:QHWNYQ5XRNAI.^O4$K8?S1<>@
M,H6CW/9J9K9$1HMI(HA)I2ZU4.L]HT13M%D2%9'%-D[P]F]^-!"H+/0Z_O/L
MZAS;=1K_,1GY></ @&<\Z:7/A =10K?&DY"X(R@=0QG3SFWC3[=\ZZ.!1D5A
M=^QRWT7I^^'LMU=3@-?C.:!1UXP &UBGM:*1D\Q*>,"'1'PVI?]-!I,]*SC>
M$QBWO?=)0&-O@?=5=[+(##LFLI96D^"@7$!&,\\!2L1QW-Y0&,JF'M/GQU1]
MT;FIN+W C[_Z@C$ #1Z(5QX/0V<2FKR1E>FOTH24T&:JT^WR(55?;*7RUM47
MVXB^Y[1Z&]*^5U_LH,8M\NN[Z*#O(IU(#7<NX&IPIL1!(PDA%L^9E^B48=Q6
MZJ3X8*HO:J%C&]%W/0VDA,4OO:R&R&$>0EH&QPV-1@$>MF!+X:MWDGC# >UH
MFC42%IAN8YO>_98CL41W4<9Z@J$;2?8UY*--K+F#N>H[O::WL/]6D]:--X8F
M#\)*D%IJ9UQ*/$B10V*4M;M$VO'(]?LL9VL=E!2ESJ9,B$57V G$H2JHDV6Z
M$?1X::ZS,/Q*T"?CU#SXZI7<G\'/+J:-U?UZ_/FBM#7.3"=CB%*EIU-0I6Q.
M4"*4 0Y>.F=4%1EL0^61;(.[(6?]N*NFGK[NG2Z<A62<"BY1HD,LOB>7Q.;
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M?VIJB3Z>^?%J60NK!-@@2%".$ZD4D!(Y)!D5Q+)G7%3*FQV,Y2>S>@XNZ:W
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M7&D%\- Z&=YIIQW405SK3'M]P 8ND;Q<(MJ9,C/8$:.2(#(I07P.B20*.KK
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M.T:O2=.)9']J!Z2ORD; PJC+ <\]X<>,RF0C[/NA!*GU.(@?;C$>YTZA:U&
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M K>)8<!'E>"=(=3UN@J7L#L_5 9E0C1&[#_,=%\>B+687W\YJ2FZWS+35#_
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M&I:Y'V;P(V1:-NNI&IFE'$I.MX%"R7^UR; D*09S?19F$MB\;%*K<P7V[\7
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MCRVAW%('Y^LJ\C2FU+7QG7O+EF[)P3KO-=T;TV6=*)GN'=>J1G\O-#E?P7P
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M\ ;6Z7_>"0?+_N(A > <YJ]V"]8)?'"B7E.AD5FR<F/I<L"70?3:(C!KA@Y
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MHA<,JC_=)[M)?5]>M9QY?>6V_/8DS\J7CW8:?CZ@X$#> SKY5Y<"[QEAC:@
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MX.]]^XH'RS1E^$ OL-Z>\5H SLSTR3H4!.>#Z]3IE>XT _A4>LD18%7M-;@
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M?\_S+UJ5"S3Q2+_H%^M.?2[HHJ3<[&7>+!]IOI@%<98&"*?0U-:#.$98ZZL
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MP+P*P9'%]@RY:J5(5W7UQ"JN4)O1[0/FA^5<LZU-;F9DJCQ:8CF?TZ)^3O4
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MV\,/&5!;YJ4IL_C!]*-L]H55.'I+(K 3"6QD<M3#=O-BJ6N]<SVT/NVF<J@
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MU-+%[X.GH?< +RD:JNSX.2[\.OE/CC:NE_^<T =N_K,W]-,-QC'TBWX+FN+
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M& <H,F?(&:1<(!C'24!XJB@. UN]9S/@U)2@@0S>?OKPP?[3MN+UO!KTS=;
M.K$FJH%;9Y*"#>"^.5U63-IK3-^,CJ0^SS+K1XVZL-.A4ZT>,YJ"=1&JK6V=
M[NOG&WLCE2P*LTTUA7 _TZ^M)EYZ/SMC(L),$;VK)$IHS2MCR)2@,$R#1)(X
M%50XE4$Z,][4%.\&+EC1KV#>0/WFYO(Z1[&=G\LC<4-O.3><U5"KIEHML%=
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M,HG%/1<4'KE[JC(^%_=U'<^W7TW)-VG*R@J2HB!0%)+8Y+ )2B 5IH4OR]*
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M&&0>G/R,XV'L\4&.>.AD_LGQ"G=]ES<\Q6TI$7*Y^+*E)I'M]Q^/;+-:%+S
MD&<%P&E. 60F1YWD.4A221B-]:^P5=CUV9/GM@ TPD6U=':T<PY7/Y/?!$)@
MDK;4W_ISOZKK!<.SE/POWS8O_ZSOJ6U._4/UG5??^/F3)OE\KRK0?IG7+W"W
MWW[GWZ5X7AW"XTRP7!T^4I;/CW6:Z1=SUF@BA:I H44N,)(YS0$KI-YE8R(
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M!ZS ?'%49+D%+<1&=QB-4-653X=[K<K*5]3NJ:I\[0Z/^7G5>>XBR:5@G'%
M8%P *%0,2(PQ8%!QHF+&,GI[>EXUU.QXXGJ6626OC^2\&F,[TO"#W"3G)6-
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M&09*%3%60F^ALF1D^>KPTKNPVW1%L0<+I[*+5;-?NWRJ[1N#,$$*L1P(F5
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M2\5<'&G:^C!]RIX5A>F]V&/@^<?G7;FC53;@0L9$2<$2;07(6-L#J2: %*9
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M),-9X,,>@*B#0/2E[R5S/PF<UY3Z/6.<B6[3GE[.1.EKYZ(S$\_]Q+42JV[
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M 20UU0<0P8 *+$",949)HCA6T*6[SX4QG%AJ@KX^A\]EI:5SXZ%+$-H1SHW
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MZ#??RUV,:1/ 1L-TEA$V_DEC8X?6Y6:U%-6&[)/^B?\X6#=8XACE$((<J@+
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M$P 3A0!-I !$IEE6,!0KZ91%>#Z$TS9B@B3"+V:,B#=1;YW$9K>=Q 4L[78
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MF/I<X7 ZW+FF]Z@CG;.'37:0<TV-[O'-U6M&6FEMV:CJHU](I2TI15.00Y(
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MA[=MGS099SNJUN5KUUO=N?K^R41$T(<U_TN3 1:K--. (I! I'?;W/0K$4P
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M,N"UI<.1W34LA%K$6I\T:6.K]LIPMQSOTD[QMVW905K8&T:?<3E=9-HPR_5
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M0PM>!04LN214<CZSTM_.&/<4Z!/H.ZER]/F-P[!L0S;&FE+[1\GKYP4A*H7
M"JHJ;J>#^T[1VRQOWREZ=U%E+TWA9Y\_SS:B#+-+4;Z:E\7RT[DR+X6J7=12
M.@XBUH>'/=(6%=J 00Q*.YM2HUO*+0D<=RQ:,SRV4$\'\=R-[-J</I>VU'DB
M!/,$*1I-@O9.846!<L6"XQQ!:$WBXIRQW*90Z#&J1N[I;0&#QS*>A^BD WQ=
MRNC7Q3S1EZ_F7XB9&FS.\SV!Y_/I*LT6J[,E7HMX"[&K(BB6ZCOKBH%CO#K1
M)1B-"F5H] C3@92/.\&OZ;E\-(7V,,7O@11QSCYYGRVD&&H!5!9 &SN!UM:D
MHC&2A[Q%AO[0K'PS0W=</=\>VC> T#LP?K<:Z4[C^6M#K^:7>8*7B^7-UKNK
MZI-)<!FE#@9R?>]:A=ISES&!$8EQ8W(2M]MRAGKY:7^BQ[U'&@6QQU;UR!;Q
M0K:GA5;>Y+LV1<F38*15.DHP7!<2GTC@C+/ F).Z,&2!J2V,X?V?/FX><C0[
M.("H^WU]_#E>F?=%^>5L17MEM;I)]E;SJ.[_G(%F4&U!Y$!SITZ7'\)\^I\;
M*FN;WV(VS><(G^<WUS@X+1>8"[,K!^^;6R=Y9DZ$#+ELZL^4A1AM?9. .6U%
M5)ZUN9<8A/Q##]N#B+BV;^?YW?3#?%JF*<S7%V7O=70P?5ZB'?Z>5/[+K):=
M.(U%IN A&T;B1I\@)D-.M=!<2^,E2QV*>P].QW5$C[\W;I_M72.K7QO_>OJ/
MLVFN;N'N=OW;OQW(EC] 3%?V&U4N,?@,H3Z$K(*+X*PV$(J4+ 97*/;ISZ ,
M9;_/-;19YY>PFJY.R[<M\FUK%%&+#QAYR!OW)W ./D@*",DI2B5:C*I-2G(K
M\GX$2[D+"F];RN%U^!V8M^?U$>'9/M[KG8\8VMC=2UI7-L]9EH/*'H*U'E2J
M%\Y&$2!\\%R0K+1LTX?2A<U[ESYB/IMMZIE)C7%1\P-?\*36"'ZX6&J>:R3X
MP(_?TU>KL!EDLSI_X3C07A5U+D@4=22_,(*V;^$0,RNTN[3"T&BBV^"\_ C6
M=!=\W[ER'!<='210:QJ8#%E8?GT7JAPVN>&3/Z:K">?".5%"=9$U*&,M.!DX
MA)2Y3IF^*]M,AWF0I)'O)4?&RIW;\B$4UP,"OY'_:_A$7UZ3T_/%IS"=3Y(,
MF)+0@-QS4%XA!*,42"V<5+)DG]K4.3]-V]AWY8. X#:TAM7(V%>,Q,WJY,,2
M-YOPK_@IXG*2+ 9DY"#G8A70Z>' 8946=RQY;C/R;<9AWO?9(R-B8-TM!A1D
M#\:&-@S^XXSH?_&EFF3Z9YOM8CB*P$1]^*X^:8Q8R(F0"JP/.8NDDF[ET]U/
MT,A-K_T==8<JK4_L7>Q(9-8%VH@0O0N@6&3@D;XB(QYS,5%PV:K@\ &2QC_6
M#E;XTR#:0_K]P>C2#BM,-AD#(M:I@CP8\&28P9><?"16T+8I9KB7G.[@LX^J
M'P?0'G+O #P#V//7TSF^HB!\-?'%9Z9" H/>@E(8P?/@P.AD@A:)!];FN9XA
MN1BY!ZNODW8T>'2P-=[B>4'1B["<U]G4)RF=?3J;U;E\S[%,TW0]\4KEF#0Q
M$]" LD)"M#J J_SP[)R)L@G@GZ9MY%+&T7!SNTAL6"7V,]#QYFM!*)D/K-33
M*_E:I1DALLQ 9">8-"+Z;AY6;5>,V OF]E=-5_#:=CA6+"KH&#78F!PH[VC_
M<*LAHM=<9Y%MHU#Y>YEKUA,P6RBU']3N.=*7MJ+7FI';CQR!HD8$GY!#$BFB
M\(J91E4@#:<S-VN>[@;-1U!V!U[HHP,SWR)%GF=X\4C\?V*>9$WQK X:7! )
M% 6;$$Q@P(M7-D5><J/7Q7:C<]P.ZFX@W%"Y/1OE6Y.M2>KWS!QF7L7@:ZU]
M<;7KDDGPSFF06BH>@T;Z^9&,\C;TCMN#W0VBCZ#L?I!],2:Y[LW+G?QLL5J?
M?%HLUQ=E+)-05/'<)Y!&<PHQ(P(Y5@Z*T46Q;*-J]/+#%L2-VR_;#6:'5N/X
M#6.;21X?P_)#G5W,I9&V:-"\2% E"0CUXC\9&Y@4)>7;,U4?:A2[]JE;(<?]
ML,@Y4,P=%$!<EH:<K3\NEA7YA':RTI,8 D:I H@D&"B1R20'+8%'78(N):GL
MMD#+(TML!1W_0T-G* 5TA*/Z:MY+Q#>X3%6='^@'?UDN5JO+P1H3$Z)+3F2@
M@*ORQ3QX3:=6-BE$*UD6<:OF_1W6W"X%SOY_ [5!==1!:'R]M.FL7K[27^KS
MS5=/CEX3Y41X69R.!IRRK@YQ\1!\=H Q)R,RIL+;M [N0N5VB/WQ;VV::;8O
MU+Y93E/=CAO>)MXS5EQA0,)!4)&DYJ(W('Q,V7$3$VM>U'J#HNW0^./?YPRB
ML;Z0=^-AV\M!5Z<WMI4UB@X%)6LM*#FTR9(CXGEMBZ7H)W@,Z-KD7W8B<SN,
M_OA7.^UTV]'S#6])NT1(G4/Y'+_@;/&Y"O.:7/\ZG>%JO9CCF_!UHX8)6I-0
M>_*?/9),.;/DTN@ VI7L;&0>U39/;1]&Q78@_7%O;(ZLQY$1^R1W;Q9K^N\T
MS.ZP^7[Q"UZ-'8S6>G2& 6W&3*>+T.376%,+!UCD.2AEG^IV'9"<[3#\XU[9
MC*79#OR&B]&_MP;^GJR?A>7RZW3^X=_#[ PG*G@CHV+ 35)TII!'%.B, 5WG
M8Q:1"X62C1+=6Y"W'7Q__/N9X779 4#O3*E^@KT852(9\?K@..T_% R\C!'0
M,%-"+C+R-C/S=R1T.]#^^!<T+?4[=@[UX=&;S\Z654L3341KXP0P<G1 R9 A
M<I&!,S1((BPV;-6:^.1*V\'MQ[[5&5@?_<Y2V0R+693K8Q7"$].R;C*UU;B5
M?589:"++P0P.-+3E[C)7DRJ2E-EI27&WJI,J-%DL'ZT 9Y!IR2)JP9N<0P_3
M='".:;MQ:T)'X0UY% E+?51+6W $&T"=6;),JL#:-$Y\#^/W!D+,G131\*K9
MV[Q]P65<=&?@CFOH.C!X8QF^F(7**,@CTW4@I$P,7%:*#FMN$PJ?E6US&=?.
M\-T9OK99X.OY?[_M+J62298G<$FX.IS(@"^TE9VV')..:%R;<K#MZ.O6\.V"
MF-N&KX%J.@AZ;PS(NLU+=JX4EB)P6XO<E2;W-WH-5GB*?8KD"1LE8QZA:MSV
ML$;@&DP-'4#JS7*Z6)Z_MTAA#QTPJ\W)L=%0_C]GJW6-MZZ-Z)[$@-G4R>HH
M5'UIT=.6T10/<9,TDI\22J.78G:E=-P&L$;0:ZJN#N"XN60GXUW+<C_55I[S
MX7^?+R8"OIK7,J;I%WPS"_-S5^;KA-N0A4\%-"L4]S-'KK+Q!0(G.1NAO,R-
MYO;L3NRX?5R-0-E::1W@\K*7_+(.Y+;5-XPIH[*%S%D@J^\<Q%08Y,1=*H$;
M)]H\:OD$8>,V737"VY#*Z !;O^+OUP2U7,SIRW2>!KW?:Q6Q%,>5A<*Y A6J
M["02.E@JGCB,.F$3L.U*Z;@-4HW0UU1=/U3R>#.+YDB9E8NUQLNKW,?L$=+)
M7DL?:SEBQ/I4FU<4NTH.WN3L%(N.ES9)U8;IY*MQ2"?T^7DZ.ZN^PSM,9\M-
MX^"+/^HS\)AK55'U-\XN!T3?/A:^[< 01,ZEE@[54T'%2 +*M VUET$S*0/]
MOXV'.#@OW69K=D'BPR.X1U'Y#V5T'[G-W/\)A39TC&>L=Q52>T-NBE29.P&T
M6WCM 6,0,$B@[P;M<Z'HO<VD]6,8\HVX?_GZK.8KS@?4"8'.Z^! %R07/3,-
MT4MRP*0-RN60#&N317J$J&Y-ZR[8>-BT'J:$#N*DAR;"ILPD-TP 8AV_F4NM
M^] <@N))HDO<-WH__9"YS4=XHN! A6\Y@'D7Z?<)HHNYL+[0&: #.0O)U6GY
MZ""R4DA6)F01DO>I367&=S: >2>%;SV >1?I]P>CBT' M=)09)W)\ZU.IV$%
MR/65P(LMB1Q.C:7=<RG?S0#FG52]U0#F7>3> 7@V%OG"/K^^*E^45KFH2P:A
MN !5N*93O@3P$0WJI",WC:;&W$=.+X\/#'N('2[Y#N"S4Z>TTUIS)C-8$R4H
MKC0X86A_1*V42R::T&@F_. ]\,V*D \'Q2&][+MHJ"_T;=%U*IECGAP&B+DX
MDB)J\%8D2%D9[@HZ*;Z7CN)V3>\M\3>PCGZH5-G[Z2?\=URM,7_K-MD([;?Y
M=+TZ:K9L.U)&O-W8753M<V;>!JGKV'86O <5D4&0!<%$9WTQMKC\_>;,#LV$
M;WPE4SP+6GD(QM8Y]W3*!+(>8"E(BYFVNT^-)N ,RD>WF;E=$-CNTF-G57?@
M1IS\'I;Y*J>0Z8PI=+*!U+H>=BZ"=T0\<\)[KWP6V*:BX089O23NCH^'Q5#*
MZ0!9]U>C76\N_.7KM]^Y:-;?</R-[7FNM6KU\<2+G$6P2;KL"@1K:*-S$H37
MQH%AD:.-D3RE1LG!!MR,;$[W!]=6=8='U'0':+_/'7O[[K?+Q!BC"%)* [R.
M2-M4PGD4'B*3VFLO,V^4D'R4K)'M[.BH>;#5_5 5=H#' \^N;_&O<9E;1U&O
ML;)._TFV]E&0=4#C558J9=_FAG@H#GK)H([O38P!B0ZVPI.&YE$[4Z/M&G)L
M>CWX1&=%]B5Q0*LU11H!(7";H00L3/(B$1LET@;D8F3'8Q0<[NJSM +%#Y6Y
MNU^51\W8/4[">)FZ'41SA*JVK!B&S,&Y>C'K0P%O600Z+W)1LKZD\-U-NQCX
M8%4)71&"_#DOZ_L^AF3%&&@>F$:>3;@]K/*_,G0[U<[M@,#6&;H=5-V!^W(@
MS[]\O?\#-E%_I*B>.Z$@\_JJ%87Z$*.68*TMV5)XDU2;6H>&3/U8V<-=L#JL
MOS\8<+K=0]?R!N1'RN2DAZ)M-4_US5CA$"C><B5%S*%19\I3E'W7KOIP$-H*
MVGOJLP-\_BW4P..RC$X[ZY&7 BCKP&53;[.<LA!Y-(IK%XQNT\1\@XP>D;>O
MAA=#B;L#K+R@.&KQ%7&3I#QO[K]@I$29&)<.F#5T6-BHZO.J"KA/A0<O@DUM
M<A,/DC3RV)F6&!I&#1W@Z?&TMTH&A386C.7L_#'JX+D#@?2'UJB<;>,A'GYS
MT6ZF3$M<#:>.#K U6*I/D>A4+!JL9P642@7<)OF-B><B3;.WE?_K%J*OJ&0_
M2'S_6^'BB4+I.)..7.6<M0=2@R'+HLEA25;5-^)("VW25(.0WZ-+V1IYP\)_
M#QCT>^'P,DR7FZGQ?\6P.EN>7_KO<6MP_^<,E/K?@LB!\O=7*SV?KM)L41?[
MEC]%'VP)=/![*^IH8)/ AU! 9*M"C:2M-$TV_F-4'6H37T[G89ZF8?9J3A]X
MMA'MMV6^#9%@'K$H5Y]C=8(VG S@1*"_,F+=2Z%4:5.6N"6!X]JUP7!SVU:U
M4,]W9HWV'IWTV*>UM$P-QQ\]BK,<BQ1%:\@R4F""',%I14#@)17#1,%&#48M
M[=,WM_EJE9/5"C?/8KR>ACB=;4[O"_GGT]K8<[9<TH&]N3#>Z.+;-N$NA6B\
M@8R*MJ*LL9NAV$W2J9VD%%*JUK,V!F"C8UNW"P8?OF,\MJH[B$VN6-Z"T]_F
MB[C"Y69&SZLY>:KTXP6=$K/I!@3?9! #1Z$Q@F;&U(<N(X0Z?4_+F+ ^F.!S
MFY>>6G S;OC>#/6C*_X[<P>>+3;5#?3EF[-E^AA6N'F5^$9SYZ7\POK%:CW]
M%-84UEU^UN*63/>OE#HJ>2T=EJ.(]!@>D,P6I2 OF&,M MQ,^+8J@E0E*2:-
MY*K-%7+3"&W'P_#\O;#EW;-QHFQTR%.=+&V1K()T=?JJ@>"<,2ZDE$UC\1S*
M0L>>SR[8>_ ,.*J*>_)Z?OEZS2"]7&[FVJ2OFR(%';(57#@01=17)'P$9TT!
MB9%SKY@-K$WCSA;$=8+'X\+F(? .I,.>8'D?0Q<7C D99R@3>,XYJ) %1(D(
M*?ND1.3%*]$6E@\3UPDLAP+$0X ;2#N= FYUM6\O+IY]$EXJ8P%16%!6U(RB
MK(^["I&\,=&Y-C5)VU#7">2&@L06D#M(/SUA[I>O5U_^VY3<?0H!OKZN#[QO
M=JK-)@9D&<IFH%P1BHX&68^&Z+7Q]+-&?;/;T==)5J"7$W@H3?:$S^M[[BY_
M%[L;E5%!,P0LR=69ZZ$^9,<A>6\#BLRU:',KOQ.9G5C) 7&RC:$<1&D](7*3
M>UMM),8OC'_21@E/QG_3^JY"(GF%DL"A4EH'SY-O;";O$M4)VH:'PD.@.U O
MG4),7+#")=$<LX=22UF5K/Z%J0\ZL<R+C(F<F3:75X\0U<GQ.PK$]M%+IQ"3
M%ZP$5323JD LU?1GDH[+"LGT9]I#UF5L]'#J(T2-6V@\+L3VT4M/$#O +7Y]
M5>N7@_&%E?HDNPJ@>*Y;BYB/(;AD=+*"-SY:AV"C$QCW$:@<'1<=;(ISGN^Y
M0[BZ0BC&2,\,[7)1)R?Y5*>XQP*8BA+%&AY\HW?AGR*M$T_R^+"Y73H\J X[
M .6SL/I(XJI_O/C'V?1+F-TXW[XQ2%X.DYI9.GA"BJ"$D. MMR2V+'3@DB+#
MU 2<6Y,X<FG[L-"X/:V_B9Y&!.!JMKK69[4]>SHJKUD48%5.H(S54!_) !;1
M):T\TA]/U&WLN?3(C91-X'4,+71@Y1X4WL03V=[%!(;76WMK-(FOUDT+*5(T
MY+2S1M-V'R)IY+[*IE9L&#WL#ZC%.LP& =0U_^,Q60EKHR%O&4KAOEXY60C$
M)R!Z<C1\UCJUZ1C9CKY.DC>C>W4-M#GRR7K%QFFY&+2P>K-8DU*F83;[^@[7
MZQF>%Y%68S])FJ<HC0)M?08E"YESR0,P8UGF.M<4PQ:'ZFZKCNNNM=#YXB@*
MV!M:7W 9%P.=J+^<K6CKK5;/%I_B=+[1VK<JTAN%HY>"_CIA7 MI1*@E^(5L
M/'<0BB,FN7 2 _W8V";6< ]BQS6-#<%Y+ 5VX/4]+L5)1N]C?4O(:Y5J!SU"
M"$E#)M%Y#";'1H_,/4[7N/[?$9 WH%H&\P2/T[IPLUMC4<Y3_-?D,7 OPM;K
MM6PNV(_IH_1+2I54#3*,3.0R&F' !\: >26859J$VR;=>I1N@0':B3;Y_F0Q
MB8(6BF:67!,K(.;:7IQ\C"5*&5K?O@S$22<Y[$.1V+)_;&>%=W#*;UG4E$-)
MOI@ -M>G4J6-%!I:"A)5()Y0>67:I*\'+&-L#\Y1,+1?->,N"NT)IEO5$4@O
MC;<HH?"L0#D28N!90QWCD(-ES*3&:/UAJAEWPLE!U8R[**TG1-Y3;^*SR-Z'
M %Q8"<I;#I[% B8()4RHC#;N%-RS#JB3:L:=H+!#'= N>ND)8H>?*]\RO<&8
MP@O)-F5+&SJH^DR:S/6EJ51R")PWNK)IP4TG*?BNSOVQP/)C;9AG89;.9N=O
M72]FLY>+97TU9Y*CC#YI R[6F]L8-,3ZYB W008;O0NJS3,DS5GKY'P8#;WM
MMM, 4.II;UT[P?\V77^\P_RME-7J[:TKQXMT^.:S)H5Q;YG-0"R38NI36$&*
M E)QKY13*J7C]1T=S,X/LX>&@.P6P<!Q\;/W)OJ\>23MW3HLUZ-NI0<D\1=R
MF5\O5JM7\_,1K*_FI^N/N*Q36)?X$>>KZ1?ZN+3X1.(*K$AK.!19+QYB=."4
M]^!-T<K(S)EN/./NV"S_,!YB1UORN#CLXL*^C?72J6:G608ON "%%.+&3/$H
MCU8$Y[C1_'A#,(YS^K5OT?BAMMIP^#GP]'LQST>_\/VUEO[4,>,#7^S>^=R6
M%[B/,W&,BUJ!IA2" L14AQOGD"&0F05,S#.=DC6F\>"3KL>Z\9B\CM& ]=Z!
M8BC I:3!!A6$<$P7W3@A]@./==L%>^W&NNVBX@Y"[<OBLI/TC[/I:KI1Y.8N
MQFFI5!%@4MED,0)$P<CF!^9#42X3+4TK &\1U GNC@N/!PH!#]%5IY"K7R[Q
M\D4HU(4%)BTX5X?T:@JWH\V%PNW$4 7NE&P3.CY)VK@P' 0 6X!J?VV,7$Q_
M\KE&@8$BOS]?7L,9S4H6"%8;79,VY%)S4KP1(:G-.#%AG_#K[OW@_H!P@-(6
M0TFP ^MRS1_>!#GOZ=^=STHJ3B#3 J1W2!+)$AP3 AAS.HI<N&%M9K(\1%$G
MZ:)1C[1!M-4IZBYV8N2)<2L*>(R1."$+'1)*B"X*PU5TLM&H@(=I&M=X#:/S
M+8"TAP)&/K]N<_$WG'[XN,9\\H5L\@=\MEBM3\NS\'FZ#K,+\YRYXQB,JB<^
M13U>T;&O6 2?DM R!3H%_!8'W.XK]P>B??2].)KP.X/6.3O/,5X^[.R$S<BR
M 9$*.W_8.0IO*(:NSZ5&@?GV\.ZM@'1[G7%/O2/ YB#!C@F2Y7KR-LP_G-OB
MQ#/SA4AU&@NH6I7IM6>@C4#.O%;%;_6$+'WJM1.+_G;[M+JQ;"=I_5%<HOWE
MWP-H+H,%)E%KM("QO@XO3:*P(V4HTE ($J22M]N3#X7-F(?1 2J[K?0]Y#>R
MVO\ZG4\_G7VZ?&K;U-)9K8$94<>,!%6;^DD,ILX?T5C3$(,I_L;2(ZM^'\4M
MAI#BV.H/?UPC/(=L.18+W(E,CA!Y[4&D!!;IZ&0Q^IB'.RYN+#V./S&8^O>6
M8@=![[!C08(F1Q(5<9NM(<1G1VZTSH"<T.]91M.Z7NAHLR/5C^G!C(^+#C;%
M]M,:3NJPD0\7K=?UJ]-R>K:N-4NKBTZ5#Q\G)'DZ$.K0)NXY*.YU?10C0?#!
M9(4F6]>F:'58/K[_Z[L] ;GW+(_!T='!WG@3OFZ>>UDLGQI@<O&8-JDBK:=?
M-GJ:N,1]U+9 4ER#"J5V!IH,WM/9RXVU3&WE8^R\%0XB^_O/\@^#_./IO@.@
M[S.R)QLL!14Y?X9VL!)*@*_3&IF(*C*3I0IM2J=:S5SJ.D]S;'.^GYZ_*R@_
M=6*]7OP^\5PS4\^J$"DZ4H'S.CR(A"U=HF@W4YC3IEM^4#:^?R>_-V]F5VQ\
M5QOC:N_?OBJ8V,U;$5R"$2R"<AK!!<% DHW &)(+O,W4T0&(WVH3Z/_:!$/C
M8.1[Q/WV_/OI)_J-T_+7Z0Q7ZP5]P,1Z+;1E#%)P"I1G!D@-$H3(UBI&.U]O
M<]\X%#U;P=G\N' >3;>#X7GP1I%?PHP"$7SW$7%]DM+BC)C=HR_DWH\9J WD
M:1('ZOHX77X(\^E_7F)BM9A-\SD2YOG--09.RT7X%F;OZ#OG"+DJT=<N)<4(
MDSG[.OK9**  CBQ>'4FN@G"LM*F%&H3\0SV&=V>?"2WU(\/LNN*N-3.\)W7]
M0O_F[Y-2F.7!(A3,M1A*18B6]K#@*#QF6T1NDP[?A<IQTWK'Q^3ML[^91K\O
MH[BY,AC*-%Y\6$,#>1^Y79E).K7II/0.K*F#T R%0QZM!Q$<8U$Z*4.;><==
MF,GG%WBOA52KBWJ[Z7]B)>!SF&8B9=/K?>XI?=MIWS9:H)UKD1<H4B90*DKP
M(BA@/GN=;)8VMYF#>BCE/X(YW06[M\WI437?00KA7?J(^6R&IX5,T_(,KSO]
M&R/UC3.+QIIH"MAD&7%6NS""T\!4<"5JJ9"WR0YO3^.X-QWCH[>1-K\O5^!B
MJ[[XXS/.5[@*%UOV&<6IM.C%SMV[Q?[0%1LZ%7LSWI7G43!9R8.&HH.I4Q[(
M&2:_%*0RAFG)K/5MIH1TX7E<Z/#5G$Z5JN )%X:+K#EHJVB?%I*)MX7$$4V4
MD7$;<IMW4&Y3\B-X!KM@Z\[M\2&:&3EC>D'[6Y)3'3Q+,GM>!\4N/E?Q3*)(
M+%A9PT"7B9%:O;%Y.3H58TMT*GO^A%5\<I$?X63>!SW#2K\/&+U9+@JN5B0O
M$A,NOTP3KB:2913H!7"LU<(8/9"S$B&C5T'EJ(W;YE6P1Y88]\:_"P@=+/D.
M(HZ-3W+35;GP4"8*O<O": C)>5!..7)]30(4M$<H?$*,C7*S#](T[CW[^*?>
M0-KJ '<WF;@9R%^R9 4Q91('(R6""EI ]!0CL9"C<%9K@XWJ^YXF;MS+[O&1
M.+3^^GT.[+[8[B*>?R"V&^15L$&6;1C>'B:"KF)<KPT%#K* \+665%;3F;@!
MH8NVP:<<7)N@;M08MSHR]3*_?L:E,_PF?-TT>RCK>.)* K-(.S<Q ]7S!8D\
M!84!:4-OX3X^\/$_0NRZ"V:NNXY#2+R#X_L%6;#%5R1#.B/17$]L7AK_^O"9
MD-Y "3R $F3\G52)0%*0%_I1$FT21T^2]B,$O_O KXWN.@#CQ5%T/1Q[B=^X
MX4*KK)*#XEAU0R(CS[@0;@++T3M.?D^;CJG'Z?H1 NA#8#B@UCK X+G[>^>:
MYY(;5H(*3"N(*I.K+<G&^U!MO),%L8C(>9NG6QZGZT>(IP_!X(!:ZP"##S-B
MO8P\J0+%L,WT< G!H ;B+3AM1;:LS6%\&/(ZCY\'L'X'ZJK?J/G9XM.GZ7HC
M+PH-KXJ&TW2OLK#'/FV@&'=K@@<*7:^M=W)KO7L>;=<I>N'K*&M9)%!@$,%G
MJ\&[8D*P,HC8IDUJ)S(/-6!;+7:MN,=JJRQYJ*Q6^"BC HE')JB[QV<RW:Y1
MB+$;G>.&N^UP=MND-=1>OR4OCYB-O8M@G_[,]C:O84GL;HCTVML2*0X0R=0B
M:3I?O;026+:<9^&4T6VBMZ-:OM<4 B&>?MYTT\P_O,:PPF_=86%]MJ0_;]6,
M1<&3K-DBDQ.G*#UD<"R0WZ"+,R4@UZQ-4? >Q'Y/-G 7Q-VV@:WU^%T:P@&>
MTMGET]L;QZ,\J[,;:(6/)6'.8$,]3>L[OCY+ ;Q$8R.33L<VSW,<U4S^BK]?
MW#_1(F^6BSE]F<ZCLM/ELX^U _'5_/IO3(D00M?Y""LL,CC#,Z#BM-'\9DPO
M.G#<H^8EU]%L361T$-G?D^G<!86W3>?Q=-M!JF9S,%S>!9V%V7M<?MK,#'7,
MUFY8"U(S>5$^I+( JY(2S&$PV\U-W.-0OY^B<>%W1%#<.<D'T%"G2+L8<*VM
MM+Q(#@(].3JU$L1QXHDE(;VU20?6QK5^F*9QT3:,SK< TAX*&+G8]+24:<)W
MGT/"#4,O_O@\K8,&GF/:C"J5G'2M+L:6,JEILWD/HM3&UN@=1&YJ'9 HD0N!
MQ6SS!,$N:_8'G'UTO#B"P#NP2?M:]==7 RU\D8XKIT'[:,G1*!:"):D&Q:5+
M*O!HVYBN@TD?M_I@O//TN#KO .0WDP"WW@ZIOG/E]&U8XQM<IGKQD[72.A<'
MZ#(#Y<X'7WFH+[9)2Z)/K,WLIUTI_3Y=PCV!=/O&N*56QS[C;_#V%NOY=?FW
M>J)-HI;,.$8;7F(&I:.&D(FK9 P7*>F29-GF7']BG>_31!Z&K\'EWYT%O*@4
MGB3.7' R0:G/F2LF$IT?*@)]6R4A$@;=:);%?>2,6X75DRW;1S_=@>QBJ/!J
MPK().E0_V)/M5:@\N)C(]K)J<G60IE&C[OWTC%MHU1/,]M)0!SA[O:AC\"[3
MGU^?S<+T4TV!?IJN5IA_/=O$89JS' +M&&LK3S[F6BL6@!5AHO.BA.T>R=H]
MH[(%=>.67(V+P<&U]UU>Q%U<0-)7BW+C:I*^XY1H<CVWY9KM+^WV87Z4JSSN
MLC'"6Y"E>%"VCCT.LH"S2K@D%4L.FQB1?BH>+@^)<Q^8#%,MQ%RE,/L/#,L)
M4P9%Y@P8G1-T<DB$B$8 YL@IJA(VN#;CO/:G^7NZQ-L%?SO5/PRGU1[\@6TX
M?7Z&OY(->?\[SK[@7TGN'U<3BM.D-9*#%EQ1$.<2>!D46%.2Y;D8<H+&0^\]
M%(\;CG>&W4,U^ATAM^[*][\O)D&IB,X:X+G>8(@<(&"M#D7FI6;&F=+J2GHG
M0L<-Y?O#Z3[Z^][@27C#B=:HM;4*G+(D3!_JP%XNP9/3SAU+)L@VQ?$[DSIN
M&J!3B.ZLP^\(I),BE%>N<,BROO6=62:OAB=P6O&HO5;!MKG4V9;"<;,"_4%R
M)XT-UG_5"(F_S?/%E52=U)'H5T\^U;]-K&0Z*$G>BA &5 H&H@D.N/?&JAR1
M=N/Q8?D0N>,^Q=$)1@?1Y>Z ]>> G>.'.BS@?:.\_;?7T(IU)1?%P:A80 41
MP)MB0 @;E8@LRWB,Q/UN+]O9[Q][0^CC!TZ*3FY%<,=)B]*JO21&;PO@*C7Z
M\_Y:>;=>I+]_7,QH#ZU>_..L[K;=A7S/APPDLZ?(&R@[?/[1WZ:RL>0%.1J0
M>:A%5LJ#Y\*"*$;)%)U(OLU@]YMT'#S*_H[P?EVL\;Y&4.&LJ$8&)%DI4(Q3
M?&I3!LX\-V1AO!1M$F);DSAN]O8 ?-R92-]$*?V:_;O\[MV4^^!'-3,V#5MP
M;T$J6HP^H 3'2>-U:"-XRSP4@T[RD%SB;6Z<AC$YYW/5/GU:S#="/%EBG:ZV
M_(+YY6+Y\HQ.-WRU6IW5$8:W6B]-D2'H&* HH>HKTK7=/3K Y)/4,M3TV!8%
M;7LMWI51V04!-\?9M1;[]V1<!FATW>)#FQF<H[2UW@)>0"&YY0J<C[X^?FW!
MT0%'ATVAT *%=Z%-(?^PWLZ;2VANI/KN(^W!U<G9^N-B69\KFC"7<VT4 A:C
M!%7C)^^= 9F,*D%;U*5-%O!QNKHR0;L@X9YIQ$.)OX/D\DUNWH3EZ7(S?2IO
M'H1]@\L-@Q.E2$B1&R#;P>L#!0RBMP4"67(9HS79MLGA;4??N-?&S< UB#HZ
M -FUD_O.?A&8BLP1Z7RVY WX+"C$T!0+,$8[R*#%1N_E/4+4N+>[ \)I*,'W
MA:$'MX7125G++7%3ZI@G02Q%1?])F7&==."F3;G_%L2->QW;!E.#*.)[<KJO
M\1Z^A2#E=@@RI$N^XY+-'/9#6&_CSFN?6/%1@Q<Y$<@"17:6PDHFHTA<"BY9
MFS$T R<OKUYNW.R=7\*JOD'ZJ3;(A-NOW?_R]=OO7-PCG_P>EOF\938%(72)
MEK99J>W?6I-7H!!$]E8EEJQCK9_I/)"%KH*$7?#U\'.<QU1J!\?T.>7TRYM9
M%CH)EJ-E4$1M(LS)UE[4VD[H:VE#DC*T2;??(&-<5(T$A=LS@/?62P>@VE]P
MW]B>YS>S,/\U?,*+81G!1B.*,B1(1S%42?45#!*)E45+AUS:1F-N6W S+L0/
M -=MNSFVICM ._E6Z^4TK2^2 +_-I^O5VW>_78Q?";PXE3F'M)&I\^2Z:Z&@
MD(S1"2E,;@/;1\D:V<2.CII%*Q5V@,=+N6PV=RQ">$FR\*@T*%8+P$A*D+A7
MM-T]$ZZ-TWV=BG'3?7T<Z'MKI2-$7>RT[+ST06@H1<7Z[KV"8$2H];#2<1GI
M"&ET8]'1&;J_/A\ QA["'7DFS(E@W)\'8:_F=:#-] M6;B[,9A+:,L\1?*[%
M*$%0/,9DKK.2E<J.99]OW4'<>X'^^"I]@& ?W2V:"')\2 A^^8C8><[Q;)D^
MUMD.W_@1&7G(Q@&77H(B]Q)<\L2/EZ98FXR\/0GA(6 \N=:X)\]P\!A6J..#
MA-NG^$FQ*.%L?=XK;^I + G+6K!9,:$-)UG:+:W'4VN->WTTH T95*@=^!U/
M^FL/N6NOKP:#(!>2*VE %.U)G*@I*D #M?$A1JNL=6T:5 ^G?5Q8]N$U'QD!
M'6#^V2RL5J?E;[7>:KX^7;ZM4P1/S]:K=9CGZ?S#)%L9@D%+ECU;4,D+"$AA
MKQ86+4.+R38: ?($99WG% 9&RNU;UB'5MC<,O^ R+L8VOJ>?ZR^NKC%_,4/)
M.9-X#A%0&I)O9 A1)7)FM8B"JZRE:G3?-30K(R<TQH7ZN,#XOO?&99"W6B_/
MSN>;U5=&WW\,\POA_+J8?\'5^FKN6,E>29<32!T<J.(+F8T80(CDO XJ.MVF
MW.IH+([LYGRG>ZDID#IP@_86S#F[%U[KZN1+F,ZJ%_IRL?Q+/9DG*@2*BXL'
M*V*B<S@6<$7281R9XBX6KE6CCK)&'(U;J/:][I\A8=+!=KE6[?4L?)ZNP^R<
ML0>[;B9<U_>)ZX!^.E]!^?H<DR4&H^>U53!+X=OTTN],ZKA32,:.*YHJMM\W
MHB\"J=5Z<9+HJ%OB.=N+<DT@>]1K;O6Q ]5D[L["0'67EPN?S/,F#%W=;.2]
M*IA+5AN=F824)2%%2PG>!P2K54'O.)>I39/(E@0>/D:DJNT52?0/S.\7=8=<
ME<<^QU5:3C>_\*WWT,;@!4<&AM6-RLA;<CYHR+EHFVA?E4:3;W:E=-Q42PM\
MW1TYTE!W_9:P;V,S]FY3W^'#CV@"&[:R;PM4KH7)5M2)7I:</<<,.*$8>".E
ML59C:#16H[$AK/="W_+X%XN=I/7TR]V7AC5RYXK-P*-6M<@I0M":=JR*WANG
M!-/\"7SML-SW8<!VP<7UN[@6,A_YSO8.2[6!Z%QA9)H_G><<;K$G.4NBMJ@I
MDVK'FHW@JH5.V9$KRB(6Q_:!U--+CYN?/3J\!M;%R% [?_!A]6K^,DR7FSZU
M*T:O1H_=XB['HKE(AH18[[4=9MI#@O@,J'BRS)JTS>-3NZ\\;O*R-= ::^+[
M=L,N?^?:=<;^?80'+GA$=VU;MH_LPC&6XZ:O7FR>G\S.@4_6D?NO0V8^)QV^
MZUCVWOOE\_H*SH.W!34(EVC+T8Z&P*V%Z*.D[R-&T\9[?9BF[\.]VP4S6]WW
M[ZZ/'E+']W%R7M5LBL@I9Y!!.5#<:V*$XFH6**!V+!N*YH\'K/$[ X?2^390
MVED!O2+IHJR1&<N5B C"5S_$D L2#$G))<S.6Z4=;U.']PA1':)I=[5O Z8]
M=#!R#/#_G,V^DD+9FU=O7IP66I[<C,M"YYAM8$Q!S$Z#BK3+O#0!!$J?@R(O
MTVR3J'AXA0YAL8\"%X-+<VQ,A/E96&X8N<V$4-89+J#(^C@?;1,(GC'00;+D
M8LX\RVT@\= "([]RU (1@\AR;$!L8,W]+0YRI"C3,0$AFPA*4_09 R&\]LDH
M%C/7?IMDP/V?/O)#0LV,PT%2'!D'%^)X\0<NTW2%)Q^6N+F9OVQZR 6CCK(^
MP67(S:^/%AM>>_6D3UI8GUW8 @^/KS+RZST-<#&@5$>MV;R&<7<+XSXZPPH%
M@#RS0*)Q!1RKL[40F1&*:6NV:42[_]-'?CRGG:4X1(JC(V%3)GDAE<VE\NK2
MWAF#5O)RWEJIO&$0>:W_DIA,R9H5N4VWZD.?/_(S-0W0,(@D>XU:7U\5;Y%+
MK%61#&QQA&[!R1_BP4%PS$OGH\F^S0"%Q^GJT"5ME G93Q5CWV%53A:7G"SN
MM .]7<QF+Q?+6B<X(7GIH*,[?X]'<5O+9 R"S3)RYLFTIKC-Y=7V2W88X>ZI
MY45[D?=JHJXWEUF>DN,4MH>DZH2:&,%9<MN#-2&2@9?Q-H1^Z)[ IG#8M?%O
M%]WLC;7/Y) M\KMU6*Z'L5VW.;JLE[^\6]F<^'F2$X6(@7/(NE:P;-Z/373@
MBV30B:@BOWTZ/FR[MEMRG(/O&(AJ*?L>CL.GV+J,-/-$8I;<:P/<Z3J3/VF(
M5FC@UI.OBB(P\]2%^NZKCI/9Z0I8^VG@T'<CVSA;SVHSQ SSZ?+%'Y^G1-*$
MW%)M"PDL*%NO58R :&*B0">*A(:EXK8J$MIJM7'R04=%T[ 2[^?UT2=/])"+
M"87IVLI/F\,Z":[4E]!4E"B3CXJ7?KVMP5-.77E;N^CF0&_KQ?RZZ1JE!NVJ
M+N]*]*OIZL5J/?U4M\1O*Y+(+[.0_OXN?:2/7)TW5;Q93E/-WBTRSMI6K U&
MWA'KV]J(],C5<(%'G>N3C()E 0IK,HY3S.&1RQ2E]$:TJ=P9OQK.<UF,<@:B
MQSH+ELCTJ!"\L%DXG[3+1RQ:^HZJX7;!S [5<+OHH]=4RZ8JAW-$@P$AZ!!J
M!7V&J!,GOS@I&W-FIM7#1]]=-=Q..M^Z&FX7!?2*I(L[EYB8%=[7S>7KHSLF
M08P48RDA7&#"<N$:-=]_?]5P.ZE]AVJX770P<OID<]5VU7&Q86I:II@O+MPL
M2U9C\H"N>KK!*PCV_VOORGK<.G+U^_TO!&I?7B[@Q$E@((D-.YG!?1)8FRVD
M+66D;L]D?OUEJ=6+Y5Z.I%,ZI9YYR3CC3I\B^9%%LKB(#"RR8HB0P,V0/JNG
MO](A/ X1Y.X#YCA<[=7<W+VJZ, 42V2#E4JU/9KH(D-L:SQNI7).,=5F#<&9
M/F..?H4=)HI>@74_Y#88I*[[0[SS5>M<(0,M%%B5I51:&+F;5^LI'3+5,^=>
M*-@W"[*/2/HHWOMPN9K_D6L<G6<,F7(R*_"*)U"%$VN,X: %<W3;IR!9''"?
M??N;.[0VQP%B! 9.+/XG.DOO-3/_\*\_<[Q.\GZ>1<YJQ9($LL1X31TBKX,_
MF+&)R<@'-?ON_^4.:W^/AT]C ?1A7=:W5#Y T]^6%R3$2O!,E"BMP@(BR/I@
M81%"$IY\/F\9Y\;[?4J%!WZUP]+AT:Q2"\9W#*GW\_4?/ZYR?K.@;^7UY7N\
MS#/GC=$L"BB\5DIC2(#%UM%L)=N"O.K,D:!ZZ+L=UA^WA=71S#_O>02_UI^I
MFV/:ONE\\YD3OLT\3>*)WUBLYSP:PFPT1I#)XA%\R!Z\=$HYA<ZY-G/XIW]C
M2=;KX!/=^"%6%:;(PI5 .A9#3EK42M\3IL+/Z(UE'\SL\<:RCSPZR"C\DK%R
MI383O5G\>75YNXD4M;8F" ,FDYU6G%P!)U*]%2R+1@;/66J"J\=.U&$&X0")
M+QNPOU,8;5/"5A3)I3$0G*$(I=:9A!0,5#*,H A%--KZ\_B9IH72.#(? *0#
M!- AE!YR)6^>!2)7J3J4.@I+E"D)CM4V2&0\UV(F:=ID.X>?L3^H'8**9\ V
MDH@Z!-]->/QZ_F6>R*.]1YE#G4QP# HC8Z]JH0;F@L U4ASCM45^F@OR\3-.
MFV,]$?A&$E$'X'LN3G?.Y]K,:XJE\)E9)%^5@G5=7T"595KE$S86]?]L>(Q?
M-J(H.@#6-R'1O?>I776:*2S<)&M!Z[J[/>@Z\4@RD-IFD5%Y;T\TO>^)4W88
M#!R(CN6)1'7>";7M]-/YXMN2X-LGDK:YMGU.<,(TW,&,.7&&+@67#/("I .^
M]@(4\$@Z(3/S0M+UK+&-JSY]AHZ1.>!>AMJ%7Q--29,Y4 I,TBZ3^A;MVQC4
M<\_0[8.9/3)T^\BC@\O[\6I,)+E[JQB0-Z.)D,UVH8Q@DU4B!*^\:Q.!G%\5
M]%XR'UP%O8\ >D72-B(K6LB4R5/)ABE0Y#P 6D<N#+%&IF1RL2?$4@]INI'$
MOD<5]#XRZ+L*6C@I4FWU$P%)W6KJQ^<8 &-.H9#=-BB>\<G.N0IZ+T$.KX+>
MAZN]FIN[*"F$:#ACH8;GNBY"T.!RJM7=6A2&E@*9$TXA[C^=,?H5=I@H>IA>
ML=O<?!O[W&]M3EDDSEV&$(JE*)R X.M4-:9<3"(%X^7!(P8>^F"'YNA "3\W
M7.!H=G=7Y[J^,;KSO)XIYQUZY2"A(0YESR%X#!"DBY$'AQ+5 . \_97.AC$=
M+](GRU@/YF\?0Y@V.9:G-N]4LF30B1.3P!$00)4<:M8O@BC2V$@<BW;0Z+@A
M'^ML\-*HZ!F?VYV;&Y^T=85#$I+7[B9RZ&JGB(\J1F-="GZ(KSR"N3G=0*63
MFIL]^-OW%)*?YS$OUO2??,F+J_S/^>4G^?J7G.JXB[H8;*>-9%#F^]E?.5(J
M>[^CCY2;WG[M1\+C]\O%)J?X=_KR]U?KR^7GO+K-,Y9 X7MA NIP0%!>;H;D
M(L5LTML4I(JA30?XP ,>&X@]\YF[A7$L$33J-G3+BJQSYA4$9GQ]5/)<HE86
MV\SK&'K":7WL%GC:C=2:R*K?M[_G[,+!^Y4'_N(3F;>&>Y6'@E(E13$>J9YP
MNH)29'!T(T(N$J73!%C=ID[\1$;NP=^]7N?+5W0I/[(@TZ7"-4<))H8,RM9.
M)PJ%29%TH!"YF"0;C?[8_[#G8?KV0=DW2:K&$CQ?*SA".]'>GSB193Q)&]%0
M].K,%7+K0089*51 !UX8PE7*+"M74+$V+_6-;62-DMZ3# G[GTB97M/7+I9_
MUCJB5S5>^K@I*?H>UY_>X5_UC^]SS"22-$.KI#<>P2IM0$6EP=6*.H$Y(:+0
MS@P9*7W(M\_#WNV#F/LQ:W-I3)SS>):^=TO2[,LY7OPR)\_H<KG(6VK7ORV_
MRS<D_X+_FG^^^CQ#%JWW=9*HE!J4THG"]Z1 "JMCE$7&W2FOA^%PKU--^U(T
M.4+;2;!W[+Y?_H47-;=$!%=W9$OC9AY#*8'.8PU$5NK.=2;!2^F 1R<-XU([
M/62-U3%GF'8TQN2X'$LZ9X?"^>*63JZ5R-QS<%H'HI.8&RQ&< ZY4*B2WITY
M.Q(*[\XP[22-_E!XH'0ZJ./8\O)]KK4M\\7'=WE5EJO/=<+\VW Q_[@1ZJRH
M8I0OL7;S('&2>? E<8BE:*EC-B*W:<$?=+QI!W"T1&,[*?5N &_]CO6[U3)4
M)7M;OLM$^BL21ZX.<S'(D)&7837?;&4AAUD;!RZF@M&@4X.V3!Q_DFDW#DYN
M#,>5U,2X)!)BSFE=V3F<\AO?>,9SM,44#KS8!$IR!$1R1AS]@XD2$=F0"43'
MG6(0'NVYXO&$$NK=1@X+TF969Q4T2Q"S((]$LK)9B0:"JZ@+8K!\2 W"2,<9
MA$YWKNB<0F93%VT^P,?;C/ZO^9\W?W_KP\3EQ\7\WT1D\*2#SA9@6%UE7Z\$
M)S5D9EA4K#@S:)SVP0<8!$5_KE \C5PZ"&&^QS_GEWA1CWY#T_?+]>5/J^5Z
M/2N<UW>I.M3>AEH@E,!G08JDM58F1B5#HW'<3YQJ6/J;G2/R1A=*OP![]7FY
MNIS_^SKV2A1;19;)I1"U+9PT"#P2ZSBBD*5DY5N]-C]_N&%P.\OGEE8BZ@%U
M=/ZWY:?E,M5>V@]Y]64>\_K#\B+-DB1>* JC>!"2^$.!/B8CB5T!?=%1.]MH
M5?JC9QJ&L;-\,!E9(.=;J?!Z>]KM#[2K5WCD0R>J6AA"YHEK%VP*+ <M(912
M-SE2U!JR-Z -XZHH95-IT\![HOJN7Y9?MI-/=IA_OX2<E9Q%3@:$4(QB(J,@
M1)6!"U489U@,-IHU..!TYU'1L ^.OAG--;:,NKACGXB1OK]:5=Z3<4^V,%7J
M4@]!S@,30+X#!Q,M1B]9+)$WNFV?/]W$(PA'Q\2 LL&C!#1YS]D-9731K#*N
MZ7JY_M\WBR=IG25OJO)J2*Q.U=.25^\B@K/<U8G&1O@V ^+V/.C$8PE; [*E
MV,XVD:="P!R(ET9@J&W'Y/G:X,@'=CYZYB0W]AF7L'TBKUE13#/,G4XH'>V$
M'V+P7<1L(A&DT'M0BGR94$=)I>08!5R>^-EH6.98-W*SVI@^;N1]!-1W6^9F
M#M]W9.C3]\O/?U+<>)U1VS_F?>07C133#CGF2#'KW2RWM^7^Q][GBVH*:I9D
MO9EE&.IQ;EZW;D,0)@*+R0H(K&[[5)J#8RA *J:9J@V[NX\^(^GN<><^UJX-
M_OIW][]^UPLCG;*B: \\J[H*S&8(7BE@PG!A,*3@)F;;PP>?-CXY(59W[>0I
M!=YO2O%ANW1PX^>3OZZI*6W8Y'DD2)42.D=T$'WMD@O.$U * ^L)(HJSG'B;
MM-BT!O5#_)3352TVN].B^Z?8B/'M]<*R5_%R_N7;_D+TQ13T%HSF5;V= ,=%
M@8+&4I#F"O(V;W;'G_VLS>H^B-TUJR<6>P<YRCN*?R +N?PKY^W3T\,,>'6Q
M^97TI[?E+AI\M_&5-X*Y8T32/O'"'/G]R.F*"1:\SP6X<8DQI65N](S8C*1I
MDT]=J,64(.E*6[YQKE[5V/>^?:ASA:[9<;?;<L=6Y(Q$L<B V9&M8!3-.I$I
MI)4Y\F*9EJ%-T_"X=$R;(.M"+TX.ATZ5X6L!$(OG=;_.A@^_+^;$]LJ61V[.
M[#QWJG#0-EE0VBG 6")(EE6B*U2&T";O-C(ATZ;H.E.'4P'BW(+4$>9R#/S%
M30/7D\S@.!+2A!1NF$0(6,OSLF- P#)U^G%RL1BG4IOQ17V'L/?:!M;?_?7P
M!78]/EIER\@2*(@\$0.M2N!J_5E$(T.*L01N)C',@TDXZX!V'_SN:Y+;@* #
MY^3=!9)Q^GR]'=4'B<;3I69E':IO"6RU= .R4E$HG;FW;=+;]T\Q+08G L)R
M)*ETA*CMH@8GF2?/2(+6C)P3SS6$D TXZ[74WAJAVGBK7Y]C6E0=+L]'@'$
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MS0]?-\+,"F-)I>0 7:"8.F@&H:0")G/MO.+"B(;)BC%(F#@)UX$-/SD0>M&
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M4H.G..O$:^ F3#-VAX0.G+=VYN+V-UW_1V\O/^75;Y]P<6-"I-,RNR A:"]
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M83!G&Q"RJP_6FOB*BOXUZ:+12"ERF6BHY@'43 OQ(\ UVE"OD23= =K?9[J
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M_IO97&P=*Z]3P,%N8SV%CY$'A=V>\HV3Z/+JC\7= ?WQ_P!02P,$%     @
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M+3(P,C$P-C,P+FAT;5!+ 0(4 Q0    ( ":"#%,M";" BQ   $ZL   0
M          "  1*G 0!S;',M,C R,3 V,S N>'-D4$L! A0#%     @ )H(,
M4[P$?03(%@  "]   !0              ( !R[<! '-L<RTR,#(Q,#8S,%]C
M86PN>&UL4$L! A0#%     @ )H(,4]CWUSAW.0  ;X$" !0
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M2P$"% ,4    "  F@@Q3]^N1Q0H(  #W'P  %0              @ 'RD@,
M<VQS+3(P,C$P-C,P97@S,3$N:'1M4$L! A0#%     @ )H(,4PU4_ H+"
M^Q\  !4              ( !+YL# '-L<RTR,#(Q,#8S,&5X,S$R+FAT;5!+
M 0(4 Q0    ( ":"#%/,F*'F:P8  ,,9   5              "  6VC P!S
J;',M,C R,3 V,S!E>#,R,2YH=&U02P4&      L "P#1 @  "ZH#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
